{"PMC7102649": [["IntroductionSince December 2019, dozens of unexplained pneumonia cases have occurred in Wuhan City, Hubei Province, China, and there are reports suggesting that the outbreak is related to exposure at the Wuhan South China Seafood Market [1,2].", [["pneumonia", "DISEASE", 55, 64], ["unexplained pneumonia cases", "PROBLEM", 43, 70], ["pneumonia", "OBSERVATION", 55, 64]]], ["In subsequent months, pneumonia has spread in China and globally.", [["pneumonia", "DISEASE", 22, 31], ["pneumonia", "PROBLEM", 22, 31], ["pneumonia", "OBSERVATION", 22, 31], ["spread", "OBSERVATION_MODIFIER", 36, 42]]], ["Studies have shown that a new beta-coronavirus known as COVID-19 (formerly known as 2019-nCoV).", [["COVID-19", "GENE_OR_GENE_PRODUCT", 56, 64], ["COVID-19", "DNA", 56, 64], ["2019", "PROTEIN", 84, 88], ["nCoV", "PROTEIN", 89, 93], ["a new beta-coronavirus", "TEST", 24, 46], ["COVID", "TEST", 56, 61]]], ["As of March 15, 2020, there are 142,539 confirmed cases of COVID-19 infections worldwide.", [["infections", "DISEASE", 68, 78], ["COVID-19", "SPECIES", 59, 67], ["COVID-19 infections", "PROBLEM", 59, 78], ["infections", "OBSERVATION", 68, 78]]], ["Of these, there have been 81,021 confirmed cases in China with 3,194 deaths.", [["deaths", "DISEASE", 69, 75]]], ["There have been 61,518 confirmed cases and 2,199 deaths in 134 countries outside China, including Italy, Iran, South Korea, France, Japan, Singapore, Thailand, Malaysia, Germany, United States, etc [5].IntroductionAt present, confirmation of COVID-19 infection mainly depends on detection through reverse transcription polymerase chain reaction (RT-PCR) of sputum, throat swabs, lower respiratory tract secretions, and other specimens [6].", [["sputum", "ANATOMY", 357, 363], ["throat swabs", "ANATOMY", 365, 377], ["lower respiratory tract secretions", "ANATOMY", 379, 413], ["specimens", "ANATOMY", 425, 434], ["deaths", "DISEASE", 49, 55], ["infection", "DISEASE", 251, 260], ["COVID-19", "ORGANISM", 242, 250], ["throat swabs", "ORGANISM_SUBDIVISION", 365, 377], ["lower", "ORGANISM_SUBDIVISION", 379, 384], ["respiratory tract", "ORGANISM_SUBDIVISION", 385, 402], ["secretions", "ORGANISM_SUBSTANCE", 403, 413], ["COVID-19", "SPECIES", 242, 250], ["COVID", "TEST", 242, 247], ["19 infection", "PROBLEM", 248, 260], ["reverse transcription polymerase chain reaction", "PROBLEM", 297, 344], ["RT-PCR", "TEST", 346, 352], ["sputum", "TEST", 357, 363], ["throat swabs", "TEST", 365, 377], ["lower respiratory tract secretions", "PROBLEM", 379, 413], ["other specimens", "TEST", 419, 434], ["infection", "OBSERVATION", 251, 260], ["throat", "ANATOMY", 365, 371], ["lower", "ANATOMY_MODIFIER", 379, 384], ["respiratory tract", "ANATOMY", 385, 402]]], ["However, nucleic acid detection is affected by factors such as insufficient kits, patients' immune status, disease course, and slow test reports, which complicate the diagnostic process.", [["nucleic acid", "CHEMICAL", 9, 21], ["nucleic acid", "SIMPLE_CHEMICAL", 9, 21], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["nucleic acid detection", "TEST", 9, 31], ["slow test reports", "TEST", 127, 144]]], ["Chest high-resolution computed tomography (HRCT) is an important method for detecting lung abnormalities.", [["lung", "ANATOMY", 86, 90], ["lung abnormalities", "DISEASE", 86, 104], ["lung", "ORGAN", 86, 90], ["lung abnormalities", "PROBLEM", 86, 104], ["lung", "ANATOMY", 86, 90], ["abnormalities", "OBSERVATION", 91, 104]]], ["It plays an irreplaceable role in the screening of suspected patients, the diagnosis and differential diagnosis of diseases, clinical classification, assessment of disease progression, detection of pulmonary complications, and follow-up after discharge [6].IntroductionStudies have shown that, compared to middle-aged and elderly people with COVID-19 infection, children or young people have milder symptoms, are more easily cured, and have a good prognosis [7].", [["pulmonary", "ANATOMY", 198, 207], ["pulmonary complications", "DISEASE", 198, 221], ["infection", "DISEASE", 351, 360], ["patients", "ORGANISM", 61, 69], ["pulmonary", "ORGAN", 198, 207], ["people", "ORGANISM", 330, 336], ["COVID-19", "ORGANISM", 342, 350], ["children", "ORGANISM", 362, 370], ["people", "ORGANISM", 380, 386], ["patients", "SPECIES", 61, 69], ["people", "SPECIES", 330, 336], ["children", "SPECIES", 362, 370], ["people", "SPECIES", 380, 386], ["diseases", "PROBLEM", 115, 123], ["clinical classification", "TEST", 125, 148], ["disease progression", "PROBLEM", 164, 183], ["pulmonary complications", "PROBLEM", 198, 221], ["COVID-19 infection", "PROBLEM", 342, 360], ["milder symptoms", "PROBLEM", 392, 407], ["pulmonary", "ANATOMY", 198, 207], ["complications", "OBSERVATION", 208, 221], ["infection", "OBSERVATION", 351, 360]]], ["In this study, we analyzed the HRCT lung manifestations and related signs in 98 patients of different ages.", [["lung", "ANATOMY", 36, 40], ["lung", "ORGAN", 36, 40], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["this study", "TEST", 3, 13], ["the HRCT lung manifestations", "PROBLEM", 27, 55], ["lung", "ANATOMY", 36, 40]]], ["We also aimed to contribute to information needed urgently in clinics and to determine the relationship between the age of onset and chest HRCT signs to assist in combatting the epidemic.Data collection ::: MethodsThis retrospective study was approved by the Ethics Review Committee of Hangzhou Xixi Hospital affiliated to Zhejiang Chinese Medical University.", [["chest HRCT signs", "TEST", 133, 149], ["the epidemic", "PROBLEM", 174, 186], ["Methods", "TREATMENT", 207, 214], ["This retrospective study", "TEST", 214, 238], ["chest", "ANATOMY", 133, 138]]], ["We collected clinical and laboratory data for analysis, derived from an electronic medical record system, concerning patients admitted to our hospital from January 20, 2020 to February 17, 2020, who had been confirmed as having COVID-19 infection using RT-PCR.", [["infection", "DISEASE", 237, 246], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["analysis", "TEST", 46, 54], ["COVID-19 infection", "PROBLEM", 228, 246], ["RT-PCR", "TREATMENT", 253, 259], ["infection", "OBSERVATION", 237, 246]]], ["Chest HRCT images were collected and evaluated using the Picture Archiving and Communication Systems (PACS).HRCT inspection ::: MethodsAll chest HRCT scans were performed using a GE Revolution Evo CT scanner (GE Medical Systems, Tokyo, Japan).", [["Chest HRCT images", "TEST", 0, 17], ["HRCT inspection", "TEST", 108, 123], ["Methods", "TREATMENT", 128, 135], ["All chest HRCT scans", "TEST", 135, 155], ["chest", "ANATOMY", 139, 144]]], ["Patients underwent a non-contrast HRCT scan on admission day.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["a non-contrast HRCT scan", "TEST", 19, 43]]], ["The mean time between the first symptom onset and the CT scan was 4.2 \u00b1 3.8 days (range, 0\u201315 days).", [["the CT scan", "TEST", 50, 61]]], ["Patients were placed in a supine position with head first.", [["head", "ANATOMY", 47, 51], ["Patients", "ORGANISM", 0, 8], ["head", "ORGANISM_SUBDIVISION", 47, 51], ["Patients", "SPECIES", 0, 8], ["head", "ANATOMY", 47, 51]]], ["Scanning parameters were tube voltage (100 kV), tube current (10\u2212240 mA), slice thickness (5 mm), interval between slices(5 mm), consecutive 1.25 mm slices for high-resolution reconstruction scan, and scanning time (<5 s).HRCT image analysis ::: MethodsTwo senior radiologists evaluated the scanned images separately to identify HRCT characteristics of each patient.", [["tube", "ANATOMY", 48, 52], ["slice", "ANATOMY", 74, 79], ["slices", "ANATOMY", 115, 121], ["slices", "ANATOMY", 149, 155], ["tube", "TISSUE", 25, 29], ["tube", "TISSUE", 48, 52], ["slice", "TISSUE", 74, 79], ["patient", "ORGANISM", 358, 365], ["patient", "SPECIES", 358, 365], ["Scanning parameters", "TEST", 0, 19], ["tube voltage", "TEST", 25, 37], ["slice thickness", "TEST", 74, 89], ["slices", "TEST", 115, 121], ["consecutive 1.25 mm slices", "TEST", 129, 155], ["high-resolution reconstruction scan", "TEST", 160, 195], ["scanning time", "TEST", 201, 214], ["HRCT image analysis", "TEST", 222, 241], ["the scanned images", "TEST", 287, 305]]], ["The focus was to observe whether lesions identified on the HRCT images involved both lungs and several lung lobes.", [["lesions", "ANATOMY", 33, 40], ["lungs", "ANATOMY", 85, 90], ["lung lobes", "ANATOMY", 103, 113], ["lesions", "PATHOLOGICAL_FORMATION", 33, 40], ["lungs", "ORGAN", 85, 90], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 103, 113], ["lesions", "PROBLEM", 33, 40], ["the HRCT images", "TEST", 55, 70], ["lesions", "OBSERVATION", 33, 40], ["both", "ANATOMY_MODIFIER", 80, 84], ["lungs", "ANATOMY", 85, 90], ["several", "ANATOMY_MODIFIER", 95, 102], ["lung", "ANATOMY", 103, 107], ["lobes", "ANATOMY_MODIFIER", 108, 113]]], ["A detailed analysis and evaluation of the imaging appearance concerning each of the lesions identified included: (i) the number of lesions, (\u2171) the specific distribution of the lung lobe, (iii) the area of the lung field involved, (iv) lesion size, (v) lesion density, and (vi) whether signs of air bronchogram and dilatation were combined.", [["lesions", "ANATOMY", 84, 91], ["lesions", "ANATOMY", 131, 138], ["lung lobe", "ANATOMY", 177, 186], ["area", "ANATOMY", 198, 202], ["lung", "ANATOMY", 210, 214], ["lesion", "ANATOMY", 236, 242], ["lesion", "ANATOMY", 253, 259], ["lesions", "CANCER", 84, 91], ["lesions", "PATHOLOGICAL_FORMATION", 131, 138], ["lung lobe", "MULTI-TISSUE_STRUCTURE", 177, 186], ["lung", "ORGAN", 210, 214], ["A detailed analysis", "TEST", 0, 19], ["evaluation", "TEST", 24, 34], ["the imaging appearance", "TEST", 38, 60], ["the lesions", "PROBLEM", 80, 91], ["lesions", "PROBLEM", 131, 138], ["(iv) lesion size, (v) lesion density", "PROBLEM", 231, 267], ["air bronchogram", "PROBLEM", 295, 310], ["dilatation", "PROBLEM", 315, 325], ["lesions", "OBSERVATION", 84, 91], ["lesions", "OBSERVATION", 131, 138], ["lung", "ANATOMY", 177, 181], ["lobe", "ANATOMY_MODIFIER", 182, 186], ["area", "OBSERVATION_MODIFIER", 198, 202], ["lung", "ANATOMY", 210, 214], ["field", "ANATOMY_MODIFIER", 215, 220], ["lesion", "OBSERVATION_MODIFIER", 236, 242], ["size", "OBSERVATION_MODIFIER", 243, 247], ["(v", "OBSERVATION_MODIFIER", 249, 251], ["lesion", "OBSERVATION_MODIFIER", 253, 259], ["density", "OBSERVATION", 260, 267], ["signs of", "UNCERTAINTY", 286, 294], ["air bronchogram", "OBSERVATION", 295, 310], ["dilatation", "OBSERVATION", 315, 325]]], ["In this study, lung lobe distribution information included the right upper lobe, the right middle lobe, the right lower lobe, the left upper lobe, and the left lower lobe.", [["lung lobe", "ANATOMY", 15, 24], ["right upper lobe", "ANATOMY", 63, 79], ["right middle lobe", "ANATOMY", 85, 102], ["right lower lobe", "ANATOMY", 108, 124], ["left upper lobe", "ANATOMY", 130, 145], ["left lower lobe", "ANATOMY", 155, 170], ["lung lobe", "MULTI-TISSUE_STRUCTURE", 15, 24], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 69, 79], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 91, 102], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 114, 124], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 135, 145], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 160, 170], ["this study", "TEST", 3, 13], ["lung", "ANATOMY", 15, 19], ["lobe", "ANATOMY_MODIFIER", 20, 24], ["right upper lobe", "ANATOMY", 63, 79], ["right middle lobe", "ANATOMY", 85, 102], ["right lower lobe", "ANATOMY", 108, 124], ["left upper lobe", "ANATOMY", 130, 145], ["left lower lobe", "ANATOMY", 155, 170]]], ["The distribution of the lung field included the periphery (the outer one-third region of the lung), the central zone (the area inside the inner two-third region of the lung), and whether the peripheral and central zones were affected simultaneously.", [["lung", "ANATOMY", 24, 28], ["lung", "ANATOMY", 93, 97], ["central zone", "ANATOMY", 104, 116], ["area", "ANATOMY", 122, 126], ["inner two-third region", "ANATOMY", 138, 160], ["lung", "ANATOMY", 168, 172], ["peripheral", "ANATOMY", 191, 201], ["central zones", "ANATOMY", 206, 219], ["lung", "ORGAN", 24, 28], ["lung", "ORGAN", 93, 97], ["central zone", "TISSUE", 104, 116], ["lung", "ORGAN", 168, 172], ["peripheral", "TISSUE", 191, 201], ["central zones", "MULTI-TISSUE_STRUCTURE", 206, 219], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["lung", "ANATOMY", 24, 28], ["field", "ANATOMY_MODIFIER", 29, 34], ["periphery", "ANATOMY_MODIFIER", 48, 57], ["outer", "OBSERVATION_MODIFIER", 63, 68], ["third", "ANATOMY_MODIFIER", 73, 78], ["region", "ANATOMY_MODIFIER", 79, 85], ["lung", "ANATOMY", 93, 97], ["central", "ANATOMY_MODIFIER", 104, 111], ["zone", "ANATOMY_MODIFIER", 112, 116], ["inner", "ANATOMY_MODIFIER", 138, 143], ["two", "ANATOMY_MODIFIER", 144, 147], ["third", "ANATOMY_MODIFIER", 148, 153], ["region", "ANATOMY_MODIFIER", 154, 160], ["lung", "ANATOMY", 168, 172], ["peripheral", "ANATOMY_MODIFIER", 191, 201], ["central", "ANATOMY_MODIFIER", 206, 213], ["zones", "ANATOMY_MODIFIER", 214, 219]]], ["The transverse CT consecutive 1.25 mm slice thickness for high-resolution reconstruction scan, the largest layer of the lesion was selected, and the largest diameter of the lesion was measured.", [["slice", "ANATOMY", 38, 43], ["lesion", "ANATOMY", 120, 126], ["lesion", "ANATOMY", 173, 179], ["lesion", "CANCER", 120, 126], ["lesion", "CANCER", 173, 179], ["high-resolution reconstruction scan", "TEST", 58, 93], ["the lesion", "PROBLEM", 169, 179], ["largest", "OBSERVATION_MODIFIER", 99, 106], ["layer", "OBSERVATION_MODIFIER", 107, 112], ["lesion", "OBSERVATION", 120, 126], ["largest", "OBSERVATION_MODIFIER", 149, 156], ["diameter", "OBSERVATION_MODIFIER", 157, 165], ["lesion", "OBSERVATION", 173, 179]]], ["Lesions were divided into small patchy or nodular opacity (size of <1 cm in long diameter), patchy or nodular opacity (1\u22123 cm), medium patchy opacity (3\u22125 cm), and large patchy opacity (5\u221210 cm), and larger patchy opacity (size \u226510 cm).", [["nodular opacity", "ANATOMY", 42, 57], ["nodular opacity", "ANATOMY", 102, 117], ["opacity", "DISEASE", 214, 221], ["Lesions", "PROBLEM", 0, 7], ["small patchy or nodular opacity", "PROBLEM", 26, 57], ["patchy or nodular opacity", "PROBLEM", 92, 117], ["medium patchy opacity", "PROBLEM", 128, 149], ["large patchy opacity", "PROBLEM", 164, 184], ["larger patchy opacity", "PROBLEM", 200, 221], ["small", "OBSERVATION_MODIFIER", 26, 31], ["patchy", "OBSERVATION_MODIFIER", 32, 38], ["nodular", "OBSERVATION_MODIFIER", 42, 49], ["opacity", "OBSERVATION", 50, 57], ["size", "OBSERVATION_MODIFIER", 59, 63], ["<1 cm", "OBSERVATION_MODIFIER", 67, 72], ["long diameter", "OBSERVATION_MODIFIER", 76, 89], ["patchy", "OBSERVATION_MODIFIER", 92, 98], ["nodular", "OBSERVATION_MODIFIER", 102, 109], ["opacity", "OBSERVATION", 110, 117], ["1\u22123 cm", "OBSERVATION_MODIFIER", 119, 125], ["medium", "OBSERVATION_MODIFIER", 128, 134], ["patchy", "OBSERVATION_MODIFIER", 135, 141], ["opacity", "OBSERVATION", 142, 149], ["3\u22125 cm", "OBSERVATION_MODIFIER", 151, 157], ["large", "OBSERVATION_MODIFIER", 164, 169], ["patchy", "OBSERVATION_MODIFIER", 170, 176], ["opacity", "OBSERVATION", 177, 184], ["5\u221210 cm", "OBSERVATION_MODIFIER", 186, 193], ["larger", "OBSERVATION_MODIFIER", 200, 206], ["patchy", "OBSERVATION_MODIFIER", 207, 213], ["opacity", "OBSERVATION", 214, 221], ["size", "OBSERVATION_MODIFIER", 223, 227], ["10 cm", "OBSERVATION_MODIFIER", 229, 234]]], ["In terms of density of a lesion identified using HRCT, this was assessed as either pure ground-glass opacity (PGGO), ground-glass opacity (GGO) with interlobular septa thickening or with a crazy-paving pattern, a mixed GGO with consolidation<50 %, a mixed GGO with consolidation\u226550 %, and a complete consolidation.", [["lesion", "ANATOMY", 25, 31], ["interlobular septa", "ANATOMY", 149, 167], ["GGO", "DISEASE", 139, 142], ["GGO", "DISEASE", 219, 222], ["GGO", "DISEASE", 256, 259], ["lesion", "CANCER", 25, 31], ["interlobular septa", "TISSUE", 149, 167], ["a lesion", "PROBLEM", 23, 31], ["HRCT", "TEST", 49, 53], ["pure ground-glass opacity", "PROBLEM", 83, 108], ["ground-glass opacity", "PROBLEM", 117, 137], ["interlobular septa thickening", "PROBLEM", 149, 178], ["a mixed GGO", "PROBLEM", 211, 222], ["consolidation", "PROBLEM", 228, 241], ["a mixed GGO", "PROBLEM", 248, 259], ["consolidation", "PROBLEM", 265, 278], ["a complete consolidation", "PROBLEM", 289, 313], ["density", "OBSERVATION", 12, 19], ["lesion", "OBSERVATION", 25, 31], ["glass opacity", "OBSERVATION", 95, 108], ["ground", "OBSERVATION_MODIFIER", 117, 123], ["glass opacity", "OBSERVATION", 124, 137], ["GGO", "OBSERVATION_MODIFIER", 139, 142], ["interlobular", "ANATOMY_MODIFIER", 149, 161], ["septa", "ANATOMY_MODIFIER", 162, 167], ["thickening", "OBSERVATION", 168, 178], ["crazy", "OBSERVATION_MODIFIER", 189, 194], ["mixed", "OBSERVATION_MODIFIER", 213, 218], ["GGO", "OBSERVATION", 219, 222], ["consolidation", "OBSERVATION", 228, 241], ["mixed", "OBSERVATION_MODIFIER", 250, 255], ["GGO", "OBSERVATION", 256, 259], ["consolidation", "OBSERVATION", 265, 278], ["50 %", "OBSERVATION_MODIFIER", 279, 283], ["complete", "OBSERVATION_MODIFIER", 291, 299], ["consolidation", "OBSERVATION", 300, 313]]], ["When the number of lesions per lobe was >5, only 5 obvious lesions t were analyzed.", [["lesions", "ANATOMY", 19, 26], ["lobe", "ANATOMY", 31, 35], ["lesions", "ANATOMY", 59, 66], ["lesions", "CANCER", 19, 26], ["lobe", "CANCER", 31, 35], ["lesions", "CANCER", 59, 66], ["lesions per lobe", "PROBLEM", 19, 35], ["5 obvious lesions t", "PROBLEM", 49, 68], ["lesions", "OBSERVATION", 19, 26], ["lobe", "ANATOMY", 31, 35], ["obvious", "OBSERVATION_MODIFIER", 51, 58], ["lesions", "OBSERVATION", 59, 66]]], ["We determined whether mediastinal lymphadenopathy (defined as lymph node size of \u22651 cm in short-axis dimension), pleural effusion, and other abnormal changes were also present.", [["mediastinal lymphadenopathy", "ANATOMY", 22, 49], ["lymph node", "ANATOMY", 62, 72], ["pleural", "ANATOMY", 113, 120], ["mediastinal lymphadenopathy", "DISEASE", 22, 49], ["pleural effusion", "DISEASE", 113, 129], ["lymph node", "MULTI-TISSUE_STRUCTURE", 62, 72], ["pleural", "ORGAN", 113, 120], ["mediastinal lymphadenopathy", "PROBLEM", 22, 49], ["lymph node size", "TEST", 62, 77], ["pleural effusion", "PROBLEM", 113, 129], ["other abnormal changes", "PROBLEM", 135, 157], ["mediastinal", "ANATOMY", 22, 33], ["lymphadenopathy", "OBSERVATION", 34, 49], ["lymph node", "OBSERVATION", 62, 72], ["size", "OBSERVATION_MODIFIER", 73, 77], ["\u22651 cm", "OBSERVATION_MODIFIER", 81, 86], ["short-axis dimension", "OBSERVATION_MODIFIER", 90, 110], ["pleural", "ANATOMY", 113, 120], ["effusion", "OBSERVATION", 121, 129], ["abnormal", "OBSERVATION_MODIFIER", 141, 149]]], ["If there was disagreement concerning analysis of the signs, a third chief physician (Zuhua Chen) was consulted to reach a consensus.Statistical analysis ::: MethodsStatistical analyses were performed using SPSS 24.0.", [["MethodsStatistical analyses", "TEST", 157, 184], ["SPSS", "TEST", 206, 210]]], ["Measurement data are expressed as mean \u00b1 standard deviation, and numerical data are described as frequency.", [["Measurement data", "TEST", 0, 16], ["numerical data", "TEST", 65, 79]]], ["Patients were divided into 4 groups according to age as follows: group A, <18 years old; group B, 18\u201344 years old; group C, 45\u201359 years old; and group D, \u226560 years old.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["We used one-way ANOVA analysis of variance (post-hoc multiple comparisons using least significant difference [LSD] and a q-test), chi-square test, and rank sum test to compare the HRCT signs of COVID-19-infected patients in different age groups, and the difference was statistically significant with a P-value <0.05.Baseline information ::: ResultsIn total, 98 patients (men, 52; women, 46) were identified, ranging in age from 4 to 88 years (average age, 43.0 \u00b1 17.2 years): group A, n = 8; group B, n = 46; group C, n = 24; group D, n = 20.", [["COVID-19-infected", "DISEASE", 194, 211], ["COVID-19", "GENE_OR_GENE_PRODUCT", 194, 202], ["patients", "ORGANISM", 212, 220], ["patients", "ORGANISM", 361, 369], ["men", "ORGANISM", 371, 374], ["women", "ORGANISM", 380, 385], ["patients", "SPECIES", 212, 220], ["patients", "SPECIES", 361, 369], ["men", "SPECIES", 371, 374], ["women", "SPECIES", 380, 385], ["a q-test)", "TEST", 119, 128], ["chi-square test", "TEST", 130, 145], ["rank sum test", "TEST", 151, 164], ["the HRCT signs", "TEST", 176, 190], ["COVID", "TEST", 194, 199], ["a P-value", "TEST", 300, 309], ["group B, n", "TEST", 492, 502], ["group C", "TEST", 509, 516], ["group D, n", "TEST", 526, 536]]], ["At first presentation, fever was the most common clinical symptom (87.8 %).", [["fever", "DISEASE", 23, 28], ["fever", "PROBLEM", 23, 28]]], ["Large volumes of sputum were not observed.", [["sputum", "ANATOMY", 17, 23], ["sputum", "ORGANISM_SUBSTANCE", 17, 23], ["Large volumes of sputum", "PROBLEM", 0, 23], ["volumes", "OBSERVATION_MODIFIER", 6, 13], ["sputum", "OBSERVATION", 17, 23]]], ["Of all patients, 78 (79.6 %) had been in direct or indirect contact with people from Wuhan, China.", [["patients", "ORGANISM", 7, 15], ["people", "ORGANISM", 73, 79], ["patients", "SPECIES", 7, 15], ["people", "SPECIES", 73, 79]]], ["These clinical manifestations in infected patients of different age groups were not statistically significant (P > 0.05), nor was there a statistically significant difference in the interval between the first symptom onset and the HRCT scan (P = 0.921) (Table 1).Baseline information ::: ResultsAll patients underwent comprehensive laboratory blood biochemical examinations.", [["blood", "ANATOMY", 343, 348], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 299, 307], ["blood", "ORGANISM_SUBSTANCE", 343, 348], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 299, 307], ["These clinical manifestations", "PROBLEM", 0, 29], ["the HRCT scan", "TEST", 227, 240], ["P", "TEST", 242, 243], ["comprehensive laboratory blood biochemical examinations", "TEST", 318, 373], ["infected", "OBSERVATION_MODIFIER", 33, 41], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["difference", "OBSERVATION_MODIFIER", 164, 174]]], ["C-reactive protein (CRP) levels were elevated in 51 (52.0 %) patients, and serum amylase-like protein (SSA) levels increased in 75 (76.5 %) patients.", [["serum", "ANATOMY", 75, 80], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["CRP", "GENE_OR_GENE_PRODUCT", 20, 23], ["patients", "ORGANISM", 61, 69], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["amylase-like protein", "GENE_OR_GENE_PRODUCT", 81, 101], ["SSA", "GENE_OR_GENE_PRODUCT", 103, 106], ["patients", "ORGANISM", 140, 148], ["C-reactive protein", "PROTEIN", 0, 18], ["CRP", "PROTEIN", 20, 23], ["serum amylase-like protein", "PROTEIN", 75, 101], ["SSA", "PROTEIN", 103, 106], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 140, 148], ["C-reactive protein", "TEST", 0, 18], ["CRP) levels", "TEST", 20, 31], ["elevated", "PROBLEM", 37, 45], ["serum amylase", "TEST", 75, 88], ["protein (SSA", "TEST", 94, 106], ["reactive protein", "OBSERVATION", 2, 18]]], ["Eleven (11.2 %) patients had abnormal white blood cell (WBC) counts (decreased WBC counts, n = 2; elevated WBC counts, n = 9).", [["white blood cell", "ANATOMY", 38, 54], ["WBC", "ANATOMY", 56, 59], ["WBC", "ANATOMY", 79, 82], ["WBC", "ANATOMY", 107, 110], ["patients", "ORGANISM", 16, 24], ["white blood cell", "CELL", 38, 54], ["WBC", "CELL", 56, 59], ["patients", "SPECIES", 16, 24], ["abnormal white blood cell", "PROBLEM", 29, 54], ["WBC) counts", "TEST", 56, 67], ["WBC counts", "TEST", 79, 89], ["n", "TEST", 91, 92], ["elevated WBC counts", "PROBLEM", 98, 117]]], ["In total, 58 patients (59.2 %) had abnormal neutrophil counts (decreased neutrophil counts, n = 44; increased neutrophil counts, n = 14).", [["neutrophil", "ANATOMY", 44, 54], ["neutrophil", "ANATOMY", 73, 83], ["neutrophil", "ANATOMY", 110, 120], ["patients", "ORGANISM", 13, 21], ["neutrophil", "CELL", 44, 54], ["neutrophil", "CELL", 73, 83], ["neutrophil", "CELL", 110, 120], ["neutrophil", "CELL_TYPE", 110, 120], ["patients", "SPECIES", 13, 21], ["abnormal neutrophil counts", "PROBLEM", 35, 61], ["neutrophil counts", "TEST", 73, 90], ["n", "TEST", 92, 93], ["increased neutrophil counts", "TEST", 100, 127], ["neutrophil counts", "OBSERVATION", 44, 61]]], ["Fifty-one (52.0 %) patients had abnormal lymphocyte counts.", [["lymphocyte", "ANATOMY", 41, 51], ["patients", "ORGANISM", 19, 27], ["lymphocyte", "CELL", 41, 51], ["patients", "SPECIES", 19, 27], ["abnormal lymphocyte counts", "PROBLEM", 32, 58], ["lymphocyte counts", "OBSERVATION", 41, 58]]], ["Baseline information, clinical symptoms, and biochemical indicators of the patients are shown in Table 1.HRCT evaluation ::: ResultsThis study first analyzed the chest HRCT scans of patients in different age groups in terms of bilateral lung and lobe involvement (Table 2).", [["lung", "ANATOMY", 237, 241], ["lobe", "ANATOMY", 246, 250], ["bilateral lung and lobe involvement", "DISEASE", 227, 262], ["patients", "ORGANISM", 75, 83], ["chest HRCT", "PATHOLOGICAL_FORMATION", 162, 172], ["patients", "ORGANISM", 182, 190], ["lung", "ORGAN", 237, 241], ["lobe", "MULTI-TISSUE_STRUCTURE", 246, 250], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 182, 190], ["clinical symptoms", "PROBLEM", 22, 39], ["HRCT evaluation", "TEST", 105, 120], ["This study", "TEST", 132, 142], ["the chest HRCT scans", "TEST", 158, 178], ["bilateral lung and lobe involvement", "PROBLEM", 227, 262], ["chest", "ANATOMY", 162, 167], ["bilateral", "ANATOMY_MODIFIER", 227, 236], ["lung", "ANATOMY", 237, 241], ["lobe", "ANATOMY_MODIFIER", 246, 250]]], ["Chest HRCT findings in 7 patients (7.1 %) were normal.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["Chest HRCT findings", "TEST", 0, 19], ["normal", "OBSERVATION", 47, 53]]], ["We identified 91 (92.9 %) patients with involvement of at least one lobe, and 58 (59.2 %) patients with bilateral lung involvement.", [["lobe", "ANATOMY", 68, 72], ["lung", "ANATOMY", 114, 118], ["patients", "ORGANISM", 26, 34], ["lobe", "CANCER", 68, 72], ["patients", "ORGANISM", 90, 98], ["lung", "ORGAN", 114, 118], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 90, 98], ["bilateral lung involvement", "PROBLEM", 104, 130], ["lobe", "ANATOMY_MODIFIER", 68, 72], ["bilateral", "ANATOMY_MODIFIER", 104, 113], ["lung", "ANATOMY", 114, 118], ["involvement", "OBSERVATION", 119, 130]]], ["There were significantly fewer cases of bilateral lung involvement in patients in group A than in patients in groups C and D (P < 0.05).HRCT evaluation ::: ResultsThe number of lung lesions on chest HRCT scans were counted for each infected patient and comprised a total of 701 lesions: 10 in group A, 272 in group B, 235 in group C, and 184 in group D. The number of lung lesions observed using HRCT in patients across different age groups was statistically significantly different (F = 4.826, P = 0.004) (Table 2).", [["lung", "ANATOMY", 50, 54], ["lung lesions", "ANATOMY", 177, 189], ["chest HRCT", "ANATOMY", 193, 203], ["lesions", "ANATOMY", 278, 285], ["lung lesions", "ANATOMY", 368, 380], ["lung lesions", "DISEASE", 368, 380], ["lung", "ORGAN", 50, 54], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 98, 106], ["lung lesions", "CANCER", 177, 189], ["chest HRCT", "PATHOLOGICAL_FORMATION", 193, 203], ["patient", "ORGANISM", 241, 248], ["lesions", "PATHOLOGICAL_FORMATION", 278, 285], ["lung lesions", "CANCER", 368, 380], ["patients", "ORGANISM", 404, 412], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 98, 106], ["patient", "SPECIES", 241, 248], ["patients", "SPECIES", 404, 412], ["bilateral lung involvement", "PROBLEM", 40, 66], ["HRCT evaluation", "TEST", 136, 151], ["lung lesions", "PROBLEM", 177, 189], ["chest HRCT scans", "TEST", 193, 209], ["lung lesions", "PROBLEM", 368, 380], ["HRCT", "TEST", 396, 400], ["P", "TEST", 495, 496], ["significantly", "OBSERVATION_MODIFIER", 11, 24], ["fewer", "OBSERVATION_MODIFIER", 25, 30], ["bilateral", "ANATOMY_MODIFIER", 40, 49], ["lung", "ANATOMY", 50, 54], ["involvement", "OBSERVATION", 55, 66], ["number", "OBSERVATION_MODIFIER", 167, 173], ["lung", "ANATOMY", 177, 181], ["lesions", "OBSERVATION", 182, 189], ["chest", "ANATOMY", 193, 198], ["lung", "ANATOMY", 368, 372], ["lesions", "OBSERVATION", 373, 380]]], ["Pairwise comparison test results showed that the number of lesions per person in group A was less than that in groups C (P = 0.002) and D (P = 0.004), and that the number of lesions per person in group B was less than that in group C (P = 0.019).HRCT evaluation ::: ResultsOverall, 113 (16.1 %) lesions were located in the right upper lobe, 87 (12.4 %) lesions were located in the right middle lobe, and 198 (28.3 %) lesions were located in the right lower lobe.", [["lesions", "ANATOMY", 59, 66], ["lesions", "ANATOMY", 174, 181], ["lesions", "ANATOMY", 295, 302], ["right upper lobe", "ANATOMY", 323, 339], ["lesions", "ANATOMY", 353, 360], ["right middle lobe", "ANATOMY", 381, 398], ["lesions", "ANATOMY", 417, 424], ["right lower lobe", "ANATOMY", 445, 461], ["lesions", "PATHOLOGICAL_FORMATION", 59, 66], ["lesions", "PATHOLOGICAL_FORMATION", 174, 181], ["lesions", "CANCER", 295, 302], ["upper lobe", "CANCER", 329, 339], ["lesions", "CANCER", 353, 360], ["middle lobe", "CANCER", 387, 398], ["lesions", "PATHOLOGICAL_FORMATION", 417, 424], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 451, 461], ["person", "SPECIES", 71, 77], ["person", "SPECIES", 186, 192], ["Pairwise comparison test", "TEST", 0, 24], ["lesions", "PROBLEM", 59, 66], ["P", "TEST", 121, 122], ["lesions", "PROBLEM", 174, 181], ["HRCT evaluation", "TEST", 246, 261], ["ResultsOverall", "TEST", 266, 280], ["lesions", "PROBLEM", 295, 302], ["lesions", "PROBLEM", 353, 360], ["lesions", "PROBLEM", 417, 424], ["lesions", "OBSERVATION", 59, 66], ["lesions", "OBSERVATION", 174, 181], ["lesions", "OBSERVATION", 295, 302], ["right upper lobe", "ANATOMY", 323, 339], ["lesions", "OBSERVATION", 353, 360], ["right middle lobe", "ANATOMY", 381, 398], ["lesions", "OBSERVATION", 417, 424], ["right lower lobe", "ANATOMY", 445, 461]]], ["There were 140 (20.0 %) lesions located in the left upper lobe, and 163 (23.3 %) lesions were located in the lower lobes of the left lung.", [["lesions", "ANATOMY", 24, 31], ["left upper lobe", "ANATOMY", 47, 62], ["lesions", "ANATOMY", 81, 88], ["lower lobes", "ANATOMY", 109, 120], ["left lung", "ANATOMY", 128, 137], ["lesions", "CANCER", 24, 31], ["upper lobe", "CANCER", 52, 62], ["lesions", "PATHOLOGICAL_FORMATION", 81, 88], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 109, 120], ["lung", "ORGAN", 133, 137], ["lesions", "TEST", 24, 31], ["lesions", "PROBLEM", 81, 88], ["lesions", "OBSERVATION", 24, 31], ["left upper lobe", "ANATOMY", 47, 62], ["lesions", "OBSERVATION", 81, 88], ["lower lobes", "ANATOMY_MODIFIER", 109, 120], ["left", "ANATOMY_MODIFIER", 128, 132], ["lung", "ANATOMY", 133, 137]]], ["Table 3shows the distribution of lung lobe lesions by age group.", [["lung lobe lesions", "ANATOMY", 33, 50], ["lung lobe lesions", "DISEASE", 33, 50], ["lung lobe lesions", "CANCER", 33, 50], ["lung lobe lesions", "PROBLEM", 33, 50], ["distribution", "OBSERVATION_MODIFIER", 17, 29], ["lung", "ANATOMY", 33, 37], ["lobe", "ANATOMY_MODIFIER", 38, 42], ["lesions", "OBSERVATION", 43, 50]]], ["Lesions of the right upper lobe were less common in patients in groups A and B than in patients in groups C (P = 0.014, P = 0.011) and D (P = 0.006, P = 0.003).", [["right upper lobe", "ANATOMY", 15, 31], ["Lesions of the right upper lobe", "DISEASE", 0, 31], ["upper lobe", "ORGAN", 21, 31], ["patients", "ORGANISM", 52, 60], ["B", "CELL", 77, 78], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 87, 95], ["Lesions of the right upper lobe", "PROBLEM", 0, 31], ["P", "TEST", 109, 110], ["P", "TEST", 120, 121], ["D", "TEST", 135, 136], ["P", "TEST", 138, 139], ["P", "TEST", 149, 150], ["right upper lobe", "ANATOMY", 15, 31], ["less", "OBSERVATION_MODIFIER", 37, 41], ["common", "OBSERVATION_MODIFIER", 42, 48]]], ["Concerning involvement of the right middle lobe, lesions were more common in patients in group D than in those in groups A (P = 0.039) and B (P = 0.028).", [["right middle lobe", "ANATOMY", 30, 47], ["lesions", "ANATOMY", 49, 56], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 36, 47], ["lesions", "CANCER", 49, 56], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["involvement of the right middle lobe", "PROBLEM", 11, 47], ["lesions", "PROBLEM", 49, 56], ["right middle lobe", "ANATOMY", 30, 47], ["lesions", "OBSERVATION", 49, 56], ["more", "OBSERVATION_MODIFIER", 62, 66], ["common", "OBSERVATION_MODIFIER", 67, 73]]], ["The number of lesions in the right lower lobe in different age groups was statistically significantly different (F = 2.830, P = 0.043), with patients in group A having fewer lesions in the right lower lobe than patients in groups B (P = 0.009), C (P = 0.008), and D (P = 0.009).", [["lesions", "ANATOMY", 14, 21], ["right lower lobe", "ANATOMY", 29, 45], ["lesions", "ANATOMY", 174, 181], ["right lower lobe", "ANATOMY", 189, 205], ["lesions", "PATHOLOGICAL_FORMATION", 14, 21], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 35, 45], ["patients", "ORGANISM", 141, 149], ["lesions", "PATHOLOGICAL_FORMATION", 174, 181], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 195, 205], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 211, 219], ["lesions in the right lower lobe", "PROBLEM", 14, 45], ["P", "TEST", 124, 125], ["fewer lesions in the right lower lobe", "PROBLEM", 168, 205], ["P", "TEST", 233, 234], ["C", "TEST", 245, 246], ["P", "TEST", 248, 249], ["number", "OBSERVATION_MODIFIER", 4, 10], ["lesions", "OBSERVATION", 14, 21], ["right lower lobe", "ANATOMY", 29, 45], ["different", "OBSERVATION_MODIFIER", 49, 58], ["significantly", "OBSERVATION_MODIFIER", 88, 101], ["different", "OBSERVATION_MODIFIER", 102, 111], ["fewer", "OBSERVATION_MODIFIER", 168, 173], ["lesions", "OBSERVATION", 174, 181], ["right lower lobe", "ANATOMY", 189, 205]]], ["Furthermore, the distribution of lesions in the left upper (F = 5.666, P = 0.001) and left lower lobes (F = 3.403, P = 0.021) in different age groups was statistically significant.", [["lesions", "ANATOMY", 33, 40], ["left upper", "ANATOMY", 48, 58], ["left lower lobes", "ANATOMY", 86, 102], ["lesions", "PATHOLOGICAL_FORMATION", 33, 40], ["upper", "ORGAN", 53, 58], ["lesions in the left upper (F", "PROBLEM", 33, 61], ["P", "TEST", 71, 72], ["= 0.001) and left lower lobes", "PROBLEM", 73, 102], ["P", "TEST", 115, 116], ["distribution", "OBSERVATION_MODIFIER", 17, 29], ["lesions", "OBSERVATION", 33, 40], ["left", "ANATOMY_MODIFIER", 48, 52], ["upper", "ANATOMY_MODIFIER", 53, 58], ["left lower lobes", "ANATOMY", 86, 102], ["significant", "OBSERVATION_MODIFIER", 168, 179]]], ["Among them, patients in group A and B showed less often lies in the left upper lobe compared to group C (P = 0.004, P = 0.002) and D (P = 0.011, P = 0.013).", [["left upper lobe", "ANATOMY", 68, 83], ["patients", "ORGANISM", 12, 20], ["B", "CANCER", 36, 37], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 73, 83], ["patients", "SPECIES", 12, 20], ["P", "TEST", 105, 106], ["P", "TEST", 116, 117], ["D (P", "TEST", 131, 135], ["P", "TEST", 145, 146], ["left upper lobe", "ANATOMY", 68, 83]]], ["The involvement of lesions in the left lower lobe of patients in groups A (P = 0.003) and B (P = 0.048) was lower than that of patients in group C. In general, younger patients (especially group A) have fewer lung lesions than older patients (group C or D), which is reflected in any lobe (right upper lobe, right middle lobe, right lower lobe, left upper lobe, and left lower lobe) of the entire lung.", [["lesions", "ANATOMY", 19, 26], ["left lower lobe", "ANATOMY", 34, 49], ["lung lesions", "ANATOMY", 209, 221], ["lobe", "ANATOMY", 284, 288], ["right upper lobe", "ANATOMY", 290, 306], ["right middle lobe", "ANATOMY", 308, 325], ["right lower lobe", "ANATOMY", 327, 343], ["left upper lobe", "ANATOMY", 345, 360], ["left lower lobe", "ANATOMY", 366, 381], ["lung", "ANATOMY", 397, 401], ["lung lesions", "DISEASE", 209, 221], ["lesions", "PATHOLOGICAL_FORMATION", 19, 26], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 39, 49], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 127, 135], ["patients", "ORGANISM", 168, 176], ["lung lesions", "CANCER", 209, 221], ["patients", "ORGANISM", 233, 241], ["lobe", "ORGAN", 284, 288], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 296, 306], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 314, 325], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 333, 343], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 350, 360], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 371, 381], ["lung", "ORGAN", 397, 401], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 168, 176], ["patients", "SPECIES", 233, 241], ["lesions in the left lower lobe", "PROBLEM", 19, 49], ["fewer lung lesions", "PROBLEM", 203, 221], ["any lobe (right upper lobe, right middle lobe, right lower lobe, left upper lobe, and left lower lobe", "PROBLEM", 280, 381], ["lesions", "OBSERVATION", 19, 26], ["left lower lobe", "ANATOMY", 34, 49], ["fewer", "OBSERVATION_MODIFIER", 203, 208], ["lung", "ANATOMY", 209, 213], ["lesions", "OBSERVATION", 214, 221], ["lobe", "ANATOMY_MODIFIER", 284, 288], ["right upper lobe", "ANATOMY", 290, 306], ["right middle lobe", "ANATOMY", 308, 325], ["right lower lobe", "ANATOMY", 327, 343], ["left upper lobe", "ANATOMY", 345, 360], ["left lower lobe", "ANATOMY", 366, 381], ["entire", "ANATOMY_MODIFIER", 390, 396], ["lung", "ANATOMY", 397, 401]]], ["But, the number of lesions in the left upper and lower lobes of infected patients was not statistically significant between groups A and B and groups C and D (P > 0.05).HRCT evaluation ::: ResultsOverall, 566 (80.7 %) of 701 lesions were located in the peripheral zone.", [["lesions", "ANATOMY", 19, 26], ["left upper", "ANATOMY", 34, 44], ["lower lobes", "ANATOMY", 49, 60], ["lesions", "ANATOMY", 225, 232], ["peripheral zone", "ANATOMY", 253, 268], ["lesions", "PATHOLOGICAL_FORMATION", 19, 26], ["left upper", "ORGAN", 34, 44], ["lower lobes", "ORGAN", 49, 60], ["patients", "ORGANISM", 73, 81], ["lesions", "CANCER", 225, 232], ["peripheral zone", "MULTI-TISSUE_STRUCTURE", 253, 268], ["patients", "SPECIES", 73, 81], ["lesions in the left upper and lower lobes", "PROBLEM", 19, 60], ["A and B and groups C and D (P", "TEST", 131, 160], ["HRCT evaluation", "TEST", 169, 184], ["ResultsOverall", "TEST", 189, 203], ["lesions", "PROBLEM", 225, 232], ["number", "OBSERVATION_MODIFIER", 9, 15], ["lesions", "OBSERVATION", 19, 26], ["left", "ANATOMY_MODIFIER", 34, 38], ["upper", "ANATOMY_MODIFIER", 39, 44], ["lower lobes", "ANATOMY", 49, 60], ["infected", "OBSERVATION", 64, 72], ["lesions", "OBSERVATION", 225, 232], ["peripheral", "ANATOMY_MODIFIER", 253, 263], ["zone", "ANATOMY_MODIFIER", 264, 268]]], ["The involvement of peripheral lung lesions in group A was less than that in groups C (P = 0.001) and D (P = 0.005) (Table 4).", [["peripheral lung lesions", "ANATOMY", 19, 42], ["peripheral lung lesions", "DISEASE", 19, 42], ["peripheral lung lesions", "PATHOLOGICAL_FORMATION", 19, 42], ["peripheral lung lesions", "PROBLEM", 19, 42], ["P", "TEST", 86, 87], ["D (P", "TEST", 101, 105], ["peripheral", "ANATOMY_MODIFIER", 19, 29], ["lung", "ANATOMY", 30, 34], ["lesions", "OBSERVATION", 35, 42]]], ["The number of lesions distributed within this area in patients in group B were also less than those in patients in group C (P = 0.009).", [["lesions", "ANATOMY", 14, 21], ["area", "ANATOMY", 46, 50], ["lesions", "PATHOLOGICAL_FORMATION", 14, 21], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 103, 111], ["lesions", "PROBLEM", 14, 21], ["number", "OBSERVATION_MODIFIER", 4, 10], ["lesions", "OBSERVATION", 14, 21], ["area", "OBSERVATION_MODIFIER", 46, 50]]], ["There was no significant difference in the distribution of lesions in the central zone between patients of different ages (P > 0.05).", [["lesions", "ANATOMY", 59, 66], ["central zone", "ANATOMY", 74, 86], ["lesions", "PATHOLOGICAL_FORMATION", 59, 66], ["central zone", "TISSUE", 74, 86], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["lesions in the central zone", "PROBLEM", 59, 86], ["P", "TEST", 123, 124], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["distribution", "OBSERVATION_MODIFIER", 43, 55], ["lesions", "OBSERVATION", 59, 66], ["central", "ANATOMY_MODIFIER", 74, 81], ["zone", "ANATOMY_MODIFIER", 82, 86]]], ["In addition, lesions involving both the peripheral and central zones were more common in patients in group D than in those in group B (P = 0.049).HRCT evaluation ::: ResultsWe also analyzed the density characteristics of each lesion, as detailed in Table 5.", [["lesions", "ANATOMY", 13, 20], ["peripheral", "ANATOMY", 40, 50], ["central zones", "ANATOMY", 55, 68], ["lesion", "ANATOMY", 226, 232], ["lesions", "PATHOLOGICAL_FORMATION", 13, 20], ["peripheral", "TISSUE", 40, 50], ["central zones", "TISSUE", 55, 68], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["lesions", "PROBLEM", 13, 20], ["HRCT evaluation", "TEST", 146, 161], ["each lesion", "PROBLEM", 221, 232], ["lesions", "OBSERVATION", 13, 20], ["both", "ANATOMY_MODIFIER", 31, 35], ["peripheral", "ANATOMY_MODIFIER", 40, 50], ["central", "ANATOMY_MODIFIER", 55, 62], ["zones", "ANATOMY_MODIFIER", 63, 68], ["more", "OBSERVATION_MODIFIER", 74, 78], ["common", "OBSERVATION_MODIFIER", 79, 85], ["density", "OBSERVATION_MODIFIER", 194, 201], ["each", "OBSERVATION_MODIFIER", 221, 225], ["lesion", "OBSERVATION", 226, 232]]], ["GGO is a commonly observed HRCT finding in lung lesions in patients (Fig. 1).", [["lung lesions", "ANATOMY", 43, 55], ["GGO", "DISEASE", 0, 3], ["lung lesions", "DISEASE", 43, 55], ["lung lesions", "CANCER", 43, 55], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["GGO", "PROBLEM", 0, 3], ["lung lesions", "PROBLEM", 43, 55], ["lung", "ANATOMY", 43, 47], ["lesions", "OBSERVATION", 48, 55]]], ["In this study, the most common lesions, 342 (48.8 %), were GGO with a crazy paving pattern or interlobular septa thickening were the most common (Fig. 2).", [["lesions", "ANATOMY", 31, 38], ["interlobular septa", "ANATOMY", 94, 112], ["GGO", "DISEASE", 59, 62], ["lesions", "CANCER", 31, 38], ["interlobular septa", "MULTI-TISSUE_STRUCTURE", 94, 112], ["this study", "TEST", 3, 13], ["the most common lesions", "PROBLEM", 15, 38], ["GGO", "TEST", 59, 62], ["a crazy paving pattern", "PROBLEM", 68, 90], ["interlobular septa thickening", "PROBLEM", 94, 123], ["most", "OBSERVATION_MODIFIER", 19, 23], ["common", "OBSERVATION_MODIFIER", 24, 30], ["lesions", "OBSERVATION", 31, 38], ["crazy", "OBSERVATION_MODIFIER", 70, 75], ["interlobular", "ANATOMY_MODIFIER", 94, 106], ["septa", "ANATOMY_MODIFIER", 107, 112], ["thickening", "OBSERVATION", 113, 123]]], ["The relative representation of GGO with a crazy paving and interlobular septal thickening were more common in group C and D than in groups A(P = 0.002, P = 0.003) and B (P < 0.001, P = 0.001).", [["interlobular septal", "ANATOMY", 59, 78], ["GGO", "DISEASE", 31, 34], ["GGO", "CANCER", 31, 34], ["interlobular septal", "MULTI-TISSUE_STRUCTURE", 59, 78], ["GGO", "PROBLEM", 31, 34], ["a crazy paving", "PROBLEM", 40, 54], ["interlobular septal thickening", "PROBLEM", 59, 89], ["P", "TEST", 141, 142], ["P", "TEST", 152, 153], ["B (P", "TEST", 167, 171], ["P", "TEST", 181, 182], ["GGO", "OBSERVATION", 31, 34], ["crazy", "OBSERVATION_MODIFIER", 42, 47], ["interlobular", "ANATOMY_MODIFIER", 59, 71], ["septal", "ANATOMY_MODIFIER", 72, 78], ["thickening", "OBSERVATION", 79, 89], ["more", "OBSERVATION_MODIFIER", 95, 99], ["common", "OBSERVATION_MODIFIER", 100, 106]]], ["The density characteristics of the lesions were not significantly different between groups A and B, and between groups C and D (P > 0.05).", [["lesions", "ANATOMY", 35, 42], ["lesions", "PATHOLOGICAL_FORMATION", 35, 42], ["the lesions", "PROBLEM", 31, 42], ["groups C and D (P", "TEST", 112, 129], ["density", "OBSERVATION", 4, 11], ["lesions", "OBSERVATION", 35, 42], ["significantly different", "OBSERVATION_MODIFIER", 52, 75]]], ["In addition, there was no statistically significant difference among PGGO, mixed GGO with consolidation <50 % and mixed GGO with consolidation \u226550 % (Fig. 3, Fig. 4), with complete consolidation (Fig. 5) in the different age groups (P > 0.05).HRCT evaluation ::: ResultsThis study showed that HRCT image lesions size in all patients of 1\u22123 cm (49.4 %) were most common, followed by <1 cm (32.4 %).", [["lesions", "ANATOMY", 304, 311], ["GGO", "DISEASE", 81, 84], ["GGO", "DISEASE", 120, 123], ["PGGO", "SIMPLE_CHEMICAL", 69, 73], ["lesions", "PATHOLOGICAL_FORMATION", 304, 311], ["patients", "ORGANISM", 324, 332], ["patients", "SPECIES", 324, 332], ["mixed GGO", "PROBLEM", 75, 84], ["consolidation", "PROBLEM", 90, 103], ["mixed GGO", "PROBLEM", 114, 123], ["consolidation", "PROBLEM", 129, 142], ["complete consolidation (Fig. 5", "PROBLEM", 172, 202], ["HRCT evaluation", "TEST", 243, 258], ["This study", "TEST", 270, 280], ["HRCT image lesions size", "TEST", 293, 316], ["no", "UNCERTAINTY", 23, 25], ["mixed", "OBSERVATION_MODIFIER", 75, 80], ["GGO", "OBSERVATION", 81, 84], ["consolidation", "OBSERVATION", 90, 103], ["mixed", "OBSERVATION_MODIFIER", 114, 119], ["GGO", "OBSERVATION", 120, 123], ["consolidation", "OBSERVATION", 129, 142], ["complete", "OBSERVATION_MODIFIER", 172, 180], ["consolidation", "OBSERVATION", 181, 194], ["lesions", "OBSERVATION", 304, 311], ["size", "OBSERVATION_MODIFIER", 312, 316], ["all", "OBSERVATION_MODIFIER", 320, 323], ["1\u22123 cm", "OBSERVATION_MODIFIER", 336, 342]]], ["Lesion sizes across different age groups are shown in Table 6.", [["Lesion", "ANATOMY", 0, 6], ["Lesion sizes", "PROBLEM", 0, 12], ["sizes", "OBSERVATION_MODIFIER", 7, 12], ["different", "OBSERVATION_MODIFIER", 20, 29]]], ["The differences between the lesions size of 1\u22123 cm, 3\u22125 cm, 5\u201310 cm, and \u226510 cm was statistically significant (P < 0.05).", [["lesions", "ANATOMY", 28, 35], ["lesions", "CANCER", 28, 35], ["lesions", "OBSERVATION_MODIFIER", 28, 35], ["size", "OBSERVATION_MODIFIER", 36, 40], ["1\u22123 cm", "OBSERVATION_MODIFIER", 44, 50], ["3\u22125 cm", "OBSERVATION_MODIFIER", 52, 58], ["5\u201310 cm", "OBSERVATION_MODIFIER", 60, 67], ["10 cm", "OBSERVATION_MODIFIER", 74, 79], ["significant", "OBSERVATION_MODIFIER", 98, 109]]], ["There were no statistically significant differences between the lesions size of <1 cm at different ages (P > 0.05).", [["lesions", "ANATOMY", 64, 71], ["lesions", "PATHOLOGICAL_FORMATION", 64, 71], ["statistically significant differences between the lesions size", "PROBLEM", 14, 76], ["P", "TEST", 105, 106], ["no", "UNCERTAINTY", 11, 13], ["statistically", "OBSERVATION_MODIFIER", 14, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["differences", "OBSERVATION_MODIFIER", 40, 51], ["lesions", "OBSERVATION", 64, 71], ["size", "OBSERVATION_MODIFIER", 72, 76], ["<1 cm", "OBSERVATION_MODIFIER", 80, 85]]], ["The lesions size of 1\u22123 cm was more common in groups C and D than in group A (P = 0.003, P = 0.006) and group B (P = 0.01, P = 0.034).", [["lesions", "ANATOMY", 4, 11], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["The lesions size", "PROBLEM", 0, 16], ["P", "TEST", 78, 79], ["P", "TEST", 89, 90], ["group B (P", "TEST", 104, 114], ["P", "TEST", 123, 124], ["lesions", "OBSERVATION", 4, 11], ["size", "OBSERVATION_MODIFIER", 12, 16], ["1\u22123 cm", "OBSERVATION_MODIFIER", 20, 26], ["common", "OBSERVATION_MODIFIER", 36, 42]]], ["The lesions size of 3\u22125 cm was more common in group C than in group B (P = 0.004).", [["lesions", "ANATOMY", 4, 11], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["The lesions size", "PROBLEM", 0, 16], ["lesions", "OBSERVATION", 4, 11], ["size", "OBSERVATION_MODIFIER", 12, 16], ["3\u22125 cm", "OBSERVATION_MODIFIER", 20, 26], ["more common", "OBSERVATION_MODIFIER", 31, 42]]], ["For the lesions size of 5\u201310 cm and \u226510 cm in size, group D had greater numbers of lesions than group B (P < 0.001, P = 0.008) and group C (P = 0.006, P = 0.011).HRCT evaluation ::: ResultsWe assessed the scans for signs of air bronchogram in each patient's lesion (Fig. 2).", [["lesions", "ANATOMY", 8, 15], ["lesions", "ANATOMY", 83, 90], ["lesion", "ANATOMY", 258, 264], ["lesions", "CANCER", 8, 15], ["lesions", "PATHOLOGICAL_FORMATION", 83, 90], ["patient", "ORGANISM", 248, 255], ["patient", "SPECIES", 248, 255], ["the lesions size", "PROBLEM", 4, 20], ["greater numbers of lesions", "PROBLEM", 64, 90], ["P", "TEST", 105, 106], ["P", "TEST", 116, 117], ["group C", "TEST", 131, 138], ["P", "TEST", 140, 141], ["P", "TEST", 151, 152], ["HRCT evaluation", "TEST", 162, 177], ["the scans", "TEST", 201, 210], ["air bronchogram in each patient's lesion", "PROBLEM", 224, 264], ["lesions", "OBSERVATION", 8, 15], ["size", "OBSERVATION_MODIFIER", 16, 20], ["5\u201310 cm", "OBSERVATION_MODIFIER", 24, 31], ["10 cm", "OBSERVATION_MODIFIER", 37, 42], ["size", "OBSERVATION_MODIFIER", 46, 50], ["group D", "OBSERVATION_MODIFIER", 52, 59], ["greater", "OBSERVATION_MODIFIER", 64, 71], ["numbers", "OBSERVATION_MODIFIER", 72, 79], ["lesions", "OBSERVATION", 83, 90], ["air bronchogram", "OBSERVATION", 224, 239], ["lesion", "OBSERVATION", 258, 264]]], ["There were no signs of air bronchogram in any of the lesions in group A. Groups D and C were found to have more lesions with air bronchogram (161 and 148 lesions, respectively).", [["lesions", "ANATOMY", 53, 60], ["lesions", "ANATOMY", 112, 119], ["lesions", "ANATOMY", 154, 161], ["lesions", "PATHOLOGICAL_FORMATION", 53, 60], ["lesions", "PATHOLOGICAL_FORMATION", 112, 119], ["lesions", "PATHOLOGICAL_FORMATION", 154, 161], ["air bronchogram", "PROBLEM", 23, 38], ["the lesions", "PROBLEM", 49, 60], ["group A. Groups D and C", "TEST", 64, 87], ["more lesions", "PROBLEM", 107, 119], ["air bronchogram (161 and 148 lesions", "PROBLEM", 125, 161], ["no signs of", "UNCERTAINTY", 11, 22], ["air bronchogram", "OBSERVATION", 23, 38], ["lesions", "OBSERVATION", 53, 60], ["more", "OBSERVATION_MODIFIER", 107, 111], ["lesions", "OBSERVATION", 112, 119], ["air bronchogram", "OBSERVATION", 125, 140]]], ["The mean number of lesions associated with air bronchogram signs in group C and D were 6.7 \u00b1 6.4 and 7.4 \u00b1 5.6, respectively, which was significantly more than those in group B (1.9 \u00b1 2.6) (P < 0.001 and P < 0.001, respectively).HRCT evaluation ::: ResultsOne of the 98 patients in this study was found to have bilateral pleural effusion.", [["lesions", "ANATOMY", 19, 26], ["air bronchogram", "ANATOMY", 43, 58], ["pleural", "ANATOMY", 321, 328], ["pleural effusion", "DISEASE", 321, 337], ["lesions", "PATHOLOGICAL_FORMATION", 19, 26], ["patients", "ORGANISM", 270, 278], ["pleural", "ORGAN", 321, 328], ["patients", "SPECIES", 270, 278], ["lesions", "PROBLEM", 19, 26], ["air bronchogram signs", "TEST", 43, 64], ["group C and D", "TEST", 68, 81], ["P", "TEST", 190, 191], ["P", "TEST", 204, 205], ["HRCT evaluation", "TEST", 229, 244], ["this study", "TEST", 282, 292], ["bilateral pleural effusion", "PROBLEM", 311, 337], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["lesions", "OBSERVATION", 19, 26], ["air bronchogram", "OBSERVATION", 43, 58], ["bilateral", "ANATOMY_MODIFIER", 311, 320], ["pleural", "ANATOMY", 321, 328], ["effusion", "OBSERVATION", 329, 337]]], ["A 56-year-old male presented with no underlying disease.", [["male", "ORGANISM", 14, 18], ["underlying disease", "PROBLEM", 37, 55], ["no", "UNCERTAINTY", 34, 36], ["disease", "OBSERVATION", 48, 55]]], ["His HRCT scan results revealed 1 lesion, located in the left lower lobe and peripheral zone, with PGGO, which appeared as a <1 cm small nodular shadow.HRCT evaluation ::: ResultsNo signs of hilar or mediastinal lymphadenopathy were found in any of the patients.DiscussionIn this study, fever was found to be the most common clinical manifestation (87.8 %) in 86/98 patients.", [["lesion", "ANATOMY", 33, 39], ["left lower lobe", "ANATOMY", 56, 71], ["peripheral zone", "ANATOMY", 76, 91], ["hilar", "ANATOMY", 190, 195], ["mediastinal lymphadenopathy", "ANATOMY", 199, 226], ["lymphadenopathy", "DISEASE", 211, 226], ["fever", "DISEASE", 286, 291], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 61, 71], ["peripheral zone", "TISSUE", 76, 91], ["PGGO", "CANCER", 98, 102], ["hilar", "CANCER", 190, 195], ["patients", "ORGANISM", 252, 260], ["patients", "ORGANISM", 365, 373], ["patients", "SPECIES", 252, 260], ["patients", "SPECIES", 365, 373], ["His HRCT scan", "TEST", 0, 13], ["1 lesion", "PROBLEM", 31, 39], ["PGGO", "PROBLEM", 98, 102], ["a <1 cm small nodular shadow", "PROBLEM", 122, 150], ["HRCT evaluation", "TEST", 151, 166], ["hilar or mediastinal lymphadenopathy", "PROBLEM", 190, 226], ["this study", "TEST", 274, 284], ["fever", "PROBLEM", 286, 291], ["lesion", "OBSERVATION", 33, 39], ["left lower lobe", "ANATOMY", 56, 71], ["peripheral", "ANATOMY_MODIFIER", 76, 86], ["zone", "ANATOMY_MODIFIER", 87, 91], ["<1 cm", "OBSERVATION_MODIFIER", 124, 129], ["small", "OBSERVATION_MODIFIER", 130, 135], ["nodular", "OBSERVATION_MODIFIER", 136, 143], ["shadow", "OBSERVATION", 144, 150], ["No signs of", "UNCERTAINTY", 178, 189], ["hilar", "ANATOMY", 190, 195], ["mediastinal", "ANATOMY", 199, 210], ["lymphadenopathy", "OBSERVATION", 211, 226]]], ["Most patients (79.6 %) had a history of direct or indirect contact with people from Wuhan, China, and were found to have abnormally elevated CRP levels (52.0 %) and SSA (76.5 %).", [["patients", "ORGANISM", 5, 13], ["people", "ORGANISM", 72, 78], ["CRP", "GENE_OR_GENE_PRODUCT", 141, 144], ["CRP", "PROTEIN", 141, 144], ["patients", "SPECIES", 5, 13], ["people", "SPECIES", 72, 78], ["abnormally elevated CRP levels", "PROBLEM", 121, 151], ["SSA", "TEST", 165, 168], ["abnormally", "OBSERVATION_MODIFIER", 121, 131], ["elevated", "OBSERVATION", 132, 140]]], ["This information is critical for the diagnosis of COVID-19.DiscussionThis study also described common chest HRCT imaging features in patients with COVID-19 infection and distinguished imaging signs between patients of different ages.", [["infection", "DISEASE", 156, 165], ["chest HRCT", "PATHOLOGICAL_FORMATION", 102, 112], ["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 206, 214], ["COVID", "TEST", 50, 55], ["This study", "TEST", 69, 79], ["common chest HRCT imaging", "TEST", 95, 120], ["COVID", "TEST", 147, 152], ["19 infection", "PROBLEM", 153, 165], ["imaging signs", "TEST", 184, 197], ["chest", "ANATOMY", 102, 107], ["infection", "OBSERVATION", 156, 165]]], ["Moreover, this study was detailed to the level of single lesions, with a close analysis of each lesion\u2019s size, density, lung lobe distribution, and lung field distribution.DiscussionIn the chest HRCT manifestations patients in this study, patchy GGO and consolidation were common features.", [["lesions", "ANATOMY", 57, 64], ["lesion", "ANATOMY", 96, 102], ["lung lobe", "ANATOMY", 120, 129], ["lung", "ANATOMY", 148, 152], ["GGO", "DISEASE", 246, 249], ["lesions", "CANCER", 57, 64], ["lung lobe", "MULTI-TISSUE_STRUCTURE", 120, 129], ["lung", "ORGAN", 148, 152], ["chest HRCT", "CANCER", 189, 199], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223], ["this study", "TEST", 10, 20], ["single lesions", "PROBLEM", 50, 64], ["a close analysis", "TEST", 71, 87], ["density, lung lobe distribution, and lung field distribution", "PROBLEM", 111, 171], ["the chest HRCT manifestations", "TEST", 185, 214], ["this study", "TEST", 227, 237], ["patchy GGO", "PROBLEM", 239, 249], ["consolidation", "PROBLEM", 254, 267], ["lesions", "OBSERVATION", 57, 64], ["lesion", "OBSERVATION", 96, 102], ["size", "OBSERVATION_MODIFIER", 105, 109], ["density", "OBSERVATION", 111, 118], ["lung", "ANATOMY", 120, 124], ["lobe", "ANATOMY_MODIFIER", 125, 129], ["distribution", "OBSERVATION_MODIFIER", 130, 142], ["lung", "ANATOMY", 148, 152], ["field", "OBSERVATION_MODIFIER", 153, 158], ["distribution", "OBSERVATION_MODIFIER", 159, 171], ["chest", "ANATOMY", 189, 194], ["patchy", "OBSERVATION_MODIFIER", 239, 245], ["GGO", "OBSERVATION", 246, 249], ["consolidation", "OBSERVATION", 254, 267]]], ["Similar manifestations were also present in severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) infections, as shown in previous studies [8,9].", [["acute respiratory syndrome", "DISEASE", 51, 77], ["SARS", "DISEASE", 79, 83], ["Middle East respiratory syndrome (MERS) infections", "DISEASE", 89, 139], ["Middle East respiratory syndrome (MERS)", "SPECIES", 89, 128], ["Similar manifestations", "PROBLEM", 0, 22], ["severe acute respiratory syndrome", "PROBLEM", 44, 77], ["SARS)", "PROBLEM", 79, 84], ["Middle East respiratory syndrome (MERS) infections", "PROBLEM", 89, 139], ["previous studies", "TEST", 153, 169], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["respiratory syndrome", "OBSERVATION", 57, 77], ["Middle", "ANATOMY_MODIFIER", 89, 95], ["respiratory syndrome", "OBSERVATION", 101, 121], ["infections", "OBSERVATION", 129, 139]]], ["In this study, the lesions of patients were mainly located in the lower lobe of the right lung.", [["lesions", "ANATOMY", 19, 26], ["lower lobe", "ANATOMY", 66, 76], ["right lung", "ANATOMY", 84, 94], ["lesions", "PATHOLOGICAL_FORMATION", 19, 26], ["patients", "ORGANISM", 30, 38], ["lower lobe", "ORGAN", 66, 76], ["lung", "ORGAN", 90, 94], ["patients", "SPECIES", 30, 38], ["this study", "TEST", 3, 13], ["lesions", "OBSERVATION", 19, 26], ["lower lobe", "ANATOMY_MODIFIER", 66, 76], ["right", "ANATOMY_MODIFIER", 84, 89], ["lung", "ANATOMY", 90, 94]]], ["This finding may be related to the thick and short physiological structure of the right lower lobe bronchus, which may have allowed the virus to enter this area more easily.", [["right lower lobe bronchus", "ANATOMY", 82, 107], ["lower lobe bronchus", "MULTI-TISSUE_STRUCTURE", 88, 107], ["the thick and short physiological structure of the right lower lobe bronchus", "PROBLEM", 31, 107], ["the virus", "PROBLEM", 132, 141], ["may be related to", "UNCERTAINTY", 13, 30], ["thick", "OBSERVATION", 35, 40], ["short", "OBSERVATION_MODIFIER", 45, 50], ["right lower lobe bronchus", "ANATOMY", 82, 107], ["virus", "OBSERVATION", 136, 141]]], ["In addition, whether the air bronchogram is associated with the central representation needs further study.", [["the air bronchogram", "PROBLEM", 21, 40], ["further study", "TEST", 93, 106], ["air bronchogram", "OBSERVATION", 25, 40], ["central", "OBSERVATION_MODIFIER", 64, 71]]], ["The lesions of patients were mostly distributed in peripheral zone of the lung (80.7 %), probably because the virus mainly affects the terminal bronchioles and lung parenchyma around the respiratory bronchioles in the early stage [10].", [["lesions", "ANATOMY", 4, 11], ["peripheral zone", "ANATOMY", 51, 66], ["lung", "ANATOMY", 74, 78], ["terminal bronchioles", "ANATOMY", 135, 155], ["lung parenchyma", "ANATOMY", 160, 175], ["respiratory bronchioles", "ANATOMY", 187, 210], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["patients", "ORGANISM", 15, 23], ["peripheral zone", "MULTI-TISSUE_STRUCTURE", 51, 66], ["lung", "ORGAN", 74, 78], ["terminal bronchioles", "MULTI-TISSUE_STRUCTURE", 135, 155], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 160, 175], ["respiratory bronchioles", "MULTI-TISSUE_STRUCTURE", 187, 210], ["patients", "SPECIES", 15, 23], ["the virus", "PROBLEM", 106, 115], ["lesions", "OBSERVATION", 4, 11], ["mostly", "OBSERVATION_MODIFIER", 29, 35], ["distributed", "OBSERVATION_MODIFIER", 36, 47], ["peripheral", "ANATOMY_MODIFIER", 51, 61], ["zone", "ANATOMY_MODIFIER", 62, 66], ["lung", "ANATOMY", 74, 78], ["virus", "OBSERVATION", 110, 115], ["terminal", "ANATOMY_MODIFIER", 135, 143], ["bronchioles", "ANATOMY", 144, 155], ["lung", "ANATOMY", 160, 164], ["parenchyma", "ANATOMY_MODIFIER", 165, 175], ["respiratory bronchioles", "ANATOMY", 187, 210], ["early", "OBSERVATION_MODIFIER", 218, 223], ["stage", "OBSERVATION_MODIFIER", 224, 229]]], ["In patients, GGO with a crazy paving pattern or interlobular septum thickening was the most common sign (48.8 %), with PGGO (33.2 %) the second-most common.", [["interlobular septum", "ANATOMY", 48, 67], ["GGO", "DISEASE", 13, 16], ["PGGO", "DISEASE", 119, 123], ["patients", "ORGANISM", 3, 11], ["interlobular septum", "MULTI-TISSUE_STRUCTURE", 48, 67], ["patients", "SPECIES", 3, 11], ["GGO", "PROBLEM", 13, 16], ["a crazy paving pattern", "PROBLEM", 22, 44], ["interlobular septum thickening", "PROBLEM", 48, 78], ["PGGO", "TEST", 119, 123], ["GGO", "OBSERVATION", 13, 16], ["interlobular", "ANATOMY_MODIFIER", 48, 60], ["septum", "ANATOMY_MODIFIER", 61, 67], ["thickening", "OBSERVATION", 68, 78], ["most common", "OBSERVATION_MODIFIER", 144, 155]]], ["The lesions were mostly 1\u22123 cm patchy or nodular opacity (49.4 %), and 56.2 % of the lesions were accompanied with signs of air bronchogram.DiscussionThere were fewer lesions in younger adolescents and adolescents than in middle aged and older patients.", [["lesions", "ANATOMY", 4, 11], ["nodular opacity", "ANATOMY", 41, 56], ["lesions", "ANATOMY", 85, 92], ["lesions", "ANATOMY", 167, 174], ["lesions", "CANCER", 4, 11], ["nodular opacity", "CANCER", 41, 56], ["lesions", "PATHOLOGICAL_FORMATION", 85, 92], ["lesions", "PATHOLOGICAL_FORMATION", 167, 174], ["patients", "ORGANISM", 244, 252], ["adolescents", "SPECIES", 202, 213], ["patients", "SPECIES", 244, 252], ["The lesions", "PROBLEM", 0, 11], ["1\u22123 cm patchy or nodular opacity", "PROBLEM", 24, 56], ["the lesions", "PROBLEM", 81, 92], ["air bronchogram", "PROBLEM", 124, 139], ["fewer lesions", "PROBLEM", 161, 174], ["lesions", "OBSERVATION", 4, 11], ["mostly", "OBSERVATION_MODIFIER", 17, 23], ["1\u22123 cm", "OBSERVATION_MODIFIER", 24, 30], ["patchy", "OBSERVATION_MODIFIER", 31, 37], ["nodular", "OBSERVATION_MODIFIER", 41, 48], ["opacity", "OBSERVATION", 49, 56], ["lesions", "OBSERVATION", 85, 92], ["air bronchogram", "OBSERVATION", 124, 139], ["fewer", "OBSERVATION_MODIFIER", 161, 166], ["lesions", "OBSERVATION", 167, 174]]], ["The lesions showed varying age-related differences in distributions of the lung lobe and lung field.", [["lesions", "ANATOMY", 4, 11], ["lung lobe", "ANATOMY", 75, 84], ["lung", "ANATOMY", 89, 93], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["lung lobe", "MULTI-TISSUE_STRUCTURE", 75, 84], ["lung", "ORGAN", 89, 93], ["The lesions", "PROBLEM", 0, 11], ["lesions", "OBSERVATION", 4, 11], ["varying", "OBSERVATION_MODIFIER", 19, 26], ["lung", "ANATOMY", 75, 79], ["lobe", "ANATOMY_MODIFIER", 80, 84], ["lung", "ANATOMY", 89, 93], ["field", "ANATOMY_MODIFIER", 94, 99]]], ["With increase in age, the lesions appeared to be mostly GGO with interlobular septum thickening or a crazy paving pattern, and the possibility of the appearance of 5\u201310 cm large patchy opacity and \u226510 cm larger patchy opacity was likely to increase.", [["lesions", "ANATOMY", 26, 33], ["interlobular septum", "ANATOMY", 65, 84], ["GGO", "DISEASE", 56, 59], ["opacity", "DISEASE", 185, 192], ["opacity", "DISEASE", 218, 225], ["lesions", "PATHOLOGICAL_FORMATION", 26, 33], ["interlobular septum", "TISSUE", 65, 84], ["the lesions", "PROBLEM", 22, 33], ["GGO", "PROBLEM", 56, 59], ["interlobular septum thickening", "PROBLEM", 65, 95], ["a crazy paving pattern", "PROBLEM", 99, 121], ["5\u201310 cm large patchy opacity", "PROBLEM", 164, 192], ["\u226510 cm larger patchy opacity", "PROBLEM", 197, 225], ["increase", "OBSERVATION_MODIFIER", 5, 13], ["lesions", "OBSERVATION", 26, 33], ["appeared to be", "UNCERTAINTY", 34, 48], ["mostly", "OBSERVATION_MODIFIER", 49, 55], ["GGO", "OBSERVATION", 56, 59], ["interlobular", "ANATOMY_MODIFIER", 65, 77], ["septum", "ANATOMY_MODIFIER", 78, 84], ["thickening", "OBSERVATION", 85, 95], ["crazy", "OBSERVATION_MODIFIER", 101, 106], ["paving", "OBSERVATION_MODIFIER", 107, 113], ["pattern", "OBSERVATION_MODIFIER", 114, 121], ["5\u201310 cm", "OBSERVATION_MODIFIER", 164, 171], ["large", "OBSERVATION_MODIFIER", 172, 177], ["patchy", "OBSERVATION_MODIFIER", 178, 184], ["opacity", "OBSERVATION", 185, 192], ["10 cm", "OBSERVATION_MODIFIER", 198, 203], ["larger", "OBSERVATION_MODIFIER", 204, 210], ["patchy", "OBSERVATION_MODIFIER", 211, 217], ["opacity", "OBSERVATION", 218, 225], ["likely to", "UNCERTAINTY", 230, 239], ["increase", "OBSERVATION_MODIFIER", 240, 248]]], ["Our study findings showed that middle-aged and older patients had more severe lung involvement and lobe involvement and, at the same time, the lesions were accompanied more often by air bronchograms.", [["lung", "ANATOMY", 78, 82], ["lobe", "ANATOMY", 99, 103], ["lesions", "ANATOMY", 143, 150], ["patients", "ORGANISM", 53, 61], ["lung", "ORGAN", 78, 82], ["lobe", "ORGAN", 99, 103], ["lesions", "PATHOLOGICAL_FORMATION", 143, 150], ["patients", "SPECIES", 53, 61], ["Our study findings", "TEST", 0, 18], ["more severe lung involvement", "PROBLEM", 66, 94], ["lobe involvement", "PROBLEM", 99, 115], ["the lesions", "PROBLEM", 139, 150], ["air bronchograms", "PROBLEM", 182, 198], ["middle", "OBSERVATION_MODIFIER", 31, 37], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["lung", "ANATOMY", 78, 82], ["involvement", "OBSERVATION", 83, 94], ["lobe", "ANATOMY_MODIFIER", 99, 103], ["lesions", "OBSERVATION", 143, 150], ["air bronchograms", "OBSERVATION", 182, 198]]], ["Possible reasons for these findings are as follows: 1) adolescent cases are mostly third-generation infection cases, which may involve mainly family cluster cases.", [["infection", "DISEASE", 100, 109], ["third-generation infection cases", "PROBLEM", 83, 115], ["infection", "OBSERVATION", 100, 109]]], ["Furthermore, COVID-19 has weak virulence, resulting in lighter imaging signs in these patients [7]; 2) minors have immature lung structure development, resulting in atypical HRCT signs, and; 3) a COVID-19 attack on the immune system is more likely to cause diffuse alveolar damage and a large number of inflammatory exudations in middle-aged and older patients with more baseline diseases.", [["lung structure", "ANATOMY", 124, 138], ["immune system", "ANATOMY", 219, 232], ["alveolar", "ANATOMY", 265, 273], ["COVID-19", "CHEMICAL", 13, 21], ["alveolar damage", "DISEASE", 265, 280], ["COVID-19", "GENE_OR_GENE_PRODUCT", 13, 21], ["patients", "ORGANISM", 86, 94], ["lung", "ORGAN", 124, 128], ["alveolar", "TISSUE", 265, 273], ["patients", "ORGANISM", 352, 360], ["COVID", "PROTEIN", 13, 18], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 352, 360], ["COVID", "TEST", 13, 18], ["weak virulence", "PROBLEM", 26, 40], ["lighter imaging signs", "TEST", 55, 76], ["immature lung structure development", "PROBLEM", 115, 150], ["atypical HRCT signs", "PROBLEM", 165, 184], ["a COVID-19 attack on the immune system", "PROBLEM", 194, 232], ["diffuse alveolar damage", "PROBLEM", 257, 280], ["inflammatory exudations", "PROBLEM", 303, 326], ["more baseline diseases", "PROBLEM", 366, 388], ["immature", "OBSERVATION_MODIFIER", 115, 123], ["lung", "ANATOMY", 124, 128], ["atypical", "OBSERVATION_MODIFIER", 165, 173], ["HRCT signs", "OBSERVATION", 174, 184], ["more likely to cause", "UNCERTAINTY", 236, 256], ["diffuse", "OBSERVATION_MODIFIER", 257, 264], ["alveolar", "ANATOMY_MODIFIER", 265, 273], ["damage", "OBSERVATION", 274, 280], ["large", "OBSERVATION_MODIFIER", 287, 292], ["number", "OBSERVATION_MODIFIER", 293, 299], ["inflammatory", "OBSERVATION_MODIFIER", 303, 315], ["middle", "ANATOMY_MODIFIER", 330, 336], ["more baseline", "OBSERVATION_MODIFIER", 366, 379], ["diseases", "OBSERVATION", 380, 388]]], ["In one patient, bilateral pleural effusion was found, which may be due to the adjacent inflammation stimulating the pleura.DiscussionThese study findings are likely to help with understanding and evaluating the condition of infected patients of different ages, and provide insight into the possible subsequent evolution of the disease in infected patients of different ages, which should facilitate more accurate diagnosis and the development of treatment strategies.", [["pleural", "ANATOMY", 26, 33], ["pleura", "ANATOMY", 116, 122], ["pleural effusion", "DISEASE", 26, 42], ["inflammation", "DISEASE", 87, 99], ["patient", "ORGANISM", 7, 14], ["pleural", "ORGAN", 26, 33], ["pleura", "ORGAN", 116, 122], ["patients", "ORGANISM", 233, 241], ["patients", "ORGANISM", 347, 355], ["patient", "SPECIES", 7, 14], ["patients", "SPECIES", 233, 241], ["patients", "SPECIES", 347, 355], ["bilateral pleural effusion", "PROBLEM", 16, 42], ["the adjacent inflammation stimulating the pleura", "PROBLEM", 74, 122], ["These study", "TEST", 133, 144], ["the disease", "PROBLEM", 323, 334], ["treatment strategies", "TREATMENT", 446, 466], ["bilateral", "ANATOMY_MODIFIER", 16, 25], ["pleural", "ANATOMY", 26, 33], ["effusion", "OBSERVATION", 34, 42], ["may be due to", "UNCERTAINTY", 60, 73], ["inflammation", "OBSERVATION", 87, 99], ["pleura", "ANATOMY", 116, 122], ["disease", "OBSERVATION", 327, 334], ["infected", "OBSERVATION_MODIFIER", 338, 346]]], ["In this study, the key finding is that the middle-aged and elderly patients have the most severe representation of parenchymal findings, and follow with the morphological appearance that seems to be particularly limited in youngest group, which provides certain support for clinical individualized treatment of patients of different ages.", [["parenchymal", "ANATOMY", 115, 126], ["patients", "ORGANISM", 67, 75], ["parenchymal", "TISSUE", 115, 126], ["patients", "ORGANISM", 311, 319], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 311, 319], ["this study", "TEST", 3, 13], ["parenchymal findings", "PROBLEM", 115, 135], ["clinical individualized treatment", "TREATMENT", 274, 307], ["middle", "ANATOMY_MODIFIER", 43, 49], ["most severe", "OBSERVATION_MODIFIER", 85, 96], ["parenchymal", "ANATOMY_MODIFIER", 115, 126], ["findings", "OBSERVATION", 127, 135]]], ["Chest HRCT scans are helpful for screening, treatment management, and follow-up evaluation of suspected patients with COVID-19 infections, and they are complementary to clinical symptoms (fever), epidemiological history (direct or indirect exposure to people from Wuhan), and laboratory indicators.", [["infections", "DISEASE", 127, 137], ["fever", "DISEASE", 188, 193], ["patients", "ORGANISM", 104, 112], ["people", "ORGANISM", 252, 258], ["patients", "SPECIES", 104, 112], ["people", "SPECIES", 252, 258], ["Chest HRCT scans", "TEST", 0, 16], ["screening", "TEST", 33, 42], ["treatment management", "TREATMENT", 44, 64], ["follow-up evaluation", "TEST", 70, 90], ["COVID-19 infections", "PROBLEM", 118, 137], ["clinical symptoms", "PROBLEM", 169, 186], ["fever", "PROBLEM", 188, 193], ["infections", "OBSERVATION", 127, 137]]], ["Therefore, it is essential to make full use of chest HRCT scans to achieve a comprehensive diagnosis and guide treatment for patients with COVID-19 infection.", [["COVID-19", "CHEMICAL", 139, 147], ["infection", "DISEASE", 148, 157], ["chest", "ORGAN", 47, 52], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["chest HRCT scans", "TEST", 47, 63], ["guide treatment", "TREATMENT", 105, 120], ["COVID-19 infection", "PROBLEM", 139, 157], ["chest", "ANATOMY", 47, 52], ["infection", "OBSERVATION", 148, 157]]], ["It is worth noting that the epidemiological pre-test risk drives the diagnosis towards COVID-19, which otherwise does not have a specific pattern compared to any other infectious interstitial infiltrate with further diffuse alveolar damage (DAD) or organizing pneumonia (OP).DiscussionThis study had some limitations.", [["interstitial infiltrate", "ANATOMY", 179, 202], ["alveolar", "ANATOMY", 224, 232], ["alveolar damage", "DISEASE", 224, 239], ["DAD", "DISEASE", 241, 244], ["pneumonia", "DISEASE", 260, 269], ["OP", "DISEASE", 271, 273], ["COVID-19", "CELL", 87, 95], ["alveolar", "TISSUE", 224, 232], ["COVID", "TEST", 87, 92], ["any other infectious interstitial infiltrate", "PROBLEM", 158, 202], ["further diffuse alveolar damage (DAD)", "PROBLEM", 208, 245], ["organizing pneumonia", "PROBLEM", 249, 269], ["This study", "TEST", 285, 295], ["infectious", "OBSERVATION_MODIFIER", 168, 178], ["interstitial", "ANATOMY_MODIFIER", 179, 191], ["infiltrate", "OBSERVATION", 192, 202], ["diffuse", "OBSERVATION_MODIFIER", 216, 223], ["alveolar damage", "OBSERVATION", 224, 239], ["organizing", "OBSERVATION_MODIFIER", 249, 259], ["pneumonia", "OBSERVATION", 260, 269]]], ["First, there were fewer adolescent patients in the <18-year-old age group, which may have affected the results.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["fewer", "OBSERVATION_MODIFIER", 18, 23]]], ["Larger sample sizes are needed for further investigation.", [["Larger sample sizes", "TREATMENT", 0, 19], ["further investigation", "TEST", 35, 56], ["sizes", "OBSERVATION_MODIFIER", 14, 19]]], ["Second, the gradual dynamic evolution of the disease may be accompanied with weakening, enhancement, or transformation of the imaging signs, such as the absorption stage \u226514 days after the onset of the initial symptoms, with the crazy paving pattern gradually disappearing [6].", [["the disease", "PROBLEM", 41, 52], ["weakening", "PROBLEM", 77, 86], ["enhancement", "PROBLEM", 88, 99], ["the imaging signs", "TEST", 122, 139], ["the initial symptoms", "PROBLEM", 198, 218], ["gradual", "OBSERVATION_MODIFIER", 12, 19], ["dynamic", "OBSERVATION_MODIFIER", 20, 27], ["disease", "OBSERVATION", 45, 52], ["may be accompanied with", "UNCERTAINTY", 53, 76], ["weakening", "OBSERVATION", 77, 86], ["enhancement", "OBSERVATION_MODIFIER", 88, 99]]], ["Finally, it's worth noting that the HRCT is depicting one second within the entire development of COVID-19, therefore different patterns might be expected in patients that undergo follow up.", [["patients", "ORGANISM", 158, 166], ["COVID-19", "DNA", 98, 106], ["patients", "SPECIES", 158, 166], ["the HRCT", "TEST", 32, 40], ["COVID", "TEST", 98, 103]]], ["According to previous studies, the lesions are related to the evolution time:Discussionthey mainly manifests as GGO in the early stage (0\u20134 days),an increased crazy-paving pattern in the progressive stage (5\u20138 days), consolidation in the peak stage (9\u201313 days), gradient resolution of consolidation in the dissipative stage (\u226514 days) [6].DiscussionIn conclusion, age-related differences in chest HRCT scans were observed, such as the distribution, size, and density of lung lesions in patients with COVID-19 infection.", [["lesions", "ANATOMY", 35, 42], ["lung lesions", "ANATOMY", 470, 482], ["GGO", "DISEASE", 112, 115], ["lung lesions", "DISEASE", 470, 482], ["COVID-19", "CHEMICAL", 500, 508], ["infection", "DISEASE", 509, 518], ["lesions", "PATHOLOGICAL_FORMATION", 35, 42], ["chest HRCT", "MULTI-TISSUE_STRUCTURE", 391, 401], ["lung lesions", "CANCER", 470, 482], ["patients", "ORGANISM", 486, 494], ["patients", "SPECIES", 486, 494], ["previous studies", "TEST", 13, 29], ["the lesions", "PROBLEM", 31, 42], ["GGO", "PROBLEM", 112, 115], ["an increased crazy", "PROBLEM", 146, 164], ["consolidation in the peak stage", "PROBLEM", 217, 248], ["consolidation", "PROBLEM", 285, 298], ["chest HRCT scans", "TEST", 391, 407], ["lung lesions", "PROBLEM", 470, 482], ["COVID-19 infection", "PROBLEM", 500, 518], ["lesions", "OBSERVATION", 35, 42], ["GGO", "OBSERVATION", 112, 115], ["increased", "OBSERVATION_MODIFIER", 149, 158], ["crazy", "OBSERVATION", 159, 164], ["progressive", "OBSERVATION_MODIFIER", 187, 198], ["stage", "OBSERVATION_MODIFIER", 199, 204], ["consolidation", "OBSERVATION", 217, 230], ["peak stage", "OBSERVATION_MODIFIER", 238, 248], ["gradient", "OBSERVATION_MODIFIER", 262, 270], ["resolution", "OBSERVATION_MODIFIER", 271, 281], ["consolidation", "OBSERVATION", 285, 298], ["dissipative stage", "OBSERVATION_MODIFIER", 306, 323], ["chest", "ANATOMY", 391, 396], ["distribution", "OBSERVATION_MODIFIER", 435, 447], ["size", "OBSERVATION_MODIFIER", 449, 453], ["density", "OBSERVATION_MODIFIER", 459, 466], ["lung", "ANATOMY", 470, 474], ["lesions", "OBSERVATION", 475, 482], ["infection", "OBSERVATION", 509, 518]]], ["These lesions appeared to be milder in younger populations.CRediT authorship contribution statement", [["lesions", "ANATOMY", 6, 13], ["lesions", "PATHOLOGICAL_FORMATION", 6, 13], ["These lesions", "PROBLEM", 0, 13], ["lesions", "OBSERVATION", 6, 13], ["milder", "OBSERVATION_MODIFIER", 29, 35]]]], "b51446743acc3643136dfea62fcca8da0556bb85": [["IntroductionPorcine epidemic diarrhoea virus (PEDV) and transmissible gastroenteritis virus (TGEV) are members of the Coronaviridae family (Sestak and Saif, 2002) .", [["IntroductionPorcine epidemic diarrhoea virus", "DISEASE", 0, 44], ["transmissible gastroenteritis virus", "DISEASE", 56, 91], ["IntroductionPorcine epidemic diarrhoea virus", "ORGANISM", 0, 44], ["transmissible gastroenteritis virus", "ORGANISM", 56, 91], ["TGEV", "ORGANISM", 93, 97], ["epidemic diarrhoea virus", "SPECIES", 20, 44], ["transmissible gastroenteritis virus", "SPECIES", 56, 91], ["TGEV", "SPECIES", 93, 97], ["IntroductionPorcine epidemic diarrhoea virus", "SPECIES", 0, 44], ["PEDV", "SPECIES", 46, 50], ["transmissible gastroenteritis virus", "SPECIES", 56, 91], ["TGEV", "SPECIES", 93, 97], ["IntroductionPorcine epidemic diarrhoea virus", "PROBLEM", 0, 44], ["PEDV", "PROBLEM", 46, 50], ["transmissible gastroenteritis virus", "PROBLEM", 56, 91], ["diarrhoea virus", "OBSERVATION", 29, 44]]], ["They both replicate in the differentiated enterocytes covering the villi of the porcine small intestine (Kim and Chae, 2003) and cause acute enteritis in swine of all ages, which is characterised by vomiting, diarrhoea, and dehydration; the mortality rate in seronegative suckling piglets may reach 100% (Chae et al., 2000) .", [["enterocytes", "ANATOMY", 42, 53], ["villi", "ANATOMY", 67, 72], ["small intestine", "ANATOMY", 88, 103], ["acute enteritis", "DISEASE", 135, 150], ["vomiting", "DISEASE", 199, 207], ["diarrhoea", "DISEASE", 209, 218], ["dehydration", "DISEASE", 224, 235], ["enterocytes", "CELL", 42, 53], ["villi", "MULTI-TISSUE_STRUCTURE", 67, 72], ["porcine", "ORGANISM", 80, 87], ["small intestine", "ORGAN", 88, 103], ["piglets", "ORGANISM", 281, 288], ["differentiated enterocytes", "CELL_TYPE", 27, 53], ["porcine", "SPECIES", 80, 87], ["swine", "SPECIES", 154, 159], ["piglets", "SPECIES", 281, 288], ["swine", "SPECIES", 154, 159], ["acute enteritis", "PROBLEM", 135, 150], ["vomiting", "PROBLEM", 199, 207], ["diarrhoea", "PROBLEM", 209, 218], ["dehydration", "PROBLEM", 224, 235], ["the mortality rate", "PROBLEM", 237, 255], ["seronegative suckling piglets", "TREATMENT", 259, 288], ["differentiated enterocytes", "OBSERVATION", 27, 53], ["villi", "ANATOMY_MODIFIER", 67, 72], ["porcine", "ANATOMY_MODIFIER", 80, 87], ["small intestine", "ANATOMY", 88, 103], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["enteritis", "OBSERVATION", 141, 150], ["dehydration", "OBSERVATION_MODIFIER", 224, 235]]], ["Despite the similar clinical diseases and lesions induced, PEDV and TGEV are distinct viral entities.", [["lesions", "ANATOMY", 42, 49], ["lesions", "PATHOLOGICAL_FORMATION", 42, 49], ["TGEV", "ORGANISM", 68, 72], ["TGEV", "SPECIES", 68, 72], ["PEDV", "SPECIES", 59, 63], ["TGEV", "SPECIES", 68, 72], ["the similar clinical diseases", "PROBLEM", 8, 37], ["lesions", "PROBLEM", 42, 49], ["PEDV", "PROBLEM", 59, 63], ["TGEV", "PROBLEM", 68, 72], ["lesions", "OBSERVATION", 42, 49], ["distinct", "OBSERVATION_MODIFIER", 77, 85], ["viral entities", "OBSERVATION", 86, 100]]], ["PEDV is unable to grow in porcine cell cultures permissive to the growth of TGEV, such as PK15 cells, and is more closely related to the human respiratory coronavirus HCoV 229E than to TGEV according to the amino acid sequence of the membrane protein (Kim et al., 1999) .Enterocytes are connected to each other to form a barrier that separates the inside of the organism from its environment.", [["cell cultures", "ANATOMY", 34, 47], ["PK15 cells", "ANATOMY", 90, 100], ["membrane", "ANATOMY", 234, 242], ["Enterocytes", "ANATOMY", 271, 282], ["amino acid", "CHEMICAL", 207, 217], ["amino acid", "CHEMICAL", 207, 217], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["porcine", "ORGANISM", 26, 33], ["cell cultures", "CELL", 34, 47], ["TGEV", "ORGANISM", 76, 80], ["PK15 cells", "CELL", 90, 100], ["human", "ORGANISM", 137, 142], ["respiratory coronavirus HCoV 229E", "ORGANISM", 143, 176], ["TGEV", "ORGANISM", 185, 189], ["amino acid", "AMINO_ACID", 207, 217], ["membrane", "CELLULAR_COMPONENT", 234, 242], ["Enterocytes", "CELL", 271, 282], ["PEDV", "PROTEIN", 0, 4], ["porcine cell cultures", "CELL_LINE", 26, 47], ["PK15 cells", "CELL_LINE", 90, 100], ["amino acid sequence", "PROTEIN", 207, 226], ["membrane protein", "PROTEIN", 234, 250], ["Enterocytes", "CELL_TYPE", 271, 282], ["human", "SPECIES", 137, 142], ["respiratory coronavirus HCoV", "SPECIES", 143, 171], ["PEDV", "SPECIES", 0, 4], ["porcine", "SPECIES", 26, 33], ["TGEV", "SPECIES", 76, 80], ["human respiratory coronavirus", "SPECIES", 137, 166], ["TGEV", "SPECIES", 185, 189], ["PEDV", "PROBLEM", 0, 4], ["porcine cell cultures", "TEST", 26, 47], ["TGEV", "PROBLEM", 76, 80], ["PK15 cells", "PROBLEM", 90, 100], ["the human respiratory coronavirus HCoV", "PROBLEM", 133, 171], ["the amino acid sequence", "TEST", 203, 226], ["a barrier", "TREATMENT", 319, 328]]], ["Essential components of this epithelial fence are the tight and adherens junctions (TJs and AJs) (Cereijido et al., 2008) .", [["epithelial", "ANATOMY", 29, 39], ["adherens junctions", "ANATOMY", 64, 82], ["TJs", "ANATOMY", 84, 87], ["AJs", "ANATOMY", 92, 95], ["epithelial", "TISSUE", 29, 39], ["adherens junctions", "CELLULAR_COMPONENT", 64, 82], ["TJs", "CELLULAR_COMPONENT", 84, 87], ["AJs", "CELLULAR_COMPONENT", 92, 95], ["TJs", "CELL_TYPE", 84, 87], ["AJs", "CELL_TYPE", 92, 95], ["this epithelial fence", "TREATMENT", 24, 45], ["components", "OBSERVATION_MODIFIER", 10, 20], ["epithelial fence", "OBSERVATION", 29, 45], ["tight", "OBSERVATION_MODIFIER", 54, 59], ["adherens junctions", "OBSERVATION", 64, 82]]], ["Some pathogens use tight junction proteins as receptors for their attachment and subsequent internalisation, such as Hepatitis C virus (HCV) and reoviruses (Evans et al., 2007; Guglielmi et al., 2007) .", [["tight junction", "ANATOMY", 19, 33], ["Hepatitis C virus (HCV) and reoviruses", "DISEASE", 117, 155], ["tight junction proteins", "GENE_OR_GENE_PRODUCT", 19, 42], ["Hepatitis C virus", "ORGANISM", 117, 134], ["HCV", "ORGANISM", 136, 139], ["tight junction proteins", "PROTEIN", 19, 42], ["Hepatitis C virus", "SPECIES", 117, 134], ["Hepatitis C virus", "SPECIES", 117, 134], ["HCV", "SPECIES", 136, 139], ["Some pathogens", "PROBLEM", 0, 14], ["tight junction proteins", "TREATMENT", 19, 42], ["their attachment", "PROBLEM", 60, 76], ["subsequent internalisation", "PROBLEM", 81, 107], ["Hepatitis C virus (HCV)", "PROBLEM", 117, 140], ["pathogens", "OBSERVATION", 5, 14]]], ["Infectious enteric agents that alter tight junctions often elicit inflammatory cascades and cause diarrhoea.", [["tight junctions", "ANATOMY", 37, 52], ["diarrhoea", "DISEASE", 98, 107], ["tight junctions", "CELLULAR_COMPONENT", 37, 52], ["Infectious enteric agents", "TREATMENT", 0, 25], ["inflammatory cascades", "PROBLEM", 66, 87], ["diarrhoea", "PROBLEM", 98, 107], ["inflammatory", "OBSERVATION_MODIFIER", 66, 78]]], ["Rotaviruses are a major cause of viral gastroenteritis leading to diarrhoea and morbidity in mammals.", [["Rotaviruses", "DISEASE", 0, 11], ["viral gastroenteritis", "DISEASE", 33, 54], ["diarrhoea", "DISEASE", 66, 75], ["Rotaviruses", "PROBLEM", 0, 11], ["viral gastroenteritis", "PROBLEM", 33, 54], ["diarrhoea", "PROBLEM", 66, 75], ["morbidity in mammals", "PROBLEM", 80, 100], ["viral gastroenteritis", "OBSERVATION", 33, 54], ["diarrhoea", "OBSERVATION", 66, 75], ["morbidity", "OBSERVATION", 80, 89]]], ["Its VP8 protein alters the localisation of claudin-3, ZO-1 and occludin, which consequently leads to disruption of the barrier integrity of tight junctions during their infection (Nava et al., 2004) .", [["barrier", "ANATOMY", 119, 126], ["tight junctions", "ANATOMY", 140, 155], ["infection", "DISEASE", 169, 178], ["VP8", "GENE_OR_GENE_PRODUCT", 4, 7], ["claudin-3", "GENE_OR_GENE_PRODUCT", 43, 52], ["ZO-1", "GENE_OR_GENE_PRODUCT", 54, 58], ["occludin", "GENE_OR_GENE_PRODUCT", 63, 71], ["barrier", "TISSUE", 119, 126], ["tight junctions", "CELLULAR_COMPONENT", 140, 155], ["VP8 protein", "PROTEIN", 4, 15], ["claudin-3", "PROTEIN", 43, 52], ["ZO-1", "PROTEIN", 54, 58], ["occludin", "PROTEIN", 63, 71], ["claudin", "TEST", 43, 50], ["their infection", "PROBLEM", 163, 178], ["barrier", "OBSERVATION_MODIFIER", 119, 126], ["integrity", "OBSERVATION_MODIFIER", 127, 136], ["tight junctions", "OBSERVATION", 140, 155], ["infection", "OBSERVATION", 169, 178]]], ["TGEV and PEDV also cause severe diarrhoea in piglets, but it is not known whether this is related to damage to the TJs and AJs of epithelial cells.In addition, TJs and AJs use a variety of transmembrane proteins linked to the microfilaments and to intracellular signalling molecules (Etournay et al., 2007; Gonzalez-Mariscal et al., 2008) .", [["TJs", "ANATOMY", 115, 118], ["AJs", "ANATOMY", 123, 126], ["epithelial cells", "ANATOMY", 130, 146], ["TJs", "ANATOMY", 160, 163], ["AJs", "ANATOMY", 168, 171], ["transmembrane", "ANATOMY", 189, 202], ["microfilaments", "ANATOMY", 226, 240], ["intracellular", "ANATOMY", 248, 261], ["PEDV", "CHEMICAL", 9, 13], ["diarrhoea", "DISEASE", 32, 41], ["TGEV", "ORGANISM", 0, 4], ["PEDV", "GENE_OR_GENE_PRODUCT", 9, 13], ["piglets", "ORGANISM", 45, 52], ["TJs", "CELL", 115, 118], ["AJs", "CELLULAR_COMPONENT", 123, 126], ["epithelial cells", "CELL", 130, 146], ["TJs", "CELL", 160, 163], ["AJs", "CELLULAR_COMPONENT", 168, 171], ["transmembrane", "CELLULAR_COMPONENT", 189, 202], ["microfilaments", "CELLULAR_COMPONENT", 226, 240], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 248, 261], ["TJs", "CELL_TYPE", 115, 118], ["AJs", "CELL_TYPE", 123, 126], ["epithelial cells", "CELL_TYPE", 130, 146], ["TJs", "CELL_TYPE", 160, 163], ["AJs", "CELL_TYPE", 168, 171], ["transmembrane proteins", "PROTEIN", 189, 211], ["intracellular signalling molecules", "PROTEIN", 248, 282], ["TGEV", "SPECIES", 0, 4], ["piglets", "SPECIES", 45, 52], ["TGEV", "SPECIES", 0, 4], ["PEDV", "SPECIES", 9, 13], ["TGEV", "PROBLEM", 0, 4], ["PEDV", "PROBLEM", 9, 13], ["severe diarrhoea in piglets", "PROBLEM", 25, 52], ["damage to the TJs", "PROBLEM", 101, 118], ["epithelial cells", "PROBLEM", 130, 146], ["transmembrane proteins", "PROBLEM", 189, 211], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["diarrhoea", "OBSERVATION", 32, 41], ["epithelial cells", "OBSERVATION", 130, 146]]], ["Following the changes to TJs and AJs, the microfilaments of the host cell are often co-opted by viruses at many stages of their life cycle, such as attachment, internalisation, endocytosis, nuclear targeting, replication, assembly, or cell-to-cell spread.", [["TJs", "ANATOMY", 25, 28], ["AJs", "ANATOMY", 33, 36], ["microfilaments", "ANATOMY", 42, 56], ["cell", "ANATOMY", 69, 73], ["nuclear", "ANATOMY", 190, 197], ["cell", "ANATOMY", 235, 239], ["cell", "ANATOMY", 243, 247], ["TJs", "CELL", 25, 28], ["AJs", "CELLULAR_COMPONENT", 33, 36], ["microfilaments", "CELLULAR_COMPONENT", 42, 56], ["host cell", "CELL", 64, 73], ["nuclear", "CELLULAR_COMPONENT", 190, 197], ["cell", "CELL", 235, 239], ["cell", "CELL", 243, 247], ["TJs", "CELL_TYPE", 25, 28], ["AJs", "CELL_TYPE", 33, 36], ["endocytosis", "PROBLEM", 177, 188], ["host cell", "OBSERVATION", 64, 73], ["viruses", "OBSERVATION", 96, 103], ["cell spread", "OBSERVATION", 243, 254]]], ["Viruses induce rearrangements of microfilaments so that they can utilise them as tracks or move them aside when they represent barriers.", [["microfilaments", "ANATOMY", 33, 47], ["microfilaments", "CELLULAR_COMPONENT", 33, 47]]], ["Viral particles recruit molecular motors in order to hitchhike rides to different subcellular sites which provide the proper molecular environment for uncoating, replicating and packaging viral genomes (Burckhardt and Greber, 2009; Vaughan et al., 2009) .", [["subcellular sites", "ANATOMY", 82, 99], ["viral genomes", "DNA", 188, 201], ["Viral particles", "PROBLEM", 0, 15], ["different subcellular sites", "PROBLEM", 72, 99], ["particles", "OBSERVATION_MODIFIER", 6, 15], ["molecular motors", "OBSERVATION", 24, 40], ["viral genomes", "OBSERVATION", 188, 201]]], ["However, there are few reports about the interactions of PEDV and TGEV with microfilaments of host cells.Mitogen-activated protein (MAP) kinases are Ser/Thr protein kinases that respond to extracellular stimuli such as growth factors and stress, among others.", [["microfilaments", "ANATOMY", 76, 90], ["cells", "ANATOMY", 99, 104], ["extracellular", "ANATOMY", 189, 202], ["Ser", "CHEMICAL", 149, 152], ["Thr", "CHEMICAL", 153, 156], ["PEDV", "GENE_OR_GENE_PRODUCT", 57, 61], ["TGEV", "ORGANISM", 66, 70], ["microfilaments", "CELLULAR_COMPONENT", 76, 90], ["host cells", "CELL", 94, 104], ["Mitogen-activated protein (MAP) kinases", "GENE_OR_GENE_PRODUCT", 105, 144], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 202], ["PEDV", "PROTEIN", 57, 61], ["host cells", "CELL_TYPE", 94, 104], ["Mitogen-activated protein (MAP) kinases", "PROTEIN", 105, 144], ["Ser/Thr protein kinases", "PROTEIN", 149, 172], ["growth factors", "PROTEIN", 219, 233], ["PEDV", "SPECIES", 57, 61], ["TGEV", "SPECIES", 66, 70], ["PEDV", "PROBLEM", 57, 61], ["microfilaments of host cells", "TREATMENT", 76, 104], ["Mitogen", "TEST", 105, 112], ["activated protein (MAP) kinases", "TREATMENT", 113, 144], ["Ser/Thr protein kinases", "TREATMENT", 149, 172], ["extracellular stimuli", "TEST", 189, 210], ["few", "OBSERVATION_MODIFIER", 19, 22], ["host cells", "OBSERVATION", 94, 104]]], ["Previous studies have shown that the MAPK signalling pathway cannot only up-or down-regulate the expression of several TJ proteins to alter the molecular composition within TJ complexes, but also plays an important role in microfilament remodelling (Gerits et al., 2007; Melamed et al., 1995) .To clearly answer the questions of whether PEDV and TGEV infection could impair the tight and adherens junctions of epithelial cells, how interactions with PEDV, TGEV and microfilaments of epithelial cells occur, and how to change the proteins in the MAPK signalling pathway, we used PEDV and TGEV to infect the porcine intestinal epithelial cell line .", [["TJ complexes", "ANATOMY", 173, 185], ["microfilament", "ANATOMY", 223, 236], ["adherens junctions", "ANATOMY", 388, 406], ["epithelial cells", "ANATOMY", 410, 426], ["microfilaments", "ANATOMY", 465, 479], ["epithelial cells", "ANATOMY", 483, 499], ["intestinal epithelial cell line", "ANATOMY", 614, 645], ["PEDV", "CHEMICAL", 337, 341], ["infection", "DISEASE", 351, 360], ["MAPK", "GENE_OR_GENE_PRODUCT", 37, 41], ["TJ", "GENE_OR_GENE_PRODUCT", 119, 121], ["TJ", "GENE_OR_GENE_PRODUCT", 173, 175], ["microfilament", "CELLULAR_COMPONENT", 223, 236], ["PEDV", "GENE_OR_GENE_PRODUCT", 337, 341], ["TGEV", "ORGANISM", 346, 350], ["adherens junctions", "CELLULAR_COMPONENT", 388, 406], ["epithelial cells", "CELL", 410, 426], ["PEDV", "GENE_OR_GENE_PRODUCT", 450, 454], ["TGEV", "ORGANISM", 456, 460], ["microfilaments", "CELLULAR_COMPONENT", 465, 479], ["epithelial cells", "CELL", 483, 499], ["MAPK", "GENE_OR_GENE_PRODUCT", 545, 549], ["PEDV", "GENE_OR_GENE_PRODUCT", 578, 582], ["TGEV", "ORGANISM", 587, 591], ["porcine", "ORGANISM", 606, 613], ["intestinal epithelial cell line", "CELL", 614, 645], ["MAPK", "PROTEIN", 37, 41], ["TJ proteins", "PROTEIN", 119, 130], ["TJ complexes", "PROTEIN", 173, 185], ["epithelial cells", "CELL_TYPE", 410, 426], ["PEDV", "PROTEIN", 450, 454], ["epithelial cells", "CELL_TYPE", 483, 499], ["MAPK", "PROTEIN", 545, 549], ["PEDV", "PROTEIN", 578, 582], ["porcine intestinal epithelial cell line", "CELL_LINE", 606, 645], ["porcine", "SPECIES", 606, 613], ["PEDV", "SPECIES", 337, 341], ["TGEV", "SPECIES", 346, 350], ["TGEV", "SPECIES", 456, 460], ["TGEV", "SPECIES", 587, 591], ["porcine", "SPECIES", 606, 613], ["Previous studies", "TEST", 0, 16], ["the MAPK signalling pathway", "TEST", 33, 60], ["several TJ proteins", "PROBLEM", 111, 130], ["PEDV", "PROBLEM", 337, 341], ["TGEV infection", "PROBLEM", 346, 360], ["epithelial cells", "PROBLEM", 410, 426], ["PEDV", "PROBLEM", 450, 454], ["TGEV", "PROBLEM", 456, 460], ["epithelial cells", "PROBLEM", 483, 499], ["PEDV", "PROBLEM", 578, 582], ["TGEV", "TREATMENT", 587, 591], ["the porcine intestinal epithelial cell line", "TREATMENT", 602, 645], ["infection", "OBSERVATION", 351, 360], ["epithelial cells", "OBSERVATION", 410, 426], ["epithelial cells", "OBSERVATION", 483, 499], ["porcine", "ANATOMY_MODIFIER", 606, 613], ["intestinal", "ANATOMY", 614, 624], ["epithelial cell line", "OBSERVATION", 625, 645]]], ["Results showed that both PEDV and TGEV could infect IPEC-J2 cells, and that they could also down-regulate certain proteins of tight and adherens junctions to alter the epithelial barrier integrity.", [["IPEC-J2 cells", "ANATOMY", 52, 65], ["tight", "ANATOMY", 126, 131], ["adherens junctions", "ANATOMY", 136, 154], ["epithelial barrier", "ANATOMY", 168, 186], ["PEDV", "CHEMICAL", 25, 29], ["PEDV", "SIMPLE_CHEMICAL", 25, 29], ["TGEV", "ORGANISM", 34, 38], ["IPEC-J2 cells", "CELL", 52, 65], ["adherens junctions", "CELLULAR_COMPONENT", 136, 154], ["epithelial barrier", "TISSUE", 168, 186], ["IPEC-J2 cells", "CELL_LINE", 52, 65], ["TGEV", "SPECIES", 34, 38], ["PEDV", "SPECIES", 25, 29], ["TGEV", "SPECIES", 34, 38], ["both PEDV", "PROBLEM", 20, 29], ["TGEV", "PROBLEM", 34, 38], ["J2 cells", "PROBLEM", 57, 65], ["the epithelial barrier integrity", "TREATMENT", 164, 196], ["PEDV", "OBSERVATION", 25, 29], ["J2 cells", "OBSERVATION_MODIFIER", 57, 65], ["tight", "OBSERVATION_MODIFIER", 126, 131], ["adherens junctions", "OBSERVATION", 136, 154], ["epithelial barrier integrity", "OBSERVATION", 168, 196]]], ["In addition, they affected the polymerisation and depolymerisation of microfilaments in IPEC-J2 cells, and the disordered microfilaments could also suppress the replication and release of these viruses.", [["microfilaments", "ANATOMY", 70, 84], ["IPEC-J2 cells", "ANATOMY", 88, 101], ["microfilaments", "ANATOMY", 122, 136], ["microfilaments", "CELLULAR_COMPONENT", 70, 84], ["IPEC-J2 cells", "CELL", 88, 101], ["microfilaments", "CELLULAR_COMPONENT", 122, 136], ["IPEC-J2 cells", "CELL_LINE", 88, 101], ["the polymerisation", "PROBLEM", 27, 45], ["microfilaments in IPEC-J2 cells", "PROBLEM", 70, 101], ["the disordered microfilaments", "PROBLEM", 107, 136], ["these viruses", "PROBLEM", 188, 201], ["J2 cells", "OBSERVATION", 93, 101], ["viruses", "OBSERVATION", 194, 201]]], ["Furthermore, PEDV + TGEV co-infection enhanced the damage to tight junctions and the remodelling of microfilaments.", [["tight junctions", "ANATOMY", 61, 76], ["microfilaments", "ANATOMY", 100, 114], ["PEDV", "CHEMICAL", 13, 17], ["PEDV + TGEV", "ORGANISM", 13, 24], ["tight junctions", "CELLULAR_COMPONENT", 61, 76], ["microfilaments", "CELLULAR_COMPONENT", 100, 114], ["PEDV", "SPECIES", 13, 17], ["TGEV", "SPECIES", 20, 24], ["PEDV", "PROBLEM", 13, 17], ["TGEV co-infection", "PROBLEM", 20, 37], ["TGEV", "OBSERVATION_MODIFIER", 20, 24], ["co-infection", "OBSERVATION", 25, 37], ["tight junctions", "OBSERVATION", 61, 76]]], ["Finally, PEDV and TGEV infection impacted on activation of the MAPK signalling pathway in IPEC-J2 cells, and MAPK inhibitor could affect the tight junctions and microfilaments of cells.Cell lines and cultureThe IPEC-J2 cells (Liu et al., 2010) were donated by Zhanyong Wei from Henan Agricultural University (Henan Province, Zhengzhou, China).", [["IPEC-J2 cells", "ANATOMY", 90, 103], ["tight junctions", "ANATOMY", 141, 156], ["microfilaments", "ANATOMY", 161, 175], ["cells", "ANATOMY", 179, 184], ["Cell lines", "ANATOMY", 185, 195], ["IPEC-J2 cells", "ANATOMY", 211, 224], ["PEDV", "CHEMICAL", 9, 13], ["infection", "DISEASE", 23, 32], ["PEDV", "GENE_OR_GENE_PRODUCT", 9, 13], ["TGEV", "ORGANISM", 18, 22], ["MAPK", "GENE_OR_GENE_PRODUCT", 63, 67], ["IPEC-J2 cells", "CELL", 90, 103], ["MAPK", "GENE_OR_GENE_PRODUCT", 109, 113], ["tight junctions", "CELLULAR_COMPONENT", 141, 156], ["microfilaments", "CELLULAR_COMPONENT", 161, 175], ["cells", "CELL", 179, 184], ["Cell lines", "CELL", 185, 195], ["IPEC-J2 cells", "CELL", 211, 224], ["MAPK", "PROTEIN", 63, 67], ["IPEC-J2 cells", "CELL_LINE", 90, 103], ["MAPK", "PROTEIN", 109, 113], ["IPEC-J2 cells", "CELL_LINE", 211, 224], ["PEDV", "SPECIES", 9, 13], ["TGEV", "SPECIES", 18, 22], ["PEDV", "PROBLEM", 9, 13], ["TGEV infection", "PROBLEM", 18, 32], ["the MAPK signalling pathway", "TEST", 59, 86], ["J2 cells", "PROBLEM", 95, 103], ["MAPK inhibitor", "TREATMENT", 109, 123], ["Cell lines", "TEST", 185, 195], ["culture", "TEST", 200, 207], ["TGEV", "OBSERVATION_MODIFIER", 18, 22], ["infection", "OBSERVATION", 23, 32], ["J2 cells", "OBSERVATION", 95, 103], ["tight junctions", "OBSERVATION", 141, 156], ["J2 cells", "OBSERVATION", 216, 224]]], ["ST (pig testis cell line) and Vero (African green monkey kidney cell line) cells were provided by Jiangsu Academy of Agricultural Sciences (JAAS, Jiangsu Province, Nanjing, China).", [["testis cell line", "ANATOMY", 8, 24], ["kidney cell line) cells", "ANATOMY", 57, 80], ["pig testis cell line", "CELL", 4, 24], ["Vero", "CELL", 30, 34], ["green monkey kidney cell line) cells", "CELL", 44, 80], ["ST (pig testis cell line", "CELL_LINE", 0, 24], ["Vero (African green monkey kidney cell line) cells", "CELL_LINE", 30, 80], ["pig", "SPECIES", 4, 7], ["Vero", "SPECIES", 30, 34], ["green monkey", "SPECIES", 44, 56], ["pig", "SPECIES", 4, 7], ["African green monkey", "SPECIES", 36, 56], ["ST (pig testis cell line", "TREATMENT", 0, 24], ["Vero (African green monkey kidney cell line) cells", "TREATMENT", 30, 80], ["pig testis", "ANATOMY", 4, 14], ["cell line", "OBSERVATION", 15, 24], ["kidney", "ANATOMY", 57, 63], ["cell line", "OBSERVATION", 64, 73]]], ["IPEC-J2 cells were cultured and maintained in RPMI 1640 medium (Gibco, USA), supplemented with 7% foetal calf serum (FBS; Gibco, USA), penicillin (100 IU/ml), and streptomycin (100 mg/ml) (Invitrogen, USA).", [["IPEC-J2 cells", "ANATOMY", 0, 13], ["foetal calf serum", "ANATOMY", 98, 115], ["FBS", "ANATOMY", 117, 120], ["penicillin", "CHEMICAL", 135, 145], ["streptomycin", "CHEMICAL", 163, 175], ["penicillin", "CHEMICAL", 135, 145], ["streptomycin", "CHEMICAL", 163, 175], ["IPEC-J2 cells", "CELL", 0, 13], ["foetal", "ORGANISM", 98, 104], ["calf", "ORGANISM_SUBSTANCE", 105, 109], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["FBS", "ORGANISM_SUBSTANCE", 117, 120], ["Gibco", "ORGANISM_SUBSTANCE", 122, 127], ["penicillin", "SIMPLE_CHEMICAL", 135, 145], ["streptomycin", "SIMPLE_CHEMICAL", 163, 175], ["IPEC-J2 cells", "CELL_LINE", 0, 13], ["calf", "SPECIES", 105, 109], ["IPEC", "TEST", 0, 4], ["J2 cells", "TEST", 5, 13], ["RPMI", "TEST", 46, 50], ["7% foetal calf serum", "TEST", 95, 115], ["FBS", "TEST", 117, 120], ["Gibco", "TEST", 122, 127], ["penicillin", "TREATMENT", 135, 145], ["streptomycin", "TREATMENT", 163, 175], ["J2 cells", "OBSERVATION", 5, 13]]], ["Vero and ST cells were cultured in Dulbecco modified Eagle's medium (Gibco, USA), supplemented with 5% foetal bovine serum, penicillin (100 IU/ml), and streptomycin (100 mg/ml) solutions.Cell lines and cultureTGEV (STC3 strain) (He et al., 2001) , PEDV (CV777 strain) (Brian and Baric, 2005) were also provided by JAAS.", [["Vero", "ANATOMY", 0, 4], ["ST cells", "ANATOMY", 9, 17], ["serum", "ANATOMY", 117, 122], ["Cell lines", "ANATOMY", 187, 197], ["penicillin", "CHEMICAL", 124, 134], ["streptomycin", "CHEMICAL", 152, 164], ["penicillin", "CHEMICAL", 124, 134], ["streptomycin", "CHEMICAL", 152, 164], ["Vero", "CELL", 0, 4], ["ST cells", "CELL", 9, 17], ["foetal", "ORGANISM", 103, 109], ["bovine", "ORGANISM", 110, 116], ["serum", "ORGANISM_SUBSTANCE", 117, 122], ["penicillin", "SIMPLE_CHEMICAL", 124, 134], ["streptomycin", "SIMPLE_CHEMICAL", 152, 164], ["Cell lines", "CELL", 187, 197], ["cultureTGEV", "CELL", 202, 213], ["STC3 strain", "CELL", 215, 226], ["Vero and ST cells", "CELL_LINE", 0, 17], ["bovine", "SPECIES", 110, 116], ["bovine", "SPECIES", 110, 116], ["Vero and ST cells", "PROBLEM", 0, 17], ["5% foetal bovine serum", "TREATMENT", 100, 122], ["penicillin", "TREATMENT", 124, 134], ["streptomycin", "TREATMENT", 152, 164], ["Cell lines", "TEST", 187, 197], ["cultureTGEV", "TEST", 202, 213], ["STC3 strain", "PROBLEM", 215, 226], ["PEDV", "PROBLEM", 248, 252], ["ST cells", "ANATOMY", 9, 17]]], ["TGEV was propagated in ST cells and PEDV was propagated in Vero cells; these were purified as described by Hofmann and Wyler (1988) .Cell lines and cultureConfluent monolayers of IPEC-J2 cells were inoculated with TGEV at a multiplicity of infection (MOI) of 0.1, PEDV at an MOI of 0.1, and PEDV + TGEV both at an MOI of 0.1 for 1 h at 37 \u2022 C. Then, the inoculums and unattached viruses were removed and fresh growth medium was added.", [["ST cells", "ANATOMY", 23, 31], ["Vero cells", "ANATOMY", 59, 69], ["Cell lines", "ANATOMY", 133, 143], ["monolayers", "ANATOMY", 165, 175], ["IPEC-J2 cells", "ANATOMY", 179, 192], ["infection", "DISEASE", 240, 249], ["PEDV", "CHEMICAL", 291, 295], ["TGEV", "ORGANISM", 0, 4], ["ST cells", "CELL", 23, 31], ["PEDV", "CELL", 36, 40], ["Vero cells", "CELL", 59, 69], ["Cell lines", "CELL", 133, 143], ["monolayers", "CELL", 165, 175], ["IPEC-J2 cells", "CELL", 179, 192], ["TGEV", "ORGANISM", 214, 218], ["TGEV", "ORGANISM", 298, 302], ["ST cells", "CELL_LINE", 23, 31], ["PEDV", "PROTEIN", 36, 40], ["Vero cells", "CELL_LINE", 59, 69], ["IPEC-J2 cells", "CELL_LINE", 179, 192], ["TGEV", "SPECIES", 0, 4], ["PEDV", "SPECIES", 36, 40], ["TGEV", "SPECIES", 214, 218], ["PEDV", "SPECIES", 291, 295], ["TGEV", "SPECIES", 298, 302], ["TGEV", "PROBLEM", 0, 4], ["ST cells", "TREATMENT", 23, 31], ["PEDV", "PROBLEM", 36, 40], ["Cell lines", "TEST", 133, 143], ["culture", "TEST", 148, 155], ["Confluent monolayers of IPEC-J2 cells", "PROBLEM", 155, 192], ["TGEV", "PROBLEM", 214, 218], ["infection", "PROBLEM", 240, 249], ["PEDV", "PROBLEM", 264, 268], ["an MOI", "TEST", 272, 278], ["PEDV", "PROBLEM", 291, 295], ["TGEV", "PROBLEM", 298, 302], ["unattached viruses", "PROBLEM", 368, 386], ["fresh growth medium", "TREATMENT", 404, 423], ["Vero cells", "OBSERVATION", 59, 69], ["monolayers", "OBSERVATION_MODIFIER", 165, 175], ["J2 cells", "OBSERVATION_MODIFIER", 184, 192], ["infection", "OBSERVATION", 240, 249], ["viruses", "OBSERVATION", 379, 386]]], ["Infected cells were analysed after the required incubation period.Immunofluorescence stainingTo examine whether the PEDV/TGEV infected the IPEC-J2 cells, the TGEV-, PEDV-, TGEV + PEDV-infected and mock-infected cells at 0, 6, 12, 24, 48, 72 h post-infection (pi) were determined by indirect immunofluorescence.", [["cells", "ANATOMY", 9, 14], ["IPEC-J2 cells", "ANATOMY", 139, 152], ["cells", "ANATOMY", 211, 216], ["infection", "DISEASE", 248, 257], ["cells", "CELL", 9, 14], ["PEDV", "ORGANISM", 116, 120], ["TGEV", "ORGANISM", 121, 125], ["IPEC-J2 cells", "CELL", 139, 152], ["TGEV", "ORGANISM", 158, 162], ["PEDV", "GENE_OR_GENE_PRODUCT", 165, 169], ["TGEV + PEDV", "ORGANISM", 172, 183], ["cells", "CELL", 211, 216], ["IPEC-J2 cells", "CELL_LINE", 139, 152], ["mock-infected cells", "CELL_TYPE", 197, 216], ["TGEV", "SPECIES", 121, 125], ["TGEV", "SPECIES", 121, 125], ["TGEV", "SPECIES", 158, 162], ["TGEV", "SPECIES", 172, 176], ["PEDV", "SPECIES", 179, 183], ["Infected cells", "PROBLEM", 0, 14], ["Immunofluorescence staining", "TEST", 66, 93], ["the PEDV/TGEV", "TEST", 112, 125], ["the TGEV", "TEST", 154, 162], ["PEDV", "TEST", 165, 169], ["TGEV", "PROBLEM", 172, 176], ["PEDV", "PROBLEM", 179, 183], ["infected cells", "PROBLEM", 202, 216], ["post-infection (pi)", "PROBLEM", 243, 262], ["indirect immunofluorescence", "TEST", 282, 309], ["infected cells", "OBSERVATION", 202, 216], ["infection", "OBSERVATION", 248, 257]]], ["All group cells grown on glass cover slips in 24-well tissue culture plates were fixed with 3.7% polyoxymethylene, washed 3 times with 0.1 M PBS and permeabilised for 5 min with 0.1% Triton X-100.", [["cells", "ANATOMY", 10, 15], ["tissue", "ANATOMY", 54, 60], ["polyoxymethylene", "CHEMICAL", 97, 113], ["Triton X-100", "CHEMICAL", 183, 195], ["polyoxymethylene", "CHEMICAL", 97, 113], ["Triton X-100", "CHEMICAL", 183, 195], ["cells", "CELL", 10, 15], ["polyoxymethylene", "SIMPLE_CHEMICAL", 97, 113], ["Triton X-100", "SIMPLE_CHEMICAL", 183, 195], ["group cells", "CELL_LINE", 4, 15], ["glass cover slips", "TEST", 25, 42], ["tissue culture plates", "TEST", 54, 75], ["3.7% polyoxymethylene", "TREATMENT", 92, 113], ["group cells", "OBSERVATION_MODIFIER", 4, 15], ["grown", "OBSERVATION_MODIFIER", 16, 21]]], ["The cells were incubated with a 1% solution of BSA (30 min, room temperature, RT), then stained with FITC-conjugated TGEV polyclonal antibody (VMRD, USA) and monoclonal mouse anti-PEDV M protein (a gift of Zhang Zhi ban, Harbin Veterinary Research Institute, China) respectively (overnight, 4 \u2022 C in dark conditions).", [["cells", "ANATOMY", 4, 9], ["BSA", "CHEMICAL", 47, 50], ["FITC", "CHEMICAL", 101, 105], ["cells", "CELL", 4, 9], ["BSA", "SIMPLE_CHEMICAL", 47, 50], ["FITC", "SIMPLE_CHEMICAL", 101, 105], ["TGEV", "ORGANISM", 117, 121], ["mouse", "ORGANISM", 169, 174], ["FITC-conjugated TGEV polyclonal antibody", "PROTEIN", 101, 141], ["VMRD", "PROTEIN", 143, 147], ["USA", "PROTEIN", 149, 152], ["monoclonal mouse anti-PEDV M protein", "PROTEIN", 158, 194], ["mouse", "SPECIES", 169, 174], ["TGEV", "SPECIES", 117, 121], ["mouse", "SPECIES", 169, 174], ["a 1% solution of BSA", "TREATMENT", 30, 50], ["room temperature", "TEST", 60, 76], ["RT", "TEST", 78, 80], ["FITC", "TEST", 101, 105], ["conjugated TGEV polyclonal antibody", "TEST", 106, 141]]], ["Following washing 5 times with 0.1 M PBS, a Cy3-conjugated sheep anti-mouse IgG (A0521, Beyotime, China) was added to the cells (1:400,1 h, RT).", [["cells", "ANATOMY", 122, 127], ["Cy3", "CHEMICAL", 44, 47], ["Cy3", "SIMPLE_CHEMICAL", 44, 47], ["sheep", "ORGANISM", 59, 64], ["cells", "CELL", 122, 127], ["Cy3-conjugated sheep anti-mouse IgG", "PROTEIN", 44, 79], ["sheep", "SPECIES", 59, 64], ["anti-mouse", "SPECIES", 65, 75], ["sheep", "SPECIES", 59, 64], ["a Cy3-conjugated sheep anti-mouse IgG", "TREATMENT", 42, 79], ["Beyotime, China)", "TREATMENT", 88, 104]]], ["The negative control slices were treated in an identical manner except the primary antibodies were omitted.", [["slices", "ANATOMY", 21, 27], ["primary antibodies", "PROTEIN", 75, 93]]], ["Cells were washed 3 times with 0.01 M PBS and images were acquired using a fluorescence microscope (Zeiss, Germany).Immunofluorescence stainingTo examine the effects of PEDV/TGEV on the cytoskeletal organisation of all groups at 0, 20, 40 minpi, and 1, 2, 12, 24, 48, 96 hpi, were stained with FITC-Phalloidin and determined by immunofluorescence.", [["Cells", "ANATOMY", 0, 5], ["cytoskeletal", "ANATOMY", 186, 198], ["PEDV", "CHEMICAL", 169, 173], ["FITC", "CHEMICAL", 294, 298], ["Phalloidin", "CHEMICAL", 299, 309], ["Cells", "CELL", 0, 5], ["PEDV/TGEV", "ORGANISM", 169, 178], ["FITC-Phalloidin", "SIMPLE_CHEMICAL", 294, 309], ["PEDV", "PROTEIN", 169, 173], ["TGEV", "SPECIES", 174, 178], ["Cells", "TEST", 0, 5], ["images", "TEST", 46, 52], ["a fluorescence microscope", "TEST", 73, 98], ["Immunofluorescence staining", "TEST", 116, 143], ["PEDV/TGEV", "TREATMENT", 169, 178], ["FITC-Phalloidin", "TREATMENT", 294, 309], ["PEDV", "OBSERVATION", 169, 173]]], ["In short, washed infected cells were fixed with polyoxymethylene, and permeabilised for 5 min with 0.1% Triton X-100.", [["cells", "ANATOMY", 26, 31], ["polyoxymethylene", "CHEMICAL", 48, 64], ["Triton X-100", "CHEMICAL", 104, 116], ["polyoxymethylene", "CHEMICAL", 48, 64], ["Triton X-100", "CHEMICAL", 104, 116], ["cells", "CELL", 26, 31], ["polyoxymethylene", "SIMPLE_CHEMICAL", 48, 64], ["Triton X-100", "SIMPLE_CHEMICAL", 104, 116], ["washed infected cells", "CELL_TYPE", 10, 31], ["washed infected cells", "PROBLEM", 10, 31], ["polyoxymethylene", "TREATMENT", 48, 64], ["short", "OBSERVATION_MODIFIER", 3, 8], ["infected cells", "OBSERVATION", 17, 31]]], ["The cells were incubated with a 1% solution of BSA (30 min, RT), and stained with FITC-Phalloidin (30 min, RT, in dark conditions).", [["cells", "ANATOMY", 4, 9], ["BSA", "CHEMICAL", 47, 50], ["FITC", "CHEMICAL", 82, 86], ["Phalloidin", "CHEMICAL", 87, 97], ["cells", "CELL", 4, 9], ["BSA", "SIMPLE_CHEMICAL", 47, 50], ["FITC-Phalloidin", "SIMPLE_CHEMICAL", 82, 97], ["a 1% solution of BSA", "TREATMENT", 30, 50], ["FITC-Phalloidin", "TREATMENT", 82, 97]]], ["Images were acquired using a fluorescence microscope (Zeiss, Germany).Virus titration assayTGEV-, PEDV-infected and mock-infected cells were seeded onto 6-well plates (5 \u00d7 10 5 ) and cultured for 2, 6, 12, 24, 48, 72 h.", [["cells", "ANATOMY", 130, 135], ["Virus", "ORGANISM", 70, 75], ["PEDV", "ORGANISM", 98, 102], ["cells", "CELL", 130, 135], ["PEDV-infected and mock-infected cells", "CELL_LINE", 98, 135], ["PEDV", "SPECIES", 98, 102], ["Images", "TEST", 0, 6], ["a fluorescence microscope", "TEST", 27, 52], ["Virus titration assayTGEV", "TREATMENT", 70, 95], ["PEDV", "PROBLEM", 98, 102], ["infected cells", "PROBLEM", 121, 135], ["infected", "OBSERVATION", 103, 111], ["infected cells", "OBSERVATION", 121, 135]]], ["TGEV and PEDV were collected by freezing and thawing the plates three times, and determined by the tissue culture infectious dose 50 (TCID 50 ) in ST and Vero cells, respectively.Transepithelial electrical resistance (TEER) assayTEER, a measure of tight junctions (TJ) integrity, is measured by epithelial tissue volt-ohmmeter (Millicell ERS-2, Millipore Corporation, USA) as described previously (Shatos et al., 1992) .", [["tissue culture", "ANATOMY", 99, 113], ["Vero cells", "ANATOMY", 154, 164], ["tight junctions", "ANATOMY", 248, 263], ["TJ", "ANATOMY", 265, 267], ["epithelial tissue", "ANATOMY", 295, 312], ["TGEV", "ORGANISM", 0, 4], ["PEDV", "SIMPLE_CHEMICAL", 9, 13], ["tissue", "TISSUE", 99, 105], ["Vero cells", "CELL", 154, 164], ["tight junctions", "CELLULAR_COMPONENT", 248, 263], ["TJ", "CELLULAR_COMPONENT", 265, 267], ["epithelial tissue", "TISSUE", 295, 312], ["Vero cells", "CELL_LINE", 154, 164], ["TGEV", "SPECIES", 0, 4], ["TGEV", "SPECIES", 0, 4], ["PEDV", "SPECIES", 9, 13], ["TGEV", "PROBLEM", 0, 4], ["PEDV", "TREATMENT", 9, 13], ["the tissue culture", "TEST", 95, 113], ["Transepithelial electrical resistance (TEER) assayTEER", "PROBLEM", 179, 233], ["epithelial tissue volt", "TEST", 295, 317], ["PEDV", "OBSERVATION", 9, 13], ["Vero cells", "ANATOMY", 154, 164], ["electrical resistance", "OBSERVATION", 195, 216], ["tight junctions", "OBSERVATION", 248, 263], ["integrity", "OBSERVATION_MODIFIER", 269, 278], ["epithelial tissue", "ANATOMY", 295, 312]]], ["In short, IPEC-J2 cells were seeded on 24 collagen-coated Millicell filter inserts with a 0.4 mm pore size (Millipore, USA).", [["IPEC-J2 cells", "ANATOMY", 10, 23], ["pore", "ANATOMY", 97, 101], ["IPEC-J2 cells", "CELL", 10, 23], ["collagen", "GENE_OR_GENE_PRODUCT", 42, 50], ["IPEC-J2 cells", "CELL_LINE", 10, 23], ["collagen", "PROTEIN", 42, 50], ["IPEC-J2 cells", "TREATMENT", 10, 23], ["24 collagen-coated Millicell filter inserts", "TREATMENT", 39, 82], ["a 0.4 mm pore size (Millipore", "TREATMENT", 88, 117], ["short", "OBSERVATION_MODIFIER", 3, 8], ["J2 cells", "OBSERVATION_MODIFIER", 15, 23], ["size", "OBSERVATION_MODIFIER", 102, 106]]], ["When the IPEC-J2 cells reached confluence and were infected TGEV/PEDV at an m.o.i. of 0.1.", [["IPEC-J2 cells", "ANATOMY", 9, 22], ["IPEC-J2 cells", "CELL", 9, 22], ["TGEV", "ORGANISM", 60, 64], ["IPEC-J2 cells", "CELL_LINE", 9, 22], ["TGEV", "SPECIES", 60, 64], ["PEDV", "SPECIES", 65, 69], ["the IPEC-J2 cells", "TEST", 5, 22], ["PEDV", "PROBLEM", 65, 69], ["infected", "OBSERVATION_MODIFIER", 51, 59], ["TGEV", "OBSERVATION", 60, 64]]], ["TEER was calculated from the measured potential difference between the apical and basolateral sides of the cell layer by epithelial tissue volt-ohmmeter.", [["apical", "ANATOMY", 71, 77], ["basolateral sides", "ANATOMY", 82, 99], ["cell layer", "ANATOMY", 107, 117], ["epithelial tissue", "ANATOMY", 121, 138], ["apical", "MULTI-TISSUE_STRUCTURE", 71, 77], ["basolateral sides", "CELLULAR_COMPONENT", 82, 99], ["cell layer", "TISSUE", 107, 117], ["epithelial tissue", "TISSUE", 121, 138], ["TEER", "TEST", 0, 4], ["apical", "ANATOMY_MODIFIER", 71, 77], ["basolateral", "ANATOMY_MODIFIER", 82, 93], ["sides", "ANATOMY_MODIFIER", 94, 99], ["cell layer", "OBSERVATION", 107, 117], ["epithelial tissue", "OBSERVATION", 121, 138]]], ["All cells were measured in realtime.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["All cells", "TREATMENT", 0, 9], ["cells", "OBSERVATION", 4, 9]]], ["Resistance is expressed as both cm 2 and percent original TEER value relative to a control:Transepithelial electrical resistance (TEER) assayNormal resistance(\u02dd cm 2 ) = (TEER1 \u2212 blank) \u00d7 0.33 cm 2 (for 24 well Millicell Filter)Permeability measurementsPermeability was determined by measuring the paracellular passage of 4 kDa fluorescein isothiocyanate dextran (FITC-dextran) (Sigma-Aldrich, USA) dissolved in HBSS (1 mg/ml, Gibco, USA).", [["paracellular", "ANATOMY", 298, 310], ["fluorescein isothiocyanate dextran", "CHEMICAL", 328, 362], ["FITC-dextran", "CHEMICAL", 364, 376], ["fluorescein isothiocyanate", "CHEMICAL", 328, 354], ["FITC", "CHEMICAL", 364, 368], ["fluorescein isothiocyanate dextran", "SIMPLE_CHEMICAL", 328, 362], ["FITC-dextran", "SIMPLE_CHEMICAL", 364, 376], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 379, 392], ["USA", "SIMPLE_CHEMICAL", 394, 397], ["HBSS", "SIMPLE_CHEMICAL", 412, 416], ["Transepithelial electrical resistance", "TEST", 91, 128], ["assayNormal resistance", "TEST", 136, 158], ["24 well Millicell Filter", "TREATMENT", 203, 227], ["Permeability measurements", "TEST", 228, 253], ["4 kDa fluorescein isothiocyanate dextran (FITC-dextran", "TREATMENT", 322, 376], ["Transepithelial electrical resistance", "OBSERVATION", 91, 128]]], ["IPEC-J2 cells were seeded on 24 well collagen-coated Millicell filter inserts with a 0.4 mm pore size (Millipore, USA).", [["IPEC-J2 cells", "ANATOMY", 0, 13], ["pore", "ANATOMY", 92, 96], ["IPEC-J2 cells", "CELL", 0, 13], ["collagen", "GENE_OR_GENE_PRODUCT", 37, 45], ["IPEC-J2 cells", "CELL_LINE", 0, 13], ["collagen", "PROTEIN", 37, 45], ["IPEC-J2 cells", "TREATMENT", 0, 13], ["collagen-coated Millicell filter inserts", "TREATMENT", 37, 77], ["a 0.4 mm pore size (Millipore, USA", "TREATMENT", 83, 117], ["J2 cells", "OBSERVATION_MODIFIER", 5, 13], ["size", "OBSERVATION_MODIFIER", 97, 101]]], ["After the IPEC-J2 cells reached confluence and infected TGEV/PEDV at an MOI of 0.1.", [["IPEC-J2 cells", "ANATOMY", 10, 23], ["IPEC-J2 cells", "CELL", 10, 23], ["TGEV", "ORGANISM", 56, 60], ["IPEC-J2 cells", "CELL_LINE", 10, 23], ["TGEV", "SPECIES", 56, 60], ["PEDV", "SPECIES", 61, 65], ["the IPEC-J2 cells", "TREATMENT", 6, 23], ["infected TGEV/PEDV", "PROBLEM", 47, 65], ["an MOI", "TEST", 69, 75], ["J2 cells", "OBSERVATION", 15, 23], ["confluence", "OBSERVATION_MODIFIER", 32, 42], ["infected", "OBSERVATION_MODIFIER", 47, 55], ["TGEV", "OBSERVATION", 56, 60], ["PEDV", "OBSERVATION_MODIFIER", 61, 65]]], ["To measure flux in the apical to the basolateral direction, 200 l of the FITC-dextran tracer solution was loaded onto the apical side of the monolayer and cells were incubated for 20, 40 or 60 min at 37 \u2022 C. After this period, 100 l of the solution was measured for the tracer concentration in the basolateral compartment using a BioTek fluorescence/absorbance microplate reader at an excitation wavelength of 492 nm and emission of 520 nm.Western blottingAt 20, 40, 60 minpi and 24 hpi, the PEDV-, TGEV-, PEDV + TGEVinfected and mock-IPEC-J2 cells were harvested and prepared for Western blot, as described by McBride and Machamer (2010) .", [["apical", "ANATOMY", 23, 29], ["basolateral", "ANATOMY", 37, 48], ["apical", "ANATOMY", 122, 128], ["monolayer", "ANATOMY", 141, 150], ["cells", "ANATOMY", 155, 160], ["basolateral compartment", "ANATOMY", 298, 321], ["mock-IPEC-J2 cells", "ANATOMY", 530, 548], ["dextran", "CHEMICAL", 78, 85], ["FITC", "CHEMICAL", 73, 77], ["FITC-dextran", "SIMPLE_CHEMICAL", 73, 85], ["monolayer", "CELL", 141, 150], ["cells", "CELL", 155, 160], ["PEDV", "SIMPLE_CHEMICAL", 492, 496], ["TGEV", "ORGANISM", 499, 503], ["PEDV + TGEVinfected", "CELL", 506, 525], ["mock-IPEC-J2 cells", "CELL", 530, 548], ["PEDV-, TGEV-, PEDV + TGEVinfected and mock-IPEC-J2 cells", "CELL_LINE", 492, 548], ["TGEV", "SPECIES", 499, 503], ["the FITC-dextran tracer solution", "TREATMENT", 69, 101], ["the tracer concentration", "TEST", 266, 290], ["a BioTek fluorescence/absorbance microplate", "TREATMENT", 328, 371], ["an excitation wavelength", "TREATMENT", 382, 406], ["the PEDV", "TEST", 488, 496], ["TGEV", "TEST", 499, 503], ["PEDV", "PROBLEM", 506, 510], ["IPEC-J2 cells", "TREATMENT", 535, 548], ["flux", "OBSERVATION", 11, 15], ["apical", "ANATOMY_MODIFIER", 23, 29], ["basolateral", "ANATOMY_MODIFIER", 37, 48], ["apical", "ANATOMY_MODIFIER", 122, 128], ["basolateral", "ANATOMY_MODIFIER", 298, 309], ["520 nm", "OBSERVATION_MODIFIER", 433, 439]]], ["Polyclonal anti-occludin, polyclonal anti-claudin-1, monoclonal anti-ZO-1, and monoclonal anti-E-cadherin (Invitrogen, USA) were used at a dilution of 1:1000 in 5% BSA in TBST and HRP-conjugated anti-rabbit IgG or anti mouse IgG diluted 1:10,000 in 5% non-fat dry milk in TBST.", [["milk", "ANATOMY", 264, 268], ["BSA", "CHEMICAL", 164, 167], ["anti-occludin", "GENE_OR_GENE_PRODUCT", 11, 24], ["anti-claudin-1", "GENE_OR_GENE_PRODUCT", 37, 51], ["anti-ZO-1", "GENE_OR_GENE_PRODUCT", 64, 73], ["anti-E-cadherin", "GENE_OR_GENE_PRODUCT", 90, 105], ["Invitrogen", "ORGANISM", 107, 117], ["USA", "GENE_OR_GENE_PRODUCT", 119, 122], ["BSA", "SIMPLE_CHEMICAL", 164, 167], ["HRP", "SIMPLE_CHEMICAL", 180, 183], ["mouse", "ORGANISM", 219, 224], ["milk", "ORGANISM_SUBSTANCE", 264, 268], ["Polyclonal anti-occludin", "PROTEIN", 0, 24], ["polyclonal anti-claudin-1", "PROTEIN", 26, 51], ["monoclonal anti-ZO-1", "PROTEIN", 53, 73], ["monoclonal anti-E-cadherin", "PROTEIN", 79, 105], ["USA", "PROTEIN", 119, 122], ["TBST and HRP-conjugated anti-rabbit IgG", "PROTEIN", 171, 210], ["anti mouse IgG", "PROTEIN", 214, 228], ["anti-rabbit", "SPECIES", 195, 206], ["mouse", "SPECIES", 219, 224], ["anti-rabbit", "SPECIES", 195, 206], ["mouse", "SPECIES", 219, 224], ["Polyclonal anti-occludin", "TREATMENT", 0, 24], ["polyclonal anti-claudin", "TREATMENT", 26, 49], ["monoclonal anti-ZO", "TREATMENT", 53, 71], ["monoclonal anti-E-cadherin", "TREATMENT", 79, 105], ["TBST", "TEST", 171, 175], ["HRP", "TEST", 180, 183], ["conjugated anti-rabbit IgG", "TREATMENT", 184, 210], ["anti mouse IgG", "TREATMENT", 214, 228]]], ["The SDS gel was transferred to 0.4 m PVDF membrane (Millipore, USA) and detection with SuperSignal WestPico (Pierce, Thermo, USA).", [["membrane", "ANATOMY", 42, 50], ["PVDF", "CHEMICAL", 37, 41], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["The SDS gel", "TREATMENT", 0, 11]]], ["Western blotting was quantified by Quantity One (Quantity One \u00ae 1-D Analysis Software 170-9600, Bio-Rad).Transmission electron microscopeTGEV-, PEDV-, TGEV + PEDV-infected and mock-infected cells were harvested by 0.25% trypsinisation (Sigma, USA) and then fixed in a 2.5% glutaraldehyde solution in PBS for 24 h.", [["cells", "ANATOMY", 190, 195], ["glutaraldehyde", "CHEMICAL", 273, 287], ["glutaraldehyde", "CHEMICAL", 273, 287], ["PEDV", "SIMPLE_CHEMICAL", 144, 148], ["TGEV", "ORGANISM", 151, 155], ["cells", "CELL", 190, 195], ["glutaraldehyde", "SIMPLE_CHEMICAL", 273, 287], ["mock-infected cells", "CELL_TYPE", 176, 195], ["TGEV", "SPECIES", 151, 155], ["Software", "TEST", 77, 85], ["Transmission electron", "TEST", 105, 126], ["microscopeTGEV", "TEST", 127, 141], ["PEDV", "PROBLEM", 144, 148], ["TGEV", "PROBLEM", 151, 155], ["PEDV", "PROBLEM", 158, 162], ["infected cells", "PROBLEM", 181, 195], ["a 2.5% glutaraldehyde solution in PBS", "TREATMENT", 266, 303], ["infected", "OBSERVATION", 163, 171]]], ["After fixation, the monolayer was gently removed from the flask with a rubber policeman and the cell suspension was pelleted by low speed centrifugation (2500 \u00d7 g for 5 min).", [["monolayer", "ANATOMY", 20, 29], ["cell", "ANATOMY", 96, 100], ["monolayer", "CELL", 20, 29], ["cell", "CELL", 96, 100], ["fixation", "TREATMENT", 6, 14], ["the monolayer", "TREATMENT", 16, 29], ["a rubber policeman", "TREATMENT", 69, 87], ["the cell suspension", "TREATMENT", 92, 111], ["fixation", "OBSERVATION", 6, 14], ["monolayer", "OBSERVATION_MODIFIER", 20, 29], ["cell suspension", "OBSERVATION", 96, 111]]], ["The cells were then washed twice by centrifugation in 0.1 M PBS.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9]]], ["The pellet of cells was then fixed overnight at 4 \u2022 C for further standard treatment for transmission electron microscope (TEM), as described by Pontefract et al. (1989) .Effects of the microfilament inhibitor on PEDV and TGEV infectionMicrofilament inhibitors, Jas (jasplakinolide, Enzo Life Sciences, Switzerland) and Cyto D (cytochalasin D, Gibco, USA), could interfere with the polymerisation and depolymerisation of the microfilaments in cells.", [["cells", "ANATOMY", 14, 19], ["microfilament", "ANATOMY", 186, 199], ["microfilaments", "ANATOMY", 425, 439], ["cells", "ANATOMY", 443, 448], ["PEDV", "CHEMICAL", 213, 217], ["infection", "DISEASE", 227, 236], ["Jas", "CHEMICAL", 262, 265], ["jasplakinolide", "CHEMICAL", 267, 281], ["cytochalasin D", "CHEMICAL", 328, 342], ["jasplakinolide", "CHEMICAL", 267, 281], ["Cyto D", "CHEMICAL", 320, 326], ["cytochalasin D", "CHEMICAL", 328, 342], ["cells", "CELL", 14, 19], ["microfilament", "CELLULAR_COMPONENT", 186, 199], ["PEDV", "SIMPLE_CHEMICAL", 213, 217], ["TGEV", "ORGANISM", 222, 226], ["Jas", "SIMPLE_CHEMICAL", 262, 265], ["jasplakinolide", "SIMPLE_CHEMICAL", 267, 281], ["Cyto D", "SIMPLE_CHEMICAL", 320, 326], ["cytochalasin D", "SIMPLE_CHEMICAL", 328, 342], ["microfilaments", "CELLULAR_COMPONENT", 425, 439], ["cells", "CELL", 443, 448], ["PEDV", "SPECIES", 213, 217], ["TGEV", "SPECIES", 222, 226], ["The pellet of cells", "TREATMENT", 0, 19], ["further standard treatment", "TREATMENT", 58, 84], ["transmission electron microscope", "TEST", 89, 121], ["the microfilament inhibitor", "TREATMENT", 182, 209], ["PEDV", "PROBLEM", 213, 217], ["TGEV infectionMicrofilament inhibitors", "TREATMENT", 222, 260], ["Jas (jasplakinolide", "TREATMENT", 262, 281], ["Cyto D (cytochalasin D", "TEST", 320, 342], ["the polymerisation", "TREATMENT", 378, 396], ["the microfilaments in cells", "PROBLEM", 421, 448]]], ["Firstly, in order to study the effects of microfilament disorder on PEDV and TGEV entry, monolayer IPEC-J2 cells were pre-treated with RPMI medium containing Jas (0.2 M) or Cyto D (2 M) for 1 h at 37 \u2022 C. IPEC-J2 cells were inoculated with TGEV, PEDV, and PEDV + TGEV at an MOI of 0.1 for 1 h at 37 \u2022 C, respectively.", [["microfilament", "ANATOMY", 42, 55], ["monolayer IPEC-J2 cells", "ANATOMY", 89, 112], ["IPEC-J2 cells", "ANATOMY", 205, 218], ["microfilament disorder", "DISEASE", 42, 64], ["Jas", "CHEMICAL", 158, 161], ["Cyto D", "CHEMICAL", 173, 179], ["PEDV", "CHEMICAL", 256, 260], ["Cyto D", "CHEMICAL", 173, 179], ["microfilament", "CELLULAR_COMPONENT", 42, 55], ["PEDV", "SIMPLE_CHEMICAL", 68, 72], ["TGEV", "ORGANISM", 77, 81], ["monolayer IPEC-J2 cells", "CELL", 89, 112], ["Jas", "SIMPLE_CHEMICAL", 158, 161], ["Cyto D", "SIMPLE_CHEMICAL", 173, 179], ["IPEC-J2 cells", "CELL", 205, 218], ["TGEV", "ORGANISM", 240, 244], ["PEDV", "SIMPLE_CHEMICAL", 246, 250], ["PEDV + TGEV", "ORGANISM", 256, 267], ["monolayer IPEC-J2 cells", "CELL_LINE", 89, 112], ["IPEC-J2 cells", "CELL_LINE", 205, 218], ["PEDV", "SPECIES", 68, 72], ["TGEV", "SPECIES", 77, 81], ["TGEV", "SPECIES", 240, 244], ["PEDV", "SPECIES", 246, 250], ["PEDV", "SPECIES", 256, 260], ["TGEV", "SPECIES", 263, 267], ["microfilament disorder", "PROBLEM", 42, 64], ["PEDV", "PROBLEM", 68, 72], ["TGEV entry", "TEST", 77, 87], ["monolayer IPEC", "TEST", 89, 103], ["J2 cells", "PROBLEM", 104, 112], ["IPEC", "TEST", 205, 209], ["J2 cells", "PROBLEM", 210, 218], ["TGEV", "TEST", 240, 244], ["PEDV", "TEST", 246, 250], ["PEDV", "PROBLEM", 256, 260], ["TGEV", "PROBLEM", 263, 267], ["an MOI", "TEST", 271, 277]]], ["The unattached viruses were removed and the infected IPEC-J2 cells were collected for analysing TCID 50 or detecting the level of viral RNA by quantitative RT-PCR (qRT-PCR).", [["IPEC-J2 cells", "ANATOMY", 53, 66], ["IPEC-J2 cells", "CELL", 53, 66], ["IPEC-J2 cells", "CELL_LINE", 53, 66], ["TCID 50", "RNA", 96, 103], ["viral RNA", "RNA", 130, 139], ["The unattached viruses", "PROBLEM", 0, 22], ["the infected IPEC-J2 cells", "TREATMENT", 40, 66], ["analysing TCID", "TEST", 86, 100], ["viral RNA", "PROBLEM", 130, 139], ["quantitative RT", "TEST", 143, 158], ["PCR", "TEST", 159, 162], ["qRT", "TEST", 164, 167], ["PCR", "TEST", 168, 171], ["viruses", "OBSERVATION", 15, 22], ["infected", "OBSERVATION_MODIFIER", 44, 52], ["viral RNA", "OBSERVATION", 130, 139]]], ["Secondly, in order to study the effects of microfilament disorder on PEDV/TGEV release, monolayer IPEC-J2 cells were inoculated with TGEV, PEDV, and PEDV + TGEV at an MOI of 0.1 for 1 h at 37 \u2022 C, respectively.", [["microfilament", "ANATOMY", 43, 56], ["monolayer IPEC-J2 cells", "ANATOMY", 88, 111], ["microfilament disorder", "DISEASE", 43, 65], ["PEDV", "CHEMICAL", 149, 153], ["microfilament", "CELLULAR_COMPONENT", 43, 56], ["PEDV", "SIMPLE_CHEMICAL", 69, 73], ["TGEV", "ORGANISM", 74, 78], ["monolayer IPEC-J2 cells", "CELL", 88, 111], ["TGEV", "ORGANISM", 133, 137], ["PEDV", "SIMPLE_CHEMICAL", 139, 143], ["PEDV + TGEV", "ORGANISM", 149, 160], ["monolayer IPEC-J2 cells", "CELL_LINE", 88, 111], ["PEDV", "SPECIES", 69, 73], ["TGEV", "SPECIES", 74, 78], ["TGEV", "SPECIES", 133, 137], ["PEDV", "SPECIES", 139, 143], ["PEDV", "SPECIES", 149, 153], ["TGEV", "SPECIES", 156, 160], ["microfilament disorder", "PROBLEM", 43, 65], ["PEDV/TGEV release", "TREATMENT", 69, 86], ["monolayer IPEC", "TEST", 88, 102], ["J2 cells", "PROBLEM", 103, 111], ["TGEV", "PROBLEM", 133, 137], ["PEDV", "PROBLEM", 139, 143], ["PEDV", "PROBLEM", 149, 153], ["TGEV", "PROBLEM", 156, 160], ["an MOI", "TEST", 164, 170], ["microfilament disorder", "OBSERVATION", 43, 65], ["J2 cells", "OBSERVATION_MODIFIER", 103, 111]]], ["The unattached viruses were removed and incubated with RPMI medium.", [["The unattached viruses", "PROBLEM", 0, 22], ["RPMI medium", "TREATMENT", 55, 66], ["viruses", "OBSERVATION", 15, 22]]], ["Then the Jas (0.2 M) or Cyto D (2 M) was added to the infected cells from 6 to 9 hpi, the supernatants and the infected IPEC-J2 cells were collected for analysing TCID 50 or detecting the level of viral RNA by qRT-PCR.", [["cells", "ANATOMY", 63, 68], ["supernatants", "ANATOMY", 90, 102], ["IPEC-J2 cells", "ANATOMY", 120, 133], ["Cyto D", "CHEMICAL", 24, 30], ["Cyto D", "CHEMICAL", 24, 30], ["Jas", "SIMPLE_CHEMICAL", 9, 12], ["Cyto D", "SIMPLE_CHEMICAL", 24, 30], ["cells", "CELL", 63, 68], ["IPEC-J2 cells", "CELL", 120, 133], ["infected cells", "CELL_TYPE", 54, 68], ["IPEC-J2 cells", "CELL_LINE", 120, 133], ["viral RNA", "RNA", 197, 206], ["Cyto D (2 M)", "TREATMENT", 24, 36], ["the infected cells", "PROBLEM", 50, 68], ["the supernatants", "TEST", 86, 102], ["the infected IPEC-J2 cells", "TREATMENT", 107, 133], ["analysing TCID", "TEST", 153, 167], ["viral RNA", "PROBLEM", 197, 206], ["qRT", "TEST", 210, 213], ["infected cells", "OBSERVATION", 54, 68], ["infected", "OBSERVATION_MODIFIER", 111, 119], ["J2 cells", "OBSERVATION", 125, 133], ["viral RNA", "OBSERVATION", 197, 206]]], ["Finally, in order to study the effects of microfilament disorder on virus replication and release, monolayer IPEC-J2 cells were inoculated with TGEV, PEDV, and PEDV + TGEV at an MOI of 0.1 for 1 h at 37 \u2022 C, respectively.", [["microfilament", "ANATOMY", 42, 55], ["monolayer IPEC-J2 cells", "ANATOMY", 99, 122], ["microfilament disorder", "DISEASE", 42, 64], ["PEDV", "CHEMICAL", 160, 164], ["microfilament", "CELLULAR_COMPONENT", 42, 55], ["monolayer IPEC-J2 cells", "CELL", 99, 122], ["TGEV", "ORGANISM", 144, 148], ["PEDV", "SIMPLE_CHEMICAL", 150, 154], ["PEDV + TGEV", "ORGANISM", 160, 171], ["monolayer IPEC", "CELL_LINE", 99, 113], ["J2 cells", "CELL_LINE", 114, 122], ["TGEV", "SPECIES", 144, 148], ["PEDV", "SPECIES", 150, 154], ["PEDV", "SPECIES", 160, 164], ["TGEV", "SPECIES", 167, 171], ["microfilament disorder", "PROBLEM", 42, 64], ["virus replication", "TREATMENT", 68, 85], ["monolayer IPEC", "TEST", 99, 113], ["J2 cells", "PROBLEM", 114, 122], ["TGEV", "PROBLEM", 144, 148], ["PEDV", "PROBLEM", 150, 154], ["PEDV", "PROBLEM", 160, 164], ["TGEV", "PROBLEM", 167, 171], ["an MOI", "TEST", 175, 181], ["microfilament disorder", "OBSERVATION", 42, 64], ["J2 cells", "OBSERVATION_MODIFIER", 114, 122]]], ["The unattached viruses were removed and incubated with RPMI medium containing Jas (0.2 M) or Cyto D (2 M) was added to the infected cells from 1 to 9 hpi, only the infected IPEC-J2 cells were collected for analysing TCID 50 or detecting the level of viral RNA by qRT-PCR.Quantitative real-time PCR (qRT-PCR)Total RNA was extracted using a commercial kit (TaKaRa, Japan).", [["cells", "ANATOMY", 132, 137], ["IPEC-J2 cells", "ANATOMY", 173, 186], ["Jas", "CHEMICAL", 78, 81], ["Cyto D", "CHEMICAL", 93, 99], ["Cyto D", "CHEMICAL", 93, 99], ["Jas", "SIMPLE_CHEMICAL", 78, 81], ["Cyto D", "SIMPLE_CHEMICAL", 93, 99], ["cells", "CELL", 132, 137], ["IPEC-J2 cells", "CELL", 173, 186], ["infected cells", "CELL_TYPE", 123, 137], ["IPEC-J2 cells", "CELL_LINE", 173, 186], ["TCID 50", "RNA", 216, 223], ["viral RNA", "RNA", 250, 259], ["The unattached viruses", "PROBLEM", 0, 22], ["RPMI medium containing Jas", "TREATMENT", 55, 81], ["Cyto D (2 M)", "TREATMENT", 93, 105], ["the infected cells", "PROBLEM", 119, 137], ["the infected IPEC-J2 cells", "TREATMENT", 160, 186], ["analysing TCID", "TEST", 206, 220], ["viral RNA", "PROBLEM", 250, 259], ["qRT", "TEST", 263, 266], ["PCR", "TEST", 267, 270], ["Quantitative real-time PCR", "TEST", 271, 297], ["qRT", "TEST", 299, 302], ["PCR", "TEST", 303, 306], ["a commercial kit (TaKaRa", "TREATMENT", 337, 361], ["viruses", "OBSERVATION", 15, 22], ["infected cells", "OBSERVATION", 123, 137], ["infected", "OBSERVATION", 164, 172], ["viral RNA", "OBSERVATION", 250, 259]]], ["Then, RT-PCR was performed using an RT-PCR kit (TaKaRa, Japan) according to the manufacturer's instructions.", [["RT-PCR", "TEST", 6, 12], ["an RT-PCR kit", "TREATMENT", 33, 46], ["TaKaRa", "TREATMENT", 48, 54]]], ["To determine the gene expression profiles, individual samples were diluted 1:10 and 2 l was amplified in a 20 l reaction containing 10 l of SYBR Premix TM Ex Taq (TaKaRa), 0.4 l of ROX dye II and 0.4 M of each of the forward and reverse gene-specific primers using an ABI 7500 instrument (Applied Biosystems, USA).", [["samples", "ANATOMY", 54, 61], ["ROX dye II", "CHEMICAL", 181, 191], ["ROX dye II", "GENE_OR_GENE_PRODUCT", 181, 191], ["SYBR Premix TM Ex Taq", "PROTEIN", 140, 161], ["forward and reverse gene", "DNA", 217, 241], ["a 20 l reaction", "TREATMENT", 105, 120], ["SYBR Premix TM Ex Taq (TaKaRa)", "TREATMENT", 140, 170], ["ROX dye II", "TREATMENT", 181, 191], ["an ABI", "TEST", 265, 271]]], ["PEDV M gene was one target gene (GenBank accession no. AF353511.1), and the primers were: FP: 5 -aggtctgcattccagtgctt-3 , RP: 5 -ggacatagaaagcccaacca-3 .", [["AF353511.1", "CHEMICAL", 55, 65], ["PEDV M", "GENE_OR_GENE_PRODUCT", 0, 6], ["5 -aggtctgcattccagtgctt-3", "SIMPLE_CHEMICAL", 94, 119], ["5 -ggacatagaaagcccaacca-3", "SIMPLE_CHEMICAL", 126, 151], ["PEDV M gene", "DNA", 0, 11], ["target gene", "DNA", 20, 31], ["PEDV", "SPECIES", 0, 4], ["the primers", "TEST", 72, 83], ["FP", "TEST", 90, 92], ["aggtctgcattccagtgctt", "TEST", 97, 117], ["RP", "TEST", 122, 124], ["ggacatagaaagcccaacca", "TEST", 129, 149]]], ["TGEV M gene was another target gene (GenBank accession no. AF302262.1), and the primers were: FP: 5 -gtgcttcctctcgaaggtgt-3 , RP: 5 -cccatccagtcgcactactt-3 .", [["AF302262.1", "CHEMICAL", 59, 69], ["TGEV M", "GENE_OR_GENE_PRODUCT", 0, 6], ["5 -gtgcttcctctcgaaggtgt-3", "SIMPLE_CHEMICAL", 98, 123], ["5 -cccatccagtcgcactactt-3", "SIMPLE_CHEMICAL", 130, 155], ["TGEV M gene", "DNA", 0, 11], ["target gene", "DNA", 24, 35], ["TGEV", "SPECIES", 0, 4], ["the primers", "TEST", 76, 87], ["FP", "TEST", 94, 96], ["gtgcttcctctcgaaggtgt", "TEST", 101, 121], ["RP", "TEST", 126, 128], ["cccatccagtcgcactactt", "TEST", 133, 153]]], ["Porcine GAPDH gene was used as the internal parameter (GenBank accession no. NM 001206359.1).", [["Porcine", "ORGANISM", 0, 7], ["GAPDH", "GENE_OR_GENE_PRODUCT", 8, 13], ["Porcine GAPDH gene", "DNA", 0, 18], ["Porcine", "SPECIES", 0, 7], ["Porcine", "SPECIES", 0, 7], ["Porcine GAPDH gene", "TREATMENT", 0, 18], ["GAPDH gene", "OBSERVATION", 8, 18]]], ["The primers were: FP: tcatcatctctgccccttct, RP: gtcatgagtccctccacgat.", [["gtcatgagtccctccacgat", "TREATMENT", 48, 68]]], ["The data were analysed using the ABI PRISM 7500 software tool (Applied Biosystems, USA).", [["The data", "TEST", 0, 8], ["the ABI PRISM", "TEST", 29, 42], ["software tool", "TEST", 48, 61]]], ["7500 Real-Time PCR System (ABI) and Fast-Start Universal SYBR Green Master (Takara) were used for qRT-PCR.", [["ABI", "TEST", 27, 30], ["Fast", "TEST", 36, 40], ["Universal SYBR Green Master (Takara)", "TREATMENT", 47, 83], ["qRT", "TEST", 98, 101]]], ["Each sample and negative controls (no template) were run in at least three technical replicates.", [["sample", "ANATOMY", 5, 11], ["Each sample", "TEST", 0, 11]]], ["GAPDH was amplified under the same conditions as internal control to normalise reactions.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAPDH", "PROTEIN", 0, 5], ["GAPDH", "PROBLEM", 0, 5]]], ["After completion of the PCR amplification, the relative fold change was calculated based on the \u2212 ct calculation.FACS analysisPEDV-, TGEV-and PEDV + TGEV-infected and mock-infected IPEC-J2 cells at 1 and 24 hpi were harvested by 0.25% trypsinisation, then fixed and permeabilised in FACS permeabilisation buffer II (BD Pharmingen, USA), washed 3 times with 0.01 M PBS and incubated with a 1% solution of BSA (30 min, RT).", [["IPEC-J2 cells", "ANATOMY", 181, 194], ["BSA", "CHEMICAL", 404, 407], ["TGEV", "ORGANISM", 133, 137], ["PEDV + TGEV", "ORGANISM", 142, 153], ["IPEC-J2 cells", "CELL", 181, 194], ["BSA", "SIMPLE_CHEMICAL", 404, 407], ["IPEC-J2 cells", "CELL_LINE", 181, 194], ["TGEV", "SPECIES", 133, 137], ["PEDV", "SPECIES", 142, 146], ["TGEV", "SPECIES", 149, 153], ["the PCR amplification", "TREATMENT", 20, 41], ["the relative fold change", "PROBLEM", 43, 67], ["the \u2212 ct calculation", "TEST", 92, 112], ["FACS analysisPEDV", "TEST", 113, 130], ["TGEV", "TEST", 133, 137], ["PEDV", "PROBLEM", 142, 146], ["TGEV", "PROBLEM", 149, 153], ["J2 cells", "PROBLEM", 186, 194], ["0.01 M PBS", "TREATMENT", 357, 367], ["a 1% solution of BSA", "TREATMENT", 387, 407], ["fold", "OBSERVATION_MODIFIER", 56, 60], ["change", "OBSERVATION", 61, 67], ["J2 cells", "OBSERVATION_MODIFIER", 186, 194]]], ["Then, cells stained with the primary antibodies anti-ERK1/2 antibody, anti-ERK1/2 (phospho T202 + Y204) antibody, anti-p38 antibody, anti-p38 (phospho T180 + Y182) antibody, anti-JNK1 + JNK2 antibody and anti-JNK1 + JNK2 (phospho T183 + Y185) antibody (Abcam, Hong Kong) were incubated overnight at 4 \u2022 C. Subsequently, cells were washed 3 times with 0.01 M PBS and the PE-conjugated goat anti-rabbit IgG2b (Invitrogen, USA) was added (1 h, RT).", [["cells", "ANATOMY", 6, 11], ["cells", "ANATOMY", 320, 325], ["PE", "CHEMICAL", 370, 372], ["cells", "CELL", 6, 11], ["anti-ERK1/2 antibody", "GENE_OR_GENE_PRODUCT", 48, 68], ["anti-ERK1/2", "GENE_OR_GENE_PRODUCT", 70, 81], ["phospho", "GENE_OR_GENE_PRODUCT", 83, 90], ["Y204", "GENE_OR_GENE_PRODUCT", 98, 102], ["p38", "GENE_OR_GENE_PRODUCT", 119, 122], ["anti-p38", "GENE_OR_GENE_PRODUCT", 133, 141], ["anti-JNK1", "GENE_OR_GENE_PRODUCT", 174, 183], ["JNK2", "GENE_OR_GENE_PRODUCT", 186, 190], ["anti-JNK1 + JNK2", "GENE_OR_GENE_PRODUCT", 204, 220], ["cells", "CELL", 320, 325], ["PE", "SIMPLE_CHEMICAL", 370, 372], ["goat", "ORGANISM", 384, 388], ["IgG2b", "GENE_OR_GENE_PRODUCT", 401, 406], ["primary antibodies anti-ERK1/2 antibody", "PROTEIN", 29, 68], ["anti-ERK1/2", "PROTEIN", 70, 81], ["phospho T202 + Y204) antibody", "PROTEIN", 83, 112], ["anti-p38 antibody", "PROTEIN", 114, 131], ["anti-p38", "PROTEIN", 133, 141], ["phospho T180 + Y182) antibody", "PROTEIN", 143, 172], ["anti-JNK1", "PROTEIN", 174, 183], ["JNK2 antibody", "PROTEIN", 186, 199], ["anti-JNK1", "PROTEIN", 204, 213], ["JNK2", "PROTEIN", 216, 220], ["phospho T183 + Y185) antibody", "PROTEIN", 222, 251], ["Abcam", "PROTEIN", 253, 258], ["conjugated goat anti-rabbit IgG2b", "PROTEIN", 373, 406], ["goat", "SPECIES", 384, 388], ["anti-rabbit", "SPECIES", 389, 400], ["goat", "SPECIES", 384, 388], ["anti-rabbit", "SPECIES", 389, 400], ["the primary antibodies", "TEST", 25, 47], ["anti-ERK1", "TEST", 48, 57], ["antibody", "TEST", 60, 68], ["anti-ERK1", "TEST", 70, 79], ["phospho", "TEST", 83, 90], ["T202", "TEST", 91, 95], ["Y204", "TEST", 98, 102], ["antibody", "TEST", 104, 112], ["anti", "TEST", 114, 118], ["antibody", "TEST", 123, 131], ["anti-p38", "TEST", 133, 141], ["phospho", "TEST", 143, 150], ["T180", "TEST", 151, 155], ["Y182", "TEST", 158, 162], ["antibody", "TEST", 164, 172], ["anti-JNK1", "TEST", 174, 183], ["JNK2 antibody", "TEST", 186, 199], ["anti-JNK1", "TEST", 204, 213], ["JNK2", "TEST", 216, 220], ["phospho", "TEST", 222, 229], ["T183", "TEST", 230, 234], ["antibody", "TEST", 243, 251], ["Abcam", "TEST", 253, 258], ["the PE", "TEST", 366, 372], ["conjugated goat anti-rabbit IgG2b (Invitrogen, USA)", "TREATMENT", 373, 424], ["PE", "OBSERVATION", 370, 372]]], ["The negative control cells were treated in an identical manner, except the primary antibodies were omitted.", [["cells", "ANATOMY", 21, 26], ["cells", "CELL", 21, 26], ["primary antibodies", "PROTEIN", 75, 93], ["the primary antibodies", "TEST", 71, 93], ["negative", "OBSERVATION_MODIFIER", 4, 12], ["control cells", "OBSERVATION", 13, 26]]], ["Cells were then washed, and 1 \u00d7 10 4 cells were analysed by flow cytometry for the mean fluorescence intensity (MFI).", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 37, 42], ["Cells", "CELL", 0, 5], ["cells", "CELL", 37, 42], ["Cells", "TEST", 0, 5], ["flow cytometry", "TEST", 60, 74]]], ["The results are expressed as the mean fluorescence intensity ratio.", [["the mean fluorescence intensity ratio", "TEST", 29, 66]]], ["The mean fluorescence intensity ratio was calculated using the formula: (MFI infection phospho protein /MFI infection total protein )/ (MFI control phospho protein /MFI control total protein ).Effects of MAPK pathway inhibitor on PEDV and TGEV infection, the tight junctions and microfilaments of IPEC-J2 cellsIn order to study the effects of MAPK pathway of IPEC-J2 cells on PEDV and TGEV infection, the tight junctions and microfilaments of IPEC-J2 cells, the monolayer IPEC-J2 cells were pre-treated with RPMI medium containing 50 m/l of ERK-MAPK-specific inhibitor (PD98059), 10 m/l of p38-MAPK-specific inhibitor (SB203580) or 10 m/l of JNK-MAPK-specific inhibitor (SP600125) for 2 h at 37 \u2022 C. IPEC-J2 cells were inoculated with TGEV, PEDV and PEDV + TGEV at an MOI of 0.1 for 1 h at 37 \u2022 C, respectively.", [["tight junctions", "ANATOMY", 259, 274], ["microfilaments", "ANATOMY", 279, 293], ["IPEC-J2 cells", "ANATOMY", 297, 310], ["IPEC-J2 cells", "ANATOMY", 359, 372], ["tight junctions", "ANATOMY", 405, 420], ["microfilaments", "ANATOMY", 425, 439], ["IPEC-J2 cells", "ANATOMY", 443, 456], ["monolayer IPEC-J2 cells", "ANATOMY", 462, 485], ["IPEC-J2 cells", "ANATOMY", 700, 713], ["infection", "DISEASE", 77, 86], ["infection", "DISEASE", 108, 117], ["TGEV infection", "DISEASE", 239, 253], ["TGEV infection", "DISEASE", 385, 399], ["PD98059", "CHEMICAL", 570, 577], ["SB203580", "CHEMICAL", 619, 627], ["SP600125", "CHEMICAL", 671, 679], ["PEDV", "CHEMICAL", 750, 754], ["phospho", "CHEMICAL", 87, 94], ["phospho", "CHEMICAL", 148, 155], ["PD98059", "CHEMICAL", 570, 577], ["SB203580", "CHEMICAL", 619, 627], ["SP600125", "CHEMICAL", 671, 679], ["MAPK", "GENE_OR_GENE_PRODUCT", 204, 208], ["PEDV", "GENE_OR_GENE_PRODUCT", 230, 234], ["TGEV", "ORGANISM", 239, 243], ["tight junctions", "CELLULAR_COMPONENT", 259, 274], ["microfilaments", "CELLULAR_COMPONENT", 279, 293], ["IPEC-J2 cells", "CELL", 297, 310], ["MAPK", "GENE_OR_GENE_PRODUCT", 343, 347], ["IPEC-J2 cells", "CELL", 359, 372], ["PEDV", "CELL", 376, 380], ["TGEV", "ORGANISM", 385, 389], ["tight junctions", "CELLULAR_COMPONENT", 405, 420], ["microfilaments", "CELLULAR_COMPONENT", 425, 439], ["IPEC-J2 cells", "CELL", 443, 456], ["monolayer IPEC-J2 cells", "CELL", 462, 485], ["ERK-MAPK", "GENE_OR_GENE_PRODUCT", 541, 549], ["PD98059", "SIMPLE_CHEMICAL", 570, 577], ["p38-MAPK", "GENE_OR_GENE_PRODUCT", 590, 598], ["SB203580", "SIMPLE_CHEMICAL", 619, 627], ["JNK-MAPK", "GENE_OR_GENE_PRODUCT", 642, 650], ["SP600125", "SIMPLE_CHEMICAL", 671, 679], ["IPEC-J2 cells", "CELL", 700, 713], ["TGEV", "ORGANISM", 735, 739], ["PEDV", "SIMPLE_CHEMICAL", 741, 745], ["PEDV + TGEV", "ORGANISM", 750, 761], ["phospho protein", "PROTEIN", 87, 102], ["MFI infection total protein", "PROTEIN", 104, 131], ["MFI", "PROTEIN", 136, 139], ["phospho protein", "PROTEIN", 148, 163], ["MFI", "PROTEIN", 165, 168], ["total protein", "PROTEIN", 177, 190], ["MAPK", "PROTEIN", 204, 208], ["IPEC-J2 cells", "CELL_LINE", 297, 310], ["MAPK", "PROTEIN", 343, 347], ["IPEC-J2 cells", "CELL_LINE", 359, 372], ["IPEC-J2 cells", "CELL_LINE", 443, 456], ["monolayer IPEC-J2 cells", "CELL_LINE", 462, 485], ["ERK", "PROTEIN", 541, 544], ["MAPK", "PROTEIN", 545, 549], ["p38", "PROTEIN", 590, 593], ["MAPK", "PROTEIN", 594, 598], ["JNK", "PROTEIN", 642, 645], ["MAPK", "PROTEIN", 646, 650], ["IPEC-J2 cells", "CELL_LINE", 700, 713], ["TGEV", "SPECIES", 239, 243], ["TGEV", "SPECIES", 385, 389], ["PEDV", "SPECIES", 230, 234], ["TGEV", "SPECIES", 239, 243], ["PEDV", "SPECIES", 376, 380], ["TGEV", "SPECIES", 385, 389], ["TGEV", "SPECIES", 735, 739], ["PEDV", "SPECIES", 741, 745], ["PEDV", "SPECIES", 750, 754], ["TGEV", "SPECIES", 757, 761], ["The mean fluorescence intensity ratio", "TEST", 0, 37], ["phospho protein", "TEST", 87, 102], ["MFI infection", "PROBLEM", 104, 117], ["total protein", "TEST", 118, 131], ["MFI", "TEST", 136, 139], ["phospho protein", "TEST", 148, 163], ["MFI", "TEST", 165, 168], ["total protein", "TEST", 177, 190], ["MAPK pathway inhibitor", "TREATMENT", 204, 226], ["PEDV", "PROBLEM", 230, 234], ["TGEV infection", "PROBLEM", 239, 253], ["IPEC", "TEST", 297, 301], ["J2 cells", "PROBLEM", 302, 310], ["MAPK pathway", "TEST", 343, 355], ["IPEC", "TEST", 359, 363], ["J2 cells", "PROBLEM", 364, 372], ["PEDV", "PROBLEM", 376, 380], ["TGEV infection", "PROBLEM", 385, 399], ["IPEC", "TEST", 443, 447], ["J2 cells", "PROBLEM", 448, 456], ["the monolayer IPEC", "TEST", 458, 476], ["J2 cells", "PROBLEM", 477, 485], ["RPMI medium", "TREATMENT", 508, 519], ["ERK", "TEST", 541, 544], ["MAPK", "TEST", 545, 549], ["PD98059", "TEST", 570, 577], ["p38", "TEST", 590, 593], ["MAPK", "TEST", 594, 598], ["SB203580", "TEST", 619, 627], ["JNK", "TEST", 642, 645], ["MAPK", "TEST", 646, 650], ["IPEC", "TEST", 700, 704], ["J2 cells", "PROBLEM", 705, 713], ["TGEV", "PROBLEM", 735, 739], ["PEDV", "PROBLEM", 741, 745], ["PEDV", "PROBLEM", 750, 754], ["TGEV", "PROBLEM", 757, 761], ["an MOI", "TEST", 765, 771], ["infection", "OBSERVATION", 244, 253], ["J2 cells", "OBSERVATION", 302, 310], ["TGEV infection", "OBSERVATION", 385, 399]]], ["The unattached viruses were removed and the infected IPEC-J2 cells were cultured with RPMI medium containing those three inhibitors for the required time.", [["IPEC-J2 cells", "ANATOMY", 53, 66], ["IPEC-J2 cells", "CELL", 53, 66], ["IPEC-J2 cells", "CELL_LINE", 53, 66], ["The unattached viruses", "PROBLEM", 0, 22], ["the infected IPEC-J2 cells", "TREATMENT", 40, 66], ["RPMI medium", "TREATMENT", 86, 97], ["those three inhibitors", "TREATMENT", 109, 131], ["viruses", "OBSERVATION", 15, 22], ["infected", "OBSERVATION_MODIFIER", 44, 52], ["J2 cells", "OBSERVATION", 58, 66]]], ["The analysis of mock and treated IPEC-J2 cells is as follows:Effects of MAPK pathway inhibitor on PEDV and TGEV infection, the tight junctions and microfilaments of IPEC-J2 cells(1) Mock and treated IPEC-J2 cells at 12 and 24 hpi were added Trizol to detect the level of viral RNA by qRT-PCR.", [["IPEC-J2 cells", "ANATOMY", 33, 46], ["tight junctions", "ANATOMY", 127, 142], ["microfilaments", "ANATOMY", 147, 161], ["IPEC-J2 cells", "ANATOMY", 165, 178], ["IPEC-J2 cells", "ANATOMY", 199, 212], ["TGEV infection", "DISEASE", 107, 121], ["IPEC-J2 cells", "CELL", 33, 46], ["MAPK", "GENE_OR_GENE_PRODUCT", 72, 76], ["PEDV", "SIMPLE_CHEMICAL", 98, 102], ["TGEV", "ORGANISM", 107, 111], ["tight junctions", "CELLULAR_COMPONENT", 127, 142], ["microfilaments", "CELLULAR_COMPONENT", 147, 161], ["IPEC-J2 cells", "CELL", 165, 178], ["Mock", "CELL", 182, 186], ["IPEC-J2 cells", "CELL", 199, 212], ["IPEC-J2 cells", "CELL_LINE", 33, 46], ["MAPK", "PROTEIN", 72, 76], ["IPEC-J2 cells", "CELL_LINE", 165, 178], ["IPEC-J2 cells", "CELL_LINE", 199, 212], ["viral RNA", "RNA", 271, 280], ["PEDV", "SPECIES", 98, 102], ["TGEV", "SPECIES", 107, 111], ["The analysis of mock", "TEST", 0, 20], ["treated IPEC-J2 cells", "TREATMENT", 25, 46], ["MAPK pathway inhibitor", "TREATMENT", 72, 94], ["PEDV", "PROBLEM", 98, 102], ["TGEV infection", "PROBLEM", 107, 121], ["IPEC", "TEST", 165, 169], ["Mock", "TEST", 182, 186], ["IPEC-J2 cells", "TREATMENT", 199, 212], ["Trizol", "TREATMENT", 241, 247], ["viral RNA", "PROBLEM", 271, 280], ["TGEV infection", "OBSERVATION", 107, 121], ["viral RNA", "OBSERVATION", 271, 280]]], ["(2) Mock and treated IPEC-J2 cells at 60 minpi and 24 hpi were harvested and prepared for Western blot, as described in Section 2.6.", [["IPEC-J2 cells", "ANATOMY", 21, 34], ["Mock", "ORGANISM", 4, 8], ["IPEC-J2 cells", "CELL", 21, 34], ["IPEC-J2 cells", "CELL_LINE", 21, 34], ["Mock and treated IPEC-J2 cells", "TREATMENT", 4, 34], ["Western blot", "TEST", 90, 102]]], ["(3) Mock and treated IPEC-J2 cells at 40, 60 minpi and 12, 24 hpi were fixed with 3.7% polyoxymethylene and stained with FITC-Phalloidin for immunofluorescence, as described in Section 2.2.Statistical analysisThe statistical analysis was performed using the Statistical Product and Services Solutions (SPSS) package, version 16.0.", [["IPEC-J2 cells", "ANATOMY", 21, 34], ["polyoxymethylene", "CHEMICAL", 87, 103], ["polyoxymethylene", "CHEMICAL", 87, 103], ["FITC", "CHEMICAL", 121, 125], ["Phalloidin", "CHEMICAL", 126, 136], ["Mock", "CELL", 4, 8], ["IPEC-J2 cells", "CELL", 21, 34], ["polyoxymethylene", "SIMPLE_CHEMICAL", 87, 103], ["FITC-Phalloidin", "SIMPLE_CHEMICAL", 121, 136], ["IPEC-J2 cells", "CELL_LINE", 21, 34], ["Mock and treated IPEC-J2 cells", "TEST", 4, 34], ["minpi", "TEST", 45, 50], ["3.7% polyoxymethylene", "TREATMENT", 82, 103], ["FITC-Phalloidin", "TREATMENT", 121, 136], ["immunofluorescence", "TEST", 141, 159], ["Statistical analysis", "TEST", 189, 209], ["The statistical analysis", "TEST", 209, 233]]], ["Duncan's test was conducted to determine the differences among treated groups.", [["Duncan's test", "TEST", 0, 13]]], ["Significance was indicated by a probability of p < 0.05.IPEC-J2 cells are susceptible to PEDV and TGEVFirstly, to determine whether PEDV and TGEV could infect and replicate in IPEC-J2 cells, IPEC-J2 infected at an MOI of 0.1 PEDV and TGEV at 0, 6, 12, 24, 48, 72 h post infection (pi) were observed by immunofluorescence staining.", [["IPEC-J2 cells", "ANATOMY", 56, 69], ["IPEC-J2 cells", "ANATOMY", 176, 189], ["PEDV", "CHEMICAL", 132, 136], ["infection", "DISEASE", 270, 279], ["IPEC-J2 cells", "CELL", 56, 69], ["PEDV", "CELL", 89, 93], ["PEDV", "GENE_OR_GENE_PRODUCT", 132, 136], ["TGEV", "ORGANISM", 141, 145], ["IPEC-J2 cells", "CELL", 176, 189], ["IPEC-J2", "CELL", 191, 198], ["TGEV", "ORGANISM", 234, 238], ["IPEC-J2 cells", "CELL_LINE", 56, 69], ["PEDV", "PROTEIN", 132, 136], ["IPEC-J2 cells", "CELL_LINE", 176, 189], ["PEDV", "SPECIES", 89, 93], ["PEDV", "SPECIES", 132, 136], ["TGEV", "SPECIES", 141, 145], ["PEDV", "SPECIES", 225, 229], ["TGEV", "SPECIES", 234, 238], ["IPEC", "TEST", 56, 60], ["J2 cells", "PROBLEM", 61, 69], ["PEDV", "PROBLEM", 89, 93], ["PEDV", "PROBLEM", 132, 136], ["TGEV", "PROBLEM", 141, 145], ["IPEC", "TEST", 176, 180], ["IPEC", "TEST", 191, 195], ["an MOI", "TEST", 211, 217], ["PEDV", "PROBLEM", 225, 229], ["TGEV", "TEST", 234, 238], ["infection", "PROBLEM", 270, 279], ["immunofluorescence staining", "TEST", 302, 329], ["J2 cells", "OBSERVATION_MODIFIER", 61, 69], ["J2 cells", "OBSERVATION_MODIFIER", 181, 189], ["J2 infected", "OBSERVATION_MODIFIER", 196, 207], ["infection", "OBSERVATION", 270, 279]]], ["From the results, both PEDV and TGEV could infect the IPEC-J2 cells.", [["IPEC-J2 cells", "ANATOMY", 54, 67], ["PEDV", "CHEMICAL", 23, 27], ["PEDV", "SIMPLE_CHEMICAL", 23, 27], ["TGEV", "ORGANISM", 32, 36], ["IPEC-J2 cells", "CELL", 54, 67], ["IPEC-J2 cells", "CELL_LINE", 54, 67], ["PEDV", "SPECIES", 23, 27], ["TGEV", "SPECIES", 32, 36], ["TGEV", "PROBLEM", 32, 36], ["J2 cells", "OBSERVATION", 59, 67]]], ["After PEDV infection 6 h and TGEV infection 12 h, the immunofluorescences were read visually from images.", [["infection", "DISEASE", 11, 20], ["TGEV infection", "DISEASE", 29, 43], ["TGEV", "ORGANISM", 29, 33], ["PEDV", "SPECIES", 6, 10], ["TGEV", "SPECIES", 29, 33], ["PEDV infection", "PROBLEM", 6, 20], ["TGEV infection", "PROBLEM", 29, 43], ["the immunofluorescences", "TEST", 50, 73], ["images", "TEST", 98, 104], ["infection", "OBSERVATION", 11, 20]]], ["Initially, the immunofluorescences were distributed in the plasma membrane, then in the cytoplasm.", [["plasma membrane", "ANATOMY", 59, 74], ["cytoplasm", "ANATOMY", 88, 97], ["plasma membrane", "CELLULAR_COMPONENT", 59, 74], ["cytoplasm", "ORGANISM_SUBSTANCE", 88, 97], ["the immunofluorescences", "TEST", 11, 34], ["plasma membrane", "OBSERVATION", 59, 74]]], ["The above phenomenon might because the two viruses were first distributed in the plasma membrane, then they increased in the cytoplasm from 12 to 24 hpi.", [["plasma membrane", "ANATOMY", 81, 96], ["cytoplasm", "ANATOMY", 125, 134], ["plasma membrane", "CELLULAR_COMPONENT", 81, 96], ["cytoplasm", "ORGANISM_SUBSTANCE", 125, 134], ["The above phenomenon", "PROBLEM", 0, 20], ["the two viruses", "PROBLEM", 35, 50], ["viruses", "OBSERVATION", 43, 50], ["plasma membrane", "ANATOMY", 81, 96], ["increased", "OBSERVATION_MODIFIER", 108, 117]]], ["Finally, these viruses decreased in the cytoplasm over time due to lack of nutrients for the IPEC-J2 cells (Fig. 1A) .", [["cytoplasm", "ANATOMY", 40, 49], ["IPEC-J2 cells", "ANATOMY", 93, 106], ["cytoplasm", "ORGANISM_SUBSTANCE", 40, 49], ["IPEC-J2 cells", "CELL", 93, 106], ["Fig. 1A", "CELL", 108, 115], ["IPEC-J2 cells", "CELL_LINE", 93, 106], ["these viruses", "PROBLEM", 9, 22], ["the IPEC-J2 cells", "TREATMENT", 89, 106], ["viruses", "OBSERVATION", 15, 22], ["decreased", "OBSERVATION_MODIFIER", 23, 32]]], ["Similarly, the phenomenon of PEDV or TGEV single infection was consistent with their co-infection (Fig. 1B) .", [["PEDV", "CHEMICAL", 29, 33], ["infection", "DISEASE", 49, 58], ["PEDV", "GENE_OR_GENE_PRODUCT", 29, 33], ["TGEV", "ORGANISM", 37, 41], ["PEDV", "SPECIES", 29, 33], ["TGEV", "SPECIES", 37, 41], ["PEDV", "PROBLEM", 29, 33], ["TGEV single infection", "PROBLEM", 37, 58], ["their co-infection", "PROBLEM", 79, 97], ["PEDV", "OBSERVATION", 29, 33], ["infection", "OBSERVATION", 49, 58], ["consistent with", "UNCERTAINTY", 63, 78], ["co-infection", "OBSERVATION", 85, 97]]], ["To study the percentage of PEDV and TGEV infected IPEC-J2, TCID 50 was used to draw the viral proliferation curve.", [["PEDV", "CELL", 27, 31], ["TGEV", "ORGANISM", 36, 40], ["IPEC-J2", "CELL", 50, 57], ["TCID 50", "CELL", 59, 66], ["TGEV", "SPECIES", 36, 40], ["PEDV", "SPECIES", 27, 31], ["TGEV", "SPECIES", 36, 40], ["PEDV", "PROBLEM", 27, 31], ["TGEV infected IPEC", "TREATMENT", 36, 54], ["the viral proliferation curve", "TEST", 84, 113], ["PEDV", "OBSERVATION", 27, 31], ["infected", "OBSERVATION_MODIFIER", 41, 49], ["viral proliferation", "OBSERVATION", 88, 107]]], ["In the early infection (6 hpi), the titre of TGEV replication was lower than PEDV.", [["infection", "DISEASE", 13, 22], ["TGEV", "ORGANISM", 45, 49], ["TGEV", "SPECIES", 45, 49], ["PEDV", "SPECIES", 77, 81], ["the early infection", "PROBLEM", 3, 22], ["TGEV replication", "TREATMENT", 45, 61], ["PEDV", "PROBLEM", 77, 81], ["early", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 13, 22]]], ["At 24 hpi, although both TGEV and PEDV reached the replication peak, the titre of TGEV replication was still lower than the PEDV.", [["TGEV", "ORGANISM", 25, 29], ["PEDV", "GENE_OR_GENE_PRODUCT", 34, 38], ["TGEV", "ORGANISM", 82, 86], ["TGEV", "SPECIES", 25, 29], ["TGEV", "SPECIES", 82, 86], ["PEDV", "SPECIES", 124, 128], ["PEDV", "PROBLEM", 34, 38], ["TGEV replication", "TREATMENT", 82, 98]]], ["The data showed that the same concentration of TGEV and PEDV infected the IPEC-J2 cells, the PEDV replication was faster that TGEV.", [["IPEC-J2 cells", "ANATOMY", 74, 87], ["PEDV", "CHEMICAL", 56, 60], ["TGEV", "ORGANISM", 47, 51], ["PEDV", "SIMPLE_CHEMICAL", 56, 60], ["IPEC-J2 cells", "CELL", 74, 87], ["TGEV", "ORGANISM", 126, 130], ["IPEC-J2 cells", "CELL_LINE", 74, 87], ["TGEV", "SPECIES", 47, 51], ["PEDV", "SPECIES", 56, 60], ["PEDV", "SPECIES", 93, 97], ["TGEV", "SPECIES", 126, 130], ["The data", "TEST", 0, 8], ["TGEV", "PROBLEM", 47, 51], ["PEDV", "PROBLEM", 56, 60], ["the IPEC-J2 cells", "TREATMENT", 70, 87], ["the PEDV replication", "TREATMENT", 89, 109], ["J2 cells", "OBSERVATION", 79, 87]]], ["Moreover, the higher the concentration of virus was, the faster the virus replication was to reach the peak .", [["the higher the concentration of virus", "PROBLEM", 10, 47], ["the faster the virus replication", "PROBLEM", 53, 85], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["virus", "OBSERVATION", 42, 47], ["virus replication", "OBSERVATION", 68, 85], ["peak", "OBSERVATION_MODIFIER", 103, 107]]], ["These data showed that MOI 1 of PEDV and TGEV infection reached a peak at 24 hpi, while the MOI 0.1 of their infection reached a peak at 48 hpi and then gradually decreased (Fig. 1C) .PEDV and TGEV infection instantly destroyed the epithelial barrier integrityTo assess whether PEDV or TGEV single infection or co-infection could damage the epithelial barrier of IPEC-J2 cells, we first measured the changes in the transepithelial electrical resistance (TEER) of IPEC-J2 cells infected with them.", [["epithelial barrier", "ANATOMY", 232, 250], ["epithelial barrier", "ANATOMY", 341, 359], ["IPEC-J2 cells", "ANATOMY", 363, 376], ["transepithelial", "ANATOMY", 415, 430], ["IPEC-J2 cells", "ANATOMY", 463, 476], ["PEDV", "CHEMICAL", 32, 36], ["infection", "DISEASE", 46, 55], ["infection", "DISEASE", 109, 118], ["PEDV", "CHEMICAL", 184, 188], ["infection", "DISEASE", 198, 207], ["PEDV", "CHEMICAL", 278, 282], ["infection", "DISEASE", 298, 307], ["co-infection", "DISEASE", 311, 323], ["PEDV", "ORGANISM", 32, 36], ["TGEV", "ORGANISM", 41, 45], ["PEDV", "SIMPLE_CHEMICAL", 184, 188], ["TGEV", "ORGANISM", 193, 197], ["epithelial barrier", "TISSUE", 232, 250], ["PEDV", "GENE_OR_GENE_PRODUCT", 278, 282], ["TGEV", "ORGANISM", 286, 290], ["epithelial barrier", "TISSUE", 341, 359], ["IPEC-J2 cells", "CELL", 363, 376], ["IPEC-J2 cells", "CELL", 463, 476], ["IPEC-J2 cells", "CELL_LINE", 363, 376], ["IPEC-J2 cells", "CELL_LINE", 463, 476], ["PEDV", "SPECIES", 32, 36], ["TGEV", "SPECIES", 41, 45], ["PEDV", "SPECIES", 184, 188], ["TGEV", "SPECIES", 193, 197], ["PEDV", "SPECIES", 278, 282], ["TGEV", "SPECIES", 286, 290], ["These data", "TEST", 0, 10], ["MOI", "PROBLEM", 23, 26], ["PEDV", "PROBLEM", 32, 36], ["TGEV infection", "PROBLEM", 41, 55], ["their infection", "PROBLEM", 103, 118], ["PEDV", "PROBLEM", 184, 188], ["TGEV infection", "PROBLEM", 193, 207], ["the epithelial barrier integrity", "TREATMENT", 228, 260], ["PEDV", "PROBLEM", 278, 282], ["TGEV single infection", "PROBLEM", 286, 307], ["co-infection", "PROBLEM", 311, 323], ["J2 cells", "PROBLEM", 368, 376], ["the transepithelial electrical resistance", "TEST", 411, 452], ["IPEC", "TEST", 463, 467], ["J2 cells", "PROBLEM", 468, 476], ["infection", "OBSERVATION", 46, 55], ["infection", "OBSERVATION", 109, 118], ["decreased", "OBSERVATION_MODIFIER", 163, 172], ["TGEV", "OBSERVATION_MODIFIER", 193, 197], ["infection", "OBSERVATION", 198, 207], ["epithelial barrier integrity", "OBSERVATION", 232, 260], ["infection", "OBSERVATION", 298, 307], ["epithelial", "ANATOMY_MODIFIER", 341, 351], ["J2 cells", "OBSERVATION", 368, 376], ["transepithelial electrical resistance", "OBSERVATION", 415, 452], ["J2 cells", "OBSERVATION", 468, 476]]], ["From the results, we observed that the TEER of the control group (mock group) maintained in the 3500 cm 2 from 0 to 84 hpi, while the TEER of IPEC-J2 cells infected with PEDV declined at 20 minpi, restored after 40 min, .", [["IPEC-J2 cells", "ANATOMY", 142, 155], ["IPEC-J2", "CHEMICAL", 142, 149], ["PEDV", "CHEMICAL", 170, 174], ["IPEC-J2 cells", "CELL", 142, 155], ["PEDV", "CELL", 170, 174], ["IPEC-J2 cells", "CELL_LINE", 142, 155], ["PEDV", "SPECIES", 170, 174], ["the TEER", "TEST", 130, 138], ["IPEC", "TEST", 142, 146], ["J2 cells", "PROBLEM", 147, 155], ["PEDV", "PROBLEM", 170, 174]]], ["The symbol * indicates statistically significant differences (P < 0.05) when compared with the control group, and the symbol ** indicates statistically very significant differences (P < 0.01) when compared with the control group.", [["statistically", "OBSERVATION_MODIFIER", 23, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["differences", "OBSERVATION_MODIFIER", 49, 60], ["very", "OBSERVATION_MODIFIER", 152, 156], ["significant", "OBSERVATION_MODIFIER", 157, 168]]], ["(C) The expression of Claudin-1, E-cadherin, Occludin and ZO-1 in PEDV-, TGEV-and PEDV + TGEV-infected IPEC-J2 cells at 20, 40, 60 minpi and 24 hpi was analysed via western blotting.", [["IPEC-J2 cells", "ANATOMY", 103, 116], ["Claudin-1", "GENE_OR_GENE_PRODUCT", 22, 31], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 33, 43], ["Occludin", "GENE_OR_GENE_PRODUCT", 45, 53], ["ZO-1", "GENE_OR_GENE_PRODUCT", 58, 62], ["PEDV", "ORGANISM", 66, 70], ["TGEV", "ORGANISM", 73, 77], ["PEDV + TGEV", "ORGANISM", 82, 93], ["IPEC-J2 cells", "CELL", 103, 116], ["Claudin-1", "PROTEIN", 22, 31], ["E-cadherin", "PROTEIN", 33, 43], ["Occludin", "PROTEIN", 45, 53], ["ZO-1", "PROTEIN", 58, 62], ["PEDV-, TGEV-and PEDV + TGEV-infected IPEC-J2 cells", "CELL_LINE", 66, 116], ["TGEV", "SPECIES", 89, 93], ["TGEV", "SPECIES", 73, 77], ["PEDV", "SPECIES", 82, 86], ["TGEV", "SPECIES", 89, 93], ["Claudin", "TEST", 22, 29], ["E-cadherin", "TEST", 33, 43], ["Occludin", "TEST", 45, 53], ["ZO", "TEST", 58, 60], ["PEDV", "TEST", 66, 70], ["TGEV", "TEST", 73, 77], ["PEDV", "PROBLEM", 82, 86], ["TGEV", "PROBLEM", 89, 93], ["J2 cells", "PROBLEM", 108, 116], ["minpi", "TEST", 131, 136]]], ["The intensity of the bands in terms of political density was measured and normalised against GAPDH expression.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 93, 98], ["GAPDH", "PROTEIN", 93, 98], ["the bands", "PROBLEM", 17, 26], ["political density", "PROBLEM", 39, 56], ["GAPDH expression", "PROBLEM", 93, 109], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["bands", "OBSERVATION_MODIFIER", 21, 26], ["political", "OBSERVATION_MODIFIER", 39, 48], ["density", "OBSERVATION", 49, 56], ["GAPDH expression", "OBSERVATION", 93, 109]]], ["The symbol * indicates statistically significant differences (P < 0.05) when compared with the control group, and the symbol ** indicates statistically very significant differences (P < 0.01) when compared with the control group. declined again after 60 min, and restored again at 2 hpi.", [["statistically", "OBSERVATION_MODIFIER", 23, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["differences", "OBSERVATION_MODIFIER", 49, 60], ["very", "OBSERVATION_MODIFIER", 152, 156], ["significant", "OBSERVATION_MODIFIER", 157, 168]]], ["TEER then remains more or less unchanged.", [["more", "OBSERVATION_MODIFIER", 18, 22], ["less", "OBSERVATION_MODIFIER", 26, 30], ["unchanged", "OBSERVATION_MODIFIER", 31, 40]]], ["Compared with the control group, TGEV single infection or co-infection decreased gradually from 20 to 60 min and reached the lowest value at 60 min, especially in the case of their co-infection.", [["infection", "DISEASE", 45, 54], ["co-infection", "DISEASE", 58, 70], ["co-infection", "DISEASE", 181, 193], ["TGEV", "ORGANISM", 33, 37], ["TGEV", "SPECIES", 33, 37], ["TGEV single infection", "PROBLEM", 33, 54], ["co-infection", "PROBLEM", 58, 70], ["their co-infection", "PROBLEM", 175, 193], ["infection", "OBSERVATION", 45, 54], ["co-infection", "OBSERVATION", 58, 70], ["decreased", "OBSERVATION_MODIFIER", 71, 80], ["gradually", "OBSERVATION_MODIFIER", 81, 90], ["co-infection", "OBSERVATION", 181, 193]]], ["Then, levels all gradually restored and remained unchanged from 2 to 84 h ( Fig. 2A) .", [["levels", "TEST", 6, 12], ["unchanged", "OBSERVATION_MODIFIER", 49, 58]]], ["Finally, the TEER in TGEV and/or PEDV infected IPEC-J2 cells were unchanged compared with control group from 84 to 120 hpi, gradually decreased from 132 to 204 hpi that might be due to the IPEC-J2 cells death (Additional Fig. 1) .", [["IPEC-J2 cells", "ANATOMY", 47, 60], ["IPEC-J2 cells", "ANATOMY", 189, 202], ["death", "DISEASE", 203, 208], ["TGEV", "ORGANISM", 21, 25], ["PEDV", "CELL", 33, 37], ["IPEC-J2 cells", "CELL", 47, 60], ["IPEC-J2 cells", "CELL", 189, 202], ["IPEC-J2 cells", "CELL_LINE", 47, 60], ["IPEC-J2 cells", "CELL_LINE", 189, 202], ["TGEV", "SPECIES", 21, 25], ["PEDV", "SPECIES", 33, 37], ["the TEER", "TEST", 9, 17], ["TGEV", "PROBLEM", 21, 25], ["PEDV", "PROBLEM", 33, 37], ["J2 cells", "PROBLEM", 52, 60], ["the IPEC-J2 cells death", "PROBLEM", 185, 208], ["unchanged", "OBSERVATION_MODIFIER", 66, 75], ["J2 cells", "OBSERVATION", 194, 202]]], ["To further study whether the permeability of epithelial cells infected with PEDV, TGEV and PEDV + TGEV were changed from 20 to 60 minpi, we measured the passage of a macromolecule, FITC-dextran, across these virusinfected IPEC-J2 monolayer cells grown on Transwell membranes.", [["epithelial cells", "ANATOMY", 45, 61], ["IPEC-J2 monolayer cells", "ANATOMY", 222, 245], ["Transwell membranes", "ANATOMY", 255, 274], ["FITC-dextran", "CHEMICAL", 181, 193], ["FITC", "CHEMICAL", 181, 185], ["epithelial cells", "CELL", 45, 61], ["PEDV", "GENE_OR_GENE_PRODUCT", 76, 80], ["TGEV", "ORGANISM", 82, 86], ["PEDV + TGEV", "ORGANISM", 91, 102], ["FITC-dextran", "SIMPLE_CHEMICAL", 181, 193], ["IPEC-J2 monolayer cells", "CELL", 222, 245], ["Transwell membranes", "CELLULAR_COMPONENT", 255, 274], ["epithelial cells", "CELL_TYPE", 45, 61], ["virusinfected IPEC-J2 monolayer cells", "CELL_LINE", 208, 245], ["TGEV", "SPECIES", 82, 86], ["TGEV", "SPECIES", 98, 102], ["PEDV", "SPECIES", 76, 80], ["TGEV", "SPECIES", 82, 86], ["PEDV", "SPECIES", 91, 95], ["TGEV", "SPECIES", 98, 102], ["further study", "TEST", 3, 16], ["epithelial cells", "PROBLEM", 45, 61], ["PEDV", "PROBLEM", 76, 80], ["TGEV", "PROBLEM", 82, 86], ["PEDV", "PROBLEM", 91, 95], ["TGEV", "PROBLEM", 98, 102], ["a macromolecule", "TREATMENT", 164, 179], ["FITC-dextran", "TREATMENT", 181, 193], ["these virusinfected IPEC", "TEST", 202, 226], ["J2 monolayer cells", "TREATMENT", 227, 245], ["Transwell membranes", "TREATMENT", 255, 274], ["epithelial cells", "ANATOMY", 45, 61], ["J2 monolayer", "OBSERVATION_MODIFIER", 227, 239], ["Transwell membranes", "OBSERVATION", 255, 274]]], ["The permeability of IPEC-J2 infected with TGEV at 40 minpi was higher than other groups (p < 0.05) and the above permeability at 60 minpi was also significantly increased compared to the control group (p < 0.05) (Fig. 2B) .", [["IPEC-J2", "CHEMICAL", 20, 27], ["IPEC-J2", "CELL", 20, 27], ["TGEV", "ORGANISM", 42, 46], ["TGEV", "SPECIES", 42, 46], ["IPEC", "TEST", 20, 24], ["TGEV", "PROBLEM", 42, 46], ["the above permeability", "TEST", 103, 125], ["permeability", "OBSERVATION_MODIFIER", 4, 16], ["J2 infected", "OBSERVATION_MODIFIER", 25, 36], ["significantly", "OBSERVATION_MODIFIER", 147, 160], ["increased", "OBSERVATION_MODIFIER", 161, 170]]], ["To further investigate whether tight and adhesion junctions proteins played an important role in the instantaneous destruction of the epithelial barrier integrity at 20, 40, 60 minpi and 24 hpi, we measured the three important tight junction proteins claudin-1, occluding and ZO-1 and an adhesion junction protein E-cadherin in the PEDV-, TGEV-infected and their co-infected IPEC-J2 cells.", [["epithelial barrier", "ANATOMY", 134, 152], ["tight junction", "ANATOMY", 227, 241], ["IPEC-J2 cells", "ANATOMY", 375, 388], ["epithelial barrier", "TISSUE", 134, 152], ["claudin-1", "GENE_OR_GENE_PRODUCT", 251, 260], ["ZO-1", "GENE_OR_GENE_PRODUCT", 276, 280], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 314, 324], ["PEDV", "GENE_OR_GENE_PRODUCT", 332, 336], ["TGEV", "ORGANISM", 339, 343], ["IPEC-J2 cells", "CELL", 375, 388], ["adhesion junctions proteins", "PROTEIN", 41, 68], ["tight junction proteins", "PROTEIN", 227, 250], ["claudin-1", "PROTEIN", 251, 260], ["ZO-1", "PROTEIN", 276, 280], ["adhesion junction protein", "PROTEIN", 288, 313], ["E-cadherin", "PROTEIN", 314, 324], ["co-infected IPEC-J2 cells", "CELL_LINE", 363, 388], ["TGEV", "SPECIES", 339, 343], ["tight and adhesion junctions proteins", "PROBLEM", 31, 68], ["the epithelial barrier integrity", "TEST", 130, 162], ["ZO", "TEST", 276, 278], ["an adhesion junction protein", "TEST", 285, 313], ["the PEDV", "TEST", 328, 336], ["TGEV", "PROBLEM", 339, 343], ["infected", "PROBLEM", 344, 352], ["epithelial", "ANATOMY_MODIFIER", 134, 144], ["PEDV", "ANATOMY", 332, 336], ["infected", "OBSERVATION_MODIFIER", 344, 352], ["J2 cells", "OBSERVATION", 380, 388]]], ["The results demonstrated that the expression of E-cadherin in the PEDV + TGEV-infected IPEC-J2 cells at 20 minpi was higher than the control group and PEDV infected group (p < 0.05).", [["IPEC-J2 cells", "ANATOMY", 87, 100], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 48, 58], ["PEDV + TGEV", "ORGANISM", 66, 77], ["IPEC-J2 cells", "CELL", 87, 100], ["E-cadherin", "PROTEIN", 48, 58], ["PEDV + TGEV-infected IPEC-J2 cells", "CELL_LINE", 66, 100], ["TGEV", "SPECIES", 73, 77], ["PEDV", "SPECIES", 151, 155], ["E-cadherin", "TREATMENT", 48, 58], ["the PEDV", "TEST", 62, 70], ["TGEV", "PROBLEM", 73, 77], ["infected IPEC-J2 cells", "TREATMENT", 78, 100], ["PEDV", "PROBLEM", 151, 155], ["PEDV", "ANATOMY", 66, 70], ["infected", "OBSERVATION_MODIFIER", 78, 86], ["infected", "OBSERVATION_MODIFIER", 156, 164]]], ["Moreover, the expression of E-cadherin in the TGEV-infected and PEDV + TGEV-infected IPEC-J2 cells at 40 minpi were notably lower than other groups (p < 0.05).", [["IPEC-J2 cells", "ANATOMY", 85, 98], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 28, 38], ["TGEV", "ORGANISM", 46, 50], ["PEDV + TGEV", "ORGANISM", 64, 75], ["IPEC-J2 cells", "CELL", 85, 98], ["E-cadherin", "PROTEIN", 28, 38], ["PEDV + TGEV-infected IPEC-J2 cells", "CELL_LINE", 64, 98], ["TGEV", "SPECIES", 71, 75], ["TGEV", "SPECIES", 46, 50], ["PEDV", "SPECIES", 64, 68], ["TGEV", "SPECIES", 71, 75], ["E-cadherin in the TGEV", "PROBLEM", 28, 50], ["infected", "PROBLEM", 51, 59], ["PEDV", "PROBLEM", 64, 68], ["TGEV", "PROBLEM", 71, 75], ["J2 cells", "PROBLEM", 90, 98], ["infected", "OBSERVATION", 51, 59], ["infected", "OBSERVATION_MODIFIER", 76, 84], ["J2 cells", "OBSERVATION_MODIFIER", 90, 98], ["lower", "OBSERVATION_MODIFIER", 124, 129]]], ["The expression of E-cadherin, Occludin and ZO-1 in the TGEV infectedand PEDV + TGEV-infected IPEC-J2 cells was lowest at 60 minpi (p < 0.01).", [["IPEC-J2 cells", "ANATOMY", 93, 106], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 18, 28], ["Occludin", "GENE_OR_GENE_PRODUCT", 30, 38], ["ZO-1", "GENE_OR_GENE_PRODUCT", 43, 47], ["TGEV", "ORGANISM", 55, 59], ["PEDV + TGEV", "ORGANISM", 72, 83], ["IPEC-J2 cells", "CELL", 93, 106], ["E-cadherin", "PROTEIN", 18, 28], ["Occludin", "PROTEIN", 30, 38], ["ZO-1", "PROTEIN", 43, 47], ["TGEV infectedand PEDV + TGEV-infected IPEC-J2 cells", "CELL_LINE", 55, 106], ["TGEV", "SPECIES", 55, 59], ["TGEV", "SPECIES", 79, 83], ["TGEV", "SPECIES", 55, 59], ["TGEV", "SPECIES", 79, 83], ["E-cadherin", "TREATMENT", 18, 28], ["Occludin", "TEST", 30, 38], ["ZO", "TEST", 43, 45], ["the TGEV", "TEST", 51, 59], ["PEDV", "PROBLEM", 72, 76], ["TGEV", "PROBLEM", 79, 83], ["J2 cells", "PROBLEM", 98, 106]]], ["Finally, claudin-1, occluding, ZO-1 and E-cadherin were unchanged in TGEV, PEDV-infected and PEDV +TGEV-infected IPEC-J2 cells compared with the control group at 24 hpi (p > 0.05).", [["IPEC-J2 cells", "ANATOMY", 113, 126], ["claudin-1", "GENE_OR_GENE_PRODUCT", 9, 18], ["ZO-1", "GENE_OR_GENE_PRODUCT", 31, 35], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 40, 50], ["TGEV", "ORGANISM", 69, 73], ["PEDV", "GENE_OR_GENE_PRODUCT", 75, 79], ["PEDV +TGEV", "ORGANISM", 93, 103], ["IPEC-J2 cells", "CELL", 113, 126], ["claudin-1", "PROTEIN", 9, 18], ["ZO", "PROTEIN", 31, 33], ["E", "PROTEIN", 40, 41], ["cadherin", "PROTEIN", 42, 50], ["TGEV, PEDV-infected and PEDV +TGEV-infected IPEC-J2 cells", "CELL_LINE", 69, 126], ["TGEV", "SPECIES", 99, 103], ["TGEV", "SPECIES", 69, 73], ["PEDV", "SPECIES", 75, 79], ["PEDV", "SPECIES", 93, 97], ["TGEV", "SPECIES", 99, 103], ["claudin", "TEST", 9, 16], ["ZO", "TEST", 31, 33], ["TGEV", "PROBLEM", 69, 73], ["PEDV", "PROBLEM", 75, 79], ["infected", "PROBLEM", 80, 88], ["PEDV", "PROBLEM", 93, 97], ["TGEV", "PROBLEM", 99, 103], ["infected IPEC-J2 cells", "TREATMENT", 104, 126], ["unchanged", "OBSERVATION_MODIFIER", 56, 65], ["infected", "OBSERVATION_MODIFIER", 104, 112], ["J2 cells", "OBSERVATION", 118, 126]]], ["All of the results demonstrated that TGEV and TGEV + PEDV coinfection could instantaneously impair the integrity of epithelial barrier at early stages of infection, and then gradually return back to normal levels.", [["epithelial barrier", "ANATOMY", 116, 134], ["PEDV", "CHEMICAL", 53, 57], ["infection", "DISEASE", 154, 163], ["TGEV", "ORGANISM", 37, 41], ["TGEV + PEDV", "ORGANISM", 46, 57], ["epithelial barrier", "TISSUE", 116, 134], ["TGEV", "SPECIES", 37, 41], ["TGEV", "SPECIES", 46, 50], ["PEDV", "SPECIES", 53, 57], ["TGEV", "PROBLEM", 37, 41], ["TGEV", "PROBLEM", 46, 50], ["PEDV coinfection", "PROBLEM", 53, 69], ["epithelial barrier", "PROBLEM", 116, 134], ["infection", "PROBLEM", 154, 163], ["PEDV coinfection", "OBSERVATION", 53, 69], ["integrity", "OBSERVATION_MODIFIER", 103, 112], ["epithelial barrier", "OBSERVATION", 116, 134], ["early stages", "OBSERVATION_MODIFIER", 138, 150], ["infection", "OBSERVATION", 154, 163]]], ["In addition, ZO-1, Occludin and E-cadherin playedThe attachment, entry and release of PEDV and TGEV were dependent on the microfilamentsThere is a clear evidence that numerous tight and adhesion junction proteins can directly interact with the microfilaments, and the reestablishment of the microfilaments plays a crucial role during viral attachment, entry, replication and release (Avota et al., 2011) .", [["microfilaments", "ANATOMY", 122, 136], ["microfilaments", "ANATOMY", 244, 258], ["microfilaments", "ANATOMY", 291, 305], ["ZO-1", "GENE_OR_GENE_PRODUCT", 13, 17], ["Occludin", "GENE_OR_GENE_PRODUCT", 19, 27], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 32, 42], ["PEDV", "GENE_OR_GENE_PRODUCT", 86, 90], ["TGEV", "ORGANISM", 95, 99], ["microfilaments", "CELLULAR_COMPONENT", 122, 136], ["microfilaments", "CELLULAR_COMPONENT", 244, 258], ["microfilaments", "CELLULAR_COMPONENT", 291, 305], ["ZO", "PROTEIN", 13, 15], ["Occludin", "PROTEIN", 19, 27], ["E", "PROTEIN", 32, 33], ["cadherin", "PROTEIN", 34, 42], ["PEDV", "PROTEIN", 86, 90], ["adhesion junction proteins", "PROTEIN", 186, 212], ["PEDV", "SPECIES", 86, 90], ["TGEV", "SPECIES", 95, 99], ["PEDV", "PROBLEM", 86, 90], ["TGEV", "PROBLEM", 95, 99], ["numerous tight and adhesion junction proteins", "PROBLEM", 167, 212], ["clear", "OBSERVATION", 147, 152], ["numerous", "OBSERVATION_MODIFIER", 167, 175], ["tight", "OBSERVATION_MODIFIER", 176, 181], ["adhesion junction", "OBSERVATION", 186, 203]]], ["We hypothesised that the life cycle of PEDV and TGEV were also dependent on the microfilaments.", [["microfilaments", "ANATOMY", 80, 94], ["PEDV", "GENE_OR_GENE_PRODUCT", 39, 43], ["TGEV", "ORGANISM", 48, 52], ["microfilaments", "CELLULAR_COMPONENT", 80, 94], ["PEDV", "SPECIES", 39, 43], ["TGEV", "SPECIES", 48, 52], ["PEDV", "PROBLEM", 39, 43], ["TGEV", "PROBLEM", 48, 52]]], ["From the results of TEM, PEDV and TGEV moved along the filopodia which are formed by microfilaments and moved towards the cells (Fig. 3A) .", [["filopodia", "ANATOMY", 55, 64], ["microfilaments", "ANATOMY", 85, 99], ["cells", "ANATOMY", 122, 127], ["PEDV", "SIMPLE_CHEMICAL", 25, 29], ["TGEV", "ORGANISM", 34, 38], ["filopodia", "CELLULAR_COMPONENT", 55, 64], ["microfilaments", "CELLULAR_COMPONENT", 85, 99], ["cells", "CELL", 122, 127], ["PEDV", "SPECIES", 25, 29], ["TGEV", "SPECIES", 34, 38], ["PEDV", "PROBLEM", 25, 29], ["TGEV", "PROBLEM", 34, 38], ["filopodia", "OBSERVATION_MODIFIER", 55, 64]]], ["Many microfilaments gathered around the PEDV, and appeared to be auxiliary to form membrane vesicles for wrapping the virus when the PEDV absorbed the plasma membrane ( Fig. 3A and B) .", [["microfilaments", "ANATOMY", 5, 19], ["membrane vesicles", "ANATOMY", 83, 100], ["plasma membrane", "ANATOMY", 151, 166], ["microfilaments", "CELLULAR_COMPONENT", 5, 19], ["membrane vesicles", "CELLULAR_COMPONENT", 83, 100], ["PEDV", "SIMPLE_CHEMICAL", 133, 137], ["plasma membrane", "CELLULAR_COMPONENT", 151, 166], ["B", "GENE_OR_GENE_PRODUCT", 181, 182], ["PEDV", "PROTEIN", 40, 44], ["PEDV", "PROTEIN", 133, 137], ["PEDV", "SPECIES", 133, 137], ["Many microfilaments", "PROBLEM", 0, 19], ["membrane vesicles", "PROBLEM", 83, 100], ["the virus", "PROBLEM", 114, 123], ["microfilaments", "OBSERVATION", 5, 19], ["membrane vesicles", "OBSERVATION", 83, 100], ["virus", "OBSERVATION", 118, 123]]], ["In the cytoplasm, a large number of microfilaments gathered around the PEDV, suggesting that the movement of viruses relies on the microfilaments (Fig. 3C) .", [["cytoplasm", "ANATOMY", 7, 16], ["microfilaments", "ANATOMY", 36, 50], ["microfilaments", "ANATOMY", 131, 145], ["cytoplasm", "ORGANISM_SUBSTANCE", 7, 16], ["microfilaments", "CELLULAR_COMPONENT", 36, 50], ["PEDV", "GENE_OR_GENE_PRODUCT", 71, 75], ["microfilaments", "CELLULAR_COMPONENT", 131, 145], ["PEDV", "PROTEIN", 71, 75], ["the movement of viruses", "PROBLEM", 93, 116], ["cytoplasm", "OBSERVATION_MODIFIER", 7, 16], ["large", "OBSERVATION_MODIFIER", 20, 25], ["number", "OBSERVATION_MODIFIER", 26, 32], ["microfilaments", "OBSERVATION", 36, 50], ["movement", "OBSERVATION_MODIFIER", 97, 105], ["viruses", "OBSERVATION", 109, 116]]], ["The same phenomena were also seen in the TGEV infected ( Fig. 3D-F) and PEDV + TGEV co-infected IPEC-J2 cells (pictures not shown), and we also observed the virus binding the microfilaments in the nuclear membrane (Fig. 3D) .Fig.", [["IPEC-J2 cells", "ANATOMY", 96, 109], ["microfilaments", "ANATOMY", 175, 189], ["nuclear membrane", "ANATOMY", 197, 213], ["TGEV", "ORGANISM", 41, 45], ["3D-F", "CELL", 62, 66], ["PEDV + TGEV", "ORGANISM", 72, 83], ["IPEC-J2 cells", "CELL", 96, 109], ["microfilaments", "CELLULAR_COMPONENT", 175, 189], ["nuclear membrane", "CELLULAR_COMPONENT", 197, 213], ["PEDV + TGEV co-infected IPEC-J2 cells", "CELL_LINE", 72, 109], ["TGEV", "SPECIES", 79, 83], ["TGEV", "SPECIES", 41, 45], ["TGEV", "SPECIES", 79, 83], ["The same phenomena", "PROBLEM", 0, 18], ["the TGEV infected", "PROBLEM", 37, 54], ["PEDV", "PROBLEM", 72, 76], ["J2 cells", "PROBLEM", 101, 109], ["the virus binding", "PROBLEM", 153, 170], ["phenomena", "OBSERVATION", 9, 18], ["TGEV", "OBSERVATION_MODIFIER", 79, 83], ["co-infected", "OBSERVATION_MODIFIER", 84, 95], ["J2 cells", "OBSERVATION", 101, 109], ["virus", "OBSERVATION", 157, 162], ["nuclear membrane", "ANATOMY", 197, 213]]], ["4.Microfilaments are required for PEDV and TGEV replication and release.", [["PEDV", "GENE_OR_GENE_PRODUCT", 34, 38], ["TGEV", "ORGANISM", 43, 47], ["PEDV", "SPECIES", 34, 38], ["TGEV", "SPECIES", 43, 47], ["Microfilaments", "TREATMENT", 2, 16], ["PEDV", "PROBLEM", 34, 38], ["TGEV replication", "TREATMENT", 43, 59]]], ["(A-C) Immunofluorescence images of microfilaments in PEDV and TGEV infected and mock IPEC-J2 cells which treated with or without treated with or without microfilaments inhibitors, Cytochalasin D and Jasplakinolide at 6 hpi were stained with FTTCphalloidin.", [["microfilaments", "ANATOMY", 35, 49], ["PEDV", "ANATOMY", 53, 57], ["IPEC-J2 cells", "ANATOMY", 85, 98], ["Cytochalasin D", "CHEMICAL", 180, 194], ["Jasplakinolide", "CHEMICAL", 199, 213], ["FTTCphalloidin", "CHEMICAL", 241, 255], ["Cytochalasin D", "CHEMICAL", 180, 194], ["Jasplakinolide", "CHEMICAL", 199, 213], ["FTTCphalloidin", "CHEMICAL", 241, 255], ["microfilaments", "CELLULAR_COMPONENT", 35, 49], ["PEDV", "CELL", 53, 57], ["TGEV", "ORGANISM", 62, 66], ["IPEC-J2 cells", "CELL", 85, 98], ["Cytochalasin D", "SIMPLE_CHEMICAL", 180, 194], ["Jasplakinolide", "SIMPLE_CHEMICAL", 199, 213], ["FTTCphalloidin", "SIMPLE_CHEMICAL", 241, 255], ["PEDV", "CELL_LINE", 53, 57], ["mock IPEC-J2 cells", "CELL_LINE", 80, 98], ["FTTCphalloidin", "PROTEIN", 241, 255], ["TGEV", "SPECIES", 62, 66], ["PEDV", "SPECIES", 53, 57], ["TGEV", "SPECIES", 62, 66], ["Immunofluorescence images", "TEST", 6, 31], ["microfilaments", "PROBLEM", 35, 49], ["PEDV", "PROBLEM", 53, 57], ["TGEV infected", "PROBLEM", 62, 75], ["J2 cells", "PROBLEM", 90, 98], ["microfilaments inhibitors", "TREATMENT", 153, 178], ["Cytochalasin D", "TREATMENT", 180, 194], ["Jasplakinolide", "TREATMENT", 199, 213], ["FTTCphalloidin", "TREATMENT", 241, 255], ["J2 cells", "OBSERVATION_MODIFIER", 90, 98]]], ["Scale bars represent 10 m.", [["10 m.", "OBSERVATION_MODIFIER", 21, 26]]], ["(A) Immunofluorescence images of microfilaments of the mock IPEC-J2 cells were a complex three-dimensional network composed of microfilaments extending throughout the cell body.", [["microfilaments", "ANATOMY", 33, 47], ["IPEC-J2 cells", "ANATOMY", 60, 73], ["microfilaments", "ANATOMY", 127, 141], ["cell body", "ANATOMY", 167, 176], ["microfilaments", "CELLULAR_COMPONENT", 33, 47], ["IPEC-J2 cells", "CELL", 60, 73], ["microfilaments", "CELLULAR_COMPONENT", 127, 141], ["cell body", "CELLULAR_COMPONENT", 167, 176], ["mock IPEC-J2 cells", "CELL_LINE", 55, 73], ["Immunofluorescence images", "TEST", 4, 29], ["the mock IPEC", "TEST", 51, 64], ["J2 cells", "PROBLEM", 65, 73], ["J2 cells", "OBSERVATION", 65, 73], ["cell body", "OBSERVATION", 167, 176]]], ["(B) Microfilaments of IPEC-J2 cells treated by Cytochalasin D were irregular and non-uniformly distributed throughout the cell.", [["IPEC-J2 cells", "ANATOMY", 22, 35], ["cell", "ANATOMY", 122, 126], ["Cytochalasin D", "CHEMICAL", 47, 61], ["Cytochalasin D", "CHEMICAL", 47, 61], ["IPEC-J2 cells", "CELL", 22, 35], ["Cytochalasin D", "SIMPLE_CHEMICAL", 47, 61], ["cell", "CELL", 122, 126], ["IPEC-J2 cells", "CELL_LINE", 22, 35], ["IPEC-J2 cells", "TREATMENT", 22, 35], ["Cytochalasin D", "PROBLEM", 47, 61], ["J2 cells", "OBSERVATION", 27, 35], ["irregular", "OBSERVATION_MODIFIER", 67, 76], ["non-uniformly", "OBSERVATION_MODIFIER", 81, 94], ["distributed", "OBSERVATION_MODIFIER", 95, 106], ["cell", "OBSERVATION", 122, 126]]], ["Some areas appeared to be completely devoid of filaments, whereas had formed the dense network aggregates, clumps, or even compact foci of filamentous materials at 6 hpi.", [["filaments", "ANATOMY", 47, 56], ["clumps", "ANATOMY", 107, 113], ["foci", "ANATOMY", 131, 135], ["filaments", "CELLULAR_COMPONENT", 47, 56], ["the dense network aggregates", "PROBLEM", 77, 105], ["clumps", "PROBLEM", 107, 113], ["filaments", "OBSERVATION", 47, 56], ["dense", "OBSERVATION_MODIFIER", 81, 86], ["network aggregates", "OBSERVATION", 87, 105], ["clumps", "OBSERVATION_MODIFIER", 107, 113], ["compact", "OBSERVATION_MODIFIER", 123, 130], ["foci", "OBSERVATION", 131, 135], ["filamentous materials", "OBSERVATION_MODIFIER", 139, 160]]], ["(C) The microfilaments of IPEC-J2 cells treated by Jasplakinolide showed an increased density of microfilaments adjacent to the plasma membrane and cytoplasm at 6 hpi.", [["microfilaments", "ANATOMY", 8, 22], ["IPEC-J2 cells", "ANATOMY", 26, 39], ["microfilaments", "ANATOMY", 97, 111], ["plasma membrane", "ANATOMY", 128, 143], ["cytoplasm", "ANATOMY", 148, 157], ["Jasplakinolide", "CHEMICAL", 51, 65], ["Jasplakinolide", "CHEMICAL", 51, 65], ["microfilaments", "CELLULAR_COMPONENT", 8, 22], ["IPEC-J2 cells", "CELL", 26, 39], ["Jasplakinolide", "SIMPLE_CHEMICAL", 51, 65], ["microfilaments", "CELLULAR_COMPONENT", 97, 111], ["plasma membrane", "CELLULAR_COMPONENT", 128, 143], ["cytoplasm", "ORGANISM_SUBSTANCE", 148, 157], ["IPEC-J2 cells", "CELL_LINE", 26, 39], ["The microfilaments of IPEC-J2 cells", "TREATMENT", 4, 39], ["Jasplakinolide", "TREATMENT", 51, 65], ["an increased density of microfilaments", "PROBLEM", 73, 111], ["J2 cells", "OBSERVATION", 31, 39], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["density", "OBSERVATION", 86, 93], ["plasma membrane", "ANATOMY", 128, 143]]], ["The viral titres of PEDV and TGEV that entry (D), release (E), replication and release (F) from the IPEC-J2 cells treated with microfilaments inhibitor, Jasplakinolide and cytochalasin D were analysed by TCID50.", [["IPEC-J2 cells", "ANATOMY", 100, 113], ["Jasplakinolide", "CHEMICAL", 153, 167], ["cytochalasin D", "CHEMICAL", 172, 186], ["Jasplakinolide", "CHEMICAL", 153, 167], ["cytochalasin D", "CHEMICAL", 172, 186], ["TGEV", "ORGANISM", 29, 33], ["IPEC-J2 cells", "CELL", 100, 113], ["Jasplakinolide", "SIMPLE_CHEMICAL", 153, 167], ["cytochalasin D", "SIMPLE_CHEMICAL", 172, 186], ["IPEC-J2 cells", "CELL_LINE", 100, 113], ["TGEV", "SPECIES", 29, 33], ["PEDV", "SPECIES", 20, 24], ["TGEV", "SPECIES", 29, 33], ["The viral titres", "TEST", 0, 16], ["PEDV", "PROBLEM", 20, 24], ["TGEV", "TREATMENT", 29, 33], ["the IPEC-J2 cells", "TREATMENT", 96, 113], ["microfilaments inhibitor", "TREATMENT", 127, 151], ["Jasplakinolide", "TREATMENT", 153, 167], ["cytochalasin D", "TREATMENT", 172, 186], ["viral titres", "OBSERVATION", 4, 16], ["J2 cells", "OBSERVATION", 105, 113]]], ["The symbol * indicates statistically significant differences (P < 0.05) when compared with the control group, and the symbol ** indicates statistically very significant differences (P < 0.01) when compared with the control group.", [["statistically", "OBSERVATION_MODIFIER", 23, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["differences", "OBSERVATION_MODIFIER", 49, 60], ["very", "OBSERVATION_MODIFIER", 152, 156], ["significant", "OBSERVATION_MODIFIER", 157, 168]]], ["The viral M gene RNA relative level of PEDV and TGEV that entry (G), release (H), replication and release (I) from the IPEC-J2 cells treated with microfilaments inhibitor, Jasplakinolide and cytochalasin D were analysed by qRT-PCR.", [["IPEC-J2 cells", "ANATOMY", 119, 132], ["Jasplakinolide", "CHEMICAL", 172, 186], ["cytochalasin D", "CHEMICAL", 191, 205], ["Jasplakinolide", "CHEMICAL", 172, 186], ["cytochalasin D", "CHEMICAL", 191, 205], ["TGEV", "ORGANISM", 48, 52], ["IPEC-J2 cells", "CELL", 119, 132], ["microfilaments", "CELLULAR_COMPONENT", 146, 160], ["Jasplakinolide", "SIMPLE_CHEMICAL", 172, 186], ["cytochalasin D", "SIMPLE_CHEMICAL", 191, 205], ["PEDV", "PROTEIN", 39, 43], ["IPEC-J2 cells", "CELL_LINE", 119, 132], ["PEDV", "SPECIES", 39, 43], ["TGEV", "SPECIES", 48, 52], ["PEDV", "PROBLEM", 39, 43], ["the IPEC-J2 cells", "TREATMENT", 115, 132], ["microfilaments inhibitor", "TREATMENT", 146, 170], ["Jasplakinolide", "TREATMENT", 172, 186], ["cytochalasin D", "TREATMENT", 191, 205]]], ["The symbol * indicates statistically significant differences (P < 0.05) when compared with the control group, and the symbol ** indicates statistically very significant differences (P < 0.01) when compared with the control group.PEDV and TGEV infection reorganised the microfilaments of IPEC-J2 cellsIn order to assess how the PEDV, TGEV and PEDV + TGEV infection induced dramatic cytoskeletal reorganisation of the microfilaments, we used the FITC-Phalloidin to show filamentous actin in these infected IPEC-J2 cells.", [["microfilaments", "ANATOMY", 269, 283], ["IPEC-J2 cells", "ANATOMY", 287, 300], ["cytoskeletal", "ANATOMY", 381, 393], ["microfilaments", "ANATOMY", 416, 430], ["IPEC-J2 cells", "ANATOMY", 504, 517], ["PEDV", "CHEMICAL", 229, 233], ["infection", "DISEASE", 243, 252], ["PEDV", "CHEMICAL", 342, 346], ["infection", "DISEASE", 354, 363], ["FITC", "CHEMICAL", 444, 448], ["PEDV", "SIMPLE_CHEMICAL", 229, 233], ["TGEV", "ORGANISM", 238, 242], ["microfilaments", "CELLULAR_COMPONENT", 269, 283], ["IPEC-J2 cells", "CELL", 287, 300], ["PEDV", "GENE_OR_GENE_PRODUCT", 327, 331], ["TGEV", "ORGANISM", 333, 337], ["PEDV + TGEV", "ORGANISM", 342, 353], ["microfilaments", "CELLULAR_COMPONENT", 416, 430], ["FITC-Phalloidin", "GENE_OR_GENE_PRODUCT", 444, 459], ["filamentous actin", "GENE_OR_GENE_PRODUCT", 468, 485], ["IPEC-J2 cells", "CELL", 504, 517], ["IPEC-J2 cells", "CELL_LINE", 287, 300], ["FITC-Phalloidin", "PROTEIN", 444, 459], ["filamentous actin", "PROTEIN", 468, 485], ["IPEC-J2 cells", "CELL_LINE", 504, 517], ["PEDV", "SPECIES", 229, 233], ["TGEV", "SPECIES", 238, 242], ["PEDV", "SPECIES", 327, 331], ["TGEV", "SPECIES", 333, 337], ["PEDV", "SPECIES", 342, 346], ["TGEV", "SPECIES", 349, 353], ["PEDV", "PROBLEM", 229, 233], ["TGEV infection", "PROBLEM", 238, 252], ["IPEC", "TEST", 287, 291], ["J2 cells", "PROBLEM", 292, 300], ["the PEDV", "PROBLEM", 323, 331], ["TGEV", "PROBLEM", 333, 337], ["PEDV", "PROBLEM", 342, 346], ["TGEV infection", "PROBLEM", 349, 363], ["the FITC-Phalloidin", "TEST", 440, 459], ["filamentous actin", "PROBLEM", 468, 485], ["statistically", "OBSERVATION_MODIFIER", 23, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["differences", "OBSERVATION_MODIFIER", 49, 60], ["very", "OBSERVATION_MODIFIER", 152, 156], ["significant", "OBSERVATION_MODIFIER", 157, 168], ["TGEV", "OBSERVATION_MODIFIER", 238, 242], ["infection", "OBSERVATION", 243, 252], ["J2 cells", "OBSERVATION", 292, 300], ["dramatic", "OBSERVATION_MODIFIER", 372, 380], ["cytoskeletal reorganisation", "OBSERVATION", 381, 408], ["filamentous actin", "OBSERVATION", 468, 485], ["infected", "OBSERVATION", 495, 503], ["J2 cells", "OBSERVATION", 509, 517]]], ["The control cells showed a complex three-dimensional network composed of microfilaments extending throughout the cell body (Fig. 3G, left) .", [["cells", "ANATOMY", 12, 17], ["microfilaments", "ANATOMY", 73, 87], ["cell body", "ANATOMY", 113, 122], ["cells", "CELL", 12, 17], ["microfilaments", "CELLULAR_COMPONENT", 73, 87], ["cell body", "CELLULAR_COMPONENT", 113, 122], ["complex", "OBSERVATION_MODIFIER", 27, 34], ["microfilaments", "OBSERVATION", 73, 87], ["cell", "ANATOMY", 113, 117], ["body", "ANATOMY_MODIFIER", 118, 122], ["left", "ANATOMY_MODIFIER", 133, 137]]], ["After 40 min of infection, the microfilaments were irregularly distributed throughout the cell.", [["microfilaments", "ANATOMY", 31, 45], ["cell", "ANATOMY", 90, 94], ["infection", "DISEASE", 16, 25], ["microfilaments", "CELLULAR_COMPONENT", 31, 45], ["cell", "CELL", 90, 94], ["infection", "PROBLEM", 16, 25], ["the microfilaments", "TREATMENT", 27, 45], ["infection", "OBSERVATION", 16, 25], ["irregularly", "OBSERVATION_MODIFIER", 51, 62], ["distributed", "OBSERVATION_MODIFIER", 63, 74], ["cell", "OBSERVATION", 90, 94]]], ["They dissolved in the PEDV-infected IPEC-J2 cells, and retracted and formed pronounced foci around certain membrane structures and the plasma membrane in the TGEV-infected and PEDV + TGEV-infected IPEC-J2 cells (Fig. 3G , the first line).", [["IPEC-J2 cells", "ANATOMY", 36, 49], ["foci", "ANATOMY", 87, 91], ["membrane structures", "ANATOMY", 107, 126], ["plasma membrane", "ANATOMY", 135, 150], ["IPEC-J2 cells", "ANATOMY", 197, 210], ["PEDV", "SIMPLE_CHEMICAL", 22, 26], ["IPEC-J2 cells", "CELL", 36, 49], ["membrane structures", "CELLULAR_COMPONENT", 107, 126], ["plasma membrane", "CELLULAR_COMPONENT", 135, 150], ["TGEV", "ORGANISM", 158, 162], ["PEDV + TGEV", "ORGANISM", 176, 187], ["IPEC-J2 cells", "CELL", 197, 210], ["Fig. 3G", "CELL", 212, 219], ["PEDV-infected IPEC-J2 cells", "CELL_LINE", 22, 49], ["PEDV + TGEV-infected IPEC-J2 cells", "CELL_LINE", 176, 210], ["TGEV", "SPECIES", 183, 187], ["TGEV", "SPECIES", 158, 162], ["PEDV", "SPECIES", 176, 180], ["TGEV", "SPECIES", 183, 187], ["the PEDV", "TEST", 18, 26], ["infected IPEC-J2 cells", "PROBLEM", 27, 49], ["retracted and formed pronounced foci", "PROBLEM", 55, 91], ["the plasma membrane", "TEST", 131, 150], ["the TGEV", "TEST", 154, 162], ["infected", "PROBLEM", 163, 171], ["PEDV", "PROBLEM", 176, 180], ["TGEV", "PROBLEM", 183, 187], ["infected IPEC-J2 cells", "TREATMENT", 188, 210], ["the first line", "TREATMENT", 222, 236], ["infected", "OBSERVATION", 27, 35], ["J2 cells", "OBSERVATION", 41, 49], ["pronounced", "OBSERVATION_MODIFIER", 76, 86], ["foci", "OBSERVATION", 87, 91], ["certain membrane", "OBSERVATION_MODIFIER", 99, 115], ["plasma membrane", "OBSERVATION", 135, 150], ["infected", "OBSERVATION", 163, 171], ["TGEV", "OBSERVATION_MODIFIER", 183, 187], ["infected", "OBSERVATION_MODIFIER", 188, 196], ["J2 cells", "OBSERVATION", 202, 210]]], ["After 1 h of infection, the bundles of microfilaments were found to line the plasma membrane in all virus-infected IPEC-J2 cells (Fig. 3G , the second line).", [["bundles", "ANATOMY", 28, 35], ["microfilaments", "ANATOMY", 39, 53], ["plasma membrane", "ANATOMY", 77, 92], ["IPEC-J2 cells", "ANATOMY", 115, 128], ["infection", "DISEASE", 13, 22], ["microfilaments", "CELLULAR_COMPONENT", 39, 53], ["plasma membrane", "CELLULAR_COMPONENT", 77, 92], ["IPEC-J2 cells", "CELL", 115, 128], ["Fig. 3G", "CELL", 130, 137], ["IPEC-J2 cells", "CELL_LINE", 115, 128], ["infection", "PROBLEM", 13, 22], ["the plasma membrane", "TEST", 73, 92], ["all virus", "PROBLEM", 96, 105], ["infected IPEC-J2 cells", "TREATMENT", 106, 128], ["the second line", "TREATMENT", 140, 155], ["infection", "OBSERVATION", 13, 22], ["plasma membrane", "ANATOMY", 77, 92], ["J2 cells", "OBSERVATION", 120, 128]]], ["The plasma membrane appeared to be completely devoid of filaments, whereas dense network aggregates, clumps, or even compact foci of filamentous material had formed in the nuclear membrane of all virus-infected IPEC-J2 cells at 12 hpi (Fig. 3G , the third line).", [["plasma membrane", "ANATOMY", 4, 19], ["filaments", "ANATOMY", 56, 65], ["network aggregates", "ANATOMY", 81, 99], ["clumps", "ANATOMY", 101, 107], ["foci", "ANATOMY", 125, 129], ["filamentous material", "ANATOMY", 133, 153], ["nuclear membrane", "ANATOMY", 172, 188], ["IPEC-J2 cells", "ANATOMY", 211, 224], ["plasma membrane", "CELLULAR_COMPONENT", 4, 19], ["filaments", "CELLULAR_COMPONENT", 56, 65], ["dense network aggregates", "CELLULAR_COMPONENT", 75, 99], ["filamentous material", "CELLULAR_COMPONENT", 133, 153], ["nuclear membrane", "CELLULAR_COMPONENT", 172, 188], ["IPEC-J2 cells", "CELL", 211, 224], ["IPEC-J2 cells", "CELL_LINE", 211, 224], ["dense network aggregates", "PROBLEM", 75, 99], ["clumps", "PROBLEM", 101, 107], ["filamentous material", "PROBLEM", 133, 153], ["all virus", "PROBLEM", 192, 201], ["J2 cells", "PROBLEM", 216, 224], ["the third line", "TREATMENT", 246, 260], ["dense", "OBSERVATION_MODIFIER", 75, 80], ["network aggregates", "OBSERVATION", 81, 99], ["clumps", "OBSERVATION_MODIFIER", 101, 107], ["compact", "OBSERVATION_MODIFIER", 117, 124], ["foci", "OBSERVATION", 125, 129], ["filamentous material", "OBSERVATION", 133, 153], ["nuclear membrane", "ANATOMY", 172, 188], ["all virus", "ANATOMY", 192, 201], ["J2 cells", "OBSERVATION_MODIFIER", 216, 224]]], ["After 24 h of infection, the microfilaments in the cytoplasm were more diffusely fluorescent, and retraction of the microfilaments in a perinuclear location formed juxtanuclear caps or rings in their infected cells (Fig. 3G, the last line) .The effect of Jas and Cyto D on viral attachment, replication and releaseIn order to determine whether the microfilaments are required for PEDV and TGEV infection, we treated IPEC-J2 cells with Cyto D (Fig. 4B) , which can induce destabilisation of the microfilaments, and Jas (Fig. 4C) , which is able to promote microfilament stabilisation.", [["microfilaments", "ANATOMY", 29, 43], ["cytoplasm", "ANATOMY", 51, 60], ["microfilaments", "ANATOMY", 116, 130], ["perinuclear location", "ANATOMY", 136, 156], ["juxtanuclear caps", "ANATOMY", 164, 181], ["rings", "ANATOMY", 185, 190], ["cells", "ANATOMY", 209, 214], ["microfilaments", "ANATOMY", 348, 362], ["IPEC-J2 cells", "ANATOMY", 416, 429], ["microfilaments", "ANATOMY", 494, 508], ["microfilament", "ANATOMY", 555, 568], ["infection", "DISEASE", 14, 23], ["TGEV infection", "DISEASE", 389, 403], ["Cyto D", "CHEMICAL", 263, 269], ["microfilaments", "CELLULAR_COMPONENT", 29, 43], ["cytoplasm", "ORGANISM_SUBSTANCE", 51, 60], ["microfilaments", "CELLULAR_COMPONENT", 116, 130], ["perinuclear location", "CELLULAR_COMPONENT", 136, 156], ["juxtanuclear caps", "CELLULAR_COMPONENT", 164, 181], ["cells", "CELL", 209, 214], ["Jas", "SIMPLE_CHEMICAL", 255, 258], ["Cyto D", "SIMPLE_CHEMICAL", 263, 269], ["microfilaments", "CELLULAR_COMPONENT", 348, 362], ["PEDV", "GENE_OR_GENE_PRODUCT", 380, 384], ["TGEV", "ORGANISM", 389, 393], ["IPEC-J2 cells", "CELL", 416, 429], ["Cyto D", "SIMPLE_CHEMICAL", 435, 441], ["Fig. 4B", "ORGANISM", 443, 450], ["microfilaments", "CELLULAR_COMPONENT", 494, 508], ["microfilament", "CELLULAR_COMPONENT", 555, 568], ["infected cells", "CELL_TYPE", 200, 214], ["Jas", "PROTEIN", 255, 258], ["Cyto D", "PROTEIN", 263, 269], ["IPEC-J2 cells", "CELL_LINE", 416, 429], ["Jas", "PROTEIN", 514, 517], ["TGEV", "SPECIES", 389, 393], ["PEDV", "SPECIES", 380, 384], ["TGEV", "SPECIES", 389, 393], ["infection", "PROBLEM", 14, 23], ["the microfilaments in the cytoplasm", "PROBLEM", 25, 60], ["diffusely fluorescent", "PROBLEM", 71, 92], ["retraction of the microfilaments", "PROBLEM", 98, 130], ["juxtanuclear caps", "PROBLEM", 164, 181], ["rings in their infected cells", "PROBLEM", 185, 214], ["the last line", "TREATMENT", 225, 238], ["Jas and Cyto D", "PROBLEM", 255, 269], ["viral attachment", "TREATMENT", 273, 289], ["the microfilaments", "PROBLEM", 344, 362], ["PEDV", "PROBLEM", 380, 384], ["TGEV infection", "PROBLEM", 389, 403], ["IPEC-J2 cells", "TREATMENT", 416, 429], ["Cyto D (Fig. 4B", "TREATMENT", 435, 450], ["microfilament stabilisation", "TREATMENT", 555, 582], ["infection", "OBSERVATION", 14, 23], ["diffusely", "OBSERVATION_MODIFIER", 71, 80], ["fluorescent", "OBSERVATION_MODIFIER", 81, 92], ["retraction", "OBSERVATION_MODIFIER", 98, 108], ["perinuclear", "OBSERVATION_MODIFIER", 136, 147], ["juxtanuclear caps", "OBSERVATION", 164, 181], ["rings", "OBSERVATION_MODIFIER", 185, 190], ["infected cells", "OBSERVATION", 200, 214], ["J2 cells", "OBSERVATION_MODIFIER", 421, 429], ["microfilament stabilisation", "OBSERVATION", 555, 582]]], ["First, the data showed that neither Jas nor Cyto D affected the ability of PEDV, TGEV and PEDV + TGEV to enter the IPEC-J2 cells (p < 0.05) (Fig. 4D, left) .", [["IPEC-J2 cells", "ANATOMY", 115, 128], ["Cyto D", "CHEMICAL", 44, 50], ["Jas", "SIMPLE_CHEMICAL", 36, 39], ["Cyto D", "SIMPLE_CHEMICAL", 44, 50], ["PEDV", "ORGANISM", 75, 79], ["TGEV", "ORGANISM", 81, 85], ["PEDV + TGEV", "ORGANISM", 90, 101], ["IPEC-J2 cells", "CELL", 115, 128], ["Jas", "PROTEIN", 36, 39], ["Cyto D", "PROTEIN", 44, 50], ["IPEC-J2 cells", "CELL_LINE", 115, 128], ["PEDV", "SPECIES", 75, 79], ["TGEV", "SPECIES", 81, 85], ["PEDV", "SPECIES", 90, 94], ["TGEV", "SPECIES", 97, 101], ["the data", "TEST", 7, 15], ["PEDV", "PROBLEM", 75, 79], ["TGEV", "PROBLEM", 81, 85], ["PEDV", "PROBLEM", 90, 94], ["TGEV", "PROBLEM", 97, 101], ["J2", "ANATOMY", 120, 122], ["left", "ANATOMY_MODIFIER", 150, 154]]], ["However, Cyto D notably inhibited all viral release from IPEC-J2 (p < 0.05), and the Jas group only inhibited viral release in the PEDV + TGEV co-infection group (Fig. 4D, middle) .", [["Cyto D", "CHEMICAL", 9, 15], ["PEDV", "CHEMICAL", 131, 135], ["Cyto D", "CHEMICAL", 9, 15], ["Cyto D", "SIMPLE_CHEMICAL", 9, 15], ["IPEC-J2", "CELL", 57, 64], ["Jas", "GENE_OR_GENE_PRODUCT", 85, 88], ["PEDV + TGEV", "ORGANISM", 131, 142], ["TGEV", "SPECIES", 138, 142], ["Cyto D", "PROBLEM", 9, 15], ["all viral release", "TEST", 34, 51], ["IPEC", "TEST", 57, 61], ["viral release", "PROBLEM", 110, 123], ["the PEDV", "TEST", 127, 135], ["TGEV co-infection group", "TREATMENT", 138, 161], ["TGEV co-infection", "OBSERVATION", 138, 155], ["middle", "ANATOMY_MODIFIER", 172, 178]]], ["Finally, Cyto D and Jas treated IPEC-J2 cells significantly decreased the replication and release of all viruses, especially when using the Cyto D treatment (p < 0.01) (Fig. 4D, right) .", [["IPEC-J2 cells", "ANATOMY", 32, 45], ["Cyto D", "CHEMICAL", 140, 146], ["Cyto D", "CHEMICAL", 140, 146], ["Cyto D", "SIMPLE_CHEMICAL", 9, 15], ["Jas", "SIMPLE_CHEMICAL", 20, 23], ["IPEC-J2 cells", "CELL", 32, 45], ["Cyto D", "SIMPLE_CHEMICAL", 140, 146], ["Cyto D and Jas treated IPEC-J2 cells", "CELL_LINE", 9, 45], ["J2 cells", "PROBLEM", 37, 45], ["the replication", "TREATMENT", 70, 85], ["all viruses", "PROBLEM", 101, 112], ["the Cyto D treatment", "TREATMENT", 136, 156], ["J2 cells", "OBSERVATION_MODIFIER", 37, 45], ["all", "OBSERVATION_MODIFIER", 101, 104], ["viruses", "OBSERVATION", 105, 112], ["right", "ANATOMY_MODIFIER", 178, 183]]], ["To further validate the effects of microfilament disorder on the attachment, replication and release of PEDV and TGEV, the qRT-PCR was used to detect the viral level.", [["microfilament", "ANATOMY", 35, 48], ["microfilament disorder", "DISEASE", 35, 57], ["microfilament", "CELLULAR_COMPONENT", 35, 48], ["PEDV", "GENE_OR_GENE_PRODUCT", 104, 108], ["TGEV", "ORGANISM", 113, 117], ["PEDV", "PROTEIN", 104, 108], ["qRT", "DNA", 123, 126], ["PEDV", "SPECIES", 104, 108], ["TGEV", "SPECIES", 113, 117], ["microfilament disorder", "PROBLEM", 35, 57], ["replication", "TREATMENT", 77, 88], ["PEDV", "PROBLEM", 104, 108], ["TGEV", "PROBLEM", 113, 117], ["the qRT-PCR", "TEST", 119, 130], ["microfilament disorder", "OBSERVATION", 35, 57], ["viral", "OBSERVATION", 154, 159]]], ["Form the results, only Cyto D could affect the ability of TGEV to enter the IPEC-J2 cells (p < 0.05) (Fig. 4G) .", [["IPEC-J2 cells", "ANATOMY", 76, 89], ["Cyto D", "CHEMICAL", 23, 29], ["Cyto D", "SIMPLE_CHEMICAL", 23, 29], ["TGEV", "ORGANISM", 58, 62], ["IPEC-J2 cells", "CELL", 76, 89], ["Cyto D", "PROTEIN", 23, 29], ["IPEC-J2 cells", "CELL_LINE", 76, 89], ["TGEV", "SPECIES", 58, 62], ["Cyto D", "PROBLEM", 23, 29], ["TGEV", "PROBLEM", 58, 62], ["J2", "ANATOMY", 81, 83]]], ["Moreover, Jas and Cyto D notably inhibited all viral release from IPEC-J2 (p < 0.05) (Fig. 4H) , and Cyto D and Jas treated IPEC-J2 cells significantly decreased the replication and release of all viruses, especially when using the Cyto D treatment (p < 0.01) (Fig. I) .", [["IPEC-J2 cells", "ANATOMY", 124, 137], ["Cyto D", "CHEMICAL", 18, 24], ["Cyto D", "CHEMICAL", 232, 238], ["Cyto D", "CHEMICAL", 18, 24], ["Cyto D", "CHEMICAL", 232, 238], ["Jas", "SIMPLE_CHEMICAL", 10, 13], ["Cyto D", "SIMPLE_CHEMICAL", 18, 24], ["IPEC-J2", "CELL", 66, 73], ["Cyto D", "SIMPLE_CHEMICAL", 101, 107], ["Jas", "SIMPLE_CHEMICAL", 112, 115], ["IPEC-J2 cells", "CELL", 124, 137], ["Cyto D", "SIMPLE_CHEMICAL", 232, 238], ["Jas", "PROTEIN", 10, 13], ["Cyto D", "PROTEIN", 18, 24], ["Jas treated IPEC-J2 cells", "CELL_LINE", 112, 137], ["Jas and Cyto D", "PROBLEM", 10, 24], ["all viral release", "TEST", 43, 60], ["IPEC", "TEST", 66, 70], ["Cyto D", "TEST", 101, 107], ["Jas", "TEST", 112, 115], ["IPEC", "TEST", 124, 128], ["J2 cells", "PROBLEM", 129, 137], ["the replication", "TREATMENT", 162, 177], ["all viruses", "PROBLEM", 193, 204], ["the Cyto D treatment", "TREATMENT", 228, 248], ["viruses", "OBSERVATION", 197, 204]]], ["These results implied that microfilament disorder of IPEC-J2 cells did not affect the attachment of PEDV and TGEV, but inhibited the replication and release of them.", [["microfilament", "ANATOMY", 27, 40], ["IPEC-J2 cells", "ANATOMY", 53, 66], ["microfilament disorder", "DISEASE", 27, 49], ["microfilament", "CELLULAR_COMPONENT", 27, 40], ["IPEC-J2 cells", "CELL", 53, 66], ["PEDV", "GENE_OR_GENE_PRODUCT", 100, 104], ["TGEV", "ORGANISM", 109, 113], ["IPEC-J2 cells", "CELL_LINE", 53, 66], ["PEDV", "PROTEIN", 100, 104], ["PEDV", "SPECIES", 100, 104], ["TGEV", "SPECIES", 109, 113], ["microfilament disorder", "PROBLEM", 27, 49], ["IPEC", "TEST", 53, 57], ["J2 cells", "PROBLEM", 58, 66], ["PEDV", "PROBLEM", 100, 104], ["microfilament disorder", "OBSERVATION", 27, 49], ["J2 cells", "OBSERVATION", 58, 66]]], ["Furthermore, microfilament depolymerisation in IPEC-J2 cells significantly affected the replication and release of PEDV and TGEV.TGEV and PEDV infection affected the activation of MAPK signalling pathway in IPEC-J2 cellsThe MAPK signalling pathway is not only able to modulate the expression of several TJ proteins, but also changes the microfilament remodelling in viral infection.", [["microfilament", "ANATOMY", 13, 26], ["IPEC-J2 cells", "ANATOMY", 47, 60], ["IPEC-J2 cells", "ANATOMY", 207, 220], ["TJ", "ANATOMY", 303, 305], ["microfilament", "ANATOMY", 337, 350], ["PEDV", "CHEMICAL", 138, 142], ["infection", "DISEASE", 143, 152], ["viral infection", "DISEASE", 366, 381], ["microfilament", "CELLULAR_COMPONENT", 13, 26], ["IPEC-J2 cells", "CELL", 47, 60], ["PEDV", "GENE_OR_GENE_PRODUCT", 115, 119], ["TGEV", "ORGANISM", 124, 128], ["TGEV", "ORGANISM", 129, 133], ["PEDV", "ORGANISM", 138, 142], ["MAPK", "GENE_OR_GENE_PRODUCT", 180, 184], ["IPEC-J2 cells", "CELL", 207, 220], ["MAPK", "GENE_OR_GENE_PRODUCT", 224, 228], ["TJ", "GENE_OR_GENE_PRODUCT", 303, 305], ["microfilament", "CELLULAR_COMPONENT", 337, 350], ["IPEC-J2 cells", "CELL_LINE", 47, 60], ["PEDV", "PROTEIN", 115, 119], ["MAPK", "PROTEIN", 180, 184], ["IPEC-J2 cells", "CELL_LINE", 207, 220], ["MAPK", "PROTEIN", 224, 228], ["TJ proteins", "PROTEIN", 303, 314], ["TGEV", "SPECIES", 129, 133], ["PEDV", "SPECIES", 115, 119], ["TGEV", "SPECIES", 124, 128], ["TGEV", "SPECIES", 129, 133], ["PEDV", "SPECIES", 138, 142], ["microfilament depolymerisation", "TEST", 13, 43], ["IPEC", "TEST", 47, 51], ["J2 cells", "PROBLEM", 52, 60], ["the replication", "TREATMENT", 84, 99], ["PEDV", "PROBLEM", 115, 119], ["TGEV", "PROBLEM", 124, 128], ["TGEV", "PROBLEM", 129, 133], ["PEDV infection", "PROBLEM", 138, 152], ["MAPK signalling pathway", "PROBLEM", 180, 203], ["J2 cells", "PROBLEM", 212, 220], ["The MAPK signalling pathway", "TEST", 220, 247], ["several TJ proteins", "PROBLEM", 295, 314], ["the microfilament remodelling in viral infection", "PROBLEM", 333, 381], ["microfilament depolymerisation", "OBSERVATION", 13, 43], ["J2 cells", "OBSERVATION_MODIFIER", 52, 60], ["PEDV", "OBSERVATION_MODIFIER", 138, 142], ["infection", "OBSERVATION", 143, 152], ["J2 cells", "OBSERVATION", 212, 220], ["several", "OBSERVATION_MODIFIER", 295, 302], ["TJ proteins", "OBSERVATION_MODIFIER", 303, 314], ["microfilament", "OBSERVATION_MODIFIER", 337, 350], ["remodelling", "OBSERVATION_MODIFIER", 351, 362], ["viral infection", "OBSERVATION", 366, 381]]], ["From our results, the PEDV, TGEV and PEDV + TGEV infection resulted in a marked increase in the ratio of phospho-ERK1/2 and phospho-JNK in the IPEC-J2 cells at 60 minpi (p < 0.05), especially with regard to an increase in the intensity of phospho-JNK in TGEV infected IPEC-J2 cells (p < 0.01).", [["IPEC-J2 cells", "ANATOMY", 143, 156], ["IPEC-J2 cells", "ANATOMY", 268, 281], ["PEDV", "CHEMICAL", 37, 41], ["infection", "DISEASE", 49, 58], ["phospho", "CHEMICAL", 105, 112], ["PEDV", "SIMPLE_CHEMICAL", 22, 26], ["TGEV", "ORGANISM", 28, 32], ["PEDV + TGEV", "ORGANISM", 37, 48], ["phospho-ERK1/2", "GENE_OR_GENE_PRODUCT", 105, 119], ["phospho-JNK", "GENE_OR_GENE_PRODUCT", 124, 135], ["IPEC-J2 cells", "CELL", 143, 156], ["JNK", "GENE_OR_GENE_PRODUCT", 247, 250], ["TGEV", "ORGANISM", 254, 258], ["IPEC-J2 cells", "CELL", 268, 281], ["phospho", "PROTEIN", 105, 112], ["ERK1/2", "PROTEIN", 113, 119], ["phospho-JNK", "PROTEIN", 124, 135], ["IPEC-J2 cells", "CELL_LINE", 143, 156], ["phospho-JNK", "PROTEIN", 239, 250], ["TGEV infected IPEC-J2 cells", "CELL_LINE", 254, 281], ["PEDV", "SPECIES", 22, 26], ["TGEV", "SPECIES", 28, 32], ["PEDV", "SPECIES", 37, 41], ["TGEV", "SPECIES", 44, 48], ["TGEV", "SPECIES", 254, 258], ["the PEDV", "PROBLEM", 18, 26], ["TGEV", "PROBLEM", 28, 32], ["PEDV", "PROBLEM", 37, 41], ["TGEV infection", "PROBLEM", 44, 58], ["a marked increase", "PROBLEM", 71, 88], ["phospho", "TEST", 105, 112], ["phospho-JNK", "TEST", 124, 135], ["the IPEC", "TEST", 139, 147], ["minpi", "TEST", 163, 168], ["an increase", "PROBLEM", 207, 218], ["phospho-JNK", "TEST", 239, 250], ["TGEV infected IPEC", "PROBLEM", 254, 272], ["J2 cells", "TEST", 273, 281], ["TGEV infection", "OBSERVATION", 44, 58], ["marked", "OBSERVATION_MODIFIER", 73, 79], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["increase", "OBSERVATION_MODIFIER", 210, 218], ["J2 cells", "OBSERVATION_MODIFIER", 273, 281]]], ["However, the ratio of phosphor-p38 in the IPEC-J2 cells in all groups caused almost no alterations (Fig. 5A , left and 5B, up).", [["IPEC-J2 cells", "ANATOMY", 42, 55], ["phosphor-p38", "GENE_OR_GENE_PRODUCT", 22, 34], ["IPEC-J2 cells", "CELL", 42, 55], ["p38", "PROTEIN", 31, 34], ["IPEC-J2 cells", "CELL_LINE", 42, 55], ["the ratio", "TEST", 9, 18], ["phosphor", "TEST", 22, 30], ["the IPEC", "TEST", 38, 46], ["J2 cells", "OBSERVATION", 47, 55], ["left", "ANATOMY_MODIFIER", 110, 114]]], ["In contrast, the PEDV, TGEV and PEDV + TGEV infection resulted in a notable decrease in the ratio of phospho-ERK1/2 and phospho-p38 in the IPEC-J2 cells (p < 0.05), but the phospho-JNK in all groups did not change at 24 hpi (Fig. 5A, right and 5B, down) .", [["IPEC-J2 cells", "ANATOMY", 139, 152], ["PEDV", "CHEMICAL", 32, 36], ["infection", "DISEASE", 44, 53], ["phospho", "CHEMICAL", 101, 108], ["phospho", "CHEMICAL", 120, 127], ["TGEV", "ORGANISM", 23, 27], ["PEDV + TGEV", "ORGANISM", 32, 43], ["phospho-ERK1/2", "GENE_OR_GENE_PRODUCT", 101, 115], ["phospho-p38", "GENE_OR_GENE_PRODUCT", 120, 131], ["IPEC-J2 cells", "CELL", 139, 152], ["phospho-JNK", "GENE_OR_GENE_PRODUCT", 173, 184], ["phospho", "PROTEIN", 101, 108], ["ERK1/2", "PROTEIN", 109, 115], ["phospho", "PROTEIN", 120, 127], ["p38", "PROTEIN", 128, 131], ["IPEC-J2 cells", "CELL_LINE", 139, 152], ["phospho-JNK", "PROTEIN", 173, 184], ["PEDV", "SPECIES", 17, 21], ["TGEV", "SPECIES", 23, 27], ["PEDV", "SPECIES", 32, 36], ["TGEV", "SPECIES", 39, 43], ["the PEDV", "PROBLEM", 13, 21], ["TGEV", "PROBLEM", 23, 27], ["PEDV", "PROBLEM", 32, 36], ["TGEV infection", "PROBLEM", 39, 53], ["phospho", "TEST", 101, 108], ["phospho", "TEST", 120, 127], ["the IPEC", "TEST", 135, 143], ["the phospho-JNK", "TEST", 169, 184], ["TGEV", "OBSERVATION_MODIFIER", 39, 43], ["infection", "OBSERVATION", 44, 53], ["notable", "OBSERVATION_MODIFIER", 68, 75], ["decrease", "OBSERVATION_MODIFIER", 76, 84], ["J2", "ANATOMY", 144, 146], ["right", "ANATOMY_MODIFIER", 234, 239]]], ["Thus, these data demonstrate that PEDV, TGEV and their co-infection changed the levels of phospho-ERK1/2, phospho-p38 and phospho-JNK in IPEC-J2, and that the changes in tight junction and microfilaments of IPEC-J2 cells induced by TGEV and PEDV might be linked to activation of the MAPK signalling pathway.The effects of MAPK pathway inhibitor on the infection of PEDV and TGEV, the tight junctions and microfilaments of IPEC-J2 cellsSince the changes of phospho-MAPKs were observed in PEDV and TGEV infection, the inhibitors of MAPKs (PD98059, SB203580 and SP600125) were employed to further investigate the role of the MAPKs in the infection of PEDV and TGEV, the tight junctions and microfilaments of IPEC-J2 cells.", [["IPEC-J2", "ANATOMY", 137, 144], ["tight junction", "ANATOMY", 170, 184], ["microfilaments", "ANATOMY", 189, 203], ["IPEC-J2 cells", "ANATOMY", 207, 220], ["tight junctions", "ANATOMY", 384, 399], ["microfilaments", "ANATOMY", 404, 418], ["IPEC-J2 cells", "ANATOMY", 422, 435], ["tight junctions", "ANATOMY", 667, 682], ["microfilaments", "ANATOMY", 687, 701], ["IPEC-J2 cells", "ANATOMY", 705, 718], ["PEDV", "CHEMICAL", 241, 245], ["infection", "DISEASE", 352, 361], ["TGEV infection", "DISEASE", 496, 510], ["PD98059", "CHEMICAL", 537, 544], ["SB203580", "CHEMICAL", 546, 554], ["SP600125", "CHEMICAL", 559, 567], ["infection", "DISEASE", 635, 644], ["phospho", "CHEMICAL", 106, 113], ["phospho", "CHEMICAL", 456, 463], ["PD98059", "CHEMICAL", 537, 544], ["SB203580", "CHEMICAL", 546, 554], ["SP600125", "CHEMICAL", 559, 567], ["PEDV", "GENE_OR_GENE_PRODUCT", 34, 38], ["TGEV", "ORGANISM", 40, 44], ["phospho-ERK1/2", "GENE_OR_GENE_PRODUCT", 90, 104], ["phospho-p38", "GENE_OR_GENE_PRODUCT", 106, 117], ["phospho-JNK", "GENE_OR_GENE_PRODUCT", 122, 133], ["IPEC-J2", "CELL", 137, 144], ["tight junction", "CELLULAR_COMPONENT", 170, 184], ["microfilaments", "CELLULAR_COMPONENT", 189, 203], ["IPEC-J2 cells", "CELL", 207, 220], ["TGEV", "ORGANISM", 232, 236], ["PEDV", "GENE_OR_GENE_PRODUCT", 241, 245], ["MAPK", "GENE_OR_GENE_PRODUCT", 283, 287], ["MAPK", "GENE_OR_GENE_PRODUCT", 322, 326], ["PEDV", "CANCER", 365, 369], ["TGEV", "ORGANISM", 374, 378], ["tight junctions", "CELLULAR_COMPONENT", 384, 399], ["microfilaments", "CELLULAR_COMPONENT", 404, 418], ["IPEC-J2 cells", "CELL", 422, 435], ["phospho-MAPKs", "GENE_OR_GENE_PRODUCT", 456, 469], ["TGEV", "ORGANISM", 496, 500], ["MAPKs", "GENE_OR_GENE_PRODUCT", 530, 535], ["PD98059", "SIMPLE_CHEMICAL", 537, 544], ["SB203580", "SIMPLE_CHEMICAL", 546, 554], ["SP600125", "SIMPLE_CHEMICAL", 559, 567], ["MAPKs", "GENE_OR_GENE_PRODUCT", 622, 627], ["PEDV", "CANCER", 648, 652], ["TGEV", "ORGANISM", 657, 661], ["tight junctions", "CELLULAR_COMPONENT", 667, 682], ["microfilaments", "CELLULAR_COMPONENT", 687, 701], ["IPEC-J2 cells", "CELL", 705, 718], ["phospho", "PROTEIN", 90, 97], ["ERK1", "PROTEIN", 98, 102], ["phospho", "PROTEIN", 106, 113], ["p38", "PROTEIN", 114, 117], ["phospho-JNK", "PROTEIN", 122, 133], ["IPEC-J2", "CELL_LINE", 137, 144], ["IPEC-J2 cells", "CELL_LINE", 207, 220], ["MAPK", "PROTEIN", 283, 287], ["MAPK", "PROTEIN", 322, 326], ["IPEC-J2 cells", "CELL_LINE", 422, 435], ["phospho", "PROTEIN", 456, 463], ["MAPKs", "PROTEIN", 464, 469], ["MAPKs", "PROTEIN", 530, 535], ["MAPKs", "PROTEIN", 622, 627], ["IPEC-J2 cells", "CELL_LINE", 705, 718], ["TGEV", "SPECIES", 374, 378], ["PEDV", "SPECIES", 34, 38], ["TGEV", "SPECIES", 40, 44], ["TGEV", "SPECIES", 232, 236], ["PEDV", "SPECIES", 365, 369], ["TGEV", "SPECIES", 374, 378], ["PEDV", "SPECIES", 487, 491], ["TGEV", "SPECIES", 496, 500], ["PEDV", "SPECIES", 648, 652], ["TGEV", "SPECIES", 657, 661], ["these data", "TEST", 6, 16], ["PEDV", "PROBLEM", 34, 38], ["TGEV", "PROBLEM", 40, 44], ["their co-infection", "PROBLEM", 49, 67], ["phospho", "TEST", 90, 97], ["ERK1", "TEST", 98, 102], ["phospho", "TEST", 106, 113], ["phospho-JNK", "TEST", 122, 133], ["IPEC", "TEST", 137, 141], ["the changes in tight junction", "PROBLEM", 155, 184], ["IPEC", "TEST", 207, 211], ["J2 cells", "PROBLEM", 212, 220], ["TGEV", "PROBLEM", 232, 236], ["PEDV", "PROBLEM", 241, 245], ["MAPK pathway inhibitor", "TREATMENT", 322, 344], ["the infection", "PROBLEM", 348, 361], ["PEDV", "PROBLEM", 365, 369], ["TGEV", "PROBLEM", 374, 378], ["IPEC", "TEST", 422, 426], ["J2 cells", "PROBLEM", 427, 435], ["phospho-MAPKs", "TREATMENT", 456, 469], ["PEDV", "PROBLEM", 487, 491], ["TGEV infection", "PROBLEM", 496, 510], ["MAPKs", "TEST", 530, 535], ["PD98059", "TEST", 537, 544], ["SB203580", "TEST", 546, 554], ["the infection of PEDV", "PROBLEM", 631, 652], ["TGEV", "PROBLEM", 657, 661], ["IPEC-J2 cells", "TREATMENT", 705, 718], ["J2", "ANATOMY", 142, 144], ["tight junction", "OBSERVATION", 170, 184], ["J2 cells", "OBSERVATION", 212, 220], ["infection", "OBSERVATION", 352, 361], ["J2 cells", "OBSERVATION", 427, 435], ["TGEV infection", "OBSERVATION", 496, 510], ["infection", "OBSERVATION", 635, 644], ["J2 cells", "OBSERVATION", 710, 718]]], ["As we showed in Fig. 6A , inhibition of MAPKs failed to increase the viral replication.", [["MAPKs", "GENE_OR_GENE_PRODUCT", 40, 45], ["MAPKs", "PROTEIN", 40, 45], ["MAPKs", "TREATMENT", 40, 45], ["the viral replication", "TREATMENT", 65, 86], ["viral replication", "OBSERVATION", 69, 86]]], ["The ERK-MAPK-specific inhibitor (PD98059) and JNK-MAPK-specific inhibitor (SP600125) notably decreased the level of PEDV and TGEV infection at 12 hpi (p < 0.05) and 24 hpi (p < 0.05), and PD98059 extremely significantly inhibited the TGEV replication 24 hpi (p < 0.01), while p38-MAPK-specific inhibitor (SB203580) could not significantly inhibited the TGEV and PEDV replication (p > 0.05).", [["PD98059", "CHEMICAL", 33, 40], ["SP600125", "CHEMICAL", 75, 83], ["infection", "DISEASE", 130, 139], ["PD98059", "CHEMICAL", 188, 195], ["SB203580", "CHEMICAL", 305, 313], ["PD98059", "CHEMICAL", 33, 40], ["SP600125", "CHEMICAL", 75, 83], ["PD98059", "CHEMICAL", 188, 195], ["SB203580", "CHEMICAL", 305, 313], ["ERK", "GENE_OR_GENE_PRODUCT", 4, 7], ["MAPK", "GENE_OR_GENE_PRODUCT", 8, 12], ["PD98059", "SIMPLE_CHEMICAL", 33, 40], ["JNK-MAPK", "GENE_OR_GENE_PRODUCT", 46, 54], ["SP600125", "SIMPLE_CHEMICAL", 75, 83], ["PEDV", "GENE_OR_GENE_PRODUCT", 116, 120], ["TGEV", "ORGANISM", 125, 129], ["PD98059", "SIMPLE_CHEMICAL", 188, 195], ["p38-MAPK", "GENE_OR_GENE_PRODUCT", 276, 284], ["SB203580", "SIMPLE_CHEMICAL", 305, 313], ["TGEV", "ORGANISM", 353, 357], ["PEDV", "SIMPLE_CHEMICAL", 362, 366], ["ERK", "PROTEIN", 4, 7], ["MAPK", "PROTEIN", 8, 12], ["JNK", "PROTEIN", 46, 49], ["MAPK", "PROTEIN", 50, 54], ["p38", "PROTEIN", 276, 279], ["MAPK", "PROTEIN", 280, 284], ["TGEV", "SPECIES", 125, 129], ["TGEV", "SPECIES", 234, 238], ["TGEV", "SPECIES", 353, 357], ["PEDV", "SPECIES", 362, 366], ["The ERK", "TEST", 0, 7], ["MAPK", "TEST", 8, 12], ["specific inhibitor", "TEST", 13, 31], ["PD98059", "TEST", 33, 40], ["JNK", "TEST", 46, 49], ["MAPK", "TEST", 50, 54], ["PEDV", "PROBLEM", 116, 120], ["TGEV infection", "PROBLEM", 125, 139], ["PD98059", "TEST", 188, 195], ["the TGEV replication", "TREATMENT", 230, 250], ["p38", "TEST", 276, 279], ["the TGEV", "TREATMENT", 349, 357], ["PEDV replication", "TREATMENT", 362, 378]]], ["These results indicated that MAPKs inhibitors, especially for ERK and JNK, were involved in PEDV and TGEV infection.", [["TGEV infection", "DISEASE", 101, 115], ["MAPKs", "GENE_OR_GENE_PRODUCT", 29, 34], ["ERK", "GENE_OR_GENE_PRODUCT", 62, 65], ["JNK", "GENE_OR_GENE_PRODUCT", 70, 73], ["PEDV", "GENE_OR_GENE_PRODUCT", 92, 96], ["TGEV", "ORGANISM", 101, 105], ["MAPKs", "PROTEIN", 29, 34], ["ERK", "PROTEIN", 62, 65], ["JNK", "PROTEIN", 70, 73], ["PEDV", "SPECIES", 92, 96], ["TGEV", "SPECIES", 101, 105], ["MAPKs inhibitors", "TREATMENT", 29, 45], ["ERK", "TEST", 62, 65], ["JNK", "TEST", 70, 73], ["PEDV", "PROBLEM", 92, 96], ["TGEV infection", "PROBLEM", 101, 115], ["TGEV", "OBSERVATION_MODIFIER", 101, 105], ["infection", "OBSERVATION", 106, 115]]], ["From Fig. 6B , we could observed the PD98059 and SB203580 could significantly decreased the expression of E-cadherin and Occludin in the TGEV and PEDV infected IPEC-J2 cells at 12 hpi, and PD98059 also notably decreased the expression of E-cadherin, Occludin and Zo-1 in the TGEV and PEDV infected IPEC-J2 cells at 24 hpi.", [["IPEC-J2 cells", "ANATOMY", 160, 173], ["IPEC-J2 cells", "ANATOMY", 298, 311], ["PD98059", "CHEMICAL", 37, 44], ["SB203580", "CHEMICAL", 49, 57], ["PD98059", "CHEMICAL", 189, 196], ["PD98059", "CHEMICAL", 37, 44], ["SB203580", "CHEMICAL", 49, 57], ["PD98059", "CHEMICAL", 189, 196], ["PD98059", "SIMPLE_CHEMICAL", 37, 44], ["SB203580", "SIMPLE_CHEMICAL", 49, 57], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 106, 116], ["Occludin", "GENE_OR_GENE_PRODUCT", 121, 129], ["TGEV", "ORGANISM", 137, 141], ["PEDV", "CELL", 146, 150], ["IPEC-J2 cells", "CELL", 160, 173], ["PD98059", "SIMPLE_CHEMICAL", 189, 196], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 238, 248], ["Occludin", "GENE_OR_GENE_PRODUCT", 250, 258], ["Zo-1", "GENE_OR_GENE_PRODUCT", 263, 267], ["TGEV", "ORGANISM", 275, 279], ["PEDV", "CELL", 284, 288], ["IPEC-J2 cells", "CELL", 298, 311], ["E-cadherin", "PROTEIN", 106, 116], ["Occludin", "PROTEIN", 121, 129], ["TGEV and PEDV infected IPEC-J2 cells", "CELL_LINE", 137, 173], ["E-cadherin", "PROTEIN", 238, 248], ["Occludin", "PROTEIN", 250, 258], ["Zo-1", "PROTEIN", 263, 267], ["TGEV and PEDV infected IPEC-J2 cells", "CELL_LINE", 275, 311], ["TGEV", "SPECIES", 137, 141], ["TGEV", "SPECIES", 275, 279], ["TGEV", "SPECIES", 137, 141], ["PEDV", "SPECIES", 146, 150], ["TGEV", "SPECIES", 275, 279], ["PEDV", "SPECIES", 284, 288], ["E-cadherin", "TREATMENT", 106, 116], ["Occludin", "TREATMENT", 121, 129], ["the TGEV", "PROBLEM", 133, 141], ["PEDV infected IPEC", "PROBLEM", 146, 164], ["J2 cells", "PROBLEM", 165, 173], ["PD98059", "TEST", 189, 196], ["E-cadherin", "TREATMENT", 238, 248], ["Occludin", "TEST", 250, 258], ["Zo", "TEST", 263, 265], ["the TGEV", "PROBLEM", 271, 279], ["PEDV", "PROBLEM", 284, 288], ["J2 cells", "PROBLEM", 303, 311], ["J2 cells", "OBSERVATION_MODIFIER", 165, 173], ["decreased", "OBSERVATION_MODIFIER", 210, 219], ["TGEV", "ANATOMY", 275, 279], ["PEDV", "ANATOMY", 284, 288], ["infected", "OBSERVATION", 289, 297], ["J2 cells", "OBSERVATION", 303, 311]]], ["Moreover, SB203580 could suppress the expression of Claudin-1 in the TGEV and PEDV infected IPEC-J2 cells at 24 hpi.", [["IPEC-J2 cells", "ANATOMY", 92, 105], ["SB203580", "CHEMICAL", 10, 18], ["SB203580", "CHEMICAL", 10, 18], ["SB203580", "SIMPLE_CHEMICAL", 10, 18], ["Claudin-1", "GENE_OR_GENE_PRODUCT", 52, 61], ["TGEV", "ORGANISM", 69, 73], ["PEDV", "CELL", 78, 82], ["IPEC-J2 cells", "CELL", 92, 105], ["Claudin-1", "PROTEIN", 52, 61], ["TGEV and PEDV infected IPEC-J2 cells", "CELL_LINE", 69, 105], ["TGEV", "SPECIES", 69, 73], ["TGEV", "SPECIES", 69, 73], ["PEDV", "SPECIES", 78, 82], ["Claudin", "TEST", 52, 59], ["PEDV", "PROBLEM", 78, 82], ["J2 cells", "PROBLEM", 97, 105]]], ["Thus, the results demonstrated that MAPKs inhibitors, especially for ERK and p38, could affect the expression of tight junctions of IPEC-J2 cells.", [["tight junctions", "ANATOMY", 113, 128], ["IPEC-J2 cells", "ANATOMY", 132, 145], ["MAPKs", "GENE_OR_GENE_PRODUCT", 36, 41], ["ERK", "GENE_OR_GENE_PRODUCT", 69, 72], ["p38", "GENE_OR_GENE_PRODUCT", 77, 80], ["tight junctions", "CELLULAR_COMPONENT", 113, 128], ["IPEC-J2 cells", "CELL", 132, 145], ["MAPKs", "PROTEIN", 36, 41], ["ERK", "PROTEIN", 69, 72], ["p38", "PROTEIN", 77, 80], ["IPEC-J2 cells", "CELL_LINE", 132, 145], ["MAPKs inhibitors", "TREATMENT", 36, 52], ["ERK", "TEST", 69, 72], ["p38", "TEST", 77, 80], ["J2 cells", "PROBLEM", 137, 145], ["tight junctions", "OBSERVATION", 113, 128], ["J2 cells", "OBSERVATION", 137, 145]]], ["Finally, the results from Fig. 6C and Additional Fig. 2 showed that inhibition of MAPKs significantly affected the microfilaments of IPEC-J2 cells.", [["microfilaments", "ANATOMY", 115, 129], ["IPEC-J2 cells", "ANATOMY", 133, 146], ["MAPKs", "GENE_OR_GENE_PRODUCT", 82, 87], ["microfilaments", "CELLULAR_COMPONENT", 115, 129], ["IPEC-J2 cells", "CELL", 133, 146], ["MAPKs", "PROTEIN", 82, 87], ["IPEC-J2 cells", "CELL_LINE", 133, 146], ["Fig. 6C", "TREATMENT", 26, 33], ["Additional Fig", "TREATMENT", 38, 52], ["MAPKs", "TEST", 82, 87], ["J2 cells", "OBSERVATION", 138, 146]]], ["We observed that the microfilaments of IPEC-J2 cells treated with MAPKs inhibitors (PD98059, SB203580 and SP600125) disappeared in the cytoplasm or became more diffuse in the cytoplasm, then gathered in the plasma membrane after 40, 60 min and 12, 24 h of PEDV and TGEV infection.", [["microfilaments", "ANATOMY", 21, 35], ["IPEC-J2 cells", "ANATOMY", 39, 52], ["cytoplasm", "ANATOMY", 135, 144], ["cytoplasm", "ANATOMY", 175, 184], ["plasma membrane", "ANATOMY", 207, 222], ["PD98059", "CHEMICAL", 84, 91], ["SB203580", "CHEMICAL", 93, 101], ["SP600125", "CHEMICAL", 106, 114], ["PEDV", "CHEMICAL", 256, 260], ["TGEV infection", "DISEASE", 265, 279], ["PD98059", "CHEMICAL", 84, 91], ["SB203580", "CHEMICAL", 93, 101], ["SP600125", "CHEMICAL", 106, 114], ["microfilaments", "CELLULAR_COMPONENT", 21, 35], ["IPEC-J2 cells", "CELL", 39, 52], ["MAPKs", "GENE_OR_GENE_PRODUCT", 66, 71], ["PD98059", "SIMPLE_CHEMICAL", 84, 91], ["SB203580", "SIMPLE_CHEMICAL", 93, 101], ["SP600125", "SIMPLE_CHEMICAL", 106, 114], ["cytoplasm", "ORGANISM_SUBSTANCE", 135, 144], ["cytoplasm", "ORGANISM_SUBSTANCE", 175, 184], ["plasma membrane", "CELLULAR_COMPONENT", 207, 222], ["TGEV", "ORGANISM", 265, 269], ["IPEC-J2 cells", "CELL_LINE", 39, 52], ["MAPKs", "PROTEIN", 66, 71], ["PEDV", "SPECIES", 256, 260], ["TGEV", "SPECIES", 265, 269], ["IPEC-J2 cells", "TREATMENT", 39, 52], ["MAPKs inhibitors", "TREATMENT", 66, 82], ["PD98059", "TEST", 84, 91], ["SB203580", "TEST", 93, 101], ["PEDV", "PROBLEM", 256, 260], ["TGEV infection", "PROBLEM", 265, 279], ["more", "OBSERVATION_MODIFIER", 155, 159], ["diffuse", "OBSERVATION_MODIFIER", 160, 167], ["plasma membrane", "ANATOMY", 207, 222], ["TGEV", "OBSERVATION_MODIFIER", 265, 269], ["infection", "OBSERVATION", 270, 279]]], ["These results suggested that MAPKs inhibitors, ERK, p38 and JNK, were involved in the microfilaments of IPEC-J2 cells.DiscussionPEDV and TGEV severely replicated in the intestinal epithelial cells of the newborn piglets, resulting in fatal diarrhoea.", [["microfilaments", "ANATOMY", 86, 100], ["IPEC-J2 cells", "ANATOMY", 104, 117], ["intestinal epithelial cells", "ANATOMY", 169, 196], ["diarrhoea", "DISEASE", 240, 249], ["MAPKs", "GENE_OR_GENE_PRODUCT", 29, 34], ["ERK", "GENE_OR_GENE_PRODUCT", 47, 50], ["p38", "GENE_OR_GENE_PRODUCT", 52, 55], ["JNK", "GENE_OR_GENE_PRODUCT", 60, 63], ["microfilaments", "CELLULAR_COMPONENT", 86, 100], ["IPEC-J2 cells", "CELL", 104, 117], ["TGEV", "ORGANISM", 137, 141], ["intestinal epithelial cells", "CELL", 169, 196], ["piglets", "ORGANISM", 212, 219], ["MAPKs", "PROTEIN", 29, 34], ["ERK", "PROTEIN", 47, 50], ["p38", "PROTEIN", 52, 55], ["JNK", "PROTEIN", 60, 63], ["IPEC-J2 cells", "CELL_LINE", 104, 117], ["intestinal epithelial cells", "CELL_TYPE", 169, 196], ["piglets", "SPECIES", 212, 219], ["TGEV", "SPECIES", 137, 141], ["MAPKs inhibitors", "TEST", 29, 45], ["ERK", "TEST", 47, 50], ["p38", "TEST", 52, 55], ["JNK", "TEST", 60, 63], ["TGEV", "PROBLEM", 137, 141], ["fatal diarrhoea", "PROBLEM", 234, 249], ["J2 cells", "OBSERVATION", 109, 117], ["intestinal epithelial cells", "OBSERVATION", 169, 196], ["newborn piglets", "ANATOMY", 204, 219], ["fatal", "OBSERVATION_MODIFIER", 234, 239], ["diarrhoea", "OBSERVATION", 240, 249]]], ["Because of the limited availability of epithelial cell lines of small intestinal origin, the knowledge concerning the interaction between intestinal epithelial cells and TGEV or PEDV is limited in vitro.", [["epithelial cell lines", "ANATOMY", 39, 60], ["intestinal", "ANATOMY", 70, 80], ["intestinal epithelial cells", "ANATOMY", 138, 165], ["epithelial cell lines", "CELL", 39, 60], ["intestinal", "ORGAN", 70, 80], ["intestinal epithelial cells", "CELL", 138, 165], ["TGEV", "ORGANISM", 170, 174], ["PEDV", "GENE_OR_GENE_PRODUCT", 178, 182], ["epithelial cell lines", "CELL_LINE", 39, 60], ["intestinal epithelial cells", "CELL_TYPE", 138, 165], ["TGEV", "SPECIES", 170, 174], ["PEDV", "SPECIES", 178, 182], ["epithelial cell lines", "TREATMENT", 39, 60], ["small intestinal origin", "PROBLEM", 64, 87], ["intestinal epithelial cells", "PROBLEM", 138, 165], ["TGEV", "PROBLEM", 170, 174], ["PEDV", "PROBLEM", 178, 182], ["epithelial cell lines", "OBSERVATION", 39, 60], ["small", "OBSERVATION_MODIFIER", 64, 69], ["intestinal origin", "ANATOMY", 70, 87], ["intestinal", "ANATOMY", 138, 148], ["epithelial cells", "OBSERVATION", 149, 165], ["PEDV", "OBSERVATION", 178, 182]]], ["IPEC-J2 cells was derived from jejunum epithelium isolated from the jejunum of un-suckled 12-hour-old piglets which formed an undifferentiated porcine intestinal epithelial cell line and was immortalised; therefore, it represented a better model of normal porcine intestinal epithelium than transformed cell lines (Liu et al., 2010) .", [["IPEC-J2 cells", "ANATOMY", 0, 13], ["jejunum epithelium", "ANATOMY", 31, 49], ["jejunum", "ANATOMY", 68, 75], ["intestinal epithelial cell line", "ANATOMY", 151, 182], ["intestinal epithelium", "ANATOMY", 264, 285], ["cell lines", "ANATOMY", 303, 313], ["IPEC-J2 cells", "CELL", 0, 13], ["jejunum epithelium", "TISSUE", 31, 49], ["jejunum", "ORGAN", 68, 75], ["piglets", "ORGANISM", 102, 109], ["porcine", "ORGANISM", 143, 150], ["intestinal epithelial cell line", "CELL", 151, 182], ["porcine", "ORGANISM", 256, 263], ["intestinal epithelium", "TISSUE", 264, 285], ["cell lines", "CELL", 303, 313], ["IPEC-J2 cells", "CELL_LINE", 0, 13], ["undifferentiated porcine intestinal epithelial cell line", "CELL_LINE", 126, 182], ["transformed cell lines", "CELL_LINE", 291, 313], ["piglets", "SPECIES", 102, 109], ["porcine", "SPECIES", 143, 150], ["IPEC", "TEST", 0, 4], ["J2 cells", "PROBLEM", 5, 13], ["an undifferentiated porcine intestinal epithelial cell line", "TREATMENT", 123, 182], ["J2 cells", "OBSERVATION", 5, 13], ["jejunum", "ANATOMY", 31, 38], ["epithelium", "ANATOMY_MODIFIER", 39, 49], ["jejunum", "ANATOMY", 68, 75], ["undifferentiated", "OBSERVATION_MODIFIER", 126, 142], ["porcine intestinal epithelial cell line", "OBSERVATION", 143, 182], ["normal", "OBSERVATION", 249, 255], ["porcine intestinal epithelium", "OBSERVATION", 256, 285], ["cell lines", "OBSERVATION", 303, 313]]], ["In the present study, we have indicated that both TGEV and PEDV can also infect IPEC-J2 cells.", [["IPEC-J2 cells", "ANATOMY", 80, 93], ["PEDV", "CHEMICAL", 59, 63], ["TGEV", "ORGANISM", 50, 54], ["PEDV", "GENE_OR_GENE_PRODUCT", 59, 63], ["IPEC-J2 cells", "CELL", 80, 93], ["IPEC-J2 cells", "CELL_LINE", 80, 93], ["TGEV", "SPECIES", 50, 54], ["PEDV", "SPECIES", 59, 63], ["the present study", "TEST", 3, 20], ["TGEV", "PROBLEM", 50, 54], ["PEDV", "PROBLEM", 59, 63], ["J2 cells", "OBSERVATION", 85, 93]]], ["That might be that their common receptor (Aminopeptidase N) resides in IPEC-J2 cells.DiscussionThe epithelial barrier is a critical border that segregates luminal material from entering tissues.", [["IPEC-J2 cells", "ANATOMY", 71, 84], ["epithelial barrier", "ANATOMY", 99, 117], ["luminal material", "ANATOMY", 155, 171], ["tissues", "ANATOMY", 186, 193], ["Aminopeptidase N", "GENE_OR_GENE_PRODUCT", 42, 58], ["IPEC-J2 cells", "CELL", 71, 84], ["epithelial barrier", "TISSUE", 99, 117], ["luminal material", "TISSUE", 155, 171], ["tissues", "TISSUE", 186, 193], ["Aminopeptidase N", "PROTEIN", 42, 58], ["IPEC-J2 cells", "CELL_LINE", 71, 84], ["The epithelial barrier", "TREATMENT", 95, 117], ["J2 cells", "OBSERVATION", 76, 84], ["epithelial barrier", "OBSERVATION", 99, 117], ["luminal material", "OBSERVATION", 155, 171]]], ["Some viruses have developed specific strategies to alter or disrupt these structures as part of their pathogenesis, resulting in either viruses penetration, or other consequences such as diarrhoea (Coyne et al., 2007; Nava et al., 2004) .", [["diarrhoea", "DISEASE", 187, 196], ["Some viruses", "PROBLEM", 0, 12], ["viruses penetration", "PROBLEM", 136, 155], ["diarrhoea", "PROBLEM", 187, 196], ["viruses", "OBSERVATION", 5, 12], ["viruses", "OBSERVATION", 136, 143]]], ["Rotavirus decreases transepithelial electrical resistance (TEER) and increases paracellular permeability through decreased levels of claudin-1, occludin and ZO-1 proteins in the perijunctional region of Caco-2 monolayers; this was closely related to the fact that it caused viral astroenteritis leading to diarrhoea and morbidity in mammals (Nava et al., 2004) .", [["transepithelial", "ANATOMY", 20, 35], ["paracellular", "ANATOMY", 79, 91], ["perijunctional region", "ANATOMY", 178, 199], ["Caco-2 monolayers", "ANATOMY", 203, 220], ["Rotavirus", "DISEASE", 0, 9], ["astroenteritis", "DISEASE", 280, 294], ["diarrhoea", "DISEASE", 306, 315], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 91], ["claudin-1", "GENE_OR_GENE_PRODUCT", 133, 142], ["occludin", "GENE_OR_GENE_PRODUCT", 144, 152], ["ZO-1", "GENE_OR_GENE_PRODUCT", 157, 161], ["Caco-2 monolayers", "CELL", 203, 220], ["claudin-1", "PROTEIN", 133, 142], ["occludin", "PROTEIN", 144, 152], ["ZO-1 proteins", "PROTEIN", 157, 170], ["Caco-2 monolayers", "CELL_LINE", 203, 220], ["Rotavirus", "PROBLEM", 0, 9], ["increases paracellular permeability", "PROBLEM", 69, 104], ["claudin", "TEST", 133, 140], ["ZO", "TEST", 157, 159], ["viral astroenteritis", "PROBLEM", 274, 294], ["diarrhoea", "PROBLEM", 306, 315], ["morbidity in mammals", "PROBLEM", 320, 340], ["transepithelial electrical resistance", "OBSERVATION", 20, 57], ["paracellular permeability", "OBSERVATION", 79, 104], ["viral astroenteritis", "OBSERVATION", 274, 294]]], ["TGEV and PEDV also cause severe diarrhoea in piglets, whether this phenomenon is correlated to the damaged AJC in epithelial cells?", [["AJC", "ANATOMY", 107, 110], ["epithelial cells", "ANATOMY", 114, 130], ["PEDV", "CHEMICAL", 9, 13], ["diarrhoea", "DISEASE", 32, 41], ["TGEV", "ORGANISM", 0, 4], ["PEDV", "GENE_OR_GENE_PRODUCT", 9, 13], ["piglets", "ORGANISM", 45, 52], ["AJC", "CELL", 107, 110], ["epithelial cells", "CELL", 114, 130], ["epithelial cells", "CELL_TYPE", 114, 130], ["TGEV", "SPECIES", 0, 4], ["piglets", "SPECIES", 45, 52], ["TGEV", "SPECIES", 0, 4], ["PEDV", "SPECIES", 9, 13], ["TGEV", "PROBLEM", 0, 4], ["PEDV", "PROBLEM", 9, 13], ["severe diarrhoea in piglets", "PROBLEM", 25, 52], ["this phenomenon", "PROBLEM", 62, 77], ["the damaged AJC in epithelial cells", "PROBLEM", 95, 130], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["diarrhoea", "OBSERVATION", 32, 41], ["epithelial cells", "OBSERVATION", 114, 130]]], ["Similarly, in our work, the expression of E-cadherin and ZO-1 were significantly reduced in the TGEV and PEDV + TGEV infected IPEC-J2 cells in early infection, while these four tight and adhesion junctions proteins unchanged in the TGEV and PEDV infected IPEC-J2 cells compared the control group in 24 hpi; therefore, the TEER of IPEC-J2 decreased and the permeability of IPEC-J2 increased, leading to the barrier integrity of IPEC-J2 cells undergoing temporary destruction.", [["IPEC-J2 cells", "ANATOMY", 126, 139], ["IPEC-J2 cells", "ANATOMY", 255, 268], ["IPEC-J2 cells", "ANATOMY", 427, 440], ["infection", "DISEASE", 149, 158], ["IPEC-J2", "CHEMICAL", 372, 379], ["IPEC-J2", "CHEMICAL", 427, 434], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 42, 52], ["ZO-1", "GENE_OR_GENE_PRODUCT", 57, 61], ["TGEV", "ORGANISM", 96, 100], ["PEDV + TGEV", "ORGANISM", 105, 116], ["IPEC-J2 cells", "CELL", 126, 139], ["TGEV", "ORGANISM", 232, 236], ["IPEC-J2 cells", "CELL", 255, 268], ["IPEC-J2", "CELL", 330, 337], ["IPEC-J2", "GENE_OR_GENE_PRODUCT", 372, 379], ["IPEC-J2 cells", "CELL", 427, 440], ["E-cadherin", "PROTEIN", 42, 52], ["ZO-1", "PROTEIN", 57, 61], ["TGEV and PEDV + TGEV infected IPEC-J2 cells", "CELL_LINE", 96, 139], ["adhesion junctions proteins", "PROTEIN", 187, 214], ["TGEV and PEDV infected IPEC-J2 cells", "CELL_LINE", 232, 268], ["IPEC-J2 cells", "CELL_LINE", 427, 440], ["TGEV", "SPECIES", 96, 100], ["TGEV", "SPECIES", 112, 116], ["TGEV", "SPECIES", 96, 100], ["PEDV", "SPECIES", 105, 109], ["TGEV", "SPECIES", 112, 116], ["TGEV", "SPECIES", 232, 236], ["PEDV", "SPECIES", 241, 245], ["E-cadherin and ZO", "TEST", 42, 59], ["the TGEV", "PROBLEM", 92, 100], ["PEDV", "PROBLEM", 105, 109], ["TGEV infected IPEC", "PROBLEM", 112, 130], ["J2 cells", "PROBLEM", 131, 139], ["early infection", "PROBLEM", 143, 158], ["adhesion junctions proteins", "TEST", 187, 214], ["the TGEV", "PROBLEM", 228, 236], ["PEDV", "PROBLEM", 241, 245], ["J2 cells", "PROBLEM", 260, 268], ["the TEER", "TEST", 318, 326], ["IPEC", "TEST", 330, 334], ["J2", "PROBLEM", 335, 337], ["IPEC", "TEST", 372, 376], ["J2", "PROBLEM", 377, 379], ["J2 cells", "PROBLEM", 432, 440], ["temporary destruction", "PROBLEM", 452, 473], ["TGEV", "OBSERVATION_MODIFIER", 112, 116], ["infected", "OBSERVATION_MODIFIER", 117, 125], ["J2 cells", "OBSERVATION", 131, 139], ["early", "OBSERVATION_MODIFIER", 143, 148], ["infection", "OBSERVATION", 149, 158], ["adhesion junctions", "OBSERVATION", 187, 205], ["unchanged", "OBSERVATION_MODIFIER", 215, 224], ["PEDV", "OBSERVATION_MODIFIER", 241, 245], ["infected", "OBSERVATION_MODIFIER", 246, 254], ["J2 cells", "OBSERVATION", 260, 268], ["J2", "OBSERVATION_MODIFIER", 335, 337], ["decreased", "OBSERVATION_MODIFIER", 338, 347], ["permeability", "OBSERVATION_MODIFIER", 356, 368], ["J2", "OBSERVATION_MODIFIER", 377, 379], ["increased", "OBSERVATION_MODIFIER", 380, 389], ["barrier integrity", "OBSERVATION_MODIFIER", 406, 423], ["J2 cells", "OBSERVATION", 432, 440], ["temporary", "OBSERVATION_MODIFIER", 452, 461], ["destruction", "OBSERVATION", 462, 473]]], ["Subsequently, the barrier integrity returned to normal levels through self-repair over time.", [["barrier", "TISSUE", 18, 25], ["the barrier integrity", "TREATMENT", 14, 35], ["self-repair", "TREATMENT", 70, 81]]], ["The rapid reduction of E-cadherin, occludin and ZO-1 in infection may be related to the virus internalisation.", [["infection", "DISEASE", 56, 65], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 23, 33], ["occludin", "GENE_OR_GENE_PRODUCT", 35, 43], ["ZO-1", "GENE_OR_GENE_PRODUCT", 48, 52], ["E-cadherin", "PROTEIN", 23, 33], ["occludin", "PROTEIN", 35, 43], ["ZO-1", "PROTEIN", 48, 52], ["The rapid reduction of E-cadherin", "TREATMENT", 0, 33], ["occludin", "TREATMENT", 35, 43], ["infection", "PROBLEM", 56, 65], ["the virus internalisation", "PROBLEM", 84, 109], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["reduction", "OBSERVATION_MODIFIER", 10, 19], ["E-cadherin", "OBSERVATION", 23, 33], ["infection", "OBSERVATION", 56, 65], ["may be related to", "UNCERTAINTY", 66, 83], ["virus", "OBSERVATION", 88, 93]]], ["Previous reports have shown that adenoviruses-2 and -5 and Coxsackievirus use CAR as a receptor (Bergelson et al., 1997) for their internalisation .", [["adenoviruses-2", "ORGANISM", 33, 47], ["-5", "ORGANISM", 52, 54], ["Coxsackievirus", "ORGANISM", 59, 73], ["CAR", "GENE_OR_GENE_PRODUCT", 78, 81], ["CAR", "PROTEIN", 78, 81], ["adenoviruses", "TEST", 33, 45], ["adenoviruses", "OBSERVATION", 33, 45]]], ["White histograms represent the negative control, black histograms represent phospho-proteins and grey histograms represent Total-proteins of ERK1/2, p38 and JNK in the infected cells.", [["cells", "ANATOMY", 177, 182], ["phospho-proteins", "GENE_OR_GENE_PRODUCT", 76, 92], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 141, 147], ["p38", "GENE_OR_GENE_PRODUCT", 149, 152], ["JNK", "GENE_OR_GENE_PRODUCT", 157, 160], ["cells", "CELL", 177, 182], ["phospho-proteins", "PROTEIN", 76, 92], ["ERK1/2", "PROTEIN", 141, 147], ["p38", "PROTEIN", 149, 152], ["JNK", "PROTEIN", 157, 160], ["infected cells", "CELL_TYPE", 168, 182], ["White histograms", "TEST", 0, 16], ["black histograms", "TEST", 49, 65], ["phospho-proteins", "TEST", 76, 92], ["grey histograms", "TEST", 97, 112], ["ERK1", "TEST", 141, 145], ["p38", "TEST", 149, 152], ["JNK", "TEST", 157, 160], ["infected cells", "OBSERVATION", 168, 182]]], ["(B) Bar graphs show the relative rate of phospho-ERK1/2, phospho-p38 and phosphor-JNK in the PEDV-, TGEV-, and PEDV + TGEV-infected IPEC-J2 cells at 60 minpi (up) and 24 hpi (down).", [["IPEC-J2 cells", "ANATOMY", 132, 145], ["phospho", "CHEMICAL", 57, 64], ["phospho-ERK1/2", "GENE_OR_GENE_PRODUCT", 41, 55], ["phospho-p38", "GENE_OR_GENE_PRODUCT", 57, 68], ["phosphor-JNK", "GENE_OR_GENE_PRODUCT", 73, 85], ["PEDV", "GENE_OR_GENE_PRODUCT", 93, 97], ["TGEV", "ORGANISM", 100, 104], ["PEDV + TGEV", "ORGANISM", 111, 122], ["IPEC-J2 cells", "CELL", 132, 145], ["phospho", "PROTEIN", 41, 48], ["ERK1", "PROTEIN", 49, 53], ["phospho", "PROTEIN", 57, 64], ["p38", "PROTEIN", 65, 68], ["JNK", "PROTEIN", 82, 85], ["PEDV-, TGEV-, and PEDV + TGEV-infected IPEC-J2 cells", "CELL_LINE", 93, 145], ["TGEV", "SPECIES", 100, 104], ["TGEV", "SPECIES", 118, 122], ["Bar graphs", "TEST", 4, 14], ["phospho", "TEST", 41, 48], ["ERK1", "TEST", 49, 53], ["phospho", "TEST", 57, 64], ["phosphor", "TEST", 73, 81], ["JNK", "TEST", 82, 85], ["the PEDV", "TEST", 89, 97], ["TGEV", "TEST", 100, 104], ["PEDV", "TEST", 111, 115], ["TGEV", "TEST", 118, 122], ["J2 cells", "PROBLEM", 137, 145]]], ["The symbol * indicates statistically significant differences (P < 0.05) when compared with the control group, and the symbol ** indicates statistically very significant differences (P < 0.01) when compared with the control group. and to break the epithelial barrier during viral escape.", [["epithelial barrier", "ANATOMY", 247, 265], ["epithelial barrier", "TISSUE", 247, 265], ["statistically", "OBSERVATION_MODIFIER", 23, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["differences", "OBSERVATION_MODIFIER", 49, 60], ["very", "OBSERVATION_MODIFIER", 152, 156], ["significant", "OBSERVATION_MODIFIER", 157, 168], ["epithelial", "ANATOMY_MODIFIER", 247, 257], ["viral escape", "OBSERVATION", 273, 285]]], ["Whether the PEDV and TGEV use the AJC proteins as their receptor for their flexible invasion is not clear, but at least we observed that the epithelial barrier was destroyed in early viral infection.", [["epithelial barrier", "ANATOMY", 141, 159], ["viral infection", "DISEASE", 183, 198], ["PEDV", "GENE_OR_GENE_PRODUCT", 12, 16], ["TGEV", "ORGANISM", 21, 25], ["AJC", "GENE_OR_GENE_PRODUCT", 34, 37], ["epithelial barrier", "TISSUE", 141, 159], ["PEDV", "PROTEIN", 12, 16], ["AJC proteins", "PROTEIN", 34, 46], ["PEDV", "SPECIES", 12, 16], ["TGEV", "SPECIES", 21, 25], ["the PEDV", "PROBLEM", 8, 16], ["the AJC proteins", "TREATMENT", 30, 46], ["their flexible invasion", "PROBLEM", 69, 92], ["the epithelial barrier", "PROBLEM", 137, 159], ["early viral infection", "PROBLEM", 177, 198], ["invasion", "OBSERVATION", 84, 92], ["epithelial", "ANATOMY", 141, 151], ["early", "OBSERVATION_MODIFIER", 177, 182], ["viral", "OBSERVATION_MODIFIER", 183, 188], ["infection", "OBSERVATION", 189, 198]]], ["The expression of E-cadherin and ZO-1 were more reduced in the IPEC-J2 cells infected with TGEV and PEDV + TGEV than PEDV infection at 60 minpi probably because the virulence of TGEV is stronger than that of PEDV.DiscussionMultiple TJ components interact with the microfilaments (i.e., ZO-1/2/3, cingulin, and occludin) (Fanning et al., 2002) .", [["IPEC-J2 cells", "ANATOMY", 63, 76], ["microfilaments", "ANATOMY", 264, 278], ["PEDV", "CHEMICAL", 100, 104], ["PEDV", "CHEMICAL", 117, 121], ["infection", "DISEASE", 122, 131], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 18, 28], ["ZO-1", "GENE_OR_GENE_PRODUCT", 33, 37], ["IPEC-J2 cells", "CELL", 63, 76], ["TGEV", "ORGANISM", 91, 95], ["PEDV + TGEV", "ORGANISM", 100, 111], ["PEDV", "ORGANISM", 117, 121], ["TGEV", "ORGANISM", 178, 182], ["TJ", "GENE_OR_GENE_PRODUCT", 232, 234], ["microfilaments", "CELLULAR_COMPONENT", 264, 278], ["ZO-1/2/3", "GENE_OR_GENE_PRODUCT", 286, 294], ["cingulin", "GENE_OR_GENE_PRODUCT", 296, 304], ["occludin", "GENE_OR_GENE_PRODUCT", 310, 318], ["E-cadherin", "PROTEIN", 18, 28], ["ZO-1", "PROTEIN", 33, 37], ["IPEC-J2 cells", "CELL_LINE", 63, 76], ["TJ", "PROTEIN", 232, 234], ["ZO", "PROTEIN", 286, 288], ["1/2/3", "PROTEIN", 289, 294], ["cingulin", "PROTEIN", 296, 304], ["occludin", "PROTEIN", 310, 318], ["TGEV", "SPECIES", 91, 95], ["PEDV", "SPECIES", 100, 104], ["TGEV", "SPECIES", 107, 111], ["PEDV", "SPECIES", 117, 121], ["TGEV", "SPECIES", 178, 182], ["PEDV", "SPECIES", 208, 212], ["E-cadherin and ZO-1", "TEST", 18, 37], ["J2 cells", "PROBLEM", 68, 76], ["TGEV", "PROBLEM", 91, 95], ["PEDV", "PROBLEM", 100, 104], ["TGEV", "PROBLEM", 107, 111], ["PEDV infection", "PROBLEM", 117, 131], ["TGEV", "PROBLEM", 178, 182], ["PEDV", "PROBLEM", 208, 212], ["cingulin", "TREATMENT", 296, 304], ["J2", "ANATOMY", 68, 70], ["infection", "OBSERVATION", 122, 131], ["TGEV", "OBSERVATION", 178, 182]]], ["Regulation of the microfilaments and their interactions with TJ components play a major role in the infection of viruses.", [["microfilaments", "ANATOMY", 18, 32], ["TJ components", "ANATOMY", 61, 74], ["infection", "DISEASE", 100, 109], ["microfilaments", "CELLULAR_COMPONENT", 18, 32], ["TJ", "GENE_OR_GENE_PRODUCT", 61, 63], ["TJ components", "PROTEIN", 61, 74], ["TJ components", "TREATMENT", 61, 74], ["the infection of viruses", "PROBLEM", 96, 120], ["microfilaments", "OBSERVATION_MODIFIER", 18, 32], ["infection", "OBSERVATION", 100, 109], ["viruses", "OBSERVATION", 113, 120]]], ["Furthermore, viruses use the host microfilament transport systems and their motors for several steps during their life cycle (Taylor et al., 2011) .", [["microfilament", "ANATOMY", 34, 47], ["viruses", "OBSERVATION", 13, 20]]], ["From our TEM results, during the infection of PEDV and TGEV, their attachment, internalisation, nuclear targeting, transport of progeny viral .", [["nuclear", "ANATOMY", 96, 103], ["infection", "DISEASE", 33, 42], ["PEDV", "GENE_OR_GENE_PRODUCT", 46, 50], ["TGEV", "ORGANISM", 55, 59], ["nuclear", "CELLULAR_COMPONENT", 96, 103], ["PEDV", "SPECIES", 46, 50], ["TGEV", "SPECIES", 55, 59], ["our TEM", "TEST", 5, 12], ["the infection", "PROBLEM", 29, 42], ["PEDV", "PROBLEM", 46, 50], ["TGEV", "PROBLEM", 55, 59], ["internalisation", "PROBLEM", 79, 94]]], ["The symbol * indicates statistically significant differences (P < 0.05) when compared with the control group, and the symbol ** indicates statistically very significant differences (P < 0.01) when compared with the control group.", [["statistically", "OBSERVATION_MODIFIER", 23, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["differences", "OBSERVATION_MODIFIER", 49, 60], ["very", "OBSERVATION_MODIFIER", 152, 156], ["significant", "OBSERVATION_MODIFIER", 157, 168]]], ["(B) The expression of Claudin-1, E-cadherin, Occludin and ZO-1 in PEDV and TGEV infected and mock IPEC-J2 cells which treated with or without MAPKs inhibitors, PD98059, SB203580 and SP600125 at 60 minpi and 24 hpi was analysed via western blotting.", [["PEDV", "ANATOMY", 66, 70], ["IPEC-J2 cells", "ANATOMY", 98, 111], ["PD98059", "CHEMICAL", 160, 167], ["SB203580", "CHEMICAL", 169, 177], ["SP600125", "CHEMICAL", 182, 190], ["PD98059", "CHEMICAL", 160, 167], ["SB203580", "CHEMICAL", 169, 177], ["SP600125", "CHEMICAL", 182, 190], ["Claudin-1", "GENE_OR_GENE_PRODUCT", 22, 31], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 33, 43], ["Occludin", "GENE_OR_GENE_PRODUCT", 45, 53], ["ZO-1", "GENE_OR_GENE_PRODUCT", 58, 62], ["PEDV", "ORGANISM", 66, 70], ["TGEV", "ORGANISM", 75, 79], ["IPEC-J2 cells", "CELL", 98, 111], ["MAPKs", "GENE_OR_GENE_PRODUCT", 142, 147], ["PD98059", "SIMPLE_CHEMICAL", 160, 167], ["SB203580", "SIMPLE_CHEMICAL", 169, 177], ["SP600125", "SIMPLE_CHEMICAL", 182, 190], ["Claudin-1", "PROTEIN", 22, 31], ["E-cadherin", "PROTEIN", 33, 43], ["Occludin", "PROTEIN", 45, 53], ["ZO-1", "PROTEIN", 58, 62], ["IPEC-J2 cells", "CELL_LINE", 98, 111], ["MAPKs", "PROTEIN", 142, 147], ["TGEV", "SPECIES", 75, 79], ["PEDV", "SPECIES", 66, 70], ["TGEV", "SPECIES", 75, 79], ["Claudin", "TEST", 22, 29], ["E-cadherin", "TREATMENT", 33, 43], ["Occludin", "TREATMENT", 45, 53], ["ZO", "TEST", 58, 60], ["PEDV", "PROBLEM", 66, 70], ["TGEV", "PROBLEM", 75, 79], ["J2 cells", "PROBLEM", 103, 111], ["MAPKs inhibitors", "TREATMENT", 142, 158], ["PD98059", "TEST", 160, 167], ["SB203580", "TEST", 169, 177], ["SP600125", "TEST", 182, 190], ["PEDV", "ANATOMY", 66, 70], ["TGEV", "ANATOMY", 75, 79], ["infected", "OBSERVATION", 80, 88], ["J2 cells", "OBSERVATION", 103, 111]]], ["(C) Immunofluorescence images of microfilaments in PEDV and TGEV infected and mock IPEC-J2 cells which treated with or without treated with or without MAPKs inhibitors, PD98059, SB203580 and SP600125 at 60 minpi were stained with FTTC-phalloidin.", [["microfilaments", "ANATOMY", 33, 47], ["PEDV", "ANATOMY", 51, 55], ["IPEC-J2 cells", "ANATOMY", 83, 96], ["PD98059", "CHEMICAL", 169, 176], ["SB203580", "CHEMICAL", 178, 186], ["SP600125", "CHEMICAL", 191, 199], ["FTTC-phalloidin", "CHEMICAL", 230, 245], ["PD98059", "CHEMICAL", 169, 176], ["SB203580", "CHEMICAL", 178, 186], ["SP600125", "CHEMICAL", 191, 199], ["phalloidin", "CHEMICAL", 235, 245], ["microfilaments", "CELLULAR_COMPONENT", 33, 47], ["PEDV", "CELL", 51, 55], ["TGEV", "ORGANISM", 60, 64], ["IPEC-J2 cells", "CELL", 83, 96], ["MAPKs", "GENE_OR_GENE_PRODUCT", 151, 156], ["PD98059", "SIMPLE_CHEMICAL", 169, 176], ["SB203580", "SIMPLE_CHEMICAL", 178, 186], ["SP600125", "SIMPLE_CHEMICAL", 191, 199], ["FTTC-phalloidin", "SIMPLE_CHEMICAL", 230, 245], ["PEDV", "CELL_LINE", 51, 55], ["IPEC-J2 cells", "CELL_LINE", 83, 96], ["MAPKs", "PROTEIN", 151, 156], ["TGEV", "SPECIES", 60, 64], ["PEDV", "SPECIES", 51, 55], ["TGEV", "SPECIES", 60, 64], ["Immunofluorescence images", "TEST", 4, 29], ["microfilaments", "PROBLEM", 33, 47], ["PEDV", "PROBLEM", 51, 55], ["TGEV infected", "PROBLEM", 60, 73], ["J2 cells", "PROBLEM", 88, 96], ["MAPKs inhibitors", "TREATMENT", 151, 167], ["PD98059", "TEST", 169, 176], ["SB203580", "TEST", 178, 186], ["SP600125", "TEST", 191, 199], ["minpi", "TEST", 206, 211], ["FTTC", "TEST", 230, 234], ["J2 cells", "OBSERVATION_MODIFIER", 88, 96]]], ["Scale bars represent 10 m.", [["10 m.", "OBSERVATION_MODIFIER", 21, 26]]], ["Immunofluorescence images of microfilaments of the mock IPEC-J2 cells were a complex three-dimensional network composed of microfilaments extending throughout the cell body.", [["microfilaments", "ANATOMY", 29, 43], ["IPEC-J2 cells", "ANATOMY", 56, 69], ["microfilaments", "ANATOMY", 123, 137], ["cell body", "ANATOMY", 163, 172], ["microfilaments", "CELLULAR_COMPONENT", 29, 43], ["IPEC-J2 cells", "CELL", 56, 69], ["microfilaments", "CELLULAR_COMPONENT", 123, 137], ["cell body", "CELLULAR_COMPONENT", 163, 172], ["mock IPEC-J2 cells", "CELL_LINE", 51, 69], ["Immunofluorescence images", "TEST", 0, 25], ["the mock IPEC", "TEST", 47, 60], ["J2 cells", "PROBLEM", 61, 69], ["J2", "ANATOMY", 61, 63], ["cell body", "OBSERVATION", 163, 172]]], ["Microfilaments of IPEC-J2 cells treated by PD98059, SB203580 and SP600125 disappeared in the cytoplasm or became more diffuse in the cytoplasm, and gathered in the plasma membrane after 60 min of infecting PEDV and TGEV. particles and release was shown to be assisted by the microfilaments during the viral campaign, suggesting that actin filaments play important roles in virus life cycles.", [["IPEC-J2 cells", "ANATOMY", 18, 31], ["cytoplasm", "ANATOMY", 93, 102], ["cytoplasm", "ANATOMY", 133, 142], ["plasma membrane", "ANATOMY", 164, 179], ["microfilaments", "ANATOMY", 275, 289], ["filaments", "ANATOMY", 339, 348], ["PD98059", "CHEMICAL", 43, 50], ["SB203580", "CHEMICAL", 52, 60], ["SP600125", "CHEMICAL", 65, 73], ["PD98059", "CHEMICAL", 43, 50], ["SB203580", "CHEMICAL", 52, 60], ["SP600125", "CHEMICAL", 65, 73], ["IPEC-J2 cells", "CELL", 18, 31], ["PD98059", "SIMPLE_CHEMICAL", 43, 50], ["SB203580", "SIMPLE_CHEMICAL", 52, 60], ["SP600125", "SIMPLE_CHEMICAL", 65, 73], ["cytoplasm", "ORGANISM_SUBSTANCE", 93, 102], ["cytoplasm", "ORGANISM_SUBSTANCE", 133, 142], ["plasma membrane", "CELLULAR_COMPONENT", 164, 179], ["TGEV", "ORGANISM", 215, 219], ["microfilaments", "CELLULAR_COMPONENT", 275, 289], ["actin", "GENE_OR_GENE_PRODUCT", 333, 338], ["IPEC-J2 cells", "CELL_LINE", 18, 31], ["actin", "PROTEIN", 333, 338], ["PEDV", "SPECIES", 206, 210], ["TGEV", "SPECIES", 215, 219], ["Microfilaments", "TEST", 0, 14], ["IPEC-J2 cells", "TREATMENT", 18, 31], ["PD98059", "TEST", 43, 50], ["SB203580", "TEST", 52, 60], ["infecting PEDV", "TREATMENT", 196, 210], ["TGEV", "PROBLEM", 215, 219], ["actin filaments", "TREATMENT", 333, 348], ["virus life cycles", "TREATMENT", 373, 390], ["J2 cells", "OBSERVATION_MODIFIER", 23, 31], ["more", "OBSERVATION_MODIFIER", 113, 117], ["diffuse", "OBSERVATION_MODIFIER", 118, 125]]], ["However, the question of what changes in the distribution of microfilaments occurred during the process of viral infection remained?", [["microfilaments", "ANATOMY", 61, 75], ["viral infection", "DISEASE", 107, 122], ["microfilaments", "CELLULAR_COMPONENT", 61, 75], ["microfilaments", "PROBLEM", 61, 75], ["viral infection", "PROBLEM", 107, 122], ["microfilaments", "OBSERVATION", 61, 75], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["infection", "OBSERVATION", 113, 122]]], ["First, the microfilaments of PEDV-and TGEV-infected IPEC-J2 retracted and concentrated around certain membrane structures and the plasma membrane, which might indicate preparation for the adsorption and internalisation of the virus.", [["microfilaments", "ANATOMY", 11, 25], ["membrane structures", "ANATOMY", 102, 121], ["plasma membrane", "ANATOMY", 130, 145], ["microfilaments", "CELLULAR_COMPONENT", 11, 25], ["PEDV", "GENE_OR_GENE_PRODUCT", 29, 33], ["TGEV", "ORGANISM", 38, 42], ["IPEC-J2", "CELL", 52, 59], ["membrane structures", "CELLULAR_COMPONENT", 102, 121], ["plasma membrane", "CELLULAR_COMPONENT", 130, 145], ["TGEV", "SPECIES", 38, 42], ["PEDV", "TEST", 29, 33], ["TGEV", "PROBLEM", 38, 42], ["infected IPEC-J2", "TREATMENT", 43, 59], ["the plasma membrane", "TEST", 126, 145], ["the adsorption", "PROBLEM", 184, 198], ["the virus", "PROBLEM", 222, 231], ["infected", "OBSERVATION_MODIFIER", 43, 51], ["IPEC", "OBSERVATION_MODIFIER", 52, 56], ["J2 retracted", "OBSERVATION_MODIFIER", 57, 69], ["membrane structures", "OBSERVATION", 102, 121], ["plasma membrane", "OBSERVATION", 130, 145]]], ["Then, the bundles of microfilaments were seen to line the plasma membrane in infected IPEC-J2, which might indicate the attachment and internalisation of these viruses.", [["bundles", "ANATOMY", 10, 17], ["microfilaments", "ANATOMY", 21, 35], ["plasma membrane", "ANATOMY", 58, 73], ["IPEC-J2", "ANATOMY", 86, 93], ["microfilaments", "CELLULAR_COMPONENT", 21, 35], ["plasma membrane", "CELLULAR_COMPONENT", 58, 73], ["IPEC-J2", "CELL", 86, 93], ["the attachment", "PROBLEM", 116, 130], ["these viruses", "PROBLEM", 154, 167], ["plasma membrane", "OBSERVATION", 58, 73], ["infected", "OBSERVATION", 77, 85], ["J2", "ANATOMY", 91, 93], ["viruses", "OBSERVATION", 160, 167]]], ["Similarly, HIV, measles virus or herpes simplex virus also cause the microfilaments to concentrate around the plasma membrane for their attachment and internalisation (D\u00f6hner and Sodeik, 2005; Smith and Helenius, 2004) .", [["microfilaments", "ANATOMY", 69, 83], ["plasma membrane", "ANATOMY", 110, 125], ["HIV, measles virus", "DISEASE", 11, 29], ["herpes simplex virus", "DISEASE", 33, 53], ["HIV", "ORGANISM", 11, 14], ["measles virus", "ORGANISM", 16, 29], ["herpes simplex virus", "ORGANISM", 33, 53], ["microfilaments", "CELLULAR_COMPONENT", 69, 83], ["plasma membrane", "CELLULAR_COMPONENT", 110, 125], ["HIV", "SPECIES", 11, 14], ["measles virus", "SPECIES", 16, 29], ["herpes simplex virus", "SPECIES", 33, 53], ["HIV", "SPECIES", 11, 14], ["measles virus", "SPECIES", 16, 29], ["herpes simplex virus", "SPECIES", 33, 53], ["HIV", "PROBLEM", 11, 14], ["measles virus", "PROBLEM", 16, 29], ["herpes simplex virus", "PROBLEM", 33, 53], ["the microfilaments", "PROBLEM", 65, 83]]], ["After internalisation, these viruses are transported inside vesicles to the cytosol for replication of their genome and protein synthesis.", [["vesicles", "ANATOMY", 60, 68], ["cytosol", "ANATOMY", 76, 83], ["vesicles", "CELLULAR_COMPONENT", 60, 68], ["cytosol", "CELLULAR_COMPONENT", 76, 83], ["genome", "CELLULAR_COMPONENT", 109, 115], ["these viruses", "PROBLEM", 23, 36], ["their genome and protein synthesis", "PROBLEM", 103, 137], ["viruses", "OBSERVATION", 29, 36], ["protein synthesis", "OBSERVATION", 120, 137]]], ["Subsequently, the subviral components are found to bud from the plasma membrane via disruption of this membrane, which frees all of the progeny.", [["bud", "ANATOMY", 51, 54], ["plasma membrane", "ANATOMY", 64, 79], ["membrane", "ANATOMY", 103, 111], ["plasma membrane", "CELLULAR_COMPONENT", 64, 79], ["membrane", "CELLULAR_COMPONENT", 103, 111], ["subviral components", "PROTEIN", 18, 37], ["the subviral components", "PROBLEM", 14, 37], ["disruption of this membrane", "PROBLEM", 84, 111], ["subviral components", "OBSERVATION", 18, 37], ["plasma membrane", "OBSERVATION", 64, 79], ["disruption", "OBSERVATION", 84, 94]]], ["Thus, after 12 h of infection, the microfilaments appeared as numerous of spottinglike structures around the nuclear membrane in all virus-infected IPEC-J2 cells.", [["microfilaments", "ANATOMY", 35, 49], ["spottinglike structures", "ANATOMY", 74, 97], ["nuclear membrane", "ANATOMY", 109, 125], ["IPEC-J2 cells", "ANATOMY", 148, 161], ["infection", "DISEASE", 20, 29], ["microfilaments", "CELLULAR_COMPONENT", 35, 49], ["nuclear membrane", "CELLULAR_COMPONENT", 109, 125], ["IPEC-J2 cells", "CELL", 148, 161], ["IPEC-J2 cells", "CELL_LINE", 148, 161], ["infection", "PROBLEM", 20, 29], ["spottinglike structures", "PROBLEM", 74, 97], ["all virus", "PROBLEM", 129, 138], ["J2 cells", "PROBLEM", 153, 161], ["infection", "OBSERVATION", 20, 29], ["nuclear membrane", "ANATOMY", 109, 125], ["all virus", "ANATOMY", 129, 138], ["infected", "OBSERVATION", 139, 147], ["J2 cells", "OBSERVATION", 153, 161]]], ["These spotting-like structures might be the ER or the Golgi apparatus which were the site of viral genome replication and protein synthesis.", [["ER", "ANATOMY", 44, 46], ["Golgi apparatus", "ANATOMY", 54, 69], ["ER", "GENE_OR_GENE_PRODUCT", 44, 46], ["Golgi apparatus", "CELLULAR_COMPONENT", 54, 69], ["ER", "PROTEIN", 44, 46], ["These spotting-like structures", "PROBLEM", 0, 30], ["viral genome replication", "PROBLEM", 93, 117], ["protein synthesis", "PROBLEM", 122, 139], ["spotting", "OBSERVATION", 6, 14], ["viral genome replication", "OBSERVATION", 93, 117], ["protein synthesis", "OBSERVATION", 122, 139]]], ["The microfilaments then gradually located in the perinuclear area and the plasma membrane, and this may be an indication that these viruses were budding from the plasma membrane.", [["microfilaments", "ANATOMY", 4, 18], ["perinuclear area", "ANATOMY", 49, 65], ["plasma membrane", "ANATOMY", 74, 89], ["plasma membrane", "ANATOMY", 162, 177], ["microfilaments", "CELLULAR_COMPONENT", 4, 18], ["perinuclear area", "CELLULAR_COMPONENT", 49, 65], ["plasma membrane", "CELLULAR_COMPONENT", 74, 89], ["plasma membrane", "CELLULAR_COMPONENT", 162, 177], ["The microfilaments", "TREATMENT", 0, 18], ["the plasma membrane", "TEST", 70, 89], ["these viruses", "PROBLEM", 126, 139], ["perinuclear", "ANATOMY_MODIFIER", 49, 60], ["area", "ANATOMY_MODIFIER", 61, 65], ["plasma membrane", "OBSERVATION", 74, 89], ["may be", "UNCERTAINTY", 100, 106], ["viruses", "OBSERVATION", 132, 139], ["plasma membrane", "OBSERVATION", 162, 177]]], ["These results implied that viruses can interfere with cytoskeleton and induce actin rearrangements, supporting infection.", [["cytoskeleton", "ANATOMY", 54, 66], ["infection", "DISEASE", 111, 120], ["cytoskeleton", "CELLULAR_COMPONENT", 54, 66], ["actin", "GENE_OR_GENE_PRODUCT", 78, 83], ["actin", "PROTEIN", 78, 83], ["viruses", "PROBLEM", 27, 34], ["supporting infection", "PROBLEM", 100, 120], ["viruses", "OBSERVATION", 27, 34], ["actin rearrangements", "OBSERVATION", 78, 98], ["infection", "OBSERVATION", 111, 120]]], ["However, determination of whether those spotting-like structures were ER or Golgi apparatus requires further research.DiscussionTo further validate the role of microfilaments in the viral life cycle, we treated IPEC-J2 cells with Jas, which promotes stabilisation of the microfilaments, and Cyto D, which induces destabilisation of the microfilaments.", [["ER", "ANATOMY", 70, 72], ["Golgi apparatus", "ANATOMY", 76, 91], ["microfilaments", "ANATOMY", 160, 174], ["IPEC-J2 cells", "ANATOMY", 211, 224], ["microfilaments", "ANATOMY", 271, 285], ["microfilaments", "ANATOMY", 336, 350], ["ER", "GENE_OR_GENE_PRODUCT", 70, 72], ["Golgi", "CELLULAR_COMPONENT", 76, 81], ["microfilaments", "CELLULAR_COMPONENT", 160, 174], ["IPEC-J2 cells", "CELL", 211, 224], ["Jas", "GENE_OR_GENE_PRODUCT", 230, 233], ["microfilaments", "CELLULAR_COMPONENT", 271, 285], ["Cyto D", "SIMPLE_CHEMICAL", 291, 297], ["microfilaments", "CELLULAR_COMPONENT", 336, 350], ["ER", "PROTEIN", 70, 72], ["IPEC-J2 cells", "CELL_LINE", 211, 224], ["Cyto D", "PROTEIN", 291, 297], ["those spotting-like structures", "PROBLEM", 34, 64], ["IPEC-J2 cells", "TREATMENT", 211, 224], ["Cyto D", "PROBLEM", 291, 297], ["J2 cells", "OBSERVATION_MODIFIER", 216, 224], ["stabilisation", "OBSERVATION_MODIFIER", 250, 263]]], ["We found that neither stabilised nor depolymerised microfilaments affected the adsorption process of these viruses.", [["microfilaments", "ANATOMY", 51, 65], ["microfilaments", "CELLULAR_COMPONENT", 51, 65], ["depolymerised microfilaments", "PROBLEM", 37, 65], ["stabilised", "OBSERVATION", 22, 32], ["adsorption process", "OBSERVATION", 79, 97], ["viruses", "OBSERVATION", 107, 114]]], ["That might be because the changes in the distribution of microfilaments did not decrease the number of viral receptors, but simply affected the speed of viral adsorption.", [["microfilaments", "ANATOMY", 57, 71], ["microfilaments", "CELLULAR_COMPONENT", 57, 71], ["viral receptors", "PROTEIN", 103, 118], ["viral receptors", "PROBLEM", 103, 118], ["viral adsorption", "PROBLEM", 153, 169], ["viral receptors", "OBSERVATION", 103, 118], ["viral adsorption", "OBSERVATION", 153, 169]]], ["However, microfilament disorder, either stabilisation or depolymerisation, could inhibit the replication and release of viruses, and in particular the depolymerisation of microfilaments.", [["microfilament", "ANATOMY", 9, 22], ["microfilaments", "ANATOMY", 171, 185], ["microfilament disorder", "DISEASE", 9, 31], ["microfilament", "CELLULAR_COMPONENT", 9, 22], ["microfilaments", "CELLULAR_COMPONENT", 171, 185], ["microfilament disorder", "PROBLEM", 9, 31], ["stabilisation", "PROBLEM", 40, 53], ["depolymerisation", "PROBLEM", 57, 73], ["viruses", "PROBLEM", 120, 127], ["microfilament disorder", "OBSERVATION", 9, 31], ["stabilisation", "OBSERVATION", 40, 53], ["viruses", "OBSERVATION", 120, 127]]], ["These results were consistent with a requirement of dynamic microfilaments for other viruses, such as Echovirus 11 and herpesvirus, among others (Forest et al., 2005; Sobo et al., 2012) .", [["microfilaments", "ANATOMY", 60, 74], ["microfilaments", "CELLULAR_COMPONENT", 60, 74], ["Echovirus 11", "ORGANISM", 102, 114], ["herpesvirus", "ORGANISM", 119, 130], ["dynamic microfilaments", "TREATMENT", 52, 74], ["other viruses", "PROBLEM", 79, 92], ["Echovirus", "PROBLEM", 102, 111], ["herpesvirus", "PROBLEM", 119, 130], ["consistent with", "UNCERTAINTY", 19, 34]]], ["However, it was not clear how these stabilised or depolymerised microfilaments affected the viral production and budding.", [["microfilaments", "ANATOMY", 64, 78], ["microfilaments", "CELLULAR_COMPONENT", 64, 78], ["depolymerised microfilaments", "PROBLEM", 50, 78], ["viral production", "OBSERVATION", 92, 108]]], ["The RNA genome of human parainfluenza virus type 3 is replicated and transcribed in association with ribonucleoproteins bound to microfilaments, and depolymerisation of microfilaments inhibits viral RNA synthesis (Gupta et al., 1998) .", [["microfilaments", "ANATOMY", 129, 143], ["microfilaments", "ANATOMY", 169, 183], ["human", "ORGANISM", 18, 23], ["parainfluenza virus type 3", "ORGANISM", 24, 50], ["microfilaments", "CELLULAR_COMPONENT", 129, 143], ["microfilaments", "CELLULAR_COMPONENT", 169, 183], ["RNA genome", "DNA", 4, 14], ["human", "SPECIES", 18, 23], ["parainfluenza virus", "SPECIES", 24, 43], ["human parainfluenza virus", "SPECIES", 18, 43], ["human parainfluenza virus type 3", "PROBLEM", 18, 50], ["ribonucleoproteins bound", "PROBLEM", 101, 125], ["depolymerisation of microfilaments", "PROBLEM", 149, 183], ["viral RNA synthesis", "PROBLEM", 193, 212], ["RNA genome", "OBSERVATION", 4, 14], ["parainfluenza virus", "OBSERVATION", 24, 43], ["viral RNA", "OBSERVATION", 193, 202]]], ["Simpson-Holley reported that budding of the influenza virus is also affected by microfilament-depolymerising drugs, probably because the microfilament cortex maintains the correct structure of lipid rafts that are incorporated into the viral envelope (Simpson-Holley et al., 2002) .", [["microfilament", "ANATOMY", 80, 93], ["microfilament cortex", "ANATOMY", 137, 157], ["lipid rafts", "ANATOMY", 193, 204], ["influenza", "DISEASE", 44, 53], ["influenza virus", "ORGANISM", 44, 59], ["microfilament", "SIMPLE_CHEMICAL", 80, 93], ["microfilament cortex", "CELLULAR_COMPONENT", 137, 157], ["lipid rafts", "CELLULAR_COMPONENT", 193, 204], ["influenza virus", "SPECIES", 44, 59], ["the influenza virus", "PROBLEM", 40, 59], ["depolymerising drugs", "TREATMENT", 94, 114], ["the microfilament cortex", "PROBLEM", 133, 157], ["influenza virus", "OBSERVATION", 44, 59], ["depolymerising drugs", "OBSERVATION", 94, 114], ["microfilament cortex", "OBSERVATION", 137, 157], ["correct structure", "OBSERVATION", 172, 189], ["lipid rafts", "OBSERVATION", 193, 204], ["viral", "OBSERVATION_MODIFIER", 236, 241]]], ["The exact mechanisms why the microfilament depolymerisation or stabilisation inhibited the replication and release of PEDV and TGEV are still unclear and require further investigation.DiscussionIn our work, the lowest TEER and the highest permeability of IPEC-J2 cells infected with PEDV, TGEV and PEDV + TGEV appeared at 60 minpi.", [["microfilament", "ANATOMY", 29, 42], ["IPEC-J2 cells", "ANATOMY", 255, 268], ["PEDV", "CHEMICAL", 283, 287], ["PEDV", "CHEMICAL", 298, 302], ["microfilament", "CELLULAR_COMPONENT", 29, 42], ["PEDV", "GENE_OR_GENE_PRODUCT", 118, 122], ["TGEV", "ORGANISM", 127, 131], ["IPEC-J2 cells", "CELL", 255, 268], ["PEDV", "ORGANISM", 283, 287], ["TGEV", "ORGANISM", 289, 293], ["PEDV + TGEV", "ORGANISM", 298, 309], ["IPEC-J2 cells", "CELL_LINE", 255, 268], ["PEDV", "SPECIES", 118, 122], ["TGEV", "SPECIES", 127, 131], ["PEDV", "SPECIES", 283, 287], ["TGEV", "SPECIES", 289, 293], ["PEDV", "SPECIES", 298, 302], ["TGEV", "SPECIES", 305, 309], ["the microfilament depolymerisation", "PROBLEM", 25, 59], ["stabilisation", "TREATMENT", 63, 76], ["the replication", "TREATMENT", 87, 102], ["PEDV", "PROBLEM", 118, 122], ["TGEV", "PROBLEM", 127, 131], ["further investigation", "TEST", 162, 183], ["IPEC", "TEST", 255, 259], ["J2 cells", "PROBLEM", 260, 268], ["PEDV", "PROBLEM", 283, 287], ["TGEV", "TREATMENT", 289, 293], ["PEDV", "PROBLEM", 298, 302], ["TGEV", "PROBLEM", 305, 309]]], ["Moreover, the ratio of phospho-ERK1 and phospho-JNK of IPEC-J2 cells significantly increased at the same time postinfection.", [["IPEC-J2 cells", "ANATOMY", 55, 68], ["phospho-ERK1", "GENE_OR_GENE_PRODUCT", 23, 35], ["phospho-JNK", "GENE_OR_GENE_PRODUCT", 40, 51], ["IPEC-J2 cells", "CELL", 55, 68], ["phospho-ERK1", "PROTEIN", 23, 35], ["phospho-JNK", "PROTEIN", 40, 51], ["IPEC-J2 cells", "CELL_LINE", 55, 68], ["the ratio", "TEST", 10, 19], ["phospho-ERK1", "TEST", 23, 35], ["phospho-JNK", "TEST", 40, 51], ["IPEC", "TEST", 55, 59], ["J2 cells", "PROBLEM", 60, 68], ["J2 cells", "OBSERVATION_MODIFIER", 60, 68], ["significantly", "OBSERVATION_MODIFIER", 69, 82], ["increased", "OBSERVATION_MODIFIER", 83, 92]]], ["A similar report showed that the HIV-1 Tat protein could trigger the disappearance of ZO-1 from cell-cell contact sites in brain endothelia due to ERK1/2 activation (Andr\u00e1s et al., 2005) .", [["cell-cell contact sites", "ANATOMY", 96, 119], ["brain endothelia", "ANATOMY", 123, 139], ["HIV-1", "ORGANISM", 33, 38], ["Tat", "GENE_OR_GENE_PRODUCT", 39, 42], ["ZO-1", "GENE_OR_GENE_PRODUCT", 86, 90], ["cell-cell contact sites", "CELLULAR_COMPONENT", 96, 119], ["brain endothelia", "TISSUE", 123, 139], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 147, 153], ["HIV-1 Tat protein", "PROTEIN", 33, 50], ["ZO-1", "PROTEIN", 86, 90], ["ERK1", "PROTEIN", 147, 151], ["HIV-1", "SPECIES", 33, 38], ["HIV-1", "SPECIES", 33, 38], ["the HIV", "TEST", 29, 36], ["Tat protein", "TEST", 39, 50], ["ZO", "TEST", 86, 88], ["ERK1/2 activation", "PROBLEM", 147, 164], ["cell contact", "OBSERVATION", 101, 113], ["brain endothelia", "ANATOMY", 123, 139]]], ["Patrick indicated that TNF-\u2423 and IFN-\u2425 could damage the epithelial barrier by downregulating the expression of occludin and ZO-1 through activating ERK1/2and p38 in MDCK cells (Patrick et al., 2006) .", [["epithelial barrier", "ANATOMY", 56, 74], ["MDCK cells", "ANATOMY", 165, 175], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 23, 28], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 33, 38], ["epithelial barrier", "TISSUE", 56, 74], ["occludin", "GENE_OR_GENE_PRODUCT", 111, 119], ["ZO-1", "GENE_OR_GENE_PRODUCT", 124, 128], ["ERK1/2and p38", "GENE_OR_GENE_PRODUCT", 148, 161], ["MDCK cells", "CELL", 165, 175], ["TNF", "PROTEIN", 23, 26], ["IFN", "PROTEIN", 33, 36], ["occludin", "PROTEIN", 111, 119], ["ZO-1", "PROTEIN", 124, 128], ["ERK1/2and p38", "PROTEIN", 148, 161], ["MDCK cells", "CELL_LINE", 165, 175], ["TNF", "TEST", 23, 26], ["IFN", "PROBLEM", 33, 36], ["the epithelial barrier", "TREATMENT", 52, 74], ["ZO", "TEST", 124, 126], ["ERK1", "TEST", 148, 152], ["epithelial", "ANATOMY_MODIFIER", 56, 66]]], ["We speculated that TGEV-and PEDV-damaged barrier function of IPEC-J2 cells may be related to the phospho-ERK1/2 and phospho-38 of the MAPK pathway activation.", [["barrier", "ANATOMY", 41, 48], ["IPEC-J2 cells", "ANATOMY", 61, 74], ["PEDV", "CHEMICAL", 28, 32], ["phospho", "CHEMICAL", 116, 123], ["TGEV", "ORGANISM", 19, 23], ["PEDV", "GENE_OR_GENE_PRODUCT", 28, 32], ["barrier", "TISSUE", 41, 48], ["IPEC-J2 cells", "CELL", 61, 74], ["phospho-ERK1/2", "GENE_OR_GENE_PRODUCT", 97, 111], ["phospho-38", "GENE_OR_GENE_PRODUCT", 116, 126], ["MAPK", "GENE_OR_GENE_PRODUCT", 134, 138], ["IPEC-J2 cells", "CELL_LINE", 61, 74], ["ERK1/2", "PROTEIN", 105, 111], ["phospho-38", "PROTEIN", 116, 126], ["MAPK", "PROTEIN", 134, 138], ["TGEV", "SPECIES", 19, 23], ["TGEV", "TEST", 19, 23], ["PEDV", "PROBLEM", 28, 32], ["J2 cells", "PROBLEM", 66, 74], ["the phospho-ERK1/2", "TEST", 93, 111], ["phospho", "TEST", 116, 123], ["J2 cells", "OBSERVATION", 66, 74]]], ["The ERK and p38 inhibitors significantly decreased the expression of the E-cadherin, Occludin and Zo-1 in the TGEV and PEDV infected IPEC-J2 cells, which indicated that activation of ERK and p38 probably involved in the damage of barrier function of IPEC-J2 cells when IPEC-J2 cells were infected with PEDV and TGEV.", [["IPEC-J2 cells", "ANATOMY", 133, 146], ["barrier", "ANATOMY", 230, 237], ["IPEC-J2 cells", "ANATOMY", 250, 263], ["IPEC-J2 cells", "ANATOMY", 269, 282], ["ERK", "GENE_OR_GENE_PRODUCT", 4, 7], ["p38", "GENE_OR_GENE_PRODUCT", 12, 15], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 73, 83], ["Occludin", "GENE_OR_GENE_PRODUCT", 85, 93], ["Zo-1", "GENE_OR_GENE_PRODUCT", 98, 102], ["TGEV", "ORGANISM", 110, 114], ["PEDV", "CELL", 119, 123], ["IPEC-J2 cells", "CELL", 133, 146], ["ERK", "GENE_OR_GENE_PRODUCT", 183, 186], ["p38", "GENE_OR_GENE_PRODUCT", 191, 194], ["barrier", "TISSUE", 230, 237], ["IPEC-J2 cells", "CELL", 250, 263], ["IPEC-J2 cells", "CELL", 269, 282], ["TGEV", "ORGANISM", 311, 315], ["ERK", "PROTEIN", 4, 7], ["E-cadherin", "PROTEIN", 73, 83], ["Occludin", "PROTEIN", 85, 93], ["Zo-1", "PROTEIN", 98, 102], ["TGEV and PEDV infected IPEC-J2 cells", "CELL_LINE", 110, 146], ["ERK", "PROTEIN", 183, 186], ["p38", "PROTEIN", 191, 194], ["IPEC-J2 cells", "CELL_LINE", 250, 263], ["IPEC-J2 cells", "CELL_LINE", 269, 282], ["TGEV", "SPECIES", 110, 114], ["TGEV", "SPECIES", 110, 114], ["PEDV", "SPECIES", 119, 123], ["PEDV", "SPECIES", 302, 306], ["TGEV", "SPECIES", 311, 315], ["The ERK and p38 inhibitors", "TEST", 0, 26], ["the E-cadherin", "TREATMENT", 69, 83], ["Occludin", "TEST", 85, 93], ["Zo", "TEST", 98, 100], ["the TGEV", "PROBLEM", 106, 114], ["PEDV", "PROBLEM", 119, 123], ["J2 cells", "PROBLEM", 138, 146], ["ERK", "TEST", 183, 186], ["p38", "PROBLEM", 191, 194], ["J2 cells", "PROBLEM", 255, 263], ["IPEC", "TEST", 269, 273], ["J2 cells", "PROBLEM", 274, 282], ["PEDV", "PROBLEM", 302, 306], ["TGEV", "ANATOMY", 110, 114], ["PEDV", "ANATOMY", 119, 123], ["infected", "OBSERVATION", 124, 132], ["J2 cells", "OBSERVATION", 138, 146]]], ["Moreover, the MAPK pathway also plays an important role in microfilaments remodelling.", [["microfilaments", "ANATOMY", 59, 73], ["MAPK", "GENE_OR_GENE_PRODUCT", 14, 18], ["microfilaments", "CELLULAR_COMPONENT", 59, 73], ["MAPK", "PROTEIN", 14, 18], ["the MAPK pathway", "TEST", 10, 26], ["microfilaments remodelling", "OBSERVATION", 59, 85]]], ["After 1 h of infection, the microfilaments were found to line in the plasma membrane among all virus-infected IPEC-J2 cells.", [["microfilaments", "ANATOMY", 28, 42], ["plasma membrane", "ANATOMY", 69, 84], ["IPEC-J2 cells", "ANATOMY", 110, 123], ["infection", "DISEASE", 13, 22], ["microfilaments", "CELLULAR_COMPONENT", 28, 42], ["plasma membrane", "CELLULAR_COMPONENT", 69, 84], ["IPEC-J2 cells", "CELL", 110, 123], ["IPEC-J2 cells", "CELL_LINE", 110, 123], ["infection", "PROBLEM", 13, 22], ["the microfilaments", "TREATMENT", 24, 42], ["the plasma membrane", "TEST", 65, 84], ["all virus", "PROBLEM", 91, 100], ["infection", "OBSERVATION", 13, 22], ["plasma membrane", "ANATOMY", 69, 84], ["J2 cells", "OBSERVATION", 115, 123]]], ["Simultaneously, the ratio of phospho-ERK1/2 and phospho-JNK in these viruses infected IPEC-J2 cells significantly increased.", [["IPEC-J2 cells", "ANATOMY", 86, 99], ["phospho-ERK1/2", "GENE_OR_GENE_PRODUCT", 29, 43], ["phospho-JNK", "GENE_OR_GENE_PRODUCT", 48, 59], ["IPEC-J2 cells", "CELL", 86, 99], ["phospho-ERK1/2", "PROTEIN", 29, 43], ["phospho-JNK", "PROTEIN", 48, 59], ["IPEC-J2 cells", "CELL_LINE", 86, 99], ["the ratio", "TEST", 16, 25], ["phospho-ERK1/2", "TEST", 29, 43], ["phospho-JNK", "TEST", 48, 59], ["these viruses", "TEST", 63, 76], ["J2 cells", "PROBLEM", 91, 99], ["viruses", "OBSERVATION_MODIFIER", 69, 76], ["J2 cells", "OBSERVATION_MODIFIER", 91, 99], ["significantly", "OBSERVATION_MODIFIER", 100, 113], ["increased", "OBSERVATION_MODIFIER", 114, 123]]], ["After 24 h of infection, the microfilaments in a perinuclear location formed juxtanuclear caps or rings, while the phospho-ERK1/2 and phospho-38 in the infected IPEC-J2 cells significantly decreased.", [["microfilaments", "ANATOMY", 29, 43], ["perinuclear location", "ANATOMY", 49, 69], ["juxtanuclear caps", "ANATOMY", 77, 94], ["rings", "ANATOMY", 98, 103], ["IPEC-J2 cells", "ANATOMY", 161, 174], ["infection", "DISEASE", 14, 23], ["microfilaments", "CELLULAR_COMPONENT", 29, 43], ["perinuclear", "CELLULAR_COMPONENT", 49, 60], ["juxtanuclear caps", "CELLULAR_COMPONENT", 77, 94], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 123, 129], ["phospho-38", "GENE_OR_GENE_PRODUCT", 134, 144], ["IPEC-J2 cells", "CELL", 161, 174], ["phospho-ERK1/2", "PROTEIN", 115, 129], ["phospho-38", "PROTEIN", 134, 144], ["infected IPEC-J2 cells", "CELL_LINE", 152, 174], ["infection", "PROBLEM", 14, 23], ["the microfilaments", "TREATMENT", 25, 43], ["the phospho-ERK1/2", "TEST", 111, 129], ["phospho", "TEST", 134, 141], ["the infected IPEC", "TEST", 148, 165], ["J2 cells", "PROBLEM", 166, 174], ["infection", "OBSERVATION", 14, 23], ["juxtanuclear caps", "OBSERVATION", 77, 94], ["rings", "OBSERVATION_MODIFIER", 98, 103], ["infected", "OBSERVATION", 152, 160], ["J2 cells", "OBSERVATION_MODIFIER", 166, 174], ["significantly", "OBSERVATION_MODIFIER", 175, 188], ["decreased", "OBSERVATION_MODIFIER", 189, 198]]], ["In endothelial cells, p38 MAPK is reported to activate MAPK-activated protein (MAPKAP) kinase 2, which phosphorylates the 27 kDa heat shock protein (HSP27), an F-actin cap binding protein, which causes actin depolymerisation (Kutsuna et al., 2004) .", [["endothelial cells", "ANATOMY", 3, 20], ["endothelial cells", "CELL", 3, 20], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 22, 30], ["MAPK-activated protein (MAPKAP) kinase 2", "GENE_OR_GENE_PRODUCT", 55, 95], ["heat shock protein", "GENE_OR_GENE_PRODUCT", 129, 147], ["HSP27", "GENE_OR_GENE_PRODUCT", 149, 154], ["F-actin", "GENE_OR_GENE_PRODUCT", 160, 167], ["actin", "GENE_OR_GENE_PRODUCT", 202, 207], ["endothelial cells", "CELL_TYPE", 3, 20], ["p38 MAPK", "PROTEIN", 22, 30], ["MAPK-activated protein (MAPKAP) kinase 2", "PROTEIN", 55, 95], ["27 kDa heat shock protein", "PROTEIN", 122, 147], ["HSP27", "PROTEIN", 149, 154], ["F-actin cap binding protein", "PROTEIN", 160, 187], ["actin", "PROTEIN", 202, 207], ["p38 MAPK", "TEST", 22, 30], ["MAPK", "TEST", 55, 59], ["activated protein", "TEST", 60, 77], ["kinase", "TEST", 87, 93], ["kDa heat shock protein", "TEST", 125, 147], ["HSP27", "TEST", 149, 154], ["an F-actin cap binding protein", "TEST", 157, 187], ["actin depolymerisation", "PROBLEM", 202, 224], ["endothelial cells", "ANATOMY", 3, 20], ["actin depolymerisation", "OBSERVATION", 202, 224]]], ["SARS-CoV N protein also activates the p38 MAPK pathway to induce the reorganisation of microfilaments in cells devoid of growth factors (Surjit et al., 2004) .", [["microfilaments", "ANATOMY", 87, 101], ["cells", "ANATOMY", 105, 110], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 38, 46], ["microfilaments", "CELLULAR_COMPONENT", 87, 101], ["cells", "CELL", 105, 110], ["SARS-CoV N protein", "PROTEIN", 0, 18], ["p38 MAPK", "PROTEIN", 38, 46], ["growth factors", "PROTEIN", 121, 135], ["the p38 MAPK pathway", "TEST", 34, 54], ["microfilaments in cells", "PROBLEM", 87, 110], ["growth factors", "PROBLEM", 121, 135]]], ["TGEV-and PEDVinduced microfilament modelling might be due to the activation or inactivation of phospho-ERK1/2 and phospho-38 in the MAPK pathway.", [["phospho-", "CHEMICAL", 95, 103], ["phospho", "CHEMICAL", 114, 121], ["TGEV", "ORGANISM", 0, 4], ["phospho-ERK1/2", "GENE_OR_GENE_PRODUCT", 95, 109], ["phospho-38", "GENE_OR_GENE_PRODUCT", 114, 124], ["MAPK", "GENE_OR_GENE_PRODUCT", 132, 136], ["phospho-ERK1/2", "PROTEIN", 95, 109], ["phospho-38", "PROTEIN", 114, 124], ["MAPK", "PROTEIN", 132, 136], ["TGEV", "SPECIES", 0, 4], ["TGEV", "PROBLEM", 0, 4], ["PEDVinduced microfilament modelling", "TREATMENT", 9, 44], ["phospho-ERK1/2", "TREATMENT", 95, 109], ["phospho", "TEST", 114, 121]]], ["Using the MAPKs inhibitors to treat with the IPEC-J2 cells, the microfilaments of cells disappeared in the cytoplasm or became more diffuse in the cytoplasm, then gathered in the plasma membrane after 40, 60 min and 12, 24 h of PEDV and TGEV infection.", [["IPEC-J2 cells", "ANATOMY", 45, 58], ["microfilaments", "ANATOMY", 64, 78], ["cells", "ANATOMY", 82, 87], ["cytoplasm", "ANATOMY", 107, 116], ["cytoplasm", "ANATOMY", 147, 156], ["plasma membrane", "ANATOMY", 179, 194], ["PEDV", "CHEMICAL", 228, 232], ["TGEV infection", "DISEASE", 237, 251], ["IPEC-J2 cells", "CELL", 45, 58], ["microfilaments", "CELLULAR_COMPONENT", 64, 78], ["cells", "CELL", 82, 87], ["cytoplasm", "ORGANISM_SUBSTANCE", 107, 116], ["cytoplasm", "ORGANISM_SUBSTANCE", 147, 156], ["plasma membrane", "CELLULAR_COMPONENT", 179, 194], ["TGEV", "ORGANISM", 237, 241], ["MAPKs", "PROTEIN", 10, 15], ["IPEC-J2 cells", "CELL_LINE", 45, 58], ["PEDV", "SPECIES", 228, 232], ["TGEV", "SPECIES", 237, 241], ["the MAPKs inhibitors", "TREATMENT", 6, 26], ["the IPEC-J2 cells", "TREATMENT", 41, 58], ["the microfilaments of cells", "PROBLEM", 60, 87], ["PEDV", "PROBLEM", 228, 232], ["TGEV infection", "PROBLEM", 237, 251], ["J2 cells", "OBSERVATION", 50, 58], ["more", "OBSERVATION_MODIFIER", 127, 131], ["diffuse", "OBSERVATION_MODIFIER", 132, 139], ["plasma membrane", "ANATOMY", 179, 194], ["TGEV", "OBSERVATION_MODIFIER", 237, 241], ["infection", "OBSERVATION", 242, 251]]], ["These results suggested that MAPKs inhibitors, ERK, p38 and JNK, were involved in the microfilaments of IPEC-J2 cells.", [["microfilaments", "ANATOMY", 86, 100], ["IPEC-J2 cells", "ANATOMY", 104, 117], ["MAPKs", "GENE_OR_GENE_PRODUCT", 29, 34], ["ERK", "GENE_OR_GENE_PRODUCT", 47, 50], ["p38", "GENE_OR_GENE_PRODUCT", 52, 55], ["JNK", "GENE_OR_GENE_PRODUCT", 60, 63], ["microfilaments", "CELLULAR_COMPONENT", 86, 100], ["IPEC-J2 cells", "CELL", 104, 117], ["MAPKs", "PROTEIN", 29, 34], ["ERK", "PROTEIN", 47, 50], ["p38", "PROTEIN", 52, 55], ["JNK", "PROTEIN", 60, 63], ["IPEC-J2 cells", "CELL_LINE", 104, 117], ["MAPKs inhibitors", "TEST", 29, 45], ["ERK", "TEST", 47, 50], ["p38", "TEST", 52, 55], ["JNK", "TEST", 60, 63], ["J2 cells", "OBSERVATION", 109, 117]]], ["In addition, inhibition of MAPKs also decreased the PEDV and TGEV infection, which was consistent with the report that the effect of MAPK pathway inhibitors on HIV infection (Gong et al., 2011) .", [["TGEV infection", "DISEASE", 61, 75], ["HIV infection", "DISEASE", 160, 173], ["MAPKs", "GENE_OR_GENE_PRODUCT", 27, 32], ["PEDV", "GENE_OR_GENE_PRODUCT", 52, 56], ["TGEV", "ORGANISM", 61, 65], ["MAPK", "GENE_OR_GENE_PRODUCT", 133, 137], ["HIV", "ORGANISM", 160, 163], ["MAPKs", "PROTEIN", 27, 32], ["MAPK", "PROTEIN", 133, 137], ["HIV", "SPECIES", 160, 163], ["PEDV", "SPECIES", 52, 56], ["TGEV", "SPECIES", 61, 65], ["HIV", "SPECIES", 160, 163], ["inhibition of MAPKs", "TREATMENT", 13, 32], ["the PEDV", "PROBLEM", 48, 56], ["TGEV infection", "PROBLEM", 61, 75], ["MAPK pathway inhibitors", "TREATMENT", 133, 156], ["HIV infection", "PROBLEM", 160, 173], ["TGEV", "OBSERVATION_MODIFIER", 61, 65], ["infection", "OBSERVATION", 66, 75]]], ["However, the relationship between the PEDV and TGEV infection and MAPK pathway remains to be further investigated.", [["infection", "DISEASE", 52, 61], ["PEDV", "GENE_OR_GENE_PRODUCT", 38, 42], ["TGEV", "ORGANISM", 47, 51], ["MAPK", "GENE_OR_GENE_PRODUCT", 66, 70], ["MAPK", "PROTEIN", 66, 70], ["TGEV", "SPECIES", 47, 51], ["the PEDV", "PROBLEM", 34, 42], ["TGEV infection", "PROBLEM", 47, 61], ["MAPK pathway", "TREATMENT", 66, 78], ["PEDV", "OBSERVATION", 38, 42], ["TGEV", "OBSERVATION_MODIFIER", 47, 51], ["infection", "OBSERVATION", 52, 61]]]], "PMC7165119": [["In particular, dermatologists, pediatricians, and other health care workers (HCWs) in these offices routinely care for patients who present with infections with cutaneous manifestations.", [["cutaneous", "ANATOMY", 161, 170], ["infections", "DISEASE", 145, 155], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["infections", "PROBLEM", 145, 155], ["cutaneous manifestations", "PROBLEM", 161, 185]]], ["For pregnant HCWs, balancing patient care responsibilities and occupational safety can be challenging, especially when the risk of transmission in the clinical setting is unknown.", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["balancing patient care responsibilities", "TREATMENT", 19, 58]]], ["To our knowledge, there is no comprehensive review of the literature that specifically identifies risk of transmission of common exanthematous diseases to pregnant HCWs.", [["exanthematous diseases", "DISEASE", 129, 151], ["common exanthematous diseases", "PROBLEM", 122, 151], ["no", "UNCERTAINTY", 27, 29]]], ["This review identifies various infectious exanthems that pregnant HCWs may be exposed to and summarizes current available evidence regarding risk of transmission.", [["HCWs", "ORGANISM", 66, 70], ["various", "OBSERVATION_MODIFIER", 23, 30], ["infectious", "OBSERVATION", 31, 41]]], ["Specifically, we discuss parvovirus B19, hand, foot and mouth disease, mycoplasma-induced rash and mucositis, measles, herpes simplex virus, varicella-zoster virus, and pityriasis rosea.", [["hand", "ANATOMY", 41, 45], ["foot", "ANATOMY", 47, 51], ["mouth", "ANATOMY", 56, 61], ["parvovirus B19", "DISEASE", 25, 39], ["hand, foot and mouth disease", "DISEASE", 41, 69], ["mycoplasma-induced rash", "DISEASE", 71, 94], ["mucositis", "DISEASE", 99, 108], ["measles", "DISEASE", 110, 117], ["herpes simplex virus", "DISEASE", 119, 139], ["varicella-zoster virus", "DISEASE", 141, 163], ["pityriasis rosea", "DISEASE", 169, 185], ["parvovirus B19", "ORGANISM", 25, 39], ["hand", "ORGANISM_SUBDIVISION", 41, 45], ["foot", "ORGANISM_SUBDIVISION", 47, 51], ["mouth", "ORGANISM_SUBDIVISION", 56, 61], ["herpes simplex virus", "ORGANISM", 119, 139], ["varicella-zoster virus", "ORGANISM", 141, 163], ["pityriasis rosea", "ORGANISM", 169, 185], ["parvovirus B19", "SPECIES", 25, 39], ["herpes simplex virus", "SPECIES", 119, 139], ["varicella-zoster virus", "SPECIES", 141, 163], ["pityriasis rosea", "SPECIES", 169, 185], ["parvovirus B19", "SPECIES", 25, 39], ["herpes simplex virus", "SPECIES", 119, 139], ["varicella-zoster virus", "SPECIES", 141, 163], ["pityriasis rosea", "SPECIES", 169, 185], ["parvovirus B19, hand, foot and mouth disease", "PROBLEM", 25, 69], ["mycoplasma", "PROBLEM", 71, 81], ["induced rash", "PROBLEM", 82, 94], ["mucositis", "PROBLEM", 99, 108], ["measles", "PROBLEM", 110, 117], ["herpes simplex virus", "PROBLEM", 119, 139], ["varicella", "PROBLEM", 141, 150], ["zoster virus", "PROBLEM", 151, 163], ["pityriasis rosea", "PROBLEM", 169, 185], ["hand", "ANATOMY", 41, 45], ["foot", "ANATOMY", 47, 51], ["mouth", "ANATOMY", 56, 61], ["mycoplasma", "OBSERVATION", 71, 81], ["mucositis", "OBSERVATION", 99, 108], ["zoster virus", "OBSERVATION", 151, 163], ["pityriasis rosea", "OBSERVATION", 169, 185]]], ["We also provide guidelines for each disease in order for pregnant HCWs and HCWs of reproductive potential to appropriately minimize risk and pursue work-up and treatment, if necessary, following exposure.", [["each disease", "PROBLEM", 31, 43], ["treatment", "TREATMENT", 160, 169]]], ["Finally, given the ongoing global coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), we also summarize available safety guidelines for pregnant HCWs who are working during this time.Parvovirus:A wide range of clinical manifestations have been associated with parvovirus B19 (PVB19) infection, including erythema infectiosum, arthropathy and aplastic crisis.", [["erythema infectiosum", "ANATOMY", 369, 389], ["coronavirus disease", "DISEASE", 34, 53], ["acute respiratory syndrome coronavirus", "DISEASE", 108, 146], ["Parvovirus", "DISEASE", 248, 258], ["parvovirus B19 (PVB19) infection", "DISEASE", 325, 357], ["erythema infectiosum", "DISEASE", 369, 389], ["arthropathy", "DISEASE", 391, 402], ["aplastic crisis", "DISEASE", 407, 422], ["SARS-CoV-2", "ORGANISM", 89, 99], ["HCWs", "ORGANISM", 210, 214], ["Parvovirus", "ORGANISM", 248, 258], ["parvovirus B19", "ORGANISM", 325, 339], ["PVB19", "ORGANISM", 341, 346], ["parvovirus B19", "SPECIES", 325, 339], ["SARS-CoV-2 (severe acute respiratory syndrome coronavirus", "SPECIES", 89, 146], ["parvovirus B19", "SPECIES", 325, 339], ["PVB19", "SPECIES", 341, 346], ["the ongoing global coronavirus disease", "PROBLEM", 15, 53], ["COVID", "TEST", 60, 65], ["pandemic", "PROBLEM", 70, 78], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 101, 146], ["Parvovirus", "PROBLEM", 248, 258], ["clinical manifestations", "PROBLEM", 275, 298], ["parvovirus B19 (PVB19) infection", "PROBLEM", 325, 357], ["erythema infectiosum", "PROBLEM", 369, 389], ["arthropathy", "PROBLEM", 391, 402], ["aplastic crisis", "PROBLEM", 407, 422], ["coronavirus disease", "OBSERVATION", 34, 53], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["respiratory syndrome", "OBSERVATION", 114, 134], ["infection", "OBSERVATION", 348, 357], ["erythema infectiosum", "OBSERVATION", 369, 389], ["arthropathy", "OBSERVATION", 391, 402], ["aplastic crisis", "OBSERVATION", 407, 422]]], ["Erythema infectiosum is the most common dermatologic manifestation of PVB19, presenting in children between the ages of 5 and 14 following a prodrome.", [["Erythema infectiosum", "DISEASE", 0, 20], ["PVB19", "CANCER", 70, 75], ["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99], ["Erythema infectiosum", "PROBLEM", 0, 20], ["a prodrome", "PROBLEM", 139, 149], ["most common", "OBSERVATION_MODIFIER", 28, 39]]], ["The classic presentation involves a facial rash with a \u201cslapped-cheek\u201d appearance, followed by a morbilliform eruption on the extremities and trunk one to four days later.", [["facial", "ANATOMY", 36, 42], ["cheek", "ANATOMY", 64, 69], ["morbilliform", "ANATOMY", 97, 109], ["extremities", "ANATOMY", 126, 137], ["trunk", "ANATOMY", 142, 147], ["rash", "DISEASE", 43, 47], ["cheek", "ORGAN", 64, 69], ["extremities", "ORGANISM_SUBDIVISION", 126, 137], ["trunk", "ORGANISM_SUBDIVISION", 142, 147], ["a facial rash", "PROBLEM", 34, 47], ["a \u201cslapped-cheek\u201d appearance", "PROBLEM", 53, 81], ["a morbilliform eruption on the extremities", "PROBLEM", 95, 137], ["facial", "ANATOMY", 36, 42], ["rash", "OBSERVATION", 43, 47], ["cheek", "ANATOMY", 64, 69], ["eruption", "OBSERVATION", 110, 118], ["extremities", "ANATOMY", 126, 137], ["trunk", "ANATOMY", 142, 147]]], ["Once the rash appears, patients are no longer contagious (Servey et al., 2007).", [["rash", "DISEASE", 9, 13], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["the rash", "PROBLEM", 5, 13], ["rash", "OBSERVATION", 9, 13], ["no longer", "UNCERTAINTY", 36, 45]]], ["As such, while providers are at risk of infection during the PVB19 prodromal phase, they are likely protected if patients present with rash.Parvovirus:While the disease course itself is self-limiting, PVB19 infection during pregnancy has been attributed to several adverse fetal outcomes including intrauterine fetal demise, thrombocytopenia and hydrops fetalis.", [["fetal", "ANATOMY", 273, 278], ["fetal", "ANATOMY", 311, 316], ["infection", "DISEASE", 40, 49], ["rash", "DISEASE", 135, 139], ["Parvovirus", "DISEASE", 140, 150], ["infection", "DISEASE", 207, 216], ["intrauterine fetal demise", "DISEASE", 298, 323], ["thrombocytopenia", "DISEASE", 325, 341], ["hydrops fetalis", "DISEASE", 346, 361], ["patients", "ORGANISM", 113, 121], ["Parvovirus", "ORGANISM", 140, 150], ["fetal", "ANATOMICAL_SYSTEM", 273, 278], ["intrauterine fetal", "MULTI-TISSUE_STRUCTURE", 298, 316], ["patients", "SPECIES", 113, 121], ["infection", "PROBLEM", 40, 49], ["rash", "PROBLEM", 135, 139], ["Parvovirus", "PROBLEM", 140, 150], ["PVB19 infection", "PROBLEM", 201, 216], ["several adverse fetal outcomes", "PROBLEM", 257, 287], ["intrauterine fetal demise", "PROBLEM", 298, 323], ["thrombocytopenia", "PROBLEM", 325, 341], ["hydrops fetalis", "PROBLEM", 346, 361], ["infection", "OBSERVATION", 40, 49], ["infection", "OBSERVATION", 207, 216], ["fetal demise", "OBSERVATION", 311, 323], ["thrombocytopenia", "OBSERVATION", 325, 341], ["hydrops fetalis", "OBSERVATION", 346, 361]]], ["The rate of baseline immunity to PVB19 in pregnant populations ranges from 35% to 65% (Gillespie et al., 1990, Gratac\u00f3s et al., 1995, Valeur-Jensen et al., 1999).", [["PVB19", "CHEMICAL", 33, 38], ["PVB19", "GENE_OR_GENE_PRODUCT", 33, 38], ["The rate", "TEST", 0, 8], ["PVB19", "TEST", 33, 38], ["pregnant populations", "TEST", 42, 62]]], ["The incidence of acute PVB19 infection in susceptible pregnant women is reported to be 1-2%, with an estimated vertical transmission rate of approximately 25-35% (Gratac\u00f3s et al., 1995, Neu et al., 2015).", [["acute PVB19 infection", "DISEASE", 17, 38], ["women", "ORGANISM", 63, 68], ["women", "SPECIES", 63, 68], ["acute PVB19 infection", "PROBLEM", 17, 38], ["an estimated vertical transmission rate", "TEST", 98, 137], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["PVB19", "OBSERVATION_MODIFIER", 23, 28], ["infection", "OBSERVATION", 29, 38], ["vertical", "OBSERVATION_MODIFIER", 111, 119]]], ["A population-based cohort study in Denmark of over 30,000 pregnant women found that working as a nursery school teacher and having more children in the household were among the greatest risk factors associated with acquiring parvovirus infection (Valeur-Jensen, et al., 1999).Parvovirus:Data on the risk of transmission to HCWs, however, is conflicting (Adler et al., 1993).", [["parvovirus infection", "DISEASE", 225, 245], ["Parvovirus", "DISEASE", 276, 286], ["women", "ORGANISM", 67, 72], ["children", "ORGANISM", 136, 144], ["parvovirus", "ORGANISM", 225, 235], ["Parvovirus", "ORGANISM", 276, 286], ["women", "SPECIES", 67, 72], ["children", "SPECIES", 136, 144], ["cohort study", "TEST", 19, 31], ["acquiring parvovirus infection", "PROBLEM", 215, 245]]], ["Various case reports and case series (Harrison and Jones, 1995, Lara-Medrano et al., 2016, Sungkate et al., 2017) have demonstrated risk of transmission of parvovirus infection to HCWs following exposure to infected patients.", [["parvovirus infection", "DISEASE", 156, 176], ["parvovirus", "ORGANISM", 156, 166], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["parvovirus infection", "PROBLEM", 156, 176], ["parvovirus infection", "OBSERVATION", 156, 176]]], ["One single-center study at Children\u2019s Hospital of Philadelphia found elevated risk of infection between exposed and unexposed staff (Bell et al., 1998).", [["infection", "DISEASE", 86, 95], ["Children", "SPECIES", 27, 35], ["infection", "PROBLEM", 86, 95], ["elevated", "OBSERVATION_MODIFIER", 69, 77], ["infection", "OBSERVATION", 86, 95]]], ["However, a cohort study of 87 HCWs exposed to two patients with parvovirus B19-induced aplastic crisis found no significant increase in parvovirus B19-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies when compared with unexposed health care workers in the same facility (Ray et al., 1997).Parvovirus:While the risk of transmission to HCWs has not been definitively identified, preventing the transmission of PVB19 infection is important as it can lead to adverse pregnancy outcomes.", [["parvovirus B19", "DISEASE", 64, 78], ["aplastic crisis", "DISEASE", 87, 102], ["Parvovirus", "DISEASE", 310, 320], ["infection", "DISEASE", 435, 444], ["HCWs", "ORGANISM", 30, 34], ["patients", "ORGANISM", 50, 58], ["parvovirus B19", "ORGANISM", 64, 78], ["parvovirus B19", "ORGANISM", 136, 150], ["immunoglobulin M", "GENE_OR_GENE_PRODUCT", 160, 176], ["IgM", "GENE_OR_GENE_PRODUCT", 178, 181], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 187, 203], ["IgG", "GENE_OR_GENE_PRODUCT", 205, 208], ["Parvovirus", "ORGANISM", 310, 320], ["HCWs", "ORGANISM", 355, 359], ["PVB19", "ORGANISM", 429, 434], ["parvovirus B19-specific immunoglobulin M", "PROTEIN", 136, 176], ["IgM", "PROTEIN", 178, 181], ["immunoglobulin G (IgG) antibodies", "PROTEIN", 187, 220], ["patients", "SPECIES", 50, 58], ["parvovirus B19", "SPECIES", 64, 78], ["parvovirus B19", "SPECIES", 136, 150], ["parvovirus B19", "SPECIES", 136, 150], ["PVB19", "SPECIES", 429, 434], ["a cohort study", "TEST", 9, 23], ["parvovirus B19", "PROBLEM", 64, 78], ["aplastic crisis", "PROBLEM", 87, 102], ["significant increase", "PROBLEM", 112, 132], ["parvovirus B19", "TEST", 136, 150], ["specific immunoglobulin M", "TEST", 151, 176], ["IgM", "TEST", 178, 181], ["immunoglobulin G (IgG) antibodies", "TEST", 187, 220], ["Parvovirus", "PROBLEM", 310, 320], ["PVB19 infection", "PROBLEM", 429, 444], ["adverse pregnancy outcomes", "PROBLEM", 476, 502], ["aplastic crisis", "OBSERVATION", 87, 102], ["no", "UNCERTAINTY", 109, 111], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["increase", "OBSERVATION_MODIFIER", 124, 132], ["parvovirus B19", "OBSERVATION", 136, 150]]], ["PVB19 infection carries a 9% excess risk of miscarriage within the first 20 weeks of gestation, and 2.9% risk of fetal hydrops between weeks 9 and 20 (Miller et al., 1998).Management Recommendations:It is recommended that pregnant HCWs should not be part of the care team for patients with suspected PVB19 infection if possible.", [["fetal", "ANATOMY", 113, 118], ["PVB19", "CHEMICAL", 0, 5], ["infection", "DISEASE", 6, 15], ["miscarriage", "DISEASE", 44, 55], ["fetal hydrops", "DISEASE", 113, 126], ["infection", "DISEASE", 306, 315], ["fetal hydrops", "PATHOLOGICAL_FORMATION", 113, 126], ["HCWs", "ORGANISM", 231, 235], ["patients", "ORGANISM", 276, 284], ["patients", "SPECIES", 276, 284], ["PVB19 infection", "PROBLEM", 0, 15], ["miscarriage", "PROBLEM", 44, 55], ["fetal hydrops", "PROBLEM", 113, 126], ["PVB19 infection", "PROBLEM", 300, 315], ["miscarriage", "OBSERVATION", 44, 55], ["fetal", "ANATOMY", 113, 118], ["hydrops", "OBSERVATION", 119, 126], ["infection", "OBSERVATION", 306, 315]]], ["If exposure is suspected, risk assessment should consider the presence of an ongoing outbreak, as well as the extent of contact that the HCW had with exposed patients.", [["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["risk assessment", "TEST", 26, 41], ["an ongoing outbreak", "PROBLEM", 74, 93]]], ["Droplet precautions should be strictly followed when caring for patients with PVB19.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["Droplet precautions", "TREATMENT", 0, 19], ["PVB19", "TREATMENT", 78, 83]]], ["Please refer to Table 1for the different types of infection control and prevention precautions.", [["infection", "DISEASE", 50, 59], ["infection control", "TREATMENT", 50, 67], ["prevention precautions", "TREATMENT", 72, 94], ["infection", "OBSERVATION", 50, 59]]], ["If a pregnant HCW is exposed to a known or suspected parvovirus case, she should undergo PVB19 testing for IgM and IgG (Crowcroft et al., 1999; Katta 2002; Kho et al., 2008; Lamont et al., 2010).", [["parvovirus", "DISEASE", 53, 63], ["HCW", "ORGANISM", 14, 17], ["parvovirus", "ORGANISM", 53, 63], ["PVB19", "CANCER", 89, 94], ["IgM", "GENE_OR_GENE_PRODUCT", 107, 110], ["IgG", "ORGANISM_SUBSTANCE", 115, 118], ["IgM", "PROTEIN", 107, 110], ["IgG", "PROTEIN", 115, 118], ["PVB19 testing", "TEST", 89, 102], ["IgM", "TEST", 107, 110], ["IgG", "TEST", 115, 118]]], ["If IgM positive, pregnant HCW below 21 weeks of gestation should undergo serial ultrasound examinations scheduled per obstetrician recommendation to assess for development of fetal hydrops.", [["fetal", "ANATOMY", 175, 180], ["fetal hydrops", "DISEASE", 175, 188], ["IgM", "GENE_OR_GENE_PRODUCT", 3, 6], ["fetal hydrops", "PATHOLOGICAL_FORMATION", 175, 188], ["IgM", "PROTEIN", 3, 6], ["IgM positive", "PROBLEM", 3, 15], ["serial ultrasound examinations", "TEST", 73, 103], ["fetal hydrops", "PROBLEM", 175, 188], ["fetal", "ANATOMY", 175, 180], ["hydrops", "OBSERVATION", 181, 188]]], ["Maternal IVIG administration is not recommended.", [["IVIG", "SIMPLE_CHEMICAL", 9, 13], ["Maternal IVIG administration", "TREATMENT", 0, 28]]], ["Please refer to Table 2for a summary of infection risk, complications, prevention, and management guidelines.Hand, Foot and Mouth Disease:Hand, foot, and mouth disease (HFMD) is a highly contagious viral infection typically caused by Coxsackievirus A16 and Enterovirus 71 (EV71).", [["foot", "ANATOMY", 144, 148], ["mouth", "ANATOMY", 154, 159], ["infection", "DISEASE", 40, 49], ["Hand, Foot and Mouth Disease", "DISEASE", 109, 137], ["Hand, foot, and mouth disease", "DISEASE", 138, 167], ["HFMD", "DISEASE", 169, 173], ["viral infection", "DISEASE", 198, 213], ["foot", "ORGANISM_SUBDIVISION", 144, 148], ["mouth", "ORGAN", 154, 159], ["Coxsackievirus A16", "ORGANISM", 234, 252], ["Enterovirus 71", "ORGANISM", 257, 271], ["EV71", "ORGANISM", 273, 277], ["Coxsackievirus A16", "SPECIES", 234, 252], ["Coxsackievirus A16", "SPECIES", 234, 252], ["EV71", "SPECIES", 273, 277], ["infection risk", "PROBLEM", 40, 54], ["complications", "PROBLEM", 56, 69], ["Hand, Foot and Mouth Disease", "PROBLEM", 109, 137], ["Hand, foot, and mouth disease (HFMD", "PROBLEM", 138, 173], ["a highly contagious viral infection", "PROBLEM", 178, 213], ["Coxsackievirus A16", "PROBLEM", 234, 252], ["Enterovirus", "PROBLEM", 257, 268], ["Foot", "ANATOMY", 115, 119], ["Mouth", "ANATOMY", 124, 129], ["Disease", "OBSERVATION", 130, 137], ["Hand", "ANATOMY", 138, 142], ["foot", "ANATOMY", 144, 148], ["mouth", "ANATOMY", 154, 159], ["disease", "OBSERVATION", 160, 167], ["contagious", "OBSERVATION_MODIFIER", 187, 197], ["infection", "OBSERVATION", 204, 213]]], ["The infection, which is primarily transmitted via respiratory droplets, contact with blisters, or contact with feces, most commonly affects children under the age of 5.", [["respiratory droplets", "ANATOMY", 50, 70], ["blisters", "ANATOMY", 85, 93], ["feces", "ANATOMY", 111, 116], ["infection", "DISEASE", 4, 13], ["blisters", "DISEASE", 85, 93], ["children", "ORGANISM", 140, 148], ["children", "SPECIES", 140, 148], ["The infection", "PROBLEM", 0, 13], ["blisters", "PROBLEM", 85, 93], ["infection", "OBSERVATION", 4, 13], ["respiratory droplets", "OBSERVATION", 50, 70], ["blisters", "OBSERVATION", 85, 93]]], ["It is classically characterized by a macular, morbilliform, or vesicular rash affecting the hands, feet, and oral mucosa.", [["macular", "ANATOMY", 37, 44], ["morbilliform", "ANATOMY", 46, 58], ["vesicular", "ANATOMY", 63, 72], ["hands", "ANATOMY", 92, 97], ["feet", "ANATOMY", 99, 103], ["oral mucosa", "ANATOMY", 109, 120], ["morbilliform", "DISEASE", 46, 58], ["rash", "DISEASE", 73, 77], ["macular", "TISSUE", 37, 44], ["hands", "ORGANISM_SUBDIVISION", 92, 97], ["feet", "ORGANISM_SUBDIVISION", 99, 103], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 109, 120], ["a macular, morbilliform, or vesicular rash affecting the hands, feet, and oral mucosa", "PROBLEM", 35, 120], ["macular", "OBSERVATION", 37, 44], ["vesicular", "OBSERVATION_MODIFIER", 63, 72], ["rash", "OBSERVATION", 73, 77], ["hands", "ANATOMY", 92, 97], ["feet", "ANATOMY", 99, 103], ["oral mucosa", "ANATOMY", 109, 120]]], ["As one of the most common pediatric exanthems, HFMD is routinely seen by pediatric and dermatology HCWs, presenting a potential concern for occupational exposure.Hand, Foot and Mouth Disease:Although outbreaks of HFMD have been regularly reported worldwide in children, symptomatic infections in adults are less common (Chang et al., 2004).", [["HFMD", "DISEASE", 47, 51], ["Hand, Foot and Mouth Disease", "DISEASE", 162, 190], ["HFMD", "DISEASE", 213, 217], ["infections", "DISEASE", 282, 292], ["children", "ORGANISM", 260, 268], ["children", "SPECIES", 260, 268], ["HFMD", "PROBLEM", 47, 51], ["occupational exposure", "PROBLEM", 140, 161], ["Hand, Foot and Mouth Disease", "PROBLEM", 162, 190], ["HFMD", "PROBLEM", 213, 217], ["symptomatic infections", "PROBLEM", 270, 292], ["Foot", "ANATOMY", 168, 172], ["Mouth", "ANATOMY", 177, 182], ["Disease", "OBSERVATION", 183, 190], ["symptomatic", "OBSERVATION_MODIFIER", 270, 281], ["infections", "OBSERVATION", 282, 292]]], ["Individual cases of adult infection have been reported in the literature (Murase and Akiyama, 2018, Stewart et al., 2013).", [["adult infection", "DISEASE", 20, 35], ["adult infection", "PROBLEM", 20, 35], ["adult", "OBSERVATION_MODIFIER", 20, 25], ["infection", "OBSERVATION", 26, 35]]], ["The Coxsackievirus A6 (CVA6) serotype has been linked to several HFMD outbreaks worldwide, affecting both adults and children (Kimmis et al., 2018, Ramirez-Fort et al., 2014).", [["HFMD", "DISEASE", 65, 69], ["Coxsackievirus A6 (CVA6) serotype", "ORGANISM", 4, 37], ["children", "ORGANISM", 117, 125], ["children", "SPECIES", 117, 125], ["Coxsackievirus A6", "SPECIES", 4, 21], ["CVA6", "SPECIES", 23, 27], ["The Coxsackievirus A6 (CVA6) serotype", "PROBLEM", 0, 37], ["Coxsackievirus", "OBSERVATION", 4, 18], ["several", "OBSERVATION_MODIFIER", 57, 64], ["HFMD", "OBSERVATION", 65, 69]]], ["HFMD due to CVA6 differs in presentation from classic HFMD.", [["HFMD", "DISEASE", 0, 4], ["HFMD", "DISEASE", 54, 58], ["HFMD", "PROBLEM", 0, 4], ["CVA6", "PROBLEM", 12, 16], ["classic HFMD", "PROBLEM", 46, 58]]], ["Unlike in typical HFMD, adults with CVA6 HFMD are more likely to develop vesicular eruptions involving the dorsal hands and feet, as well as the face (Horsten et al., 2018).", [["vesicular", "ANATOMY", 73, 82], ["dorsal hands", "ANATOMY", 107, 119], ["feet", "ANATOMY", 124, 128], ["HFMD", "DISEASE", 18, 22], ["HFMD", "DISEASE", 41, 45], ["vesicular eruptions", "DISEASE", 73, 92], ["vesicular eruptions", "PATHOLOGICAL_FORMATION", 73, 92], ["dorsal hands", "ORGANISM_SUBDIVISION", 107, 119], ["feet", "ORGANISM_SUBDIVISION", 124, 128], ["CVA6 HFMD", "PROBLEM", 36, 45], ["vesicular eruptions involving the dorsal hands and feet", "PROBLEM", 73, 128], ["HFMD", "OBSERVATION", 18, 22], ["more likely", "UNCERTAINTY", 50, 61], ["vesicular", "OBSERVATION_MODIFIER", 73, 82], ["eruptions", "OBSERVATION", 83, 92], ["dorsal", "ANATOMY_MODIFIER", 107, 113], ["hands", "ANATOMY", 114, 119], ["feet", "ANATOMY", 124, 128], ["face", "ANATOMY", 145, 149]]], ["The lesions may also appear more purpuric than typical HFMD and can mimic secondary syphilis.", [["lesions", "ANATOMY", 4, 11], ["purpuric", "DISEASE", 33, 41], ["HFMD", "DISEASE", 55, 59], ["syphilis", "DISEASE", 84, 92], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["The lesions", "PROBLEM", 0, 11], ["purpuric", "PROBLEM", 33, 41], ["secondary syphilis", "PROBLEM", 74, 92], ["lesions", "OBSERVATION", 4, 11], ["may also appear", "UNCERTAINTY", 12, 27], ["more", "OBSERVATION_MODIFIER", 28, 32], ["purpuric", "OBSERVATION_MODIFIER", 33, 41], ["syphilis", "OBSERVATION", 84, 92]]], ["Later in the disease process, the rash can desquamate and mimic fungal infection (Ramirez-Fort et al., 2014).", [["rash", "DISEASE", 34, 38], ["fungal infection", "DISEASE", 64, 80], ["rash", "PATHOLOGICAL_FORMATION", 34, 38], ["the disease process", "PROBLEM", 9, 28], ["the rash", "PROBLEM", 30, 38], ["mimic fungal infection", "PROBLEM", 58, 80], ["fungal", "OBSERVATION_MODIFIER", 64, 70], ["infection", "OBSERVATION", 71, 80]]], ["Other features include widespread vesiculobullous and erosive lesions extending beyond the palms and soles, an eczema herpeticum-like eruption termed \u201ceczema coxsackium\u201d, and an eruption similar to Gianotti-Crosti in children (Mathes et al., 2013).", [["vesiculobullous", "ANATOMY", 34, 49], ["lesions", "ANATOMY", 62, 69], ["palms", "ANATOMY", 91, 96], ["soles", "ANATOMY", 101, 106], ["eczema herpeticum", "DISEASE", 111, 128], ["eruption", "DISEASE", 134, 142], ["eczema coxsackium\u201d", "DISEASE", 151, 169], ["Gianotti-Crosti", "DISEASE", 198, 213], ["erosive lesions", "PATHOLOGICAL_FORMATION", 54, 69], ["palms", "ORGANISM_SUBDIVISION", 91, 96], ["soles", "ORGANISM_SUBDIVISION", 101, 106], ["children", "ORGANISM", 217, 225], ["children", "SPECIES", 217, 225], ["widespread vesiculobullous", "PROBLEM", 23, 49], ["erosive lesions", "PROBLEM", 54, 69], ["an eczema herpeticum", "PROBLEM", 108, 128], ["like eruption", "PROBLEM", 129, 142], ["eczema coxsackium", "PROBLEM", 151, 168], ["an eruption", "PROBLEM", 175, 186], ["widespread", "OBSERVATION_MODIFIER", 23, 33], ["vesiculobullous", "OBSERVATION_MODIFIER", 34, 49], ["erosive", "OBSERVATION_MODIFIER", 54, 61], ["lesions", "OBSERVATION", 62, 69], ["palms", "ANATOMY", 91, 96], ["soles", "ANATOMY", 101, 106], ["eczema", "OBSERVATION", 111, 117], ["eczema coxsackium", "OBSERVATION", 151, 168], ["eruption", "OBSERVATION", 178, 186]]], ["There can also be occasional sparing of the oral mucosa (Second et al., 2017).", [["oral mucosa", "ANATOMY", 44, 55], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 44, 55], ["occasional sparing of the oral mucosa", "PROBLEM", 18, 55], ["occasional", "OBSERVATION_MODIFIER", 18, 28], ["sparing", "OBSERVATION_MODIFIER", 29, 36], ["oral mucosa", "ANATOMY", 44, 55]]], ["Outbreaks of HFMD in adults that have been reported in the literature have typically occurred in adults following exposure to children with HFMD (CDC MMWR, 2012) or among college students (Buttery et al., 2015) and military trainees (Banta et al., 2016).Hand, Foot and Mouth Disease:HFMD in pregnancy has been rarely reported in the literature and is largely limited to case reports (Chow et al., 2000, Deeb et al., 2019, Ogilvie and Tearne, 1980), with no reports discussing pregnant HCWs specifically.", [["HFMD", "DISEASE", 13, 17], ["HFMD", "DISEASE", 140, 144], ["Hand, Foot and Mouth Disease", "DISEASE", 254, 282], ["HFMD", "DISEASE", 283, 287], ["children", "ORGANISM", 126, 134], ["HCWs", "ORGANISM", 485, 489], ["children", "SPECIES", 126, 134], ["HFMD", "PROBLEM", 13, 17], ["Hand, Foot and Mouth Disease", "PROBLEM", 254, 282], ["HFMD", "PROBLEM", 283, 287], ["HFMD", "OBSERVATION", 13, 17], ["Foot", "ANATOMY", 260, 264], ["Mouth", "ANATOMY", 269, 274], ["Disease", "OBSERVATION", 275, 282], ["HFMD", "OBSERVATION", 283, 287]]], ["One report identifies fetal demise secondary to maternal Coxsackievirus A16 infection with confirmed massive placental perivillous fibrinoid deposition (Heller et al., 2015), while another found no evidence to suggest that HFMD impacted pregnancy course or newborn development (Second et al., 2017).", [["fetal", "ANATOMY", 22, 27], ["placental perivillous fibrinoid", "ANATOMY", 109, 140], ["Coxsackievirus A16 infection", "DISEASE", 57, 85], ["HFMD", "DISEASE", 223, 227], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 22, 27], ["Coxsackievirus A16", "ORGANISM", 57, 75], ["placental perivillous fibrinoid", "PATHOLOGICAL_FORMATION", 109, 140], ["Coxsackievirus A16", "SPECIES", 57, 75], ["fetal demise", "PROBLEM", 22, 34], ["maternal Coxsackievirus A16 infection", "PROBLEM", 48, 85], ["massive placental perivillous fibrinoid deposition", "PROBLEM", 101, 151], ["HFMD impacted pregnancy course", "PROBLEM", 223, 253], ["fetal demise", "OBSERVATION", 22, 34], ["Coxsackievirus", "OBSERVATION", 57, 71], ["massive", "OBSERVATION_MODIFIER", 101, 108], ["placental", "ANATOMY_MODIFIER", 109, 118], ["perivillous", "ANATOMY", 119, 130], ["fibrinoid deposition", "OBSERVATION", 131, 151], ["no evidence to suggest", "UNCERTAINTY", 195, 217], ["HFMD", "OBSERVATION", 223, 227]]], ["A retrospective observational study in Italy of 128 pregnant patients with clinically suspected HFMD or documented exposure found no conclusive evidence that HFMD impacted fetal or neonatal outcomes (Giache et al., 2019).", [["fetal", "ANATOMY", 172, 177], ["HFMD", "DISEASE", 96, 100], ["HFMD", "DISEASE", 158, 162], ["patients", "ORGANISM", 61, 69], ["fetal", "ANATOMICAL_SYSTEM", 172, 177], ["patients", "SPECIES", 61, 69], ["A retrospective observational study", "TEST", 0, 35], ["HFMD", "PROBLEM", 96, 100], ["HFMD impacted fetal or neonatal outcomes", "PROBLEM", 158, 198], ["no conclusive evidence", "UNCERTAINTY", 130, 152]]], ["The CDC also reports no clear evidence that non-polio enterovirus infection during pregnancy increases risk of severe complications including miscarriage, stillbirth or congenital defects (CDC, 2019).Management Recommendations:Although the rate of HFMD is high among children, transmission to adults is less likely and often confers an asymptomatic or milder course.", [["enterovirus infection", "DISEASE", 54, 75], ["miscarriage", "DISEASE", 142, 153], ["stillbirth", "DISEASE", 155, 165], ["congenital defects", "DISEASE", 169, 187], ["HFMD", "DISEASE", 248, 252], ["non-polio enterovirus", "ORGANISM", 44, 65], ["children", "ORGANISM", 267, 275], ["adults", "ORGANISM", 293, 299], ["children", "SPECIES", 267, 275], ["non-polio enterovirus infection", "PROBLEM", 44, 75], ["severe complications", "PROBLEM", 111, 131], ["miscarriage", "PROBLEM", 142, 153], ["stillbirth or congenital defects", "PROBLEM", 155, 187], ["HFMD", "PROBLEM", 248, 252], ["no clear evidence", "UNCERTAINTY", 21, 38], ["enterovirus", "OBSERVATION_MODIFIER", 54, 65], ["infection", "OBSERVATION", 66, 75], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["complications", "OBSERVATION", 118, 131], ["congenital", "OBSERVATION_MODIFIER", 169, 179], ["defects", "OBSERVATION", 180, 187]]], ["The literature regarding HFMD outcomes in pregnant women is limited.", [["HFMD", "DISEASE", 25, 29], ["women", "ORGANISM", 51, 56], ["women", "SPECIES", 51, 56]]], ["As such, we recommend proper and consistent hand hygiene and strict droplet and contact precautions for any pregnant HCW who participates in the care of a suspected HFMD case.", [["hand", "ANATOMY", 44, 48], ["HFMD", "DISEASE", 165, 169], ["hand", "ORGANISM_SUBDIVISION", 44, 48], ["strict droplet", "TREATMENT", 61, 75], ["contact precautions", "TREATMENT", 80, 99]]], ["It is also prudent to inform the HCW\u2019s obstetric provider for close monitoring (Ventarola et al., 2015).", [["close monitoring", "TEST", 62, 78]]], ["If case is severe and requires hospitalization, we recommend isolation of patient.", [["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["severe", "OBSERVATION_MODIFIER", 11, 17]]], ["If possible, we recommend having another provider to assume care for HFMD patients in these cases.Mycoplasma-induced Rash and Mucositis (MIRM):Mycoplasma infections are associated with various adverse outcomes in pregnancy.", [["HFMD", "DISEASE", 69, 73], ["Mycoplasma-induced Rash and Mucositis", "DISEASE", 98, 135], ["Mycoplasma infections", "DISEASE", 143, 164], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Mycoplasma", "PROBLEM", 98, 108], ["induced Rash", "PROBLEM", 109, 121], ["Mucositis (MIRM)", "PROBLEM", 126, 142], ["Mycoplasma infections", "PROBLEM", 143, 164], ["various adverse outcomes in pregnancy", "PROBLEM", 185, 222], ["Rash", "OBSERVATION", 117, 121], ["Mucositis", "OBSERVATION", 126, 135], ["Mycoplasma infections", "OBSERVATION", 143, 164]]], ["Although the incidence of Mycoplasma pneumoniae infection in pregnancy is unknown (Matsuda et al., 2017), pneumonia during pregnancy is well-associated with preterm labor and low birth weight (Chen et al., 2013).Mycoplasma-induced Rash and Mucositis (MIRM):Mycoplasma-induced rash and mucositis (MIRM) refers to Mycoplasma pnuemoniae associated mucocutaneous disease with prominent mucositis and varying degrees of cutaneous involvement (Canavan et al., 2015).", [["mucocutaneous", "ANATOMY", 345, 358], ["cutaneous", "ANATOMY", 415, 424], ["Mycoplasma pneumoniae infection", "DISEASE", 26, 57], ["pneumonia", "DISEASE", 106, 115], ["preterm labor", "DISEASE", 157, 170], ["Rash and Mucositis", "DISEASE", 231, 249], ["Mycoplasma-induced rash", "DISEASE", 257, 280], ["mucositis", "DISEASE", 285, 294], ["MIRM", "DISEASE", 296, 300], ["Mycoplasma pnuemoniae", "DISEASE", 312, 333], ["mucocutaneous disease", "DISEASE", 345, 366], ["mucositis", "DISEASE", 382, 391], ["Mycoplasma pneumoniae", "ORGANISM", 26, 47], ["rash", "PATHOLOGICAL_FORMATION", 276, 280], ["mucositis", "PATHOLOGICAL_FORMATION", 285, 294], ["Mycoplasma pnuemoniae", "ORGANISM", 312, 333], ["cutaneous", "ORGANISM_SUBDIVISION", 415, 424], ["Mycoplasma pneumoniae", "SPECIES", 26, 47], ["Mycoplasma pnuemoniae", "SPECIES", 312, 333], ["Mycoplasma pneumoniae", "SPECIES", 26, 47], ["Mycoplasma pnuemoniae", "SPECIES", 312, 333], ["Mycoplasma pneumoniae infection", "PROBLEM", 26, 57], ["pneumonia", "PROBLEM", 106, 115], ["preterm labor", "PROBLEM", 157, 170], ["low birth weight", "PROBLEM", 175, 191], ["Mycoplasma", "PROBLEM", 212, 222], ["induced Rash", "PROBLEM", 223, 235], ["Mucositis (MIRM)", "PROBLEM", 240, 256], ["Mycoplasma", "PROBLEM", 257, 267], ["induced rash", "PROBLEM", 268, 280], ["mucositis (MIRM)", "PROBLEM", 285, 301], ["Mycoplasma pnuemoniae", "PROBLEM", 312, 333], ["mucocutaneous disease", "PROBLEM", 345, 366], ["prominent mucositis", "PROBLEM", 372, 391], ["varying degrees of cutaneous involvement", "PROBLEM", 396, 436], ["Mycoplasma", "OBSERVATION_MODIFIER", 26, 36], ["pneumoniae", "OBSERVATION_MODIFIER", 37, 47], ["infection", "OBSERVATION", 48, 57], ["pneumonia", "OBSERVATION", 106, 115], ["Rash", "OBSERVATION", 231, 235], ["Mucositis", "OBSERVATION", 240, 249], ["Mycoplasma", "ANATOMY", 257, 267], ["mucositis", "OBSERVATION", 285, 294], ["Mycoplasma pnuemoniae", "OBSERVATION", 312, 333], ["mucocutaneous disease", "OBSERVATION", 345, 366], ["prominent", "OBSERVATION_MODIFIER", 372, 381], ["mucositis", "OBSERVATION", 382, 391], ["varying degrees", "OBSERVATION_MODIFIER", 396, 411], ["cutaneous", "ANATOMY", 415, 424]]], ["Classically, MIRM presents as severe conjunctivitis and blepharitis, severe oral mucositis with hemorrhagic crusting, and sparse vesiculobullous eruption in children and adolescents with a 2:1 male to female predominance (Canavan et al., 2015).", [["oral", "ANATOMY", 76, 80], ["MIRM", "DISEASE", 13, 17], ["conjunctivitis", "DISEASE", 37, 51], ["blepharitis", "DISEASE", 56, 67], ["oral mucositis", "DISEASE", 76, 90], ["hemorrhagic crusting", "DISEASE", 96, 116], ["vesiculobullous eruption", "DISEASE", 129, 153], ["oral", "ORGANISM_SUBDIVISION", 76, 80], ["children", "ORGANISM", 157, 165], ["children", "SPECIES", 157, 165], ["severe conjunctivitis", "PROBLEM", 30, 51], ["blepharitis", "PROBLEM", 56, 67], ["severe oral mucositis", "PROBLEM", 69, 90], ["hemorrhagic crusting", "PROBLEM", 96, 116], ["sparse vesiculobullous eruption", "PROBLEM", 122, 153], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["conjunctivitis", "OBSERVATION", 37, 51], ["blepharitis", "OBSERVATION", 56, 67], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["oral", "OBSERVATION_MODIFIER", 76, 80], ["mucositis", "OBSERVATION", 81, 90], ["hemorrhagic", "OBSERVATION_MODIFIER", 96, 107], ["crusting", "OBSERVATION", 108, 116], ["sparse", "OBSERVATION_MODIFIER", 122, 128], ["vesiculobullous", "OBSERVATION_MODIFIER", 129, 144], ["eruption", "OBSERVATION", 145, 153]]], ["To our knowledge, there are no reports in the literature of MIRM occurring during pregnancy.", [["MIRM", "DISEASE", 60, 64], ["MIRM", "CANCER", 60, 64]]], ["Care for MIRM patients involves supportive care including fluids, analgesia, and ophthalmology and urology evaluation (Canavan et al., 2015).Management Recommendations:To our knowledge, MIRM has not been reported in a pregnant patient or HCW.", [["MIRM", "DISEASE", 9, 13], ["patients", "ORGANISM", 14, 22], ["patient", "ORGANISM", 227, 234], ["patients", "SPECIES", 14, 22], ["patient", "SPECIES", 227, 234], ["supportive care", "TREATMENT", 32, 47], ["fluids", "TREATMENT", 58, 64], ["analgesia", "TREATMENT", 66, 75], ["urology evaluation", "TEST", 99, 117]]], ["We recommend dermatology consultation if HCW is symptomatic following exposure to patients with mycoplasma manifesting as MIRM, with close monitoring of symptom resolution.", [["mycoplasma", "DISEASE", 96, 106], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["symptomatic", "PROBLEM", 48, 59], ["mycoplasma", "PROBLEM", 96, 106], ["symptom resolution", "PROBLEM", 153, 171]]], ["Treatment should be similar to that for a non-pregnant patient with MIRM, which includes evaluation and monitoring by a physician, antibiotics, systemic corticosteroids, or rarely, intravenous immunoglobulin (IVIG) administration.Measles:The global incidence of measles has climbed in recent years.", [["intravenous", "ANATOMY", 181, 192], ["Measles", "DISEASE", 230, 237], ["measles", "DISEASE", 262, 269], ["patient", "ORGANISM", 55, 62], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 181, 207], ["IVIG", "SIMPLE_CHEMICAL", 209, 213], ["immunoglobulin", "PROTEIN", 193, 207], ["patient", "SPECIES", 55, 62], ["measles", "SPECIES", 262, 269], ["Treatment", "TREATMENT", 0, 9], ["evaluation", "TEST", 89, 99], ["monitoring", "TEST", 104, 114], ["antibiotics", "TREATMENT", 131, 142], ["systemic corticosteroids", "TREATMENT", 144, 168], ["intravenous immunoglobulin (IVIG)", "TREATMENT", 181, 214], ["measles", "PROBLEM", 262, 269], ["global", "OBSERVATION_MODIFIER", 242, 248], ["measles", "OBSERVATION", 262, 269]]], ["Sizeable outbreaks continue to occur around the world, largely due to decreased vaccination rates.", [["Sizeable outbreaks", "PROBLEM", 0, 18], ["decreased vaccination rates", "PROBLEM", 70, 97], ["outbreaks", "OBSERVATION", 9, 18]]], ["While the skin manifestations of measles are non-diagnostic, it is increasingly important that HCWs be able to recognize the disease.Measles:The clinical manifestations of measles virus infection classically begin with a prodrome characterized by fever, malaise, cough, coryza, and conjunctivitis.", [["skin", "ANATOMY", 10, 14], ["measles", "DISEASE", 33, 40], ["Measles", "DISEASE", 133, 140], ["measles virus infection", "DISEASE", 172, 195], ["fever", "DISEASE", 247, 252], ["cough", "DISEASE", 263, 268], ["coryza", "DISEASE", 270, 276], ["conjunctivitis", "DISEASE", 282, 296], ["skin", "ORGAN", 10, 14], ["measles", "ORGANISM", 33, 40], ["HCWs", "ORGANISM", 95, 99], ["measles virus", "ORGANISM", 172, 185], ["measles virus", "SPECIES", 172, 185], ["measles virus", "SPECIES", 172, 185], ["measles", "PROBLEM", 33, 40], ["the disease", "PROBLEM", 121, 132], ["measles virus infection", "PROBLEM", 172, 195], ["a prodrome", "PROBLEM", 219, 229], ["fever", "PROBLEM", 247, 252], ["malaise", "PROBLEM", 254, 261], ["cough", "PROBLEM", 263, 268], ["coryza", "PROBLEM", 270, 276], ["conjunctivitis", "PROBLEM", 282, 296], ["skin", "ANATOMY", 10, 14], ["disease", "OBSERVATION", 125, 132], ["fever", "OBSERVATION", 247, 252], ["coryza", "ANATOMY", 270, 276], ["conjunctivitis", "OBSERVATION", 282, 296]]], ["Koplik spots may appear during the prodromal phase.", [["Koplik spots", "PROBLEM", 0, 12]]], ["An erythematous, morbilliform exanthem appears approximately three to five days after the onset of symptoms with cranial to caudal progression.", [["morbilliform exanthem", "ANATOMY", 17, 38], ["cranial", "ANATOMY", 113, 120], ["caudal", "ANATOMY", 124, 130], ["exanthem", "DISEASE", 30, 38], ["exanthem", "CANCER", 30, 38], ["cranial", "ORGAN", 113, 120], ["caudal", "ORGANISM_SUBDIVISION", 124, 130], ["An erythematous, morbilliform exanthem", "PROBLEM", 0, 38], ["symptoms", "PROBLEM", 99, 107], ["cranial to caudal progression", "PROBLEM", 113, 142], ["erythematous", "OBSERVATION", 3, 15], ["cranial", "ANATOMY", 113, 120], ["caudal", "ANATOMY_MODIFIER", 124, 130], ["progression", "OBSERVATION", 131, 142]]], ["The patient is considered contagious from four days before and after the appearance of the rash.", [["rash", "DISEASE", 91, 95], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["contagious", "PROBLEM", 26, 36], ["the rash", "PROBLEM", 87, 95], ["contagious", "OBSERVATION_MODIFIER", 26, 36], ["rash", "OBSERVATION", 91, 95]]], ["Notably, exanthem may be absent in immunocompromised patients and pregnant women, making measles more difficult to recognize.Measles:Measles during pregnancy has been associated with increased risk of adverse maternal, fetal, and neonatal outcomes.", [["fetal", "ANATOMY", 219, 224], ["Measles", "DISEASE", 125, 132], ["Measles", "DISEASE", 133, 140], ["patients", "ORGANISM", 53, 61], ["women", "ORGANISM", 75, 80], ["fetal", "ANATOMICAL_SYSTEM", 219, 224], ["patients", "SPECIES", 53, 61], ["women", "SPECIES", 75, 80], ["exanthem", "PROBLEM", 9, 17], ["measles", "PROBLEM", 89, 96], ["adverse maternal, fetal, and neonatal outcomes", "PROBLEM", 201, 247], ["may be", "UNCERTAINTY", 18, 24], ["immunocompromised", "OBSERVATION", 35, 52]]], ["One retrospective cohort analysis of 55 pregnant women with measles in Namibia showed increased risks for low birth weight, spontaneous abortion, intrauterine fetal death, and maternal death when compared with pregnancies without measles (Ogbuanu et al., 2014).", [["intrauterine fetal", "ANATOMY", 146, 164], ["measles", "DISEASE", 60, 67], ["low birth weight", "DISEASE", 106, 122], ["spontaneous abortion", "DISEASE", 124, 144], ["intrauterine fetal death", "DISEASE", 146, 170], ["death", "DISEASE", 185, 190], ["measles", "DISEASE", 230, 237], ["women", "ORGANISM", 49, 54], ["fetal", "ORGANISM_SUBDIVISION", 159, 164], ["women", "SPECIES", 49, 54], ["One retrospective cohort analysis", "TEST", 0, 33], ["measles in Namibia", "PROBLEM", 60, 78], ["increased risks", "PROBLEM", 86, 101], ["low birth weight", "PROBLEM", 106, 122], ["spontaneous abortion", "PROBLEM", 124, 144], ["intrauterine fetal death", "PROBLEM", 146, 170], ["maternal death", "PROBLEM", 176, 190], ["pregnancies", "PROBLEM", 210, 221], ["measles", "PROBLEM", 230, 237]]], ["In this study, 71% of the women developed measles-related complications, including diarrhea (60%), pneumonia (40%), and encephalitis (5%).", [["measles", "DISEASE", 42, 49], ["diarrhea", "DISEASE", 83, 91], ["pneumonia", "DISEASE", 99, 108], ["encephalitis", "DISEASE", 120, 132], ["women", "ORGANISM", 26, 31], ["women", "SPECIES", 26, 31], ["this study", "TEST", 3, 13], ["measles-related complications", "PROBLEM", 42, 71], ["diarrhea", "PROBLEM", 83, 91], ["pneumonia", "PROBLEM", 99, 108], ["encephalitis", "PROBLEM", 120, 132], ["complications", "OBSERVATION", 58, 71], ["pneumonia", "OBSERVATION", 99, 108], ["encephalitis", "OBSERVATION", 120, 132]]], ["Of the pregnancies with known outcomes, 60% had at least one adverse outcome, including maternal death in 12% of cases.", [["death", "DISEASE", 97, 102], ["maternal death", "PROBLEM", 88, 102]]], ["Other studies comparing women with and without measles during pregnancy have shown increased frequency of prematurity, increased likelihood of neonatal intensive care unit admission, and longer intensive care unit stays among neonates born to mothers with gestational measles (Siegel and Fuerst, 1966; Ali and Albar, 1997).", [["measles", "DISEASE", 47, 54], ["prematurity", "DISEASE", 106, 117], ["gestational measles", "DISEASE", 256, 275], ["women", "ORGANISM", 24, 29], ["neonates", "ORGANISM", 226, 234], ["women", "SPECIES", 24, 29], ["Other studies", "TEST", 0, 13], ["measles during pregnancy", "PROBLEM", 47, 71], ["increased frequency of prematurity", "PROBLEM", 83, 117], ["gestational measles", "PROBLEM", 256, 275], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["prematurity", "OBSERVATION", 106, 117], ["increased", "OBSERVATION_MODIFIER", 119, 128]]], ["The rate of congenital defects does not appear to be higher among neonates born to mothers with measles than to uninfected mothers (Siegel, 1973; Ali and Albar, 1997).", [["congenital defects", "DISEASE", 12, 30], ["measles", "DISEASE", 96, 103], ["neonates", "ORGANISM", 66, 74], ["congenital defects", "PROBLEM", 12, 30], ["congenital", "OBSERVATION_MODIFIER", 12, 22], ["defects", "OBSERVATION", 23, 30], ["does not appear to be", "UNCERTAINTY", 31, 52], ["higher", "OBSERVATION_MODIFIER", 53, 59]]], ["However, congenital measles can occur, with the severity ranging from mild to fatal (Gershon 2006).", [["congenital measles", "DISEASE", 9, 27], ["congenital measles", "PROBLEM", 9, 27], ["the severity", "PROBLEM", 44, 56], ["congenital", "OBSERVATION_MODIFIER", 9, 19], ["measles", "OBSERVATION", 20, 27], ["mild", "OBSERVATION_MODIFIER", 70, 74], ["fatal", "OBSERVATION_MODIFIER", 78, 83]]], ["Congenital measles has been reported among neonates born to women who had measles within 10 days of delivery (Charlier et al., 2015).", [["Congenital measles", "DISEASE", 0, 18], ["measles", "DISEASE", 74, 81], ["neonates", "ORGANISM", 43, 51], ["women", "ORGANISM", 60, 65], ["women", "SPECIES", 60, 65], ["Congenital measles", "PROBLEM", 0, 18], ["delivery", "TREATMENT", 100, 108]]], ["Measles is highly contagious, with up to 90% of susceptible individuals becoming infected upon exposure (McLean et al., 2013).", [["Measles", "DISEASE", 0, 7], ["individuals", "ORGANISM", 60, 71], ["Measles", "PROBLEM", 0, 7], ["susceptible individuals", "PROBLEM", 48, 71], ["highly", "OBSERVATION_MODIFIER", 11, 17], ["contagious", "OBSERVATION_MODIFIER", 18, 28], ["infected", "OBSERVATION", 81, 89]]], ["HCWs are at higher risk of being exposed to, and subsequently developing, measles than the general adult population (Shefer et al., 2011).Management Recommendations:All HCWs should provide evidence of immunity to measles prior to employment, and non-pregnant HCWs should receive the measles, mumps and rubella (MMR) vaccine in the absence of such evidence (Bolyard et al., 1998, Siegel et al., 2007; McLean et al., 2013).", [["measles", "DISEASE", 74, 81], ["measles", "DISEASE", 213, 220], ["measles, mumps and rubella", "DISEASE", 283, 309], ["HCWs", "ORGANISM", 0, 4], ["HCWs", "ORGANISM", 259, 263], ["the measles", "PROBLEM", 279, 290], ["mumps", "PROBLEM", 292, 297], ["rubella (MMR) vaccine", "TREATMENT", 302, 323]]], ["Women should avoid becoming pregnant for four weeks following vaccination (McLean et al., 2013).", [["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5]]], ["MMR vaccine is contraindicated during pregnancy due to the theoretical risk of live vaccines to the fetus, though inadvertent MMR vaccination during pregnancy has not been associated with an increased risk of adverse outcomes and is not an indication for pregnancy termination (Bar-Oz et al., 2004).", [["fetus", "ANATOMY", 100, 105], ["fetus", "ORGAN", 100, 105], ["MMR vaccine", "TREATMENT", 0, 11], ["live vaccines", "TREATMENT", 79, 92], ["inadvertent MMR vaccination", "PROBLEM", 114, 141], ["pregnancy termination", "PROBLEM", 255, 276], ["fetus", "ANATOMY", 100, 105]]], ["Close contacts of pregnant women should ensure their MMR titers are sufficient or receive an MMR vaccination or booster.Management Recommendations:Pregnant HCWs without evidence of measles immunity (seronegative), like all susceptible HCWs, should not enter the rooms of patients with known or suspected measles (Siegel et al., 2007).", [["measles immunity", "DISEASE", 181, 197], ["measles", "DISEASE", 304, 311], ["women", "ORGANISM", 27, 32], ["HCWs", "ORGANISM", 156, 160], ["patients", "ORGANISM", 271, 279], ["women", "SPECIES", 27, 32], ["patients", "SPECIES", 271, 279], ["an MMR vaccination", "TREATMENT", 90, 108], ["measles immunity", "PROBLEM", 181, 197]]], ["If exposed to measles, nonimmune pregnant women should receive intravenous immunoglobulin (IVIG) treatment within 6 days of exposure (Siegel et al., 2007).", [["intravenous", "ANATOMY", 63, 74], ["measles", "DISEASE", 14, 21], ["women", "ORGANISM", 42, 47], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 74], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 75, 89], ["IVIG", "SIMPLE_CHEMICAL", 91, 95], ["immunoglobulin", "PROTEIN", 75, 89], ["women", "SPECIES", 42, 47], ["measles", "PROBLEM", 14, 21], ["intravenous immunoglobulin (IVIG) treatment", "TREATMENT", 63, 106]]], ["Any exposed HCW without evidence of immunity should be excluded from the healthcare setting from the 5th through 21st days after exposure (Bolyard et al., 1998; Shefer et al., 2011).", [["without evidence of", "UNCERTAINTY", 16, 35], ["immunity", "OBSERVATION", 36, 44]]], ["If immune, pregnant HCWs may care for measles patients and should follow airborne and standard precautions, with respiratory protection at least as protective as a fit-tested N95 respirator (Bolyard et al., 1998, Siegel et al., 2007; Shefer et al., 2011).Herpes simplex virus:Clinical manifestations of herpes simplex virus (HSV) infection vary widely.", [["measles", "DISEASE", 38, 45], ["Herpes simplex virus", "DISEASE", 255, 275], ["herpes simplex virus (HSV) infection", "DISEASE", 303, 339], ["HCWs", "ORGANISM", 20, 24], ["patients", "ORGANISM", 46, 54], ["Herpes simplex virus", "ORGANISM", 255, 275], ["herpes simplex virus", "ORGANISM", 303, 323], ["HSV", "ORGANISM", 325, 328], ["patients", "SPECIES", 46, 54], ["Herpes simplex virus", "SPECIES", 255, 275], ["herpes simplex virus", "SPECIES", 303, 323], ["Herpes simplex virus", "SPECIES", 255, 275], ["herpes simplex virus", "SPECIES", 303, 323], ["HSV", "SPECIES", 325, 328], ["standard precautions", "TREATMENT", 86, 106], ["respiratory protection", "TREATMENT", 113, 135], ["Herpes simplex virus", "PROBLEM", 255, 275], ["herpes simplex virus (HSV) infection", "PROBLEM", 303, 339], ["simplex virus", "OBSERVATION", 262, 275], ["herpes simplex virus", "OBSERVATION", 303, 323], ["infection", "OBSERVATION", 330, 339]]], ["HSV-1 typically causes orofacial infection, while HSV-2 is predominantly responsible for genital herpes.", [["orofacial", "ANATOMY", 23, 32], ["genital", "ANATOMY", 89, 96], ["orofacial infection", "DISEASE", 23, 42], ["genital herpes", "DISEASE", 89, 103], ["HSV-1", "ORGANISM", 0, 5], ["orofacial", "ORGAN", 23, 32], ["HSV-2", "ORGANISM", 50, 55], ["genital herpes", "ORGANISM", 89, 103], ["HSV-1", "SPECIES", 0, 5], ["HSV-2", "SPECIES", 50, 55], ["HSV-1", "SPECIES", 0, 5], ["HSV-2", "SPECIES", 50, 55], ["HSV", "TEST", 0, 3], ["orofacial infection", "PROBLEM", 23, 42], ["HSV", "TEST", 50, 53], ["genital herpes", "PROBLEM", 89, 103], ["orofacial", "ANATOMY", 23, 32], ["infection", "OBSERVATION", 33, 42], ["predominantly responsible for", "UNCERTAINTY", 59, 88], ["genital", "ANATOMY", 89, 96], ["herpes", "OBSERVATION", 97, 103]]], ["However, each viral subtype can affect either anatomic location.", [["viral subtype", "OBSERVATION", 14, 27]]], ["Genital herpes is of concern to pregnant women given the risk of vertical transmission and the morbidity and mortality associated with congenital and neonatal infection.", [["Genital herpes", "DISEASE", 0, 14], ["congenital and neonatal infection", "DISEASE", 135, 168], ["Genital herpes", "ORGANISM", 0, 14], ["women", "ORGANISM", 41, 46], ["women", "SPECIES", 41, 46], ["Genital herpes", "PROBLEM", 0, 14], ["vertical transmission", "PROBLEM", 65, 86], ["the morbidity", "PROBLEM", 91, 104], ["congenital and neonatal infection", "PROBLEM", 135, 168], ["herpes", "OBSERVATION", 8, 14], ["congenital", "OBSERVATION", 135, 145], ["neonatal", "OBSERVATION_MODIFIER", 150, 158], ["infection", "OBSERVATION", 159, 168]]], ["When symptomatic, genital herpes presents as painful, pruritic vesicles and ulcers, which may be accompanied by headache, fever, dysuria, and tender inguinal lymphadenopathy.", [["genital", "ANATOMY", 18, 25], ["pruritic vesicles", "ANATOMY", 54, 71], ["ulcers", "ANATOMY", 76, 82], ["tender inguinal lymphadenopathy", "ANATOMY", 142, 173], ["genital herpes", "DISEASE", 18, 32], ["ulcers", "DISEASE", 76, 82], ["headache", "DISEASE", 112, 120], ["fever", "DISEASE", 122, 127], ["dysuria", "DISEASE", 129, 136], ["inguinal lymphadenopathy", "DISEASE", 149, 173], ["genital herpes", "ORGANISM", 18, 32], ["ulcers", "PATHOLOGICAL_FORMATION", 76, 82], ["symptomatic", "PROBLEM", 5, 16], ["genital herpes", "PROBLEM", 18, 32], ["painful", "PROBLEM", 45, 52], ["pruritic vesicles", "PROBLEM", 54, 71], ["ulcers", "PROBLEM", 76, 82], ["headache", "PROBLEM", 112, 120], ["fever", "PROBLEM", 122, 127], ["dysuria", "PROBLEM", 129, 136], ["tender inguinal lymphadenopathy", "PROBLEM", 142, 173], ["genital", "ANATOMY", 18, 25], ["herpes", "OBSERVATION", 26, 32], ["pruritic", "OBSERVATION_MODIFIER", 54, 62], ["ulcers", "OBSERVATION", 76, 82], ["headache", "OBSERVATION", 112, 120], ["dysuria", "OBSERVATION", 129, 136], ["tender", "OBSERVATION_MODIFIER", 142, 148], ["inguinal", "ANATOMY", 149, 157], ["lymphadenopathy", "OBSERVATION", 158, 173]]], ["Recurrences are typically milder than primary infection, and even primary infection may be subclinical.Herpes simplex virus:Data suggest that at least two percent of susceptible women in the U.S. acquire HSV during pregnancy (Brown et al., 1997).", [["primary infection", "DISEASE", 38, 55], ["primary infection", "DISEASE", 66, 83], ["Herpes simplex virus", "DISEASE", 103, 123], ["Herpes simplex virus", "ORGANISM", 103, 123], ["women", "ORGANISM", 178, 183], ["HSV", "ORGANISM", 204, 207], ["Herpes simplex virus", "SPECIES", 103, 123], ["women", "SPECIES", 178, 183], ["Herpes simplex virus", "SPECIES", 103, 123], ["HSV", "SPECIES", 204, 207], ["Recurrences", "PROBLEM", 0, 11], ["primary infection", "PROBLEM", 38, 55], ["primary infection", "PROBLEM", 66, 83], ["Herpes simplex virus", "PROBLEM", 103, 123], ["HSV during pregnancy", "PROBLEM", 204, 224], ["milder", "OBSERVATION_MODIFIER", 26, 32], ["primary", "OBSERVATION_MODIFIER", 38, 45], ["infection", "OBSERVATION", 46, 55], ["primary", "OBSERVATION_MODIFIER", 66, 73], ["infection", "OBSERVATION", 74, 83], ["may be", "UNCERTAINTY", 84, 90], ["subclinical", "OBSERVATION_MODIFIER", 91, 102], ["simplex virus", "OBSERVATION", 110, 123]]], ["Primary HSV infection during pregnancy may rarely lead to life-threatening disseminated disease (Young et al., 1996; Sappenfield et al., 2013), but the greatest risk is vertical transmission.", [["HSV infection", "DISEASE", 8, 21], ["HSV", "ORGANISM", 8, 11], ["HSV", "SPECIES", 8, 11], ["Primary HSV infection", "PROBLEM", 0, 21], ["life-threatening disseminated disease", "PROBLEM", 58, 95], ["HSV", "OBSERVATION_MODIFIER", 8, 11], ["infection", "OBSERVATION", 12, 21], ["threatening", "OBSERVATION_MODIFIER", 63, 74], ["disseminated", "OBSERVATION", 75, 87], ["vertical transmission", "OBSERVATION", 169, 190]]], ["Intrauterine infection is rare, but its occurrence is associated with severe neurological, ophthalmologic, and cutaneous manifestations, as well as a high risk of intrauterine or postnatal death (Marquez et al., 2011).", [["Intrauterine", "ANATOMY", 0, 12], ["neurological", "ANATOMY", 77, 89], ["cutaneous", "ANATOMY", 111, 120], ["intrauterine", "ANATOMY", 163, 175], ["Intrauterine infection", "DISEASE", 0, 22], ["intrauterine or postnatal death", "DISEASE", 163, 194], ["Intrauterine infection", "PROBLEM", 0, 22], ["severe neurological, ophthalmologic, and cutaneous manifestations", "PROBLEM", 70, 135], ["intrauterine or postnatal death", "PROBLEM", 163, 194], ["infection", "OBSERVATION", 13, 22], ["associated with", "UNCERTAINTY", 54, 69], ["severe", "OBSERVATION_MODIFIER", 70, 76]]], ["More commonly, transmission of HSV to the child is due to contact with virus shed from the genital or perianal region during labor and delivery.", [["genital", "ANATOMY", 91, 98], ["perianal region", "ANATOMY", 102, 117], ["HSV", "ORGANISM", 31, 34], ["child", "ORGANISM", 42, 47], ["genital", "ORGANISM_SUBDIVISION", 91, 98], ["child", "SPECIES", 42, 47], ["HSV", "SPECIES", 31, 34], ["HSV", "PROBLEM", 31, 34], ["contact with virus", "PROBLEM", 58, 76], ["labor", "PROBLEM", 125, 130], ["delivery", "TREATMENT", 135, 143], ["genital", "ANATOMY", 91, 98], ["perianal", "ANATOMY", 102, 110]]], ["50% to 80% of cases of neonatal HSV infection occur when genital HSV-1 or HSV-2 infection is acquired near term (Brown et al., 1997; Sullender et al., 1988).", [["HSV infection", "DISEASE", 32, 45], ["infection", "DISEASE", 80, 89], ["HSV", "ORGANISM", 32, 35], ["genital HSV-1", "ORGANISM", 57, 70], ["HSV-2", "ORGANISM", 74, 79], ["HSV-1", "SPECIES", 65, 70], ["HSV-2", "SPECIES", 74, 79], ["HSV", "SPECIES", 32, 35], ["HSV-1", "SPECIES", 65, 70], ["HSV-2", "SPECIES", 74, 79], ["neonatal HSV infection", "PROBLEM", 23, 45], ["genital HSV", "TEST", 57, 68], ["HSV", "PROBLEM", 74, 77], ["2 infection", "PROBLEM", 78, 89], ["infection", "OBSERVATION", 36, 45], ["infection", "OBSERVATION", 80, 89]]], ["The risk is greatest when HSV is acquired within six weeks of delivery, when there is insufficient time for transplacental delivery of maternal antibodies (Brown et al., 1997).", [["HSV", "ORGANISM", 26, 29], ["maternal antibodies", "PROTEIN", 135, 154], ["HSV", "SPECIES", 26, 29], ["HSV", "PROBLEM", 26, 29], ["delivery", "TREATMENT", 62, 70], ["transplacental delivery of maternal antibodies", "TREATMENT", 108, 154]]], ["Transmission to the neonate is far less frequent among women who acquire genital herpes during early pregnancy or with histories of recurrent herpes, even if lesions are present at the time of delivery (Prober et al., 1987; Foley et al., 2014).", [["lesions", "ANATOMY", 158, 165], ["genital herpes", "DISEASE", 73, 87], ["herpes", "DISEASE", 142, 148], ["neonate", "ORGANISM", 20, 27], ["women", "ORGANISM", 55, 60], ["genital herpes", "ORGANISM", 73, 87], ["herpes", "ORGANISM", 142, 148], ["lesions", "PATHOLOGICAL_FORMATION", 158, 165], ["women", "SPECIES", 55, 60], ["genital herpes", "PROBLEM", 73, 87], ["recurrent herpes", "PROBLEM", 132, 148], ["lesions", "PROBLEM", 158, 165], ["herpes", "OBSERVATION", 142, 148]]], ["Women with a history of HSV should be offered daily suppressive acyclovir or valacyclovir starting at 36 weeks\u2019 gestation to reduce the likelihood of clinical lesions and viral shedding at delivery (Money and Steben, 2017).", [["lesions", "ANATOMY", 159, 166], ["acyclovir", "CHEMICAL", 64, 73], ["valacyclovir", "CHEMICAL", 77, 89], ["acyclovir", "CHEMICAL", 64, 73], ["valacyclovir", "CHEMICAL", 77, 89], ["Women", "ORGANISM", 0, 5], ["HSV", "ORGANISM", 24, 27], ["acyclovir", "SIMPLE_CHEMICAL", 64, 73], ["valacyclovir", "SIMPLE_CHEMICAL", 77, 89], ["lesions", "PATHOLOGICAL_FORMATION", 159, 166], ["Women", "SPECIES", 0, 5], ["HSV", "SPECIES", 24, 27], ["HSV", "PROBLEM", 24, 27], ["suppressive acyclovir", "TREATMENT", 52, 73], ["valacyclovir", "TREATMENT", 77, 89], ["clinical lesions", "PROBLEM", 150, 166], ["viral shedding at delivery", "PROBLEM", 171, 197], ["lesions", "OBSERVATION", 159, 166]]], ["Caesarean section is recommended for women with primary genital herpes during the third trimester and for women with histories of genital HSV and either active lesions or prodromal symptoms at the time of labor (Money and Steben, 2017; Foley et al., 2014).", [["lesions", "ANATOMY", 160, 167], ["primary genital herpes", "DISEASE", 48, 70], ["genital HSV", "DISEASE", 130, 141], ["women", "ORGANISM", 37, 42], ["genital herpes", "ORGANISM", 56, 70], ["women", "ORGANISM", 106, 111], ["genital HSV", "ORGANISM", 130, 141], ["lesions", "PATHOLOGICAL_FORMATION", 160, 167], ["women", "SPECIES", 37, 42], ["women", "SPECIES", 106, 111], ["HSV", "SPECIES", 138, 141], ["Caesarean section", "TREATMENT", 0, 17], ["primary genital herpes", "PROBLEM", 48, 70], ["genital HSV", "PROBLEM", 130, 141], ["active lesions", "PROBLEM", 153, 167], ["prodromal symptoms", "PROBLEM", 171, 189], ["Foley", "TREATMENT", 236, 241], ["genital HSV", "ANATOMY", 130, 141], ["active", "OBSERVATION_MODIFIER", 153, 159], ["lesions", "OBSERVATION", 160, 167]]], ["Pregnant women should take appropriate precautions to avoid acquiring genital HSV, especially during the third trimester.Management Recommendations:Occupational acquisition of HSV during pregnancy is unlikely due to low rates of nosocomial HSV transmission, although contact with infectious lesions or secretions can lead to the development of herpetic whitlow.", [["lesions", "ANATOMY", 291, 298], ["secretions", "ANATOMY", 302, 312], ["nosocomial HSV transmission", "DISEASE", 229, 256], ["infectious lesions", "DISEASE", 280, 298], ["women", "ORGANISM", 9, 14], ["genital HSV", "ORGANISM", 70, 81], ["HSV", "ORGANISM", 176, 179], ["HSV", "ORGANISM", 240, 243], ["infectious lesions", "PATHOLOGICAL_FORMATION", 280, 298], ["women", "SPECIES", 9, 14], ["HSV", "SPECIES", 78, 81], ["HSV", "SPECIES", 176, 179], ["HSV", "SPECIES", 240, 243], ["appropriate precautions", "TREATMENT", 27, 50], ["acquiring genital HSV", "PROBLEM", 60, 81], ["HSV during pregnancy", "PROBLEM", 176, 196], ["nosocomial HSV transmission", "PROBLEM", 229, 256], ["infectious lesions", "PROBLEM", 280, 298], ["secretions", "PROBLEM", 302, 312], ["herpetic whitlow", "PROBLEM", 344, 360], ["herpetic", "OBSERVATION", 344, 352]]], ["HCWs who are pregnant or of childbearing age should be counseled on the risks of HSV acquisition during pregnancy, which may pose a danger to the fetus.", [["fetus", "ANATOMY", 146, 151], ["HCWs", "ORGANISM", 0, 4], ["HSV", "ORGANISM", 81, 84], ["fetus", "ORGAN", 146, 151], ["HSV", "SPECIES", 81, 84], ["HSV acquisition", "TEST", 81, 96]]], ["However, HCWs should not be routinely excluded from caring for patients with HSV solely on the basis of their pregnancy or intent to become pregnant (Bolyard et al., 1998).", [["patients", "ORGANISM", 63, 71], ["HSV", "ORGANISM", 77, 80], ["patients", "SPECIES", 63, 71], ["HSV", "SPECIES", 77, 80], ["HSV", "PROBLEM", 77, 80]]], ["Non-genital herpes poses minimal risk to the fetus given the low rate of intrauterine infection, and transmission of genital herpes is not an occupational concern as it requires sexual contact.", [["fetus", "ANATOMY", 45, 50], ["intrauterine", "ANATOMY", 73, 85], ["Non-genital herpes", "DISEASE", 0, 18], ["intrauterine infection", "DISEASE", 73, 95], ["genital herpes", "DISEASE", 117, 131], ["herpes", "ORGANISM", 12, 18], ["fetus", "ORGAN", 45, 50], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 73, 85], ["genital herpes", "ORGANISM", 117, 131], ["Non-genital herpes", "PROBLEM", 0, 18], ["the fetus", "PROBLEM", 41, 50], ["intrauterine infection", "PROBLEM", 73, 95], ["genital herpes", "PROBLEM", 117, 131], ["herpes", "OBSERVATION", 12, 18], ["infection", "OBSERVATION", 86, 95]]], ["All HCWs should follow standard precautions when caring for patients with HSV infection, and additional contact precautions are advised in certain high-risk cases, such as if the HCW is immunocompromised or if the patient has severe, disseminated HSV (Bolyard et al., 1998, Siegel et al., 2007).Varicella zoster virus:Varicella zoster virus (VZV) is responsible for varicella (chickenpox) during primary infection and herpes zoster (shingles) upon reactivation.", [["HSV infection", "DISEASE", 74, 87], ["HSV", "DISEASE", 247, 250], ["Varicella zoster", "DISEASE", 295, 311], ["Varicella zoster", "DISEASE", 318, 334], ["VZV", "DISEASE", 342, 345], ["varicella", "DISEASE", 366, 375], ["chickenpox", "DISEASE", 377, 387], ["primary infection", "DISEASE", 396, 413], ["herpes zoster", "DISEASE", 418, 431], ["shingles", "DISEASE", 433, 441], ["patients", "ORGANISM", 60, 68], ["HSV", "ORGANISM", 74, 77], ["patient", "ORGANISM", 214, 221], ["HSV", "ORGANISM", 247, 250], ["Varicella zoster virus", "ORGANISM", 295, 317], ["Varicella zoster virus", "ORGANISM", 318, 340], ["VZV", "ORGANISM", 342, 345], ["herpes zoster", "ORGANISM", 418, 431], ["patients", "SPECIES", 60, 68], ["patient", "SPECIES", 214, 221], ["Varicella zoster virus", "SPECIES", 295, 317], ["Varicella zoster virus", "SPECIES", 318, 340], ["herpes zoster", "SPECIES", 418, 431], ["HSV", "SPECIES", 74, 77], ["HSV", "SPECIES", 247, 250], ["Varicella zoster virus", "SPECIES", 295, 317], ["Varicella zoster virus", "SPECIES", 318, 340], ["VZV", "SPECIES", 342, 345], ["standard precautions", "TREATMENT", 23, 43], ["HSV infection", "PROBLEM", 74, 87], ["contact precautions", "TREATMENT", 104, 123], ["immunocompromised", "PROBLEM", 186, 203], ["severe, disseminated HSV", "PROBLEM", 226, 250], ["Varicella zoster virus", "PROBLEM", 295, 317], ["Varicella zoster virus", "PROBLEM", 318, 340], ["VZV", "PROBLEM", 342, 345], ["varicella (chickenpox", "PROBLEM", 366, 387], ["primary infection", "PROBLEM", 396, 413], ["herpes zoster", "PROBLEM", 418, 431], ["shingles", "PROBLEM", 433, 441], ["infection", "OBSERVATION", 78, 87], ["immunocompromised", "OBSERVATION", 186, 203], ["severe", "OBSERVATION_MODIFIER", 226, 232], ["disseminated", "OBSERVATION_MODIFIER", 234, 246], ["HSV", "OBSERVATION", 247, 250], ["zoster virus", "OBSERVATION", 305, 317], ["Varicella zoster virus", "OBSERVATION", 318, 340], ["responsible for", "UNCERTAINTY", 350, 365], ["infection", "OBSERVATION", 404, 413]]], ["Varicella is typically a mild disease in children, presenting as a diffuse vesicular rash.", [["vesicular", "ANATOMY", 75, 84], ["Varicella", "DISEASE", 0, 9], ["vesicular rash", "DISEASE", 75, 89], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["Varicella", "PROBLEM", 0, 9], ["a mild disease in children", "PROBLEM", 23, 49], ["a diffuse vesicular rash", "PROBLEM", 65, 89], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["disease", "OBSERVATION", 30, 37], ["diffuse", "OBSERVATION_MODIFIER", 67, 74], ["vesicular rash", "OBSERVATION", 75, 89]]], ["The rash is often pruritic and consists of lesions at different stages of development.", [["lesions", "ANATOMY", 43, 50], ["rash", "DISEASE", 4, 8], ["pruritic", "DISEASE", 18, 26], ["lesions", "PATHOLOGICAL_FORMATION", 43, 50], ["The rash", "PROBLEM", 0, 8], ["pruritic", "PROBLEM", 18, 26], ["lesions", "PROBLEM", 43, 50], ["rash", "OBSERVATION", 4, 8], ["pruritic", "OBSERVATION_MODIFIER", 18, 26], ["lesions", "OBSERVATION", 43, 50], ["different stages", "OBSERVATION_MODIFIER", 54, 70]]], ["A prodrome of fever, malaise, and myalgia may precede the exanthem.", [["fever", "DISEASE", 14, 19], ["malaise", "DISEASE", 21, 28], ["myalgia", "DISEASE", 34, 41], ["exanthem", "DISEASE", 58, 66], ["exanthem", "CANCER", 58, 66], ["fever", "PROBLEM", 14, 19], ["malaise", "PROBLEM", 21, 28], ["myalgia", "PROBLEM", 34, 41], ["the exanthem", "PROBLEM", 54, 66], ["fever", "OBSERVATION", 14, 19], ["malaise", "OBSERVATION", 21, 28], ["myalgia", "OBSERVATION", 34, 41]]], ["Primary infection is associated with higher morbidity and mortality when it occurs during adulthood, especially in immunocompromised patients and pregnant women.", [["Primary infection", "DISEASE", 0, 17], ["patients", "ORGANISM", 133, 141], ["women", "ORGANISM", 155, 160], ["patients", "SPECIES", 133, 141], ["women", "SPECIES", 155, 160], ["Primary infection", "PROBLEM", 0, 17], ["higher morbidity", "PROBLEM", 37, 53], ["infection", "OBSERVATION", 8, 17], ["higher", "OBSERVATION_MODIFIER", 37, 43], ["morbidity", "OBSERVATION", 44, 53]]], ["Varicella during pregnancy poses additional risks to the neonate.", [["Varicella", "DISEASE", 0, 9], ["neonate", "ORGANISM", 57, 64], ["Varicella during pregnancy", "PROBLEM", 0, 26]]], ["Herpes zoster typically manifests as a painful and unilateral maculopapular rash whose lesions follow a dermatomal distribution, evolving into vesicles that eventually crust within seven to ten days.", [["lesions", "ANATOMY", 87, 94], ["dermatomal", "ANATOMY", 104, 114], ["vesicles", "ANATOMY", 143, 151], ["Herpes zoster", "DISEASE", 0, 13], ["rash", "DISEASE", 76, 80], ["Herpes zoster", "ORGANISM", 0, 13], ["lesions", "PATHOLOGICAL_FORMATION", 87, 94], ["vesicles", "CELLULAR_COMPONENT", 143, 151], ["Herpes zoster", "SPECIES", 0, 13], ["Herpes zoster", "PROBLEM", 0, 13], ["a painful", "PROBLEM", 37, 46], ["unilateral maculopapular rash whose lesions", "PROBLEM", 51, 94], ["a dermatomal distribution", "PROBLEM", 102, 127], ["zoster", "OBSERVATION", 7, 13], ["painful", "OBSERVATION_MODIFIER", 39, 46], ["unilateral", "OBSERVATION_MODIFIER", 51, 61], ["maculopapular", "OBSERVATION_MODIFIER", 62, 75], ["rash", "OBSERVATION", 76, 80], ["lesions", "OBSERVATION", 87, 94], ["dermatomal distribution", "OBSERVATION_MODIFIER", 104, 127], ["vesicles", "ANATOMY", 143, 151], ["crust", "OBSERVATION_MODIFIER", 168, 173]]], ["Herpes zoster during pregnancy is not associated with birth defects or disease in the infant (Enders et al., 1994; Smith and Arvin, 2009).Varicella zoster virus:Varicella is highly contagious.", [["Herpes zoster", "DISEASE", 0, 13], ["birth defects", "DISEASE", 54, 67], ["Varicella zoster", "DISEASE", 138, 154], ["Varicella", "DISEASE", 161, 170], ["Herpes zoster", "ORGANISM", 0, 13], ["Varicella zoster virus", "ORGANISM", 138, 160], ["Varicella", "ORGANISM", 161, 170], ["Herpes zoster", "SPECIES", 0, 13], ["infant", "SPECIES", 86, 92], ["Varicella zoster virus", "SPECIES", 138, 160], ["Varicella zoster virus", "SPECIES", 138, 160], ["Herpes zoster", "PROBLEM", 0, 13], ["birth defects", "PROBLEM", 54, 67], ["disease in the infant", "PROBLEM", 71, 92], ["Varicella zoster virus", "PROBLEM", 138, 160], ["Varicella", "PROBLEM", 161, 170], ["zoster", "OBSERVATION", 7, 13], ["not associated with", "UNCERTAINTY", 34, 53], ["defects", "OBSERVATION", 60, 67], ["disease", "OBSERVATION", 71, 78], ["zoster virus", "OBSERVATION", 148, 160], ["Varicella", "OBSERVATION", 161, 170], ["highly", "OBSERVATION_MODIFIER", 174, 180], ["contagious", "OBSERVATION_MODIFIER", 181, 191]]], ["Patients are considered infectious from 48 hours prior to the onset of rash until the skin lesions have fully crusted.", [["skin lesions", "ANATOMY", 86, 98], ["rash", "DISEASE", 71, 75], ["Patients", "ORGANISM", 0, 8], ["skin lesions", "PATHOLOGICAL_FORMATION", 86, 98], ["Patients", "SPECIES", 0, 8], ["infectious", "PROBLEM", 24, 34], ["rash", "PROBLEM", 71, 75], ["the skin lesions", "PROBLEM", 82, 98], ["fully crusted", "PROBLEM", 104, 117], ["infectious", "OBSERVATION_MODIFIER", 24, 34], ["rash", "OBSERVATION", 71, 75], ["skin", "ANATOMY", 86, 90], ["lesions", "OBSERVATION", 91, 98], ["crusted", "OBSERVATION", 110, 117]]], ["The incidence of varicella is not thought to be higher among pregnant women than nonpregnant adults, and previous reports of greater severity have not been supported by recent studies (Sappenfield et al., 2013).", [["varicella", "DISEASE", 17, 26], ["women", "ORGANISM", 70, 75], ["women", "SPECIES", 70, 75], ["varicella", "PROBLEM", 17, 26], ["varicella", "OBSERVATION", 17, 26], ["not thought to be", "UNCERTAINTY", 30, 47], ["higher", "OBSERVATION_MODIFIER", 48, 54]]], ["The incidence of VZV infection in pregnancy has been estimated at 0.7 to 3 per 1,000 pregnancies (Miller et al., 1993; Sever and White, 1968).", [["VZV infection", "DISEASE", 17, 30], ["VZV", "ORGANISM", 17, 20], ["VZV", "SPECIES", 17, 20], ["VZV infection", "PROBLEM", 17, 30], ["VZV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 21, 30]]], ["Varicella pneumonia is considered the most significant complication of varicella during pregnancy, though a recent large cohort study found the incidence (2.5%) and maternal mortality (0%) to be lower than previously estimated (Zhang et al., 2015).Varicella zoster virus:Transmission of VZV to the fetus can occur in utero, perinatally, or postnatally (Enright and Prober, 2004).", [["fetus", "ANATOMY", 298, 303], ["Varicella pneumonia", "DISEASE", 0, 19], ["varicella", "DISEASE", 71, 80], ["Varicella zoster", "DISEASE", 248, 264], ["VZV to the fetus", "DISEASE", 287, 303], ["Varicella zoster virus", "ORGANISM", 248, 270], ["VZV", "ORGANISM", 287, 290], ["fetus", "ORGAN", 298, 303], ["utero", "ORGAN", 317, 322], ["Varicella zoster virus", "SPECIES", 248, 270], ["Varicella zoster virus", "SPECIES", 248, 270], ["VZV", "SPECIES", 287, 290], ["Varicella pneumonia", "PROBLEM", 0, 19], ["varicella during pregnancy", "PROBLEM", 71, 97], ["a recent large cohort study", "TEST", 106, 133], ["maternal mortality", "PROBLEM", 165, 183], ["Varicella zoster virus", "PROBLEM", 248, 270], ["VZV", "PROBLEM", 287, 290], ["pneumonia", "OBSERVATION", 10, 19], ["most significant", "OBSERVATION_MODIFIER", 38, 54], ["complication", "OBSERVATION", 55, 67], ["varicella", "OBSERVATION", 71, 80], ["large", "OBSERVATION_MODIFIER", 115, 120], ["zoster virus", "OBSERVATION", 258, 270]]], ["Maternal varicella infection during early pregnancy introduces the risk of fetal varicella syndrome (FVS), with the greatest risk (2%) when infection occurs between 13 and 20 weeks of gestation (Enders et al., 1994; Harger et al., 2002; Pastuszak et al., 1994).", [["fetal", "ANATOMY", 75, 80], ["varicella infection", "DISEASE", 9, 28], ["fetal varicella syndrome", "DISEASE", 75, 99], ["FVS", "DISEASE", 101, 104], ["infection", "DISEASE", 140, 149], ["fetal", "ORGANISM_SUBDIVISION", 75, 80], ["Maternal varicella infection", "PROBLEM", 0, 28], ["early pregnancy", "PROBLEM", 36, 51], ["fetal varicella syndrome", "PROBLEM", 75, 99], ["infection", "PROBLEM", 140, 149], ["varicella", "OBSERVATION_MODIFIER", 9, 18], ["infection", "OBSERVATION", 19, 28], ["fetal", "ANATOMY", 75, 80], ["varicella syndrome", "OBSERVATION", 81, 99]]], ["Characteristic findings in FVS include cutaneous scars in a dermatomal distribution, low birth weight, neurological abnormalities, ocular defects, and limb deformities.", [["cutaneous scars", "ANATOMY", 39, 54], ["dermatomal", "ANATOMY", 60, 70], ["neurological", "ANATOMY", 103, 115], ["ocular", "ANATOMY", 131, 137], ["limb", "ANATOMY", 151, 155], ["FVS", "DISEASE", 27, 30], ["birth weight", "DISEASE", 89, 101], ["neurological abnormalities", "DISEASE", 103, 129], ["ocular defects", "DISEASE", 131, 145], ["limb deformities", "DISEASE", 151, 167], ["FVS", "CANCER", 27, 30], ["cutaneous scars", "PATHOLOGICAL_FORMATION", 39, 54], ["ocular", "ORGAN", 131, 137], ["limb", "ORGANISM_SUBDIVISION", 151, 155], ["cutaneous scars", "PROBLEM", 39, 54], ["a dermatomal distribution", "PROBLEM", 58, 83], ["low birth weight", "PROBLEM", 85, 101], ["neurological abnormalities", "PROBLEM", 103, 129], ["ocular defects", "PROBLEM", 131, 145], ["limb deformities", "PROBLEM", 151, 167], ["cutaneous", "OBSERVATION_MODIFIER", 39, 48], ["scars", "OBSERVATION", 49, 54], ["dermatomal", "ANATOMY", 60, 70], ["low", "OBSERVATION_MODIFIER", 85, 88], ["ocular defects", "OBSERVATION", 131, 145], ["limb", "ANATOMY", 151, 155], ["deformities", "OBSERVATION", 156, 167]]], ["FVS is associated with a mortality rate of 30% during the first few months of life (Sauerbrei and Wutzler, 2000).", [["FVS", "DISEASE", 0, 3], ["a mortality rate", "TEST", 23, 39]]], ["Varicella during the second and third trimesters presents a small risk of herpes zoster during infancy or early childhood (Enders, et al. 1994).", [["Varicella", "DISEASE", 0, 9], ["herpes zoster", "DISEASE", 74, 87], ["herpes zoster", "ORGANISM", 74, 87], ["herpes zoster", "SPECIES", 74, 87], ["Varicella", "PROBLEM", 0, 9], ["herpes zoster", "PROBLEM", 74, 87], ["small", "OBSERVATION_MODIFIER", 60, 65], ["herpes zoster", "OBSERVATION", 74, 87]]], ["Maternal varicella occurring from five days before delivery to two days after delivery may result in severe neonatal varicella (Smith and Arvin, 2009), characterized by fever, vesicular lesions in various stages of development, and potential progression to disseminated disease (e.g., varicella pneumonia, hepatitis, meningioencephalitis).Management Recommendations:Nonpregnant HCWs without evidence of immunity (seronegative) to VZV should receive the varicella vaccine unless otherwise contraindicated (Shefer et al., 2011).", [["vesicular lesions", "ANATOMY", 176, 193], ["varicella", "DISEASE", 9, 18], ["varicella", "DISEASE", 117, 126], ["fever", "DISEASE", 169, 174], ["vesicular lesions", "DISEASE", 176, 193], ["disseminated disease", "DISEASE", 257, 277], ["varicella pneumonia", "DISEASE", 285, 304], ["hepatitis", "DISEASE", 306, 315], ["meningioencephalitis", "DISEASE", 317, 337], ["VZV", "DISEASE", 430, 433], ["varicella", "DISEASE", 453, 462], ["vesicular lesions", "PATHOLOGICAL_FORMATION", 176, 193], ["HCWs", "ORGANISM", 378, 382], ["VZV", "ORGANISM", 430, 433], ["VZV", "SPECIES", 430, 433], ["Maternal varicella", "PROBLEM", 0, 18], ["delivery", "TREATMENT", 51, 59], ["delivery", "TREATMENT", 78, 86], ["severe neonatal varicella", "PROBLEM", 101, 126], ["fever", "PROBLEM", 169, 174], ["vesicular lesions", "PROBLEM", 176, 193], ["disseminated disease", "PROBLEM", 257, 277], ["varicella pneumonia", "PROBLEM", 285, 304], ["hepatitis", "PROBLEM", 306, 315], ["meningioencephalitis", "PROBLEM", 317, 337], ["immunity (seronegative)", "PROBLEM", 403, 426], ["VZV", "PROBLEM", 430, 433], ["the varicella vaccine", "TREATMENT", 449, 470], ["varicella", "OBSERVATION", 9, 18], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["varicella", "OBSERVATION", 117, 126], ["fever", "OBSERVATION", 169, 174], ["vesicular", "OBSERVATION_MODIFIER", 176, 185], ["lesions", "OBSERVATION", 186, 193], ["various stages", "OBSERVATION_MODIFIER", 197, 211], ["progression", "OBSERVATION_MODIFIER", 242, 253], ["disseminated", "OBSERVATION_MODIFIER", 257, 269], ["disease", "OBSERVATION", 270, 277], ["varicella", "OBSERVATION_MODIFIER", 285, 294], ["pneumonia", "OBSERVATION", 295, 304], ["hepatitis", "OBSERVATION", 306, 315]]], ["Women should avoid becoming pregnant for one month following each injection (Marin et al., 2007).", [["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5]]], ["The vaccine is contraindicated in pregnancy due to the theoretical risk of live vaccines to the fetus (Marin et al., 2007), though inadvertent vaccination during pregnancy has not been associated with an increased risk of congenital anomalies (Wilson et al., 2008) and is not an indication for pregnancy termination (Ezeanolue et al.; World Health Organization, 2014).", [["fetus", "ANATOMY", 96, 101], ["congenital anomalies", "DISEASE", 222, 242], ["fetus", "ORGANISM", 96, 101], ["The vaccine", "TREATMENT", 0, 11], ["live vaccines", "TREATMENT", 75, 88], ["inadvertent vaccination", "PROBLEM", 131, 154], ["congenital anomalies", "PROBLEM", 222, 242], ["pregnancy termination", "PROBLEM", 294, 315], ["fetus", "ANATOMY", 96, 101], ["increased", "OBSERVATION_MODIFIER", 204, 213], ["congenital", "OBSERVATION_MODIFIER", 222, 232], ["anomalies", "OBSERVATION", 233, 242]]], ["Prenatal assessment for immunity to VZV is recommended for all pregnant women (Marin et al., 2007).", [["VZV", "ORGANISM", 36, 39], ["women", "ORGANISM", 72, 77], ["women", "SPECIES", 72, 77], ["VZV", "SPECIES", 36, 39], ["Prenatal assessment", "TEST", 0, 19], ["VZV", "TEST", 36, 39]]], ["Varicella vaccine should be administered postpartum to nonimmune pregnant HCWs (Marin et al., 2007).", [["Varicella", "DISEASE", 0, 9], ["Varicella", "ORGANISM", 0, 9], ["Varicella vaccine", "TREATMENT", 0, 17]]], ["Breastfeeding women may be vaccinated safely (Marin et al., 2007).", [["women", "ORGANISM", 14, 19], ["women", "SPECIES", 14, 19]]], ["Pregnant HCWs with no evidence of immunity, like all susceptible HCWs, should avoid contact with patients with confirmed or suspected varicella or herpes zoster (Siegel et al., 2007; Shefer et al., 2011; Chin et al., 2014, Kim et al., 2018).", [["varicella", "DISEASE", 134, 143], ["herpes zoster", "DISEASE", 147, 160], ["HCWs", "ORGANISM", 9, 13], ["patients", "ORGANISM", 97, 105], ["herpes zoster", "ORGANISM", 147, 160], ["patients", "SPECIES", 97, 105], ["herpes zoster", "SPECIES", 147, 160], ["varicella", "PROBLEM", 134, 143], ["herpes zoster", "PROBLEM", 147, 160], ["no evidence of", "UNCERTAINTY", 19, 33]]], ["Immunized pregnant HCWs should follow airborne and contact precautions when caring for patients with varicella or disseminated herpes zoster; the same is true when caring for immunocompromised patients with localized zoster until disseminated infection has been ruled out.", [["varicella", "DISEASE", 101, 110], ["herpes zoster", "DISEASE", 127, 140], ["zoster", "DISEASE", 217, 223], ["disseminated infection", "DISEASE", 230, 252], ["HCWs", "ORGANISM", 19, 23], ["patients", "ORGANISM", 87, 95], ["herpes zoster", "ORGANISM", 127, 140], ["patients", "ORGANISM", 193, 201], ["zoster", "ORGANISM", 217, 223], ["patients", "SPECIES", 87, 95], ["herpes zoster", "SPECIES", 127, 140], ["patients", "SPECIES", 193, 201], ["contact precautions", "TREATMENT", 51, 70], ["varicella", "PROBLEM", 101, 110], ["disseminated herpes zoster", "PROBLEM", 114, 140], ["localized zoster", "PROBLEM", 207, 223], ["disseminated infection", "PROBLEM", 230, 252], ["disseminated", "OBSERVATION_MODIFIER", 114, 126], ["zoster", "OBSERVATION", 217, 223], ["disseminated", "OBSERVATION_MODIFIER", 230, 242], ["infection", "OBSERVATION", 243, 252]]], ["Because airborne transmission from immunocompetent patients with localized zoster is unlikely, it is sufficient for immunized HCWs to follow standard precautions and cover all lesions until dry and crusted.", [["lesions", "ANATOMY", 176, 183], ["immunocompetent", "DISEASE", 35, 50], ["zoster", "DISEASE", 75, 81], ["patients", "ORGANISM", 51, 59], ["zoster", "ORGANISM", 75, 81], ["lesions", "PATHOLOGICAL_FORMATION", 176, 183], ["patients", "SPECIES", 51, 59], ["localized zoster", "PROBLEM", 65, 81], ["standard precautions", "TREATMENT", 141, 161], ["all lesions", "PROBLEM", 172, 183], ["crusted", "PROBLEM", 198, 205], ["zoster", "OBSERVATION", 75, 81], ["lesions", "OBSERVATION", 176, 183], ["crusted", "OBSERVATION", 198, 205]]], ["(Bolyard et al., 1998; Shefer et al., 2011).Management Recommendations:All HCWs who are exposed to VZV should be monitored daily during days 8-21 after exposure (Shefer et al., 2011).", [["VZV", "DISEASE", 99, 102], ["HCWs", "ORGANISM", 75, 79], ["VZV", "ORGANISM", 99, 102], ["VZV", "SPECIES", 99, 102], ["VZV", "TREATMENT", 99, 102]]], ["If a susceptible pregnant HCW is exposed, varicella-zoster immune globulin (e.g., VariZIG) should be administered as soon as possible, ideally within 96 hours but up to 10 days after exposure (Marin et al., 2013).", [["varicella-zoster", "DISEASE", 42, 58], ["VariZIG", "CHEMICAL", 82, 89], ["HCW", "ORGANISM", 26, 29], ["varicella-zoster", "ORGANISM", 42, 58], ["globulin", "GENE_OR_GENE_PRODUCT", 66, 74], ["varicella-zoster", "SPECIES", 42, 58], ["a susceptible pregnant HCW", "PROBLEM", 3, 29], ["varicella", "PROBLEM", 42, 51], ["zoster immune globulin", "TREATMENT", 52, 74], ["VariZIG", "TREATMENT", 82, 89], ["zoster immune globulin", "OBSERVATION", 52, 74]]], ["Susceptibility should be confirmed by serology prior to administration if possible.", [["serology", "TEST", 38, 46]]], ["Careful monitoring for signs of infection despite passive immunization is essential.", [["infection", "DISEASE", 32, 41], ["Careful monitoring", "TEST", 0, 18], ["infection", "PROBLEM", 32, 41], ["passive immunization", "TREATMENT", 50, 70], ["infection", "OBSERVATION", 32, 41]]], ["If symptoms of varicella or disseminated zoster develop, HCWs should be placed on sick leave until all lesions have crusted over (Shefer et al., 2011; Chin et al., 2014, Kim et al., 2018).", [["lesions", "ANATOMY", 103, 110], ["varicella", "DISEASE", 15, 24], ["zoster", "DISEASE", 41, 47], ["lesions", "PATHOLOGICAL_FORMATION", 103, 110], ["symptoms", "PROBLEM", 3, 11], ["varicella", "PROBLEM", 15, 24], ["disseminated zoster develop", "PROBLEM", 28, 55], ["all lesions", "PROBLEM", 99, 110], ["varicella", "OBSERVATION", 15, 24], ["disseminated", "OBSERVATION_MODIFIER", 28, 40], ["zoster", "OBSERVATION", 41, 47], ["lesions", "OBSERVATION", 103, 110], ["crusted", "OBSERVATION_MODIFIER", 116, 123]]], ["Fetal and maternal monitoring is crucial.", [["Fetal", "ANATOMY", 0, 5], ["Fetal", "ORGAN", 0, 5], ["Fetal and maternal monitoring", "TEST", 0, 29]]], ["Some experts recommend that pregnant women with uncomplicated varicella should receive oral acyclovir.", [["oral", "ANATOMY", 87, 91], ["varicella", "DISEASE", 62, 71], ["acyclovir", "CHEMICAL", 92, 101], ["acyclovir", "CHEMICAL", 92, 101], ["women", "ORGANISM", 37, 42], ["oral", "ORGANISM_SUBDIVISION", 87, 91], ["acyclovir", "SIMPLE_CHEMICAL", 92, 101], ["women", "SPECIES", 37, 42], ["uncomplicated varicella", "PROBLEM", 48, 71], ["oral acyclovir", "TREATMENT", 87, 101]]], ["In pregnant women with varicella pneumonia or other serious complications, intravenous acyclovir is advised (American Academy of Pediatrics Committee on Infectious Diseases, 2012; M\u00fcllegger et al., 2016).Pityriasis roseaPityriasis rosea (PR) is an acute, self-limiting papulosquamous disorder that characteristically begins with the appearance of a small, isolated, oval plaque referred to as the \u201cherald patch\u201d.", [["intravenous", "ANATOMY", 75, 86], ["oval plaque", "ANATOMY", 366, 377], ["varicella pneumonia", "DISEASE", 23, 42], ["acyclovir", "CHEMICAL", 87, 96], ["Infectious Diseases", "DISEASE", 153, 172], ["Pityriasis roseaPityriasis rosea", "DISEASE", 204, 236], ["papulosquamous disorder", "DISEASE", 269, 292], ["oval plaque", "DISEASE", 366, 377], ["acyclovir", "CHEMICAL", 87, 96], ["women", "ORGANISM", 12, 17], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 86], ["acyclovir", "SIMPLE_CHEMICAL", 87, 96], ["Pityriasis roseaPityriasis rosea", "ORGANISM", 204, 236], ["women", "SPECIES", 12, 17], ["Pityriasis roseaPityriasis rosea", "SPECIES", 204, 236], ["Pityriasis roseaPityriasis rosea (PR)", "SPECIES", 204, 241], ["varicella pneumonia", "PROBLEM", 23, 42], ["other serious complications", "PROBLEM", 46, 73], ["intravenous acyclovir", "TREATMENT", 75, 96], ["Pityriasis roseaPityriasis rosea", "PROBLEM", 204, 236], ["an acute", "PROBLEM", 245, 253], ["self-limiting papulosquamous disorder", "PROBLEM", 255, 292], ["a small, isolated, oval plaque", "PROBLEM", 347, 377], ["pneumonia", "OBSERVATION", 33, 42], ["acute", "OBSERVATION_MODIFIER", 248, 253], ["self-limiting", "OBSERVATION_MODIFIER", 255, 268], ["papulosquamous disorder", "OBSERVATION", 269, 292], ["small", "OBSERVATION_MODIFIER", 349, 354], ["oval", "OBSERVATION_MODIFIER", 366, 370], ["plaque", "OBSERVATION", 371, 377]]], ["A generalized eruption of smaller, but morphologically similar lesions appears on the trunk and proximal extremities within one to two weeks.", [["lesions", "ANATOMY", 63, 70], ["trunk", "ANATOMY", 86, 91], ["proximal extremities", "ANATOMY", 96, 116], ["lesions", "CANCER", 63, 70], ["trunk", "ORGANISM_SUBDIVISION", 86, 91], ["proximal extremities", "ORGANISM_SUBDIVISION", 96, 116], ["A generalized eruption", "PROBLEM", 0, 22], ["morphologically similar lesions", "PROBLEM", 39, 70], ["generalized", "OBSERVATION_MODIFIER", 2, 13], ["eruption", "OBSERVATION", 14, 22], ["smaller", "OBSERVATION_MODIFIER", 26, 33], ["morphologically", "OBSERVATION_MODIFIER", 39, 54], ["similar", "OBSERVATION_MODIFIER", 55, 62], ["lesions", "OBSERVATION", 63, 70], ["trunk", "ANATOMY", 86, 91], ["proximal", "ANATOMY_MODIFIER", 96, 104], ["extremities", "ANATOMY", 105, 116]]], ["Their long axes are classically oriented to create a \u201cChristmas tree\u201d pattern on the back or a V-shaped pattern on the upper chest.", [["back", "ANATOMY", 85, 89], ["upper chest", "ANATOMY", 119, 130], ["back", "ORGANISM_SUBDIVISION", 85, 89], ["upper chest", "ORGANISM_SUBDIVISION", 119, 130], ["a V-shaped pattern on the upper chest", "PROBLEM", 93, 130], ["back", "ANATOMY", 85, 89], ["shaped", "OBSERVATION_MODIFIER", 97, 103], ["upper", "ANATOMY_MODIFIER", 119, 124], ["chest", "ANATOMY", 125, 130]]], ["Oropharyngeal lesions may rarely be present.", [["Oropharyngeal lesions", "ANATOMY", 0, 21], ["Oropharyngeal lesions", "DISEASE", 0, 21], ["Oropharyngeal lesions", "PATHOLOGICAL_FORMATION", 0, 21], ["Oropharyngeal lesions", "PROBLEM", 0, 21], ["lesions", "OBSERVATION", 14, 21], ["may rarely be", "UNCERTAINTY", 22, 35]]], ["Prodromal symptoms may precede the exanthem.", [["exanthem", "DISEASE", 35, 43], ["exanthem", "CANCER", 35, 43], ["Prodromal symptoms", "PROBLEM", 0, 18], ["the exanthem", "PROBLEM", 31, 43]]], ["Pruritus is reported in approximately 50% of cases (Eisman and Sinclair, 2015), but PR otherwise tends to be asymptomatic and usually resolves spontaneously within four to eight weeks.Pityriasis roseaThe etiology of PR is unclear.", [["Pruritus", "DISEASE", 0, 8], ["Pityriasis rosea", "DISEASE", 184, 200], ["Pityriasis rosea", "ORGANISM", 184, 200], ["PR", "PROTEIN", 84, 86], ["PR", "PROTEIN", 216, 218], ["Pityriasis rosea", "SPECIES", 184, 200], ["Pityriasis rosea", "SPECIES", 184, 200], ["Pruritus", "PROBLEM", 0, 8], ["asymptomatic", "PROBLEM", 109, 121], ["Pityriasis rosea", "PROBLEM", 184, 200], ["PR", "PROBLEM", 216, 218], ["asymptomatic", "OBSERVATION", 109, 121]]], ["Various clinical and epidemiological features of PR support a viral origin, including its self-limiting course, low recurrence rate, occasional household clustering, possible seasonal variation, prodromal symptoms, response to acyclovir, and higher prevalence during states of impaired immunity (e.g., pregnancy).", [["acyclovir", "CHEMICAL", 227, 236], ["impaired immunity", "DISEASE", 277, 294], ["acyclovir", "CHEMICAL", 227, 236], ["acyclovir", "SIMPLE_CHEMICAL", 227, 236], ["PR", "PROTEIN", 49, 51], ["a viral origin", "PROBLEM", 60, 74], ["low recurrence rate", "PROBLEM", 112, 131], ["seasonal variation", "PROBLEM", 175, 193], ["prodromal symptoms", "PROBLEM", 195, 213], ["acyclovir", "TREATMENT", 227, 236], ["impaired immunity (e.g., pregnancy)", "PROBLEM", 277, 312], ["viral origin", "OBSERVATION", 62, 74]]], ["There is a well-established association between PR and human herpesviruses 6 and 7 (HHV-6/7) (Drago et al., 1997; Watanabe et al., 2002; Broccolo et al., 2005; Drago et al., 2009), though many patients show no evidence of active infection with HHV-6/7, and several other viruses (including reactivated HSV-2 in the case of a pregnant woman) have been implicated anecdotally in the pathogenesis of PR (Cruz et al., 2011).Pityriasis roseaPR occurs most commonly between the ages of 10 and 35 (Eisman and Sinclair, 2015) with an approximate incidence of 0.5% to 2% (VanRavenstein and Edlund, 2017).", [["infection", "DISEASE", 229, 238], ["PR", "GENE_OR_GENE_PRODUCT", 48, 50], ["human herpesviruses 6", "ORGANISM", 55, 76], ["HHV-6/7", "ORGANISM", 84, 91], ["patients", "ORGANISM", 193, 201], ["HHV-6/7", "ORGANISM", 244, 251], ["HSV-2", "ORGANISM", 302, 307], ["woman", "ORGANISM", 334, 339], ["Pityriasis roseaPR", "ORGANISM", 420, 438], ["PR", "PROTEIN", 48, 50], ["PR", "PROTEIN", 397, 399], ["human", "SPECIES", 55, 60], ["patients", "SPECIES", 193, 201], ["woman", "SPECIES", 334, 339], ["human herpesviruses", "SPECIES", 55, 74], ["HHV-6/7", "SPECIES", 244, 251], ["human herpesviruses", "TEST", 55, 74], ["HHV", "TEST", 84, 87], ["active infection", "PROBLEM", 222, 238], ["HHV", "PROBLEM", 244, 247], ["several other viruses", "PROBLEM", 257, 278], ["reactivated HSV", "PROBLEM", 290, 305], ["Pityriasis roseaPR", "PROBLEM", 420, 438], ["no evidence of", "UNCERTAINTY", 207, 221], ["active", "OBSERVATION_MODIFIER", 222, 228], ["infection", "OBSERVATION", 229, 238], ["viruses", "OBSERVATION", 271, 278]]], ["It disproportionately affects pregnant women compared with young, non-pregnant women (Corson, 1950), possibly due to increased susceptibility to HHV-6/7 reactivation in the setting of altered immunity.Pityriasis roseaThere are several reports of healthy, uncomplicated deliveries in patients with PR in the literature (Corson, 1950; Overton, 1968; Chuh et al., 2005; Bianca et al., 2007).", [["Pityriasis roseaThere", "DISEASE", 201, 222], ["women", "ORGANISM", 39, 44], ["women", "ORGANISM", 79, 84], ["HHV-6/7", "ORGANISM", 145, 152], ["Pityriasis roseaThere", "ORGANISM", 201, 222], ["patients", "ORGANISM", 283, 291], ["PR", "PROTEIN", 297, 299], ["women", "SPECIES", 39, 44], ["women", "SPECIES", 79, 84], ["patients", "SPECIES", 283, 291], ["HHV-6/7", "SPECIES", 145, 152], ["Pityriasis roseaThere", "SPECIES", 201, 222], ["increased susceptibility to HHV", "PROBLEM", 117, 148], ["altered immunity", "PROBLEM", 184, 200], ["Pityriasis", "PROBLEM", 201, 211]]], ["However, a large case series following 61 patients with gestational PR showed an association with adverse outcomes (Drago et al., 2008; Drago et al., 2014).", [["patients", "ORGANISM", 42, 50], ["PR", "PROTEIN", 68, 70], ["patients", "SPECIES", 42, 50], ["gestational PR", "TEST", 56, 70], ["large", "OBSERVATION_MODIFIER", 11, 16]]], ["The overall miscarriage rate among these cases was 13% but rose to 57% if PR developed during the first 15 weeks of gestation.", [["miscarriage", "DISEASE", 12, 23], ["PR", "PROTEIN", 74, 76], ["The overall miscarriage rate", "TEST", 0, 28], ["these cases", "TEST", 35, 46], ["PR", "PROBLEM", 74, 76], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["miscarriage", "OBSERVATION", 12, 23]]], ["The series suggested that viral reactivation of HHV-6 may have led to intrauterine transmission and subsequent fetal loss.", [["intrauterine", "ANATOMY", 70, 82], ["fetal", "ANATOMY", 111, 116], ["HHV-6", "CHEMICAL", 48, 53], ["intrauterine transmission", "DISEASE", 70, 95], ["fetal loss", "DISEASE", 111, 121], ["HHV-6", "ORGANISM", 48, 53], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 82], ["fetal", "ORGAN", 111, 116], ["HHV-6", "SPECIES", 48, 53], ["viral reactivation of HHV", "PROBLEM", 26, 51], ["intrauterine transmission", "PROBLEM", 70, 95], ["subsequent fetal loss", "PROBLEM", 100, 121], ["viral reactivation", "OBSERVATION", 26, 44], ["fetal loss", "OBSERVATION", 111, 121]]], ["Other unfavorable fetal outcomes reported included premature delivery and neonatal hypotonia.", [["fetal", "ANATOMY", 18, 23], ["hypotonia", "DISEASE", 83, 92], ["fetal", "ANATOMICAL_SYSTEM", 18, 23], ["Other unfavorable fetal outcomes", "PROBLEM", 0, 32], ["premature delivery", "PROBLEM", 51, 69], ["neonatal hypotonia", "PROBLEM", 74, 92], ["hypotonia", "OBSERVATION", 83, 92]]], ["PR development before gestational week 15, the presence of enanthem, and high HHV-6 viral load were classified as major risk factors for poor outcomes.", [["HHV-6 viral", "ORGANISM", 78, 89], ["PR", "PROTEIN", 0, 2], ["HHV-6", "SPECIES", 78, 83], ["enanthem", "PROBLEM", 59, 67], ["high HHV", "PROBLEM", 73, 81], ["viral load", "PROBLEM", 84, 94], ["poor outcomes", "PROBLEM", 137, 150]]], ["Constitutional symptoms and involvement of >50% of body surface area were considered minor risk factors (Drago et al., 2018).", [["body surface area", "ANATOMY", 51, 68], ["body", "ORGANISM_SUBDIVISION", 51, 55], ["Constitutional symptoms", "PROBLEM", 0, 23], ["minor risk factors", "PROBLEM", 85, 103]]], ["Atypical forms of PR may be associated with prolonged viral reactivation in the plasma and potential intrauterine transmission (Drago et al., 2016).", [["plasma", "ANATOMY", 80, 86], ["intrauterine", "ANATOMY", 101, 113], ["intrauterine transmission", "DISEASE", 101, 126], ["PR", "GENE_OR_GENE_PRODUCT", 18, 20], ["plasma", "ORGANISM_SUBSTANCE", 80, 86], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 113], ["PR", "PROTEIN", 18, 20], ["Atypical forms of PR", "PROBLEM", 0, 20], ["prolonged viral reactivation", "PROBLEM", 44, 72], ["the plasma", "TEST", 76, 86], ["may be associated with", "UNCERTAINTY", 21, 43], ["prolonged", "OBSERVATION_MODIFIER", 44, 53], ["viral reactivation", "OBSERVATION", 54, 72]]], ["The risk of maternal HHV-6 reactivation and intrauterine transmission has been described by others, but low rates of congenital infection (\u223c1%) were reported; furthermore, most congenital infections occurred due to chromosomal integration rather than transplacental infection (Caserta et al., 2007; Caserta et al., 2014).", [["intrauterine", "ANATOMY", 44, 56], ["chromosomal", "ANATOMY", 215, 226], ["intrauterine transmission", "DISEASE", 44, 69], ["congenital infection", "DISEASE", 117, 137], ["congenital infections", "DISEASE", 177, 198], ["transplacental infection", "DISEASE", 251, 275], ["HHV-6", "ORGANISM", 21, 26], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 56], ["chromosomal", "CELLULAR_COMPONENT", 215, 226], ["HHV-6", "SPECIES", 21, 26], ["maternal HHV", "PROBLEM", 12, 24], ["intrauterine transmission", "PROBLEM", 44, 69], ["congenital infection", "PROBLEM", 117, 137], ["congenital infections", "PROBLEM", 177, 198], ["chromosomal integration", "PROBLEM", 215, 238], ["transplacental infection", "PROBLEM", 251, 275], ["HHV", "OBSERVATION", 21, 24], ["congenital", "OBSERVATION_MODIFIER", 117, 127], ["infection", "OBSERVATION", 128, 137], ["infections", "OBSERVATION", 188, 198], ["infection", "OBSERVATION", 266, 275]]], ["Further studies are needed to substantiate the findings made by Drago\u2019s group and elucidate the effects of PR on pregnancy outcomes.Management Recommendations:Recommendations in the literature regarding PR during pregnancy are sparse and based on a paucity of evidence.", [["PR", "GENE_OR_GENE_PRODUCT", 107, 109], ["PR", "PROTEIN", 107, 109], ["PR", "PROTEIN", 203, 205], ["Further studies", "TEST", 0, 15], ["PR on pregnancy outcomes", "TREATMENT", 107, 131], ["PR during pregnancy", "PROBLEM", 203, 222]]], ["Differential diagnoses should be ruled out, with particular attention given to excluding secondary syphilis.", [["syphilis", "DISEASE", 99, 107], ["secondary syphilis", "PROBLEM", 89, 107], ["syphilis", "OBSERVATION", 99, 107]]], ["Syphilis should especially be considered if a rash is present on the palms or soles.", [["palms", "ANATOMY", 69, 74], ["soles", "ANATOMY", 78, 83], ["Syphilis", "DISEASE", 0, 8], ["rash", "DISEASE", 46, 50], ["palms", "ORGANISM_SUBDIVISION", 69, 74], ["soles", "ORGANISM_SUBDIVISION", 78, 83], ["Syphilis", "PROBLEM", 0, 8], ["a rash", "PROBLEM", 44, 50], ["rash", "OBSERVATION", 46, 50], ["soles", "ANATOMY", 78, 83]]], ["Serological screening for syphilis is strongly recommended for all pregnant women with suspected PR, as there is a serious risk of congenital infection if not promptly treated (Chuh et al., 2005; Mahajan et al., 2016).", [["syphilis", "DISEASE", 26, 34], ["congenital infection", "DISEASE", 131, 151], ["women", "ORGANISM", 76, 81], ["women", "SPECIES", 76, 81], ["Serological screening", "TEST", 0, 21], ["syphilis", "PROBLEM", 26, 34], ["congenital infection", "PROBLEM", 131, 151], ["congenital", "OBSERVATION_MODIFIER", 131, 141], ["infection", "OBSERVATION", 142, 151]]], ["Drug-related PR-like eruptions should also be considered, as these are not associated with viral reactivation and may not pose the same risk to the fetus (Drago et al., 2016).", [["fetus", "ANATOMY", 148, 153], ["fetus", "ORGAN", 148, 153], ["PR", "PROTEIN", 13, 15], ["Drug-related PR", "PROBLEM", 0, 15], ["like eruptions", "PROBLEM", 16, 30], ["viral reactivation", "PROBLEM", 91, 109], ["eruptions", "OBSERVATION", 21, 30], ["not associated with", "UNCERTAINTY", 71, 90], ["reactivation", "OBSERVATION", 97, 109]]], ["There is one reported case of a PR-like drug eruption due to ondansetron use in a pregnant woman with nausea and vomiting (Alame et al., 2018), but many other drugs are known to cause such eruptions.Management Recommendations:Since PR is self-limiting, management is generally limited to reassurance and the treatment of symptoms with emollients, antihistamines, and occasionally topical steroids.", [["drug eruption", "DISEASE", 40, 53], ["ondansetron", "CHEMICAL", 61, 72], ["nausea and vomiting", "DISEASE", 102, 121], ["steroids", "CHEMICAL", 388, 396], ["ondansetron", "CHEMICAL", 61, 72], ["steroids", "CHEMICAL", 388, 396], ["ondansetron", "SIMPLE_CHEMICAL", 61, 72], ["woman", "ORGANISM", 91, 96], ["antihistamines", "SIMPLE_CHEMICAL", 347, 361], ["PR", "PROTEIN", 32, 34], ["PR", "PROTEIN", 232, 234], ["woman", "SPECIES", 91, 96], ["a PR-like drug eruption", "PROBLEM", 30, 53], ["ondansetron", "TREATMENT", 61, 72], ["nausea", "PROBLEM", 102, 108], ["vomiting", "PROBLEM", 113, 121], ["such eruptions", "PROBLEM", 184, 198], ["management", "TREATMENT", 253, 263], ["reassurance", "TREATMENT", 288, 299], ["symptoms", "PROBLEM", 321, 329], ["emollients", "TREATMENT", 335, 345], ["antihistamines", "TREATMENT", 347, 361], ["occasionally topical steroids", "TREATMENT", 367, 396]]], ["However, there are special recommendations for management of pregnant women.", [["women", "ORGANISM", 70, 75], ["women", "SPECIES", 70, 75], ["management of pregnant women", "TREATMENT", 47, 75]]], ["Particularly close monitoring is called for if the mother develops PR within the first 15-20 weeks of gestation or experiences constitutional symptoms or an unusually diffuse, prolonged rash (Drago et al., 2008; Drago et al., 2014, Drago et al., 2016; Monastirli et al., 2016).", [["rash", "DISEASE", 186, 190], ["PR", "PROTEIN", 67, 69], ["PR", "PROBLEM", 67, 69], ["constitutional symptoms", "PROBLEM", 127, 150], ["an unusually diffuse, prolonged rash", "PROBLEM", 154, 190], ["diffuse", "OBSERVATION_MODIFIER", 167, 174]]], ["In these cases of atypical PR in pregnant women, conflicting recommendations exist in the literature.", [["women", "ORGANISM", 42, 47], ["PR", "PROTEIN", 27, 29], ["women", "SPECIES", 42, 47], ["atypical PR in pregnant women", "PROBLEM", 18, 47], ["atypical", "OBSERVATION_MODIFIER", 18, 26]]], ["Some recommend avoiding systemic therapy (Mahajan et al., 2016), while others recommend considering the use of acyclovir (Drago et al., 2015; Chuh et al., 2016, Drago et al., 2018), which has been shown to hasten the resolution of PR lesions and relieve pruritus.", [["lesions", "ANATOMY", 234, 241], ["acyclovir", "CHEMICAL", 111, 120], ["pruritus", "DISEASE", 254, 262], ["acyclovir", "CHEMICAL", 111, 120], ["acyclovir", "SIMPLE_CHEMICAL", 111, 120], ["PR lesions", "CANCER", 231, 241], ["PR", "PROTEIN", 231, 233], ["systemic therapy", "TREATMENT", 24, 40], ["acyclovir", "TREATMENT", 111, 120], ["PR lesions", "PROBLEM", 231, 241], ["pruritus", "PROBLEM", 254, 262], ["lesions", "OBSERVATION", 234, 241], ["pruritus", "OBSERVATION", 254, 262]]], ["A low-dose regimen (400 mg three times daily for 7 days) is recommended if such intervention is indicated.Management Recommendations:Given the potential increased risk of miscarriage in the first 15 weeks of gestation, pregnant HCWs should avoid contact with patients known to have PR during early stages of pregnancy, if possible, and all pregnant HCWs should utilize appropriate contact precautions when caring for patients with PR.", [["miscarriage", "DISEASE", 171, 182], ["HCWs", "ORGANISM", 228, 232], ["patients", "ORGANISM", 259, 267], ["HCWs", "ORGANISM", 349, 353], ["patients", "ORGANISM", 417, 425], ["PR", "PROTEIN", 282, 284], ["PR", "PROTEIN", 431, 433], ["patients", "SPECIES", 259, 267], ["patients", "SPECIES", 417, 425], ["A low-dose regimen", "TREATMENT", 0, 18], ["intervention", "TREATMENT", 80, 92], ["miscarriage", "PROBLEM", 171, 182], ["appropriate contact precautions", "TREATMENT", 369, 400], ["miscarriage", "OBSERVATION", 171, 182]]], ["Although PR is not thought to be contagious, and women of childbearing age have likely already been exposed to HHV-6/7, this recommendation is based upon the uncertainty surrounding its etiology and the potential danger of infection to the fetus.SARS-CoV-2Since December 2019, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has resulted in an increasingly devastating global pandemic.", [["fetus", "ANATOMY", 240, 245], ["infection", "DISEASE", 223, 232], ["SARS", "DISEASE", 246, 250], ["acute respiratory syndrome coronavirus", "DISEASE", 296, 334], ["PR", "GENE_OR_GENE_PRODUCT", 9, 11], ["women", "ORGANISM", 49, 54], ["HHV-6/7", "ORGANISM", 111, 118], ["fetus", "ORGAN", 240, 245], ["SARS-CoV-2", "ORGANISM", 277, 287], ["PR", "PROTEIN", 9, 11], ["women", "SPECIES", 49, 54], ["SARS-CoV-2 (severe acute respiratory syndrome coronavirus", "SPECIES", 277, 334], ["PR", "PROBLEM", 9, 11], ["HHV", "PROBLEM", 111, 114], ["infection to the fetus", "PROBLEM", 223, 245], ["SARS", "TEST", 277, 281], ["CoV", "TEST", 282, 285], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 289, 334], ["an increasingly devastating global pandemic", "PROBLEM", 354, 397], ["not thought to be", "UNCERTAINTY", 15, 32], ["contagious", "OBSERVATION_MODIFIER", 33, 43], ["infection", "OBSERVATION", 223, 232], ["fetus", "ANATOMY", 240, 245], ["severe", "OBSERVATION_MODIFIER", 289, 295], ["acute", "OBSERVATION_MODIFIER", 296, 301], ["respiratory syndrome", "OBSERVATION", 302, 322], ["increasingly", "OBSERVATION_MODIFIER", 357, 369], ["devastating", "OBSERVATION_MODIFIER", 370, 381], ["pandemic", "OBSERVATION", 389, 397]]], ["In response to the overwhelming number of patients with the novel coronavirus disease (COVID-19) requiring hospitalization and ICU-level care, many medical providers who do not traditionally perform roles in these settings have been called to assist.", [["coronavirus disease", "DISEASE", 66, 85], ["patients", "ORGANISM", 42, 50], ["coronavirus", "ORGANISM", 66, 77], ["patients", "SPECIES", 42, 50], ["the novel coronavirus disease", "PROBLEM", 56, 85], ["COVID", "TEST", 87, 92], ["ICU-level care", "TREATMENT", 127, 141], ["coronavirus disease", "OBSERVATION", 66, 85]]], ["The medical community\u2019s knowledge of COVID-19 continues to evolve rapidly.", [["COVID-19", "CHEMICAL", 37, 45], ["COVID-19", "CHEMICAL", 37, 45], ["COVID", "TEST", 37, 42]]], ["Information regarding any potential dermatologic manifestations of the disease, as well as the disease\u2019s impact on pregnancy, is limited as of April 2020.", [["the disease", "PROBLEM", 67, 78], ["disease", "OBSERVATION", 71, 78]]], ["Pivotal data from patients in Wuhan, China have revealed that cutaneous manifestations of COVID-19 are rare, with only 2% of over 1,000 patients having any type of documented rash (Guan et al., 2020).", [["cutaneous", "ANATOMY", 62, 71], ["rash", "DISEASE", 175, 179], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 136, 144], ["COVID", "TEST", 90, 95], ["documented rash", "PROBLEM", 164, 179], ["rash", "OBSERVATION", 175, 179]]], ["Both pregnant HCWs and patients have expressed concern regarding potential complications from COVID-19, although the disease appears to disproportionately affect men compared to women or the pediatric population.", [["HCWs", "ORGANISM", 14, 18], ["patients", "ORGANISM", 23, 31], ["men", "ORGANISM", 162, 165], ["women", "ORGANISM", 178, 183], ["patients", "SPECIES", 23, 31], ["men", "SPECIES", 162, 165], ["women", "SPECIES", 178, 183], ["potential complications", "PROBLEM", 65, 88], ["COVID", "TEST", 94, 99], ["the disease", "PROBLEM", 113, 124], ["disease", "OBSERVATION", 117, 124]]], ["Two small retrospective analyses of pregnant women with confirmed COVID-19 pneumonia did not find evidence of intrauterine vertical transmission or elevated risk of neonatal or fetal complications (Chen et al., 2020; Schwartz 2020).", [["intrauterine", "ANATOMY", 110, 122], ["fetal", "ANATOMY", 177, 182], ["pneumonia", "DISEASE", 75, 84], ["intrauterine vertical transmission", "DISEASE", 110, 144], ["women", "ORGANISM", 45, 50], ["fetal", "ORGAN", 177, 182], ["women", "SPECIES", 45, 50], ["COVID", "TEST", 66, 71], ["pneumonia", "PROBLEM", 75, 84], ["intrauterine vertical transmission", "PROBLEM", 110, 144], ["neonatal or fetal complications", "PROBLEM", 165, 196], ["small", "OBSERVATION_MODIFIER", 4, 9], ["pneumonia", "OBSERVATION", 75, 84], ["elevated", "OBSERVATION_MODIFIER", 148, 156]]], ["Another cohort study of 17 pregnant patients, including three HCWs, also did not find conclusive evidence of vertical transmission (Khan et al., 2020).", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["Another cohort study", "TEST", 0, 20]]], ["In a separate study of 13 pregnant patients with COVID-19, researchers did not find evidence of vertical transmission but did note that five patients required emergency cesarean section to avoid pregnancy-related complications (Liu et al., 2020).", [["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 141, 149], ["a separate study", "TEST", 3, 19], ["COVID", "TEST", 49, 54], ["vertical transmission", "PROBLEM", 96, 117], ["emergency cesarean section", "TREATMENT", 159, 185], ["pregnancy-related complications", "PROBLEM", 195, 226]]], ["Although data on pregnant women from previous coronavirus pandemics are limited, it does not appear that pregnant women were more likely to acquire SARS-CoV-1 or MERS-CoV, other coronaviruses similar to SARS-CoV-2, which cause severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS), respectively (Rasmussen et al., 2020).", [["coronavirus pandemics", "DISEASE", 46, 67], ["SARS", "DISEASE", 148, 152], ["SARS", "DISEASE", 203, 207], ["acute respiratory syndrome", "DISEASE", 234, 260], ["SARS", "DISEASE", 262, 266], ["Middle East Respiratory Syndrome", "DISEASE", 272, 304], ["women", "ORGANISM", 26, 31], ["coronavirus", "ORGANISM", 46, 57], ["women", "ORGANISM", 114, 119], ["SARS-CoV-1", "ORGANISM", 148, 158], ["MERS-CoV", "ORGANISM", 162, 170], ["coronaviruses", "ORGANISM", 178, 191], ["SARS-CoV-2", "ORGANISM", 203, 213], ["women", "SPECIES", 26, 31], ["women", "SPECIES", 114, 119], ["SARS-CoV-1", "SPECIES", 148, 158], ["MERS-CoV", "SPECIES", 162, 170], ["SARS-CoV", "SPECIES", 203, 211], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 272, 311], ["previous coronavirus pandemics", "PROBLEM", 37, 67], ["SARS", "TEST", 148, 152], ["CoV", "TEST", 153, 156], ["MERS", "PROBLEM", 162, 166], ["CoV", "PROBLEM", 167, 170], ["other coronaviruses", "PROBLEM", 172, 191], ["SARS", "PROBLEM", 203, 207], ["CoV", "TEST", 208, 211], ["severe acute respiratory syndrome", "PROBLEM", 227, 260], ["SARS)", "PROBLEM", 262, 267], ["Middle East Respiratory Syndrome", "PROBLEM", 272, 304], ["severe", "OBSERVATION_MODIFIER", 227, 233], ["acute", "OBSERVATION_MODIFIER", 234, 239], ["respiratory syndrome", "OBSERVATION", 240, 260], ["Middle", "ANATOMY_MODIFIER", 272, 278], ["Respiratory Syndrome", "OBSERVATION", 284, 304]]], ["However, data from pregnant patients with SARS found that when pregnant women actually did acquire SARS-CoV-1, they tended to have more neonatal and maternal complications, including increased rates of ICU admission and mortality compared to non-pregnant patients (Lam et al. 2004; Wong et al., 2004).Management Recommendations:As with all HCWs, pregnant HCWs should follow infection control recommendations from public health officials and abide by occupational health and safety guidelines established by the individual healthcare systems in which they work.", [["SARS", "DISEASE", 42, 46], ["SARS", "DISEASE", 99, 103], ["infection", "DISEASE", 374, 383], ["patients", "ORGANISM", 28, 36], ["women", "ORGANISM", 72, 77], ["SARS-CoV-1", "ORGANISM", 99, 109], ["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 28, 36], ["women", "SPECIES", 72, 77], ["patients", "SPECIES", 255, 263], ["SARS-CoV-1", "SPECIES", 99, 109], ["SARS", "PROBLEM", 42, 46], ["maternal complications", "PROBLEM", 149, 171]]], ["Pregnant HCWs should not provide any clinical care if they test positive for COVID-19.", [["HCWs", "ORGANISM", 9, 13], ["COVID", "TEST", 77, 82]]], ["Any pregnant HCW who has symptoms suggestive of COVID-19 should self-isolate following testing for SARS-CoV-2 until results are available.", [["SARS", "DISEASE", 99, 103], ["HCW", "ORGANISM", 13, 16], ["SARS-CoV", "SPECIES", 99, 107], ["symptoms", "PROBLEM", 25, 33], ["COVID", "TEST", 48, 53], ["testing", "TEST", 87, 94], ["SARS", "PROBLEM", 99, 103], ["CoV", "TEST", 104, 107]]], ["The Royal College of Obstetricians and Gynaecologists (RCOG) recommends that female HCWs who are more than 28 weeks pregnant should avoid direct contact with all patients during the ongoing pandemic, even if the HCW is asymptomatic or has not had contact with known or suspected COVID-19 patients (Rimmer, 2020).", [["HCWs", "ORGANISM", 84, 88], ["patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 288, 296], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 288, 296]]], ["Those who are less than 28 weeks pregnant, however, can continue to work in patient facing roles provided that they use proper personal protection equipment (PPE) (Rimmer, 2020).", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83]]], ["Some individual institutions have chosen to prohibit any pregnant HCW, whenever possible, from caring for patients with COVID-19.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["COVID", "TEST", 120, 125]]], ["General principles regarding management of COVID-10 during pregnancy include early isolation, aggressive infection control procedures, testing for SARS-CoV-2 and coinfection, oxygen therapy as needed, avoidance of fluid overload, empiric antibiotics (due to secondary bacterial infection risk), fetal and uterine contraction monitoring, early mechanical ventilation for progressive respiratory failure, individualized delivery planning, and a team-based approach with multispecialty consultations (Rasmussen et al., 2020).", [["fluid", "ANATOMY", 214, 219], ["fetal", "ANATOMY", 295, 300], ["uterine", "ANATOMY", 305, 312], ["respiratory", "ANATOMY", 382, 393], ["infection", "DISEASE", 105, 114], ["SARS", "DISEASE", 147, 151], ["coinfection", "DISEASE", 162, 173], ["oxygen", "CHEMICAL", 175, 181], ["fluid overload", "DISEASE", 214, 228], ["bacterial infection", "DISEASE", 268, 287], ["respiratory failure", "DISEASE", 382, 401], ["oxygen", "CHEMICAL", 175, 181], ["oxygen", "SIMPLE_CHEMICAL", 175, 181], ["fetal", "MULTI-TISSUE_STRUCTURE", 295, 300], ["uterine", "MULTI-TISSUE_STRUCTURE", 305, 312], ["SARS-CoV", "SPECIES", 147, 155], ["management of COVID", "TREATMENT", 29, 48], ["early isolation", "TREATMENT", 77, 92], ["aggressive infection control procedures", "TREATMENT", 94, 133], ["testing", "TEST", 135, 142], ["SARS", "PROBLEM", 147, 151], ["CoV", "TEST", 152, 155], ["coinfection", "PROBLEM", 162, 173], ["oxygen therapy", "TREATMENT", 175, 189], ["fluid overload", "PROBLEM", 214, 228], ["empiric antibiotics", "TREATMENT", 230, 249], ["secondary bacterial infection risk", "PROBLEM", 258, 292], ["fetal and uterine contraction monitoring", "TEST", 295, 335], ["early mechanical ventilation", "TREATMENT", 337, 365], ["progressive respiratory failure", "PROBLEM", 370, 401], ["individualized delivery planning", "TREATMENT", 403, 435], ["oxygen therapy", "OBSERVATION", 175, 189], ["fluid overload", "OBSERVATION", 214, 228], ["uterine contraction", "ANATOMY", 305, 324], ["mechanical ventilation", "OBSERVATION", 343, 365], ["progressive", "OBSERVATION_MODIFIER", 370, 381], ["respiratory failure", "OBSERVATION", 382, 401]]], ["Although breastfeeding is not currently contraindicated in patients with COVID-19, it is recommended that patients wear a face mask while breastfeeding to minimize risk of droplet transmission to the newborn (Dashraath et al., 2020).", [["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 106, 114], ["COVID", "TEST", 73, 78], ["a face mask", "TREATMENT", 120, 131]]], ["While SARS-CoV-2 has yet to be identified in breastmilk, newborns are still susceptible to transmission from contact with mothers or other family members, highlighting the importance of proper hand hygiene and social distancing measures.Conclusion:This review summarizes common exanthematous diseases that pregnant HCWs may be exposed to in the clinical environment.", [["hand", "ANATOMY", 193, 197], ["SARS", "DISEASE", 6, 10], ["SARS-CoV-2", "ORGANISM", 6, 16], ["breastmilk", "ORGANISM_SUBDIVISION", 45, 55], ["newborns", "ORGANISM", 57, 65], ["hand", "ORGANISM_SUBDIVISION", 193, 197], ["HCWs", "ORGANISM", 315, 319], ["SARS-CoV", "SPECIES", 6, 14], ["social distancing measures", "TREATMENT", 210, 236], ["common exanthematous diseases", "PROBLEM", 271, 300]]], ["Large trials on outcomes in pregnant women, especially HCWs, are limited.", [["women", "ORGANISM", 37, 42], ["women", "SPECIES", 37, 42]]], ["As such, guidelines and recommendations for prevention for pregnant HCWs are limited.", [["pregnant HCWs", "PROBLEM", 59, 72]]], ["Recommendations should ensure adequate protection for HCWs while limiting unnecessary or cumbersome practices that would unnecessarily prevent pregnant HCWs from performing clinical duties.", [["HCWs", "TREATMENT", 54, 58], ["cumbersome practices", "TREATMENT", 89, 109]]], ["In addition, vaccination prior to pregnancy of preventable diseases, such as measles and varicella, is crucial.", [["measles", "DISEASE", 77, 84], ["varicella", "DISEASE", 89, 98], ["vaccination", "TREATMENT", 13, 24], ["preventable diseases", "PROBLEM", 47, 67], ["measles", "PROBLEM", 77, 84], ["varicella", "PROBLEM", 89, 98], ["varicella", "OBSERVATION", 89, 98]]], ["All clinicians should encourage women of childbearing potential to receive appropriate vaccinations prior to conceiving.", [["women", "ORGANISM", 32, 37], ["women", "SPECIES", 32, 37], ["appropriate vaccinations", "TREATMENT", 75, 99]]], ["Mandated vaccination requirements have been shown to be highly successful; for example, influenza vaccination rates in HCWs have significantly increased when healthcare institution-based mandates have been implemented in conjunction with government mandated vaccination requirements (Lin et al., 2016, Wang et al., 2017).", [["influenza vaccination rates", "TREATMENT", 88, 115]]]], "d2126ea8305cc212ae0db6065e60a1011fd14b53": [["Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededWith more than 81 000 deaths worldwide from coronavirus disease 2019 (COVID- 19) by April 8, 2020, 1 it is incumbent on researchers to accelerate clinical trials of any readily available and potentially acceptably safe therapies that could reduce the rising death toll.", [["necrosis", "DISEASE", 22, 30], ["deaths", "DISEASE", 100, 106], ["coronavirus disease", "DISEASE", 122, 141], ["death", "DISEASE", 336, 341], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 10, 37], ["anti-tumour necrosis factor therapy", "TREATMENT", 10, 45], ["COVID", "TEST", 50, 55], ["coronavirus disease", "PROBLEM", 122, 141], ["safe therapies", "TREATMENT", 292, 306], ["the rising death toll", "PROBLEM", 325, 346], ["coronavirus disease", "OBSERVATION", 122, 141]]], ["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gains access to host cells via angiotensin-converting enzyme 2, which is expressed in the type II surfactantsecreting alveolar cells of the lungs.", [["cells", "ANATOMY", 82, 87], ["alveolar cells", "ANATOMY", 179, 193], ["lungs", "ANATOMY", 201, 206], ["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["angiotensin", "CHEMICAL", 92, 103], ["SARS-CoV-2", "ORGANISM", 49, 59], ["host cells", "CELL", 77, 87], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 92, 123], ["alveolar cells", "CELL", 179, 193], ["lungs", "ORGAN", 201, 206], ["host cells", "CELL_TYPE", 77, 87], ["angiotensin-converting enzyme 2", "PROTEIN", 92, 123], ["type II surfactantsecreting alveolar cells", "CELL_TYPE", 151, 193], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV", "SPECIES", 49, 57], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["SARS", "TEST", 49, 53], ["CoV", "TEST", 54, 57], ["angiotensin-converting enzyme 2", "TREATMENT", 92, 123], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["alveolar cells", "OBSERVATION", 179, 193], ["lungs", "ANATOMY", 201, 206]]], ["2 Severe COVID-19 is associated with a major immune inflammatory response with abundant neutrophils, lymphocytes, macrophages, and immune mediators.", [["neutrophils", "ANATOMY", 88, 99], ["lymphocytes", "ANATOMY", 101, 112], ["macrophages", "ANATOMY", 114, 125], ["neutrophils", "CELL", 88, 99], ["lymphocytes", "CELL", 101, 112], ["macrophages", "CELL", 114, 125], ["neutrophils", "CELL_TYPE", 88, 99], ["lymphocytes", "CELL_TYPE", 101, 112], ["macrophages", "CELL_TYPE", 114, 125], ["immune mediators", "PROTEIN", 131, 147], ["Severe COVID", "TEST", 2, 14], ["a major immune inflammatory response", "PROBLEM", 37, 73], ["lymphocytes", "TEST", 101, 112], ["macrophages", "TEST", 114, 125], ["immune mediators", "TREATMENT", 131, 147], ["inflammatory", "OBSERVATION", 52, 64], ["abundant", "OBSERVATION_MODIFIER", 79, 87], ["neutrophils", "OBSERVATION", 88, 99], ["lymphocytes", "OBSERVATION", 101, 112]]], ["Deaths from COVID-19 are chiefly due to diffuse alveolar damage with pulmonary oedema, hyaline membrane formation, and interstitial mononuclear inflammatory infiltrate compatible with early-phase adult respiratory distress syndrome (ARDS).", [["alveolar", "ANATOMY", 48, 56], ["pulmonary", "ANATOMY", 69, 78], ["hyaline membrane", "ANATOMY", 87, 103], ["interstitial mononuclear", "ANATOMY", 119, 143], ["respiratory", "ANATOMY", 202, 213], ["alveolar damage", "DISEASE", 48, 63], ["pulmonary oedema", "DISEASE", 69, 85], ["respiratory distress syndrome", "DISEASE", 202, 231], ["ARDS", "DISEASE", 233, 237], ["COVID-19", "CHEMICAL", 12, 20], ["alveolar", "TISSUE", 48, 56], ["pulmonary oedema", "PATHOLOGICAL_FORMATION", 69, 85], ["hyaline membrane", "CELLULAR_COMPONENT", 87, 103], ["interstitial mononuclear", "CELL", 119, 143], ["COVID", "TEST", 12, 17], ["diffuse alveolar damage", "PROBLEM", 40, 63], ["pulmonary oedema", "PROBLEM", 69, 85], ["hyaline membrane formation", "PROBLEM", 87, 113], ["interstitial mononuclear inflammatory infiltrate", "PROBLEM", 119, 167], ["early-phase adult respiratory distress syndrome", "PROBLEM", 184, 231], ["ARDS", "PROBLEM", 233, 237], ["diffuse", "OBSERVATION_MODIFIER", 40, 47], ["alveolar", "ANATOMY_MODIFIER", 48, 56], ["damage", "OBSERVATION", 57, 63], ["pulmonary", "ANATOMY", 69, 78], ["oedema", "OBSERVATION", 79, 85], ["hyaline membrane formation", "OBSERVATION", 87, 113], ["interstitial", "ANATOMY_MODIFIER", 119, 131], ["mononuclear", "OBSERVATION", 132, 143], ["inflammatory", "OBSERVATION_MODIFIER", 144, 156], ["compatible with", "UNCERTAINTY", 168, 183], ["early", "OBSERVATION_MODIFIER", 184, 189], ["phase", "OBSERVATION_MODIFIER", 190, 195], ["adult", "OBSERVATION_MODIFIER", 196, 201], ["respiratory distress syndrome", "OBSERVATION", 202, 231], ["ARDS", "OBSERVATION", 233, 237]]], ["3 Prevention of ARDS and death in patients with COVID-19 is a pressing health emergency.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededAnti-tumour necrosis factor (TNF) antibodies have been used for more than 20 years in severe cases of autoimmune inflammatory disease such as rheumatoid arthritis, inflammatory bowel disease, or ankylosing spondylitis.", [["bowel", "ANATOMY", 343, 348], ["ARDS", "DISEASE", 16, 20], ["death", "DISEASE", 25, 30], ["COVID-19", "CHEMICAL", 48, 56], ["necrosis", "DISEASE", 110, 118], ["necrosis", "DISEASE", 178, 186], ["autoimmune inflammatory disease", "DISEASE", 268, 299], ["rheumatoid arthritis", "DISEASE", 308, 328], ["inflammatory bowel disease", "DISEASE", 330, 356], ["ankylosing spondylitis", "DISEASE", 361, 383], ["patients", "ORGANISM", 34, 42], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 98, 125], ["Anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 166, 193], ["TNF", "GENE_OR_GENE_PRODUCT", 195, 198], ["bowel", "ORGAN", 343, 348], ["Anti-tumour necrosis factor (TNF) antibodies", "PROTEIN", 166, 210], ["patients", "SPECIES", 34, 42], ["ARDS", "PROBLEM", 16, 20], ["death", "PROBLEM", 25, 30], ["COVID", "TEST", 48, 53], ["anti-tumour necrosis factor therapy", "TREATMENT", 98, 133], ["COVID", "TEST", 138, 143], ["Anti-tumour necrosis factor", "PROBLEM", 166, 193], ["TNF) antibodies", "TEST", 195, 210], ["autoimmune inflammatory disease", "PROBLEM", 268, 299], ["rheumatoid arthritis", "PROBLEM", 308, 328], ["inflammatory bowel disease", "PROBLEM", 330, 356], ["ankylosing spondylitis", "PROBLEM", 361, 383], ["ARDS", "OBSERVATION", 16, 20], ["necrosis", "OBSERVATION", 178, 186], ["autoimmune", "OBSERVATION_MODIFIER", 268, 278], ["inflammatory disease", "OBSERVATION", 279, 299], ["rheumatoid arthritis", "OBSERVATION", 308, 328], ["inflammatory", "OBSERVATION_MODIFIER", 330, 342], ["bowel", "ANATOMY", 343, 348], ["disease", "OBSERVATION", 349, 356], ["ankylosing spondylitis", "OBSERVATION", 361, 383]]], ["There are ten (as reported on Sept 29, 2019) US Food and Drug Administration approved and four off-label indications for anti-TNF therapy, 4 indicating that TNF is a valid target in many inflammatory diseases.", [["inflammatory diseases", "DISEASE", 187, 208], ["anti-TNF", "SIMPLE_CHEMICAL", 121, 129], ["TNF", "GENE_OR_GENE_PRODUCT", 157, 160], ["TNF", "PROTEIN", 157, 160], ["Drug Administration", "TREATMENT", 57, 76], ["anti-TNF therapy", "TREATMENT", 121, 137], ["TNF", "PROBLEM", 157, 160], ["many inflammatory diseases", "PROBLEM", 182, 208], ["many", "OBSERVATION_MODIFIER", 182, 186], ["inflammatory", "OBSERVATION", 187, 199]]], ["TNF is present in blood and disease tissues of patients with COVID-19 5 and TNF is important in nearly all acute inflammatory reactions, acting as an amplifier of inflammation.", [["blood", "ANATOMY", 18, 23], ["disease tissues", "ANATOMY", 28, 43], ["inflammation", "DISEASE", 163, 175], ["TNF", "GENE_OR_GENE_PRODUCT", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["disease tissues", "TISSUE", 28, 43], ["patients", "ORGANISM", 47, 55], ["COVID-19 5", "GENE_OR_GENE_PRODUCT", 61, 71], ["TNF", "GENE_OR_GENE_PRODUCT", 76, 79], ["TNF", "PROTEIN", 0, 3], ["TNF", "PROTEIN", 76, 79], ["patients", "SPECIES", 47, 55], ["TNF", "TEST", 0, 3], ["COVID", "TEST", 61, 66], ["all acute inflammatory reactions", "PROBLEM", 103, 135], ["inflammation", "PROBLEM", 163, 175], ["disease", "OBSERVATION", 28, 35], ["nearly all", "OBSERVATION_MODIFIER", 96, 106], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["inflammatory", "OBSERVATION", 113, 125], ["inflammation", "OBSERVATION", 163, 175]]], ["We propose that anti-TNF therapy should be evaluated in patients with COVID-19 on hospital admission to prevent progression to needing intensive care support.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededThere is evidence of an inflammatory excess in patients with COVID-19.", [["necrosis", "DISEASE", 180, 188], ["COVID-19", "CHEMICAL", 297, 305], ["anti-TNF", "SIMPLE_CHEMICAL", 16, 24], ["patients", "ORGANISM", 56, 64], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 168, 195], ["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 283, 291], ["anti-TNF therapy", "TREATMENT", 16, 32], ["COVID", "TEST", 70, 75], ["intensive care support", "TREATMENT", 135, 157], ["anti-tumour necrosis factor therapy", "TREATMENT", 168, 203], ["COVID", "TEST", 208, 213], ["an inflammatory excess", "PROBLEM", 257, 279], ["COVID", "TEST", 297, 302], ["evidence of", "UNCERTAINTY", 245, 256], ["inflammatory", "OBSERVATION_MODIFIER", 260, 272], ["excess", "OBSERVATION", 273, 279]]], ["Lung pathology in COVID-19 is characterised by capillary leakage of fluid and recruitment of immune-inflammatory lymphocytes, neutrophils, and macrophages, 6 implying a role for adhesion molecules, chemokines, and cytokines targeting vascular endothelium.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededCytokine upregulation is documented in COVID-19.", [["Lung", "ANATOMY", 0, 4], ["capillary", "ANATOMY", 47, 56], ["fluid", "ANATOMY", 68, 73], ["immune-inflammatory lymphocytes", "ANATOMY", 93, 124], ["neutrophils", "ANATOMY", 126, 137], ["macrophages", "ANATOMY", 143, 154], ["vascular endothelium", "ANATOMY", 234, 254], ["necrosis", "DISEASE", 277, 285], ["Lung", "ORGAN", 0, 4], ["COVID-19", "CELL", 18, 26], ["capillary", "TISSUE", 47, 56], ["fluid", "ORGANISM_SUBSTANCE", 68, 73], ["immune-inflammatory lymphocytes", "CELL", 93, 124], ["neutrophils", "CELL", 126, 137], ["macrophages", "CELL", 143, 154], ["vascular endothelium", "TISSUE", 234, 254], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 265, 292], ["Cytokine", "GENE_OR_GENE_PRODUCT", 333, 341], ["COVID-19", "CELL", 372, 380], ["immune-inflammatory lymphocytes", "CELL_TYPE", 93, 124], ["neutrophils", "CELL_TYPE", 126, 137], ["macrophages", "CELL_TYPE", 143, 154], ["adhesion molecules", "PROTEIN", 178, 196], ["chemokines", "PROTEIN", 198, 208], ["cytokines", "PROTEIN", 214, 223], ["Cytokine", "PROTEIN", 333, 341], ["COVID-19", "SPECIES", 18, 26], ["Lung pathology", "TEST", 0, 14], ["COVID", "TEST", 18, 23], ["capillary leakage of fluid", "PROBLEM", 47, 73], ["inflammatory lymphocytes", "PROBLEM", 100, 124], ["neutrophils", "TEST", 126, 137], ["macrophages", "TEST", 143, 154], ["adhesion molecules", "PROBLEM", 178, 196], ["chemokines", "PROBLEM", 198, 208], ["cytokines targeting vascular endothelium", "PROBLEM", 214, 254], ["anti-tumour necrosis factor therapy", "TREATMENT", 265, 300], ["COVID", "TEST", 305, 310], ["Cytokine upregulation", "TEST", 333, 354], ["COVID", "TEST", 372, 377], ["pathology", "OBSERVATION", 5, 14], ["capillary leakage", "OBSERVATION", 47, 64], ["fluid", "OBSERVATION", 68, 73], ["inflammatory lymphocytes", "OBSERVATION", 100, 124], ["macrophages", "ANATOMY", 143, 154], ["vascular endothelium", "ANATOMY", 234, 254]]], ["In patients with COVID-19, there is upregulation of pro-inflammatory cytokines in the blood, including interleukin (IL)-1, IL-6, TNF, and interferon \u03b3, 7 Initial reports comprising a trial of 21 severe and critical COVID-19 patients in China (ChiCTR2000029765) and a case study from France 9 of clinical benefit with the anti-IL6 receptor antibody 10 tocilizumab in COVID-19 suggest that cytokines are of importance in the \"cytokine storm\" and further controlled clinical trials are in progress.", [["blood", "ANATOMY", 86, 91], ["tocilizumab", "CHEMICAL", 351, 362], ["patients", "ORGANISM", 3, 11], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 103, 121], ["IL-6", "GENE_OR_GENE_PRODUCT", 123, 127], ["TNF", "GENE_OR_GENE_PRODUCT", 129, 132], ["interferon \u03b3", "GENE_OR_GENE_PRODUCT", 138, 150], ["patients", "ORGANISM", 224, 232], ["COVID-19", "SIMPLE_CHEMICAL", 366, 374], ["pro-inflammatory cytokines", "PROTEIN", 52, 78], ["interleukin (IL)-1, IL-6", "PROTEIN", 103, 127], ["TNF", "PROTEIN", 129, 132], ["interferon \u03b3", "PROTEIN", 138, 150], ["anti-IL6 receptor antibody", "PROTEIN", 321, 347], ["cytokines", "PROTEIN", 388, 397], ["cytokine", "PROTEIN", 424, 432], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 224, 232], ["COVID", "TEST", 17, 22], ["pro-inflammatory cytokines", "PROBLEM", 52, 78], ["the blood", "TEST", 82, 91], ["interleukin (IL)", "TREATMENT", 103, 119], ["IL", "TEST", 123, 125], ["TNF", "TREATMENT", 129, 132], ["interferon", "TREATMENT", 138, 148], ["a case study", "TEST", 265, 277], ["the anti-IL6 receptor antibody", "TREATMENT", 317, 347], ["tocilizumab", "TREATMENT", 351, 362], ["COVID", "TEST", 366, 371], ["pro-inflammatory cytokines", "OBSERVATION", 52, 78], ["blood", "ANATOMY", 86, 91]]], ["Although there are many potential drug candidates for reducing inflammation in COVID-19, only a few drugs such as the anti-TNF antibodies infliximab or adalimumab are potentially effective, widely available, and have a well established safety profile.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededThe potential role of anti-TNF therapy thus warrants consideration.", [["inflammation", "DISEASE", 63, 75], ["infliximab", "CHEMICAL", 138, 148], ["adalimumab", "CHEMICAL", 152, 162], ["necrosis", "DISEASE", 273, 281], ["infliximab", "SIMPLE_CHEMICAL", 138, 148], ["adalimumab", "SIMPLE_CHEMICAL", 152, 162], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 261, 288], ["anti-TNF", "GENE_OR_GENE_PRODUCT", 351, 359], ["anti-TNF antibodies", "PROTEIN", 118, 137], ["anti-TNF", "PROTEIN", 351, 359], ["reducing inflammation", "PROBLEM", 54, 75], ["COVID", "TEST", 79, 84], ["a few drugs", "TREATMENT", 94, 105], ["the anti-TNF antibodies infliximab", "TREATMENT", 114, 148], ["adalimumab", "TREATMENT", 152, 162], ["anti-tumour necrosis factor therapy", "TREATMENT", 261, 296], ["COVID", "TEST", 301, 306], ["anti-TNF therapy", "TREATMENT", 351, 367], ["anti-TNF therapy", "OBSERVATION", 351, 367]]], ["Preclinical studies suggest that the response to severe respiratory syncytial virus (RSV) and influenza in mice is ameliorated by anti-TNF therapy, which reduces weight loss, disease duration, and cell and fluid infiltrate.", [["cell", "ANATOMY", 197, 201], ["fluid", "ANATOMY", 206, 211], ["respiratory syncytial virus", "DISEASE", 56, 83], ["RSV", "DISEASE", 85, 88], ["influenza", "DISEASE", 94, 103], ["weight loss", "DISEASE", 162, 173], ["respiratory syncytial virus", "ORGANISM", 56, 83], ["RSV", "ORGANISM", 85, 88], ["mice", "ORGANISM", 107, 111], ["anti-TNF", "SIMPLE_CHEMICAL", 130, 138], ["cell", "CELL", 197, 201], ["anti-TNF", "PROTEIN", 130, 138], ["mice", "SPECIES", 107, 111], ["respiratory syncytial virus", "SPECIES", 56, 83], ["RSV", "SPECIES", 85, 88], ["mice", "SPECIES", 107, 111], ["Preclinical studies", "TEST", 0, 19], ["severe respiratory syncytial virus", "PROBLEM", 49, 83], ["RSV", "PROBLEM", 85, 88], ["influenza", "PROBLEM", 94, 103], ["anti-TNF therapy", "TREATMENT", 130, 146], ["weight loss", "PROBLEM", 162, 173], ["disease duration", "PROBLEM", 175, 191], ["cell and fluid infiltrate", "PROBLEM", 197, 222], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["respiratory syncytial virus", "OBSERVATION", 56, 83], ["anti-TNF therapy", "OBSERVATION", 130, 146], ["fluid infiltrate", "OBSERVATION", 206, 222]]], ["11 This research suggests a potential rationale for use of anti-TNF therapy in viral pneumonia, especially given the known mechanism of action of TNF and the reversal of TNF-induced immunopathology by TNF blockade in multiple diseases.", [["viral pneumonia", "DISEASE", 79, 94], ["immunopathology", "DISEASE", 182, 197], ["anti-TNF", "SIMPLE_CHEMICAL", 59, 67], ["TNF", "GENE_OR_GENE_PRODUCT", 146, 149], ["TNF", "GENE_OR_GENE_PRODUCT", 170, 173], ["TNF", "GENE_OR_GENE_PRODUCT", 201, 204], ["TNF", "PROTEIN", 146, 149], ["TNF", "PROTEIN", 170, 173], ["TNF", "PROTEIN", 201, 204], ["anti-TNF therapy", "TREATMENT", 59, 75], ["viral pneumonia", "PROBLEM", 79, 94], ["TNF", "PROBLEM", 146, 149], ["TNF", "TREATMENT", 170, 173], ["TNF blockade", "TREATMENT", 201, 213], ["multiple diseases", "PROBLEM", 217, 234], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["pneumonia", "OBSERVATION", 85, 94], ["multiple", "OBSERVATION_MODIFIER", 217, 225], ["diseases", "OBSERVATION", 226, 234]]], ["It is known TNF is produced in most types of inflammation, especially in the acute phase, and is important in the coordination and development of the inflammatory response.", [["inflammation", "DISEASE", 45, 57], ["TNF", "GENE_OR_GENE_PRODUCT", 12, 15], ["TNF", "PROTEIN", 12, 15], ["inflammation", "PROBLEM", 45, 57], ["the inflammatory response", "PROBLEM", 146, 171], ["TNF", "OBSERVATION", 12, 15], ["most types", "OBSERVATION_MODIFIER", 31, 41], ["inflammation", "OBSERVATION", 45, 57], ["acute phase", "OBSERVATION_MODIFIER", 77, 88], ["inflammatory", "OBSERVATION", 150, 162]]], ["However, too much production of TNF for too long becomes immune suppressive.", [["TNF", "GENE_OR_GENE_PRODUCT", 32, 35], ["TNF", "PROTEIN", 32, 35], ["TNF", "PROBLEM", 32, 35], ["immune suppressive", "PROBLEM", 57, 75]]], ["12 Blockade of TNF alone is clinically effective in many circumstances and diseases, despite the presence of many other pro-inflammatory cytokines and mediators.", [["TNF", "GENE_OR_GENE_PRODUCT", 15, 18], ["TNF", "PROTEIN", 15, 18], ["pro-inflammatory cytokines", "PROTEIN", 120, 146], ["Blockade of TNF", "TREATMENT", 3, 18], ["diseases", "PROBLEM", 75, 83], ["diseases", "OBSERVATION", 75, 83], ["pro-inflammatory cytokines", "OBSERVATION", 120, 146]]], ["There is evidence of a \"TNF dependent cytokine cascade\" in rheumatoid arthritis tissue and upon bacterial challenge in baboons.", [["rheumatoid arthritis tissue", "ANATOMY", 59, 86], ["rheumatoid arthritis", "DISEASE", 59, 79], ["TNF", "GENE_OR_GENE_PRODUCT", 24, 27], ["tissue", "TISSUE", 80, 86], ["baboons", "ORGANISM", 119, 126], ["TNF", "PROTEIN", 24, 27], ["cytokine", "PROTEIN", 38, 46], ["a \"TNF dependent cytokine cascade", "PROBLEM", 21, 54], ["rheumatoid arthritis tissue", "PROBLEM", 59, 86], ["bacterial challenge in baboons", "TREATMENT", 96, 126], ["evidence of", "UNCERTAINTY", 9, 20], ["cytokine cascade", "OBSERVATION", 38, 54], ["rheumatoid arthritis", "OBSERVATION", 59, 79], ["bacterial", "OBSERVATION_MODIFIER", 96, 105]]], ["13, 14 Thus, if TNF is blocked, there is a rapid (ie, <12 h) decrease of IL-6 and IL-1 concentrations in patients with active rheumatoid arthritis 15 and, importantly, a reduction of adhesion molecules and vascular endothelial growth factor, which is also known as vascular permeability factor, denoting its importance in capillary leak.", [["vascular", "ANATOMY", 265, 273], ["capillary", "ANATOMY", 322, 331], ["rheumatoid arthritis", "DISEASE", 126, 146], ["TNF", "GENE_OR_GENE_PRODUCT", 16, 19], ["IL-6", "GENE_OR_GENE_PRODUCT", 73, 77], ["IL-1", "GENE_OR_GENE_PRODUCT", 82, 86], ["patients", "ORGANISM", 105, 113], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 206, 240], ["vascular permeability factor", "GENE_OR_GENE_PRODUCT", 265, 293], ["capillary", "TISSUE", 322, 331], ["TNF", "PROTEIN", 16, 19], ["adhesion molecules", "PROTEIN", 183, 201], ["vascular endothelial growth factor", "PROTEIN", 206, 240], ["vascular permeability factor", "PROTEIN", 265, 293], ["patients", "SPECIES", 105, 113], ["IL", "TEST", 73, 75], ["IL", "TREATMENT", 82, 84], ["active rheumatoid arthritis", "PROBLEM", 119, 146], ["adhesion molecules", "PROBLEM", 183, 201], ["vascular endothelial growth factor", "PROBLEM", 206, 240], ["vascular permeability factor", "PROBLEM", 265, 293], ["capillary leak", "PROBLEM", 322, 336], ["active", "OBSERVATION_MODIFIER", 119, 125], ["rheumatoid arthritis", "OBSERVATION", 126, 146], ["adhesion molecules", "OBSERVATION", 183, 201], ["vascular endothelial", "ANATOMY", 206, 226], ["vascular", "ANATOMY", 265, 273], ["capillary leak", "OBSERVATION", 322, 336]]], ["[15] [16] [17] [18] [19] Furthermore, a reduction in leucocyte trafficking occurs in inflamed tissues of joints due to reduction in adhesion molecules and chemokines 20 with reduction in cell content and exudate.", [["leucocyte", "ANATOMY", 53, 62], ["tissues", "ANATOMY", 94, 101], ["joints", "ANATOMY", 105, 111], ["cell", "ANATOMY", 187, 191], ["exudate", "ANATOMY", 204, 211], ["[15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 0, 24], ["leucocyte", "CELL", 53, 62], ["tissues", "TISSUE", 94, 101], ["joints", "MULTI-TISSUE_STRUCTURE", 105, 111], ["cell", "CELL", 187, 191], ["exudate", "TISSUE", 204, 211], ["adhesion molecules", "PROTEIN", 132, 150], ["chemokines 20", "PROTEIN", 155, 168], ["a reduction in leucocyte trafficking", "PROBLEM", 38, 74], ["inflamed tissues of joints", "PROBLEM", 85, 111], ["reduction in adhesion molecules", "TREATMENT", 119, 150], ["chemokines", "TEST", 155, 165], ["reduction in cell content", "PROBLEM", 174, 199], ["exudate", "PROBLEM", 204, 211], ["leucocyte trafficking", "OBSERVATION", 53, 74], ["inflamed tissues", "OBSERVATION", 85, 101], ["joints", "ANATOMY", 105, 111], ["cell content", "OBSERVATION", 187, 199], ["exudate", "OBSERVATION", 204, 211]]], ["Finally, after anti-TNF infusion tissue TNF is reduced as it passes into the blood bound to the anti-TNF antibody.", [["tissue", "ANATOMY", 33, 39], ["blood", "ANATOMY", 77, 82], ["tissue", "TISSUE", 33, 39], ["TNF", "GENE_OR_GENE_PRODUCT", 40, 43], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["anti-TNF antibody", "GENE_OR_GENE_PRODUCT", 96, 113], ["anti-TNF", "PROTEIN", 15, 23], ["TNF", "PROTEIN", 40, 43], ["anti-TNF antibody", "PROTEIN", 96, 113], ["anti-TNF infusion tissue TNF", "TREATMENT", 15, 43], ["the blood bound", "PROBLEM", 73, 88], ["the anti-TNF antibody", "TREATMENT", 92, 113]]], ["Blood concentrations of immunoreactive, but biologically inactive, TNF increase more than ten times after infusion.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["TNF", "GENE_OR_GENE_PRODUCT", 67, 70], ["TNF", "PROTEIN", 67, 70], ["Blood concentrations", "TEST", 0, 20], ["TNF", "PROBLEM", 67, 70], ["infusion", "TREATMENT", 106, 114], ["concentrations", "OBSERVATION_MODIFIER", 6, 20], ["immunoreactive", "OBSERVATION_MODIFIER", 24, 38], ["inactive", "OBSERVATION_MODIFIER", 57, 65]]], ["15 For these reasons it is possible that a single infusion of anti-TNF antibody might reduce some of the processes that occur during COVID-19 lung inflammation, reducing TNF and other inflammatory mediators, cellularity, and exudate.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededWhat would be the best time for intervention with anti-TNF therapy in patients with COVID-19?", [["lung", "ANATOMY", 142, 146], ["exudate", "ANATOMY", 225, 232], ["inflammation", "DISEASE", 147, 159], ["necrosis", "DISEASE", 255, 263], ["COVID-19", "CHEMICAL", 395, 403], ["anti-TNF antibody", "GENE_OR_GENE_PRODUCT", 62, 79], ["lung", "ORGAN", 142, 146], ["TNF", "GENE_OR_GENE_PRODUCT", 170, 173], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 243, 270], ["anti-TNF", "SIMPLE_CHEMICAL", 361, 369], ["patients", "ORGANISM", 381, 389], ["anti-TNF antibody", "PROTEIN", 62, 79], ["TNF", "PROTEIN", 170, 173], ["inflammatory mediators", "PROTEIN", 184, 206], ["patients", "SPECIES", 381, 389], ["a single infusion of anti-TNF antibody", "TREATMENT", 41, 79], ["COVID", "TEST", 133, 138], ["lung inflammation", "PROBLEM", 142, 159], ["TNF", "PROBLEM", 170, 173], ["other inflammatory mediators", "PROBLEM", 178, 206], ["cellularity", "PROBLEM", 208, 219], ["exudate", "PROBLEM", 225, 232], ["anti-tumour necrosis factor therapy", "TREATMENT", 243, 278], ["COVID", "TEST", 283, 288], ["intervention", "TREATMENT", 343, 355], ["anti-TNF therapy", "TREATMENT", 361, 377], ["COVID", "TEST", 395, 400], ["lung", "ANATOMY", 142, 146], ["inflammation", "OBSERVATION", 147, 159], ["inflammatory", "OBSERVATION_MODIFIER", 184, 196], ["cellularity", "OBSERVATION", 208, 219], ["exudate", "OBSERVATION_MODIFIER", 225, 232]]], ["We postulate that the earlier the better after hospital admission might be the answer because patients will already have initiated anti-viral immunity for several days.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["anti-viral immunity", "TREATMENT", 131, 150]]], ["There is a balance to be struck between stage of intervention and ensuring patients are at sufficient risk of a poor outcome and can be appropriately monitored.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["intervention", "TREATMENT", 49, 61]]], ["We propose that initial assessment of anti-TNF therapy in clinical trials should be in patients with moderate disease admitted to hospital and who require oxygen support but not intensive care.", [["oxygen", "CHEMICAL", 155, 161], ["oxygen", "CHEMICAL", 155, 161], ["patients", "ORGANISM", 87, 95], ["oxygen", "SIMPLE_CHEMICAL", 155, 161], ["anti-TNF", "PROTEIN", 38, 46], ["patients", "SPECIES", 87, 95], ["initial assessment", "TEST", 16, 34], ["anti-TNF therapy", "TREATMENT", 38, 54], ["moderate disease", "PROBLEM", 101, 117], ["oxygen support", "TREATMENT", 155, 169], ["intensive care", "TREATMENT", 178, 192]]], ["If this treatment approach proved beneficial with a good safety profile, treatment in the community for people identified as being at high risk of progressing to hospital admission might be considered.", [["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["this treatment approach", "TREATMENT", 3, 26], ["treatment", "TREATMENT", 73, 82]]], ["The range of available formulations and administration routes of anti-TNF products could facilitate this treatment approach.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededIs there a trade-off between immunity and virus clearance?", [["necrosis", "DISEASE", 146, 154], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 134, 161], ["anti-TNF products", "PROTEIN", 65, 82], ["available formulations", "TREATMENT", 13, 35], ["administration routes of anti-TNF products", "TREATMENT", 40, 82], ["this treatment approach", "TREATMENT", 100, 123], ["anti-tumour necrosis factor therapy", "TREATMENT", 134, 169], ["COVID", "TEST", 174, 179], ["virus clearance", "TEST", 244, 259]]], ["The use of powerful anti-inflammatory drugs in acute viral diseases has to be approached with caution because of the risk of increasing viral replication or bacterial infections.", [["acute viral diseases", "DISEASE", 47, 67], ["bacterial infections", "DISEASE", 157, 177], ["powerful anti-inflammatory drugs", "TREATMENT", 11, 43], ["acute viral diseases", "PROBLEM", 47, 67], ["increasing viral replication", "PROBLEM", 125, 153], ["bacterial infections", "PROBLEM", 157, 177], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["viral diseases", "OBSERVATION", 53, 67], ["increasing", "OBSERVATION_MODIFIER", 125, 135], ["viral replication", "OBSERVATION", 136, 153], ["bacterial", "OBSERVATION_MODIFIER", 157, 166], ["infections", "OBSERVATION", 167, 177]]], ["For lung viral infections, the higher the infectious dose, the greater the tissue damage from viral replication and the ensuing immune response.", [["lung", "ANATOMY", 4, 8], ["tissue", "ANATOMY", 75, 81], ["lung viral infections", "DISEASE", 4, 25], ["lung", "ORGAN", 4, 8], ["tissue", "TISSUE", 75, 81], ["lung viral infections", "PROBLEM", 4, 25], ["the tissue damage", "PROBLEM", 71, 88], ["viral replication", "TREATMENT", 94, 111], ["lung", "ANATOMY", 4, 8], ["viral", "OBSERVATION_MODIFIER", 9, 14], ["infections", "OBSERVATION", 15, 25], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["infectious", "OBSERVATION_MODIFIER", 42, 52], ["greater", "OBSERVATION_MODIFIER", 63, 70], ["tissue", "OBSERVATION_MODIFIER", 75, 81], ["damage", "OBSERVATION", 82, 88], ["viral replication", "OBSERVATION", 94, 111], ["immune response", "OBSERVATION", 128, 143]]], ["In animal models that resemble lung viral infection in humans, the immune response to the virus is so great that even a moderate reduction in inflammation is beneficial-eg, mice with severe pneumonia from RSV or influenza benefit from anti-TNF treatment without compromising viral clearance 11 because more of the lung architecture is preserved.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededHowever, concerns about safety are important when considering new therapy.", [["lung", "ANATOMY", 31, 35], ["lung", "ANATOMY", 314, 318], ["lung viral infection", "DISEASE", 31, 51], ["inflammation", "DISEASE", 142, 154], ["pneumonia", "DISEASE", 190, 199], ["RSV", "DISEASE", 205, 208], ["influenza", "DISEASE", 212, 221], ["necrosis", "DISEASE", 367, 375], ["lung", "ORGAN", 31, 35], ["viral", "ORGANISM", 36, 41], ["humans", "ORGANISM", 55, 61], ["mice", "ORGANISM", 173, 177], ["RSV", "ORGANISM", 205, 208], ["anti-TNF", "GENE_OR_GENE_PRODUCT", 235, 243], ["lung", "ORGAN", 314, 318], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 355, 382], ["anti-TNF", "PROTEIN", 235, 243], ["humans", "SPECIES", 55, 61], ["mice", "SPECIES", 173, 177], ["humans", "SPECIES", 55, 61], ["mice", "SPECIES", 173, 177], ["RSV", "SPECIES", 205, 208], ["lung viral infection in humans", "PROBLEM", 31, 61], ["the virus", "PROBLEM", 86, 95], ["a moderate reduction in inflammation", "PROBLEM", 118, 154], ["severe pneumonia", "PROBLEM", 183, 199], ["RSV", "PROBLEM", 205, 208], ["influenza", "PROBLEM", 212, 221], ["anti-TNF treatment", "TREATMENT", 235, 253], ["compromising viral clearance", "PROBLEM", 262, 290], ["anti-tumour necrosis factor therapy", "TREATMENT", 355, 390], ["COVID", "TREATMENT", 395, 400], ["new therapy", "TREATMENT", 485, 496], ["lung", "ANATOMY", 31, 35], ["viral", "OBSERVATION_MODIFIER", 36, 41], ["infection", "OBSERVATION", 42, 51], ["moderate", "OBSERVATION_MODIFIER", 120, 128], ["reduction", "OBSERVATION_MODIFIER", 129, 138], ["inflammation", "OBSERVATION", 142, 154], ["severe", "OBSERVATION_MODIFIER", 183, 189], ["pneumonia", "OBSERVATION", 190, 199], ["RSV", "OBSERVATION", 205, 208], ["lung", "ANATOMY", 314, 318], ["architecture", "ANATOMY_MODIFIER", 319, 331], ["preserved", "OBSERVATION", 335, 344]]], ["Would anti-TNF therapy increase the risk of bacterial or fungal super-infections?", [["fungal super-infections", "DISEASE", 57, 80], ["anti-TNF therapy", "TREATMENT", 6, 22], ["bacterial or fungal super-infections", "PROBLEM", 44, 80], ["bacterial", "OBSERVATION_MODIFIER", 44, 53], ["fungal", "OBSERVATION_MODIFIER", 57, 63], ["infections", "OBSERVATION", 70, 80]]], ["After respiratory viral infection, superinfections with other organisms occur at the most severe end of the disease spectrum.", [["respiratory viral infection", "DISEASE", 6, 33], ["superinfections", "DISEASE", 35, 50], ["respiratory viral infection", "PROBLEM", 6, 33], ["superinfections", "PROBLEM", 35, 50], ["other organisms", "PROBLEM", 56, 71], ["the disease spectrum", "PROBLEM", 104, 124], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 24, 33], ["superinfections", "OBSERVATION", 35, 50], ["most severe", "OBSERVATION_MODIFIER", 85, 96], ["disease", "OBSERVATION", 108, 115]]], ["Many research groups have elucidated the mechanisms responsible 21 and anecdotal evidence suggests that bacteria might have a role in in COVID- 19, 5, 22 although this remains to be confirmed.", [["bacteria", "PROBLEM", 104, 112], ["bacteria", "OBSERVATION", 104, 112]]], ["Bacteria gain a foothold faster in a lung that is damaged.", [["lung", "ANATOMY", 37, 41], ["lung", "ORGAN", 37, 41], ["Bacteria gain", "PROBLEM", 0, 13], ["faster", "OBSERVATION_MODIFIER", 25, 31], ["lung", "ANATOMY", 37, 41]]], ["Experimental studies suggest that if the duration of inflammation is limited, with its associated collateral lung damage, then bacterial superinfection is reduced.", [["collateral lung", "ANATOMY", 98, 113], ["inflammation", "DISEASE", 53, 65], ["collateral lung damage", "DISEASE", 98, 120], ["superinfection", "DISEASE", 137, 151], ["collateral lung", "MULTI-TISSUE_STRUCTURE", 98, 113], ["Experimental studies", "TEST", 0, 20], ["inflammation", "PROBLEM", 53, 65], ["its associated collateral lung damage", "PROBLEM", 83, 120], ["bacterial superinfection", "PROBLEM", 127, 151], ["inflammation", "OBSERVATION", 53, 65], ["collateral", "OBSERVATION_MODIFIER", 98, 108], ["lung", "ANATOMY", 109, 113], ["damage", "OBSERVATION", 114, 120], ["bacterial", "OBSERVATION_MODIFIER", 127, 136], ["superinfection", "OBSERVATION", 137, 151], ["reduced", "OBSERVATION_MODIFIER", 155, 162]]], ["23 There is concern that anti-TNF therapy might increase the risk of bacterial infection.", [["bacterial infection", "DISEASE", 69, 88], ["anti-TNF", "SIMPLE_CHEMICAL", 25, 33], ["anti-TNF therapy", "TREATMENT", 25, 41], ["bacterial infection", "PROBLEM", 69, 88], ["anti-TNF therapy", "OBSERVATION", 25, 41], ["bacterial", "OBSERVATION_MODIFIER", 69, 78], ["infection", "OBSERVATION", 79, 88]]], ["24 Yet two randomised studies in critically unwell patients with septic shock 25, 26 showed that monoclonal anti-TNF therapy had good safety data with no evidence of increased secondary bacterial infections in the anti-TNF treated group.", [["septic shock", "DISEASE", 65, 77], ["bacterial infections", "DISEASE", 186, 206], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["two randomised studies", "TEST", 7, 29], ["septic shock", "PROBLEM", 65, 77], ["monoclonal anti-TNF therapy", "TREATMENT", 97, 124], ["increased secondary bacterial infections", "PROBLEM", 166, 206], ["the anti-TNF treated group", "TREATMENT", 210, 236], ["no evidence of", "UNCERTAINTY", 151, 165], ["increased", "OBSERVATION_MODIFIER", 166, 175], ["secondary", "OBSERVATION_MODIFIER", 176, 185], ["bacterial", "OBSERVATION_MODIFIER", 186, 195], ["infections", "OBSERVATION", 196, 206]]], ["In an observational trial in rheumatoid arthritis patients with serious infections, the risk of sepsis and death was reduced in patients on TNF inhibitors compared with those on synthetic disease-modifying anti-rheumatic drugs (DMARDS).", [["rheumatoid arthritis", "DISEASE", 29, 49], ["infections", "DISEASE", 72, 82], ["sepsis", "DISEASE", 96, 102], ["death", "DISEASE", 107, 112], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 128, 136], ["TNF", "GENE_OR_GENE_PRODUCT", 140, 143], ["disease-modifying anti-rheumatic drugs", "SIMPLE_CHEMICAL", 188, 226], ["TNF", "PROTEIN", 140, 143], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 128, 136], ["rheumatoid arthritis", "PROBLEM", 29, 49], ["serious infections", "PROBLEM", 64, 82], ["sepsis", "PROBLEM", 96, 102], ["death", "PROBLEM", 107, 112], ["TNF inhibitors", "TREATMENT", 140, 154], ["synthetic disease", "PROBLEM", 178, 195], ["modifying anti-rheumatic drugs", "TREATMENT", 196, 226], ["rheumatoid", "OBSERVATION_MODIFIER", 29, 39], ["arthritis", "OBSERVATION", 40, 49], ["sepsis", "OBSERVATION", 96, 102], ["reduced", "OBSERVATION_MODIFIER", 117, 124], ["anti-rheumatic drugs", "OBSERVATION", 206, 226]]], ["27 46 (11%) of 399 patients on TNF inhibitors developed sepsis after serious infection, of whom 20 (43%) died, compared with 74 (17%) of 444 patients on DMARDS who developed sepsis, of whom 54 (74%) died.", [["sepsis", "DISEASE", 56, 62], ["infection", "DISEASE", 77, 86], ["sepsis", "DISEASE", 174, 180], ["patients", "ORGANISM", 19, 27], ["TNF", "GENE_OR_GENE_PRODUCT", 31, 34], ["patients", "ORGANISM", 141, 149], ["TNF", "PROTEIN", 31, 34], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 141, 149], ["TNF inhibitors", "TREATMENT", 31, 45], ["sepsis", "PROBLEM", 56, 62], ["serious infection", "PROBLEM", 69, 86], ["DMARDS", "TREATMENT", 153, 159], ["sepsis", "PROBLEM", 174, 180], ["sepsis", "OBSERVATION", 56, 62], ["serious", "OBSERVATION_MODIFIER", 69, 76], ["infection", "OBSERVATION", 77, 86], ["sepsis", "OBSERVATION", 174, 180]]], ["27 Paradoxically, another class of TNF inhibitor, a TNF-R2 Ig-Fc fusion protein, etanercept, was associated with moderately increased mortality in a randomised trial of this treatment for sepsis, 28 possibly due to its faster offrate for TNF potentially resulting in some redistribution and bioavailability of pathogenic TNF rather than its clearance.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededThere has been interest as to whether the safety of anti-TNF therapy in patients with COVID-19 might be gleaned from analysis of the course of COVID-19 in patients with inflammatory bowel disease (IBD) or rheumatoid arthritis who are already on anti-TNF treatment.", [["bowel", "ANATOMY", 611, 616], ["etanercept", "CHEMICAL", 81, 91], ["sepsis", "DISEASE", 188, 194], ["necrosis", "DISEASE", 373, 381], ["COVID-19", "CHEMICAL", 572, 580], ["inflammatory bowel disease", "DISEASE", 598, 624], ["IBD", "DISEASE", 626, 629], ["rheumatoid arthritis", "DISEASE", 634, 654], ["COVID-19", "CHEMICAL", 515, 523], ["COVID-19", "CHEMICAL", 572, 580], ["TNF", "GENE_OR_GENE_PRODUCT", 35, 38], ["TNF-R2 Ig-Fc", "GENE_OR_GENE_PRODUCT", 52, 64], ["etanercept", "SIMPLE_CHEMICAL", 81, 91], ["TNF", "GENE_OR_GENE_PRODUCT", 238, 241], ["TNF", "GENE_OR_GENE_PRODUCT", 321, 324], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 361, 388], ["anti-TNF", "GENE_OR_GENE_PRODUCT", 481, 489], ["patients", "ORGANISM", 501, 509], ["patients", "ORGANISM", 584, 592], ["bowel", "ORGAN", 611, 616], ["TNF", "PROTEIN", 35, 38], ["TNF-R2 Ig", "PROTEIN", 52, 61], ["Fc fusion protein", "PROTEIN", 62, 79], ["TNF", "PROTEIN", 238, 241], ["TNF", "PROTEIN", 321, 324], ["anti-TNF", "PROTEIN", 674, 682], ["patients", "SPECIES", 501, 509], ["patients", "SPECIES", 584, 592], ["TNF inhibitor", "TREATMENT", 35, 48], ["a TNF", "TEST", 50, 55], ["Ig", "TEST", 59, 61], ["etanercept", "TREATMENT", 81, 91], ["moderately increased mortality", "PROBLEM", 113, 143], ["this treatment", "TREATMENT", 169, 183], ["sepsis", "PROBLEM", 188, 194], ["TNF", "PROBLEM", 238, 241], ["some redistribution", "PROBLEM", 267, 286], ["pathogenic TNF", "PROBLEM", 310, 324], ["anti-tumour necrosis factor therapy", "TREATMENT", 361, 396], ["COVID", "TEST", 401, 406], ["anti-TNF therapy", "TREATMENT", 481, 497], ["COVID", "TEST", 515, 520], ["COVID", "TEST", 572, 577], ["inflammatory bowel disease", "PROBLEM", 598, 624], ["IBD)", "PROBLEM", 626, 630], ["rheumatoid arthritis", "PROBLEM", 634, 654], ["anti-TNF treatment", "TREATMENT", 674, 692], ["moderately", "OBSERVATION_MODIFIER", 113, 123], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["mortality", "OBSERVATION", 134, 143], ["sepsis", "OBSERVATION", 188, 194], ["redistribution", "OBSERVATION", 272, 286], ["pathogenic", "OBSERVATION_MODIFIER", 310, 320], ["TNF", "OBSERVATION", 321, 324], ["inflammatory", "OBSERVATION_MODIFIER", 598, 610], ["bowel", "ANATOMY", 611, 616], ["disease", "OBSERVATION", 617, 624], ["rheumatoid", "OBSERVATION_MODIFIER", 634, 644], ["arthritis", "OBSERVATION", 645, 654]]], ["As of April 6, 2020, on SECURE-IBD, a coronavirus and IBD reporting database with a register of outcomes of IBD patients with COVID-19, there were 116 patients on anti-TNF therapy alone, 99 of whom recovered without hospitalisation and one patient died.", [["IBD", "DISEASE", 108, 111], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 151, 159], ["patient", "ORGANISM", 240, 247], ["anti-TNF", "PROTEIN", 163, 171], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 151, 159], ["patient", "SPECIES", 240, 247], ["IBD", "PROBLEM", 31, 34], ["a coronavirus", "PROBLEM", 36, 49], ["IBD", "PROBLEM", 108, 111], ["COVID", "TEST", 126, 131], ["anti-TNF therapy", "TREATMENT", 163, 179], ["IBD", "OBSERVATION", 31, 34], ["coronavirus", "OBSERVATION", 38, 49], ["IBD", "OBSERVATION", 108, 111]]], ["By contrast, about half of 71 patients on sulfasalazine/ mesalamine recovered without hospital admission and six patients died.", [["sulfasalazine", "CHEMICAL", 42, 55], ["mesalamine", "CHEMICAL", 57, 67], ["sulfasalazine", "CHEMICAL", 42, 55], ["mesalamine", "CHEMICAL", 57, 67], ["patients", "ORGANISM", 30, 38], ["sulfasalazine", "SIMPLE_CHEMICAL", 42, 55], ["mesalamine", "SIMPLE_CHEMICAL", 57, 67], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 113, 121], ["sulfasalazine", "TREATMENT", 42, 55], ["mesalamine", "TREATMENT", 57, 67]]], ["Thus IBD patients with COVID-19 on anti-TNF therapy do not fare worse than those treated with other drugs, but there are insufficient data to make conclusions about a better outcome.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededWe believe there is sufficient evidence to support clinical trials of anti-TNF therapy in patients with COVID-19.", [["IBD", "DISEASE", 5, 8], ["necrosis", "DISEASE", 204, 212], ["patients", "ORGANISM", 9, 17], ["anti-TNF", "GENE_OR_GENE_PRODUCT", 35, 43], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 192, 219], ["anti-TNF", "SIMPLE_CHEMICAL", 330, 338], ["patients", "ORGANISM", 350, 358], ["TNF", "PROTEIN", 40, 43], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 350, 358], ["COVID", "TEST", 23, 28], ["anti-TNF therapy", "TREATMENT", 35, 51], ["other drugs", "TREATMENT", 94, 105], ["anti-tumour necrosis factor therapy", "TREATMENT", 192, 227], ["COVID", "TEST", 232, 237], ["anti-TNF therapy", "TREATMENT", 330, 346], ["COVID", "TEST", 364, 369]]], ["With an average of 2 days between hospital admission and ARDS, 7 we propose anti-TNF therapy should be initiated as early as is practicable.", [["ARDS", "DISEASE", 57, 61], ["anti-TNF", "PROTEIN", 76, 84], ["ARDS", "PROBLEM", 57, 61], ["anti-TNF therapy", "TREATMENT", 76, 92], ["ARDS", "OBSERVATION", 57, 61]]], ["If there is preliminary evidence of benefit and safety of anti-TNF therapy in hospitalised patients, we suggest consideration should be given to out of hospital treatment for patients with COVID-19 at high risk, such as older people and those with pre-existing conditions, and who can be monitored appropriately.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededMF and RNM have held patents, now expired, on use of infliximab and methotrexate in inflammatory arthritis and have received royalties from Johnson and Johnson, AbbVie, Amgen, and UCB, none of which are for respiratory or critical care.", [["necrosis", "DISEASE", 334, 342], ["infliximab", "CHEMICAL", 443, 453], ["methotrexate", "CHEMICAL", 458, 470], ["inflammatory arthritis", "DISEASE", 474, 496], ["methotrexate", "CHEMICAL", 458, 470], ["anti-TNF", "SIMPLE_CHEMICAL", 58, 66], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 175, 183], ["people", "ORGANISM", 226, 232], ["anti-tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 322, 349], ["infliximab", "SIMPLE_CHEMICAL", 443, 453], ["methotrexate", "SIMPLE_CHEMICAL", 458, 470], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 175, 183], ["people", "SPECIES", 226, 232], ["anti-TNF therapy", "TREATMENT", 58, 74], ["hospital treatment", "TREATMENT", 152, 170], ["COVID", "TEST", 189, 194], ["anti-tumour necrosis factor therapy", "TREATMENT", 322, 357], ["COVID", "TEST", 362, 367], ["infliximab", "TREATMENT", 443, 453], ["methotrexate", "TREATMENT", 458, 470], ["inflammatory arthritis", "PROBLEM", 474, 496], ["preliminary evidence of", "UNCERTAINTY", 12, 35], ["inflammatory", "OBSERVATION_MODIFIER", 474, 486], ["arthritis", "OBSERVATION", 487, 496], ["UCB", "ANATOMY", 570, 573]]], ["The financial assets of the Kennedy Trust for Rheumatology Research were largely derived from patent royalties on anti-TNF antibodies.", [["anti-TNF antibodies", "GENE_OR_GENE_PRODUCT", 114, 133], ["anti-TNF antibodies", "PROTEIN", 114, 133], ["anti-TNF antibodies", "TREATMENT", 114, 133], ["patent", "OBSERVATION", 94, 100]]], ["STH is Non-Executive Board Director (NED) and a shareholder of Synairgen.", [["a shareholder of Synairgen", "TREATMENT", 46, 72]]], ["Synairgen is conducting a clinical trial of inhaled IFN \u03b2 in COVID-19 patients, but this is unrelated to this Comment.", [["Synairgen", "CHEMICAL", 0, 9], ["Synairgen", "SIMPLE_CHEMICAL", 0, 9], ["IFN \u03b2", "GENE_OR_GENE_PRODUCT", 52, 57], ["patients", "ORGANISM", 70, 78], ["IFN \u03b2", "PROTEIN", 52, 57], ["patients", "SPECIES", 70, 78]]], ["STH has played no direct role in the Synairgen trial other than his role as a NED.", [["STH", "DISEASE", 0, 3], ["the Synairgen trial", "TREATMENT", 33, 52], ["no", "UNCERTAINTY", 15, 17]]], ["STH has no direct interests in anti-TNF or any other therapeutics referred to in this Comment.", [["STH", "DISEASE", 0, 3], ["anti-TNF", "CANCER", 31, 39], ["anti-TNF", "PROTEIN", 31, 39], ["anti-TNF", "TREATMENT", 31, 39], ["no", "UNCERTAINTY", 8, 10]]], ["GW receives directors fees that include options to shares as Founder and Director of Bicycle Therapeutics plc unrelated to the topic of this Comment and was a Founder of Cambridge Antibody Technology, which in the 1990s co-developed the anti-TNF antibody adalimumab, and pre-2003 advised Peptech and Domantis on their anti-TNF developments and patents.", [["adalimumab", "CHEMICAL", 255, 265], ["adalimumab", "SIMPLE_CHEMICAL", 255, 265], ["anti-TNF antibody", "PROTEIN", 237, 254], ["the anti-TNF antibody adalimumab", "TREATMENT", 233, 265], ["Peptech", "TREATMENT", 288, 295], ["Domantis", "TREATMENT", 300, 308]]], ["GW is a Trustee of the Kennedy Trust for Rheumatology Research, for which the financial assets were largely derived from patent royalties on anti-TNF antibodies.", [["anti-TNF antibodies", "GENE_OR_GENE_PRODUCT", 141, 160], ["anti-TNF antibodies", "PROTEIN", 141, 160], ["anti-TNF antibodies", "TREATMENT", 141, 160], ["patent", "OBSERVATION", 121, 127]]], ["DR reports personal fees for consultancy on drug safety from GlaxoSmithKline unrelated to the topic of this Comment.", [["GlaxoSmithKline", "TREATMENT", 61, 76]]], ["MR and TH declare no competing interests.", [["MR", "PROTEIN", 0, 2], ["MR", "TEST", 0, 2]]]], "PMC7454820": [], "PMC7240263": [], "0440e70beeefb9c36921bb8032ac02816f3c27a3": [["IntroductionThere is a lack of information on the interactions between hormone concentrations and diseases of the gastrointestinal tract in early postnatal calves.", [["gastrointestinal tract", "ANATOMY", 114, 136], ["diseases of the gastrointestinal tract", "DISEASE", 98, 136], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 114, 136], ["calves", "ORGANISM", 156, 162], ["calves", "SPECIES", 156, 162], ["hormone concentrations", "TREATMENT", 71, 93], ["diseases of the gastrointestinal tract", "PROBLEM", 98, 136], ["gastrointestinal tract", "ANATOMY", 114, 136], ["postnatal calves", "ANATOMY", 146, 162]]], ["The early postnatal time is a period of dramatic changes.", [["dramatic changes", "PROBLEM", 40, 56], ["dramatic", "OBSERVATION_MODIFIER", 40, 48]]], ["In particular, the gastrointestinal tract is suddenly being responsible for nutrient absorption.", [["gastrointestinal tract", "ANATOMY", 19, 41], ["gastrointestinal tract", "DISEASE", 19, 41], ["gastrointestinal tract", "ORGAN", 19, 41], ["gastrointestinal tract", "ANATOMY", 19, 41]]], ["The intestine is the most rapidly developing tissue during this time [1] .", [["intestine", "ANATOMY", 4, 13], ["tissue", "ANATOMY", 45, 51], ["intestine", "ORGAN", 4, 13], ["tissue", "TISSUE", 45, 51], ["intestine", "ANATOMY", 4, 13], ["most", "OBSERVATION_MODIFIER", 21, 25], ["rapidly", "OBSERVATION_MODIFIER", 26, 33]]], ["In the initial first few days, transport from lumen of the gut to the animal's blood stream is facilitated by a high permeability of the gut.", [["lumen", "ANATOMY", 46, 51], ["gut", "ANATOMY", 59, 62], ["blood stream", "ANATOMY", 79, 91], ["gut", "ANATOMY", 137, 140], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 51], ["gut", "ORGANISM_SUBDIVISION", 59, 62], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["gut", "ORGANISM_SUBDIVISION", 137, 140], ["lumen", "ANATOMY_MODIFIER", 46, 51], ["gut", "ANATOMY", 59, 62], ["high permeability", "OBSERVATION", 112, 129], ["gut", "ANATOMY", 137, 140]]], ["The permeability is later decreased, which may protect from bacterial infection.IntroductionStudies of cortisol and growth hormone have shown that these hormones may play a role in regulation of gut permeability and growth.", [["gut", "ANATOMY", 195, 198], ["bacterial infection", "DISEASE", 60, 79], ["cortisol", "CHEMICAL", 103, 111], ["cortisol", "CHEMICAL", 103, 111], ["cortisol", "GENE_OR_GENE_PRODUCT", 103, 111], ["gut", "ORGANISM_SUBDIVISION", 195, 198], ["bacterial infection", "PROBLEM", 60, 79], ["cortisol and growth hormone", "TREATMENT", 103, 130], ["permeability", "OBSERVATION_MODIFIER", 4, 16], ["decreased", "OBSERVATION_MODIFIER", 26, 35], ["may protect", "UNCERTAINTY", 43, 54], ["bacterial", "OBSERVATION_MODIFIER", 60, 69], ["infection", "OBSERVATION", 70, 79]]], ["The perinatal cortisol concentrations represent the maximum levels observed throughout the entire life span.", [["cortisol", "CHEMICAL", 14, 22], ["cortisol", "CHEMICAL", 14, 22], ["cortisol", "GENE_OR_GENE_PRODUCT", 14, 22], ["The perinatal cortisol concentrations", "TEST", 0, 37], ["the maximum levels", "TEST", 48, 66]]], ["Glucocorticoids involved in metabolic control play an important role in the development of tissues and organs in the neonatal calf [2] .", [["tissues", "ANATOMY", 91, 98], ["organs", "ANATOMY", 103, 109], ["tissues", "TISSUE", 91, 98], ["organs", "ORGAN", 103, 109], ["calf", "ORGANISM_SUBDIVISION", 126, 130], ["calf", "SPECIES", 126, 130], ["Glucocorticoids", "TREATMENT", 0, 15], ["metabolic control", "TREATMENT", 28, 45], ["metabolic control", "OBSERVATION", 28, 45], ["organs", "ANATOMY", 103, 109], ["neonatal calf", "ANATOMY", 117, 130]]], ["The very high cortisol levels observed up to 1 wk after birth may facilitate absorption of IgG [3] .", [["cortisol", "CHEMICAL", 14, 22], ["cortisol", "CHEMICAL", 14, 22], ["cortisol", "GENE_OR_GENE_PRODUCT", 14, 22], ["IgG", "PROTEIN", 91, 94], ["The very high cortisol levels", "PROBLEM", 0, 29]]], ["GH receptors have been demonstrated in fetal human gut tissue from Week 20 of pregnancy [4] .", [["fetal", "ANATOMY", 39, 44], ["gut tissue", "ANATOMY", 51, 61], ["GH receptors", "GENE_OR_GENE_PRODUCT", 0, 12], ["human", "ORGANISM", 45, 50], ["gut tissue", "TISSUE", 51, 61], ["GH receptors", "PROTEIN", 0, 12], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50]]], ["The high level of growth hormone is thought to mediate its biologic effect via the specific GH receptors that stimulate the proliferation of crypt cells [5] .", [["crypt cells", "ANATOMY", 141, 152], ["GH receptors", "GENE_OR_GENE_PRODUCT", 92, 104], ["crypt cells", "CELL", 141, 152], ["GH receptors", "PROTEIN", 92, 104], ["crypt cells", "CELL_TYPE", 141, 152], ["The high level of growth hormone", "PROBLEM", 0, 32], ["the specific GH receptors", "TREATMENT", 79, 104], ["crypt cells", "PROBLEM", 141, 152], ["high", "OBSERVATION_MODIFIER", 4, 8], ["growth hormone", "OBSERVATION", 18, 32], ["crypt cells", "OBSERVATION", 141, 152]]], ["Thus, particularly the high concentration of GH may be important for the development and the function of the digestive tract.IntroductionDiarrhea is a major problem in the adjustment phase of the gut.", [["digestive tract", "ANATOMY", 109, 124], ["gut", "ANATOMY", 196, 199], ["IntroductionDiarrhea", "DISEASE", 125, 145], ["GH", "GENE_OR_GENE_PRODUCT", 45, 47], ["digestive tract", "ORGAN", 109, 124], ["gut", "ORGANISM_SUBDIVISION", 196, 199], ["a major problem", "PROBLEM", 149, 164], ["digestive tract", "ANATOMY", 109, 124], ["major", "OBSERVATION_MODIFIER", 151, 156], ["problem", "OBSERVATION", 157, 164], ["gut", "ANATOMY", 196, 199]]], ["In calves, mortality related to diarrhea constituted 52% of total deaths [6] .", [["diarrhea", "DISEASE", 32, 40], ["deaths", "DISEASE", 66, 72], ["calves", "ORGANISM", 3, 9], ["calves", "SPECIES", 3, 9], ["diarrhea", "PROBLEM", 32, 40]]], ["Because retrospective surveys attempting to determine the relative importance of various stressors have characteristically identified aberrations of intestinal function as a major causative factor, an understanding of factors mediating postnatal growth and development of the gastrointestinal tract is essential [1] .", [["intestinal", "ANATOMY", 149, 159], ["gastrointestinal tract", "ANATOMY", 276, 298], ["intestinal", "ORGAN", 149, 159], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 276, 298], ["retrospective surveys", "TEST", 8, 29], ["aberrations of intestinal function", "PROBLEM", 134, 168], ["postnatal growth", "PROBLEM", 236, 252], ["intestinal", "ANATOMY", 149, 159], ["gastrointestinal tract", "ANATOMY", 276, 298]]], ["Further, the economic loss due to diarrhea that are cured are substantial because the disease interferes with growth.", [["diarrhea", "DISEASE", 34, 42], ["the economic loss", "PROBLEM", 9, 26], ["diarrhea", "PROBLEM", 34, 42], ["the disease", "PROBLEM", 82, 93], ["diarrhea", "OBSERVATION", 34, 42], ["substantial", "OBSERVATION_MODIFIER", 62, 73], ["disease", "OBSERVATION", 86, 93], ["growth", "OBSERVATION_MODIFIER", 110, 116]]], ["However, the effect of diarrhea on hormonal regulation of gut development and gonadal maturation has so far only received limited attention.", [["gut", "ANATOMY", 58, 61], ["gonadal", "ANATOMY", 78, 85], ["diarrhea", "DISEASE", 23, 31], ["gut", "ORGANISM_SUBDIVISION", 58, 61], ["gonadal", "ANATOMICAL_SYSTEM", 78, 85], ["diarrhea", "PROBLEM", 23, 31], ["hormonal regulation", "TREATMENT", 35, 54], ["gonadal maturation", "PROBLEM", 78, 96], ["diarrhea", "OBSERVATION", 23, 31]]], ["We therefore aimed to characterize the alterations of GH, cortisol, and LH concentrations in young calves affected with clinical diarrhea.", [["cortisol", "CHEMICAL", 58, 66], ["diarrhea", "DISEASE", 129, 137], ["cortisol", "CHEMICAL", 58, 66], ["GH", "GENE_OR_GENE_PRODUCT", 54, 56], ["cortisol", "SIMPLE_CHEMICAL", 58, 66], ["LH", "SIMPLE_CHEMICAL", 72, 74], ["calves", "ORGANISM", 99, 105], ["calves", "SPECIES", 99, 105], ["the alterations of GH", "PROBLEM", 35, 56], ["cortisol", "TEST", 58, 66], ["LH concentrations", "PROBLEM", 72, 89], ["clinical diarrhea", "PROBLEM", 120, 137]]], ["We further included insulin levels in the study as a measure of the metabolic status of the calves.Animals, health status, blood collection, and nutritionHolstein Friesian (n \u03ed 11) and Red Holstein (n \u03ed 9) calves, 10 males and 10 females, were clinically observed during the first three weeks of life.", [["blood", "ANATOMY", 123, 128], ["insulin", "GENE_OR_GENE_PRODUCT", 20, 27], ["calves", "ORGANISM", 92, 98], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["calves", "ORGANISM", 206, 212], ["insulin", "PROTEIN", 20, 27], ["calves", "SPECIES", 92, 98], ["calves", "SPECIES", 206, 212], ["Holstein Friesian (n \u03ed 11", "SPECIES", 154, 179], ["Red Holstein (n \u03ed 9", "SPECIES", 185, 204], ["insulin levels", "TEST", 20, 34], ["the study", "TEST", 38, 47], ["blood collection", "TEST", 123, 139], ["nutritionHolstein Friesian", "TREATMENT", 145, 171], ["Red Holstein (n \u03ed 9) calves", "TREATMENT", 185, 212], ["metabolic status", "OBSERVATION", 68, 84], ["calves", "ANATOMY", 92, 98], ["calves", "ANATOMY", 206, 212]]], ["Diarrhea occurred spontaneously, i.e., was not artificially inoculated and was attributable to hemolytic and nonhemolytic E. coli infections and one rotavirus and coronavirus infection, as determined in feces sampled at Days 3, 9, and 21 of life.", [["feces", "ANATOMY", 203, 208], ["Diarrhea", "DISEASE", 0, 8], ["hemolytic and nonhemolytic E. coli infections", "DISEASE", 95, 140], ["coronavirus infection", "DISEASE", 163, 184], ["nonhemolytic E. coli", "ORGANISM", 109, 129], ["rotavirus", "ORGANISM", 149, 158], ["coronavirus", "ORGANISM", 163, 174], ["feces", "ORGANISM_SUBSTANCE", 203, 208], ["E. coli", "SPECIES", 122, 129], ["rotavirus", "SPECIES", 149, 158], ["coronavirus", "SPECIES", 163, 174], ["E. coli", "SPECIES", 122, 129], ["rotavirus", "SPECIES", 149, 158], ["Diarrhea", "PROBLEM", 0, 8], ["hemolytic and nonhemolytic E. coli infections", "PROBLEM", 95, 140], ["one rotavirus", "PROBLEM", 145, 158], ["coronavirus infection", "PROBLEM", 163, 184], ["attributable to", "UNCERTAINTY", 79, 94], ["hemolytic", "OBSERVATION_MODIFIER", 95, 104], ["nonhemolytic", "OBSERVATION_MODIFIER", 109, 121], ["E. coli infections", "OBSERVATION", 122, 140], ["rotavirus", "OBSERVATION_MODIFIER", 149, 158], ["coronavirus", "OBSERVATION_MODIFIER", 163, 174], ["infection", "OBSERVATION", 175, 184]]], ["Respiratory rate, heart rate, rectal temperature, and hematocrit values were always in the normal range in the affected calves and further calves were free of any sign of dehydration.", [["heart", "ANATOMY", 18, 23], ["rectal", "ANATOMY", 30, 36], ["dehydration", "DISEASE", 171, 182], ["heart", "ORGAN", 18, 23], ["rectal", "ORGANISM_SUBDIVISION", 30, 36], ["calves", "ORGANISM", 120, 126], ["calves", "ORGANISM", 139, 145], ["calves", "SPECIES", 120, 126], ["calves", "SPECIES", 139, 145], ["Respiratory rate", "TEST", 0, 16], ["heart rate", "TEST", 18, 28], ["rectal temperature", "TEST", 30, 48], ["hematocrit values", "TEST", 54, 71], ["dehydration", "PROBLEM", 171, 182], ["heart", "ANATOMY", 18, 23], ["rectal", "ANATOMY", 30, 36], ["normal range", "OBSERVATION_MODIFIER", 91, 103], ["dehydration", "OBSERVATION", 171, 182]]], ["Based on the clinical investigations diarrheas were judged as mild forms of diarrhea.", [["diarrheas", "DISEASE", 37, 46], ["diarrhea", "DISEASE", 76, 84], ["the clinical investigations", "TEST", 9, 36], ["diarrheas", "PROBLEM", 37, 46], ["diarrhea", "PROBLEM", 76, 84], ["mild", "OBSERVATION_MODIFIER", 62, 66], ["diarrhea", "OBSERVATION", 76, 84]]], ["The calves were classified in three groups according to health status.", [["calves", "ORGANISM", 4, 10], ["calves", "SPECIES", 4, 10], ["calves", "ANATOMY", 4, 10]]], ["Group 1 (controls): healthy calves (n \u03ed 9).", [["calves", "ORGANISM", 28, 34], ["calves", "SPECIES", 28, 34]]], ["Group 2: calves with diarrhea at Day 9 (n \u03ed 7).", [["diarrhea", "DISEASE", 21, 29], ["calves", "ORGANISM", 9, 15], ["calves", "SPECIES", 9, 15], ["diarrhea", "PROBLEM", 21, 29], ["calves", "ANATOMY", 9, 15], ["diarrhea", "OBSERVATION", 21, 29]]], ["Group 3: calves with diarrhea at Days 3 and 9 (n \u03ed 4).", [["diarrhea", "DISEASE", 21, 29], ["calves", "ORGANISM", 9, 15], ["calves", "SPECIES", 9, 15], ["diarrhea", "PROBLEM", 21, 29], ["calves", "ANATOMY", 9, 15], ["diarrhea", "OBSERVATION", 21, 29]]], ["All animals in all groups were free of illness at Day 21.Animals, health status, blood collection, and nutritionBlood samples (10 ml) were collected using indwelling catheters implanted in the jugular vein one day before sampling every 15 min for 6 hr from 9:00 a.m. to 3:00 p.m. at Days 3, 9, and 21.", [["blood", "ANATOMY", 81, 86], ["Blood samples", "ANATOMY", 112, 125], ["jugular vein", "ANATOMY", 193, 205], ["illness", "DISEASE", 39, 46], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["Blood samples", "ORGANISM_SUBSTANCE", 112, 125], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 193, 205], ["blood collection", "TEST", 81, 97], ["nutritionBlood samples", "TREATMENT", 103, 125], ["indwelling catheters", "TREATMENT", 155, 175], ["the jugular vein", "TREATMENT", 189, 205], ["catheters", "OBSERVATION", 166, 175], ["jugular vein", "ANATOMY", 193, 205]]], ["Plasma was stored at \u03ea20\u00b0C until assayed.Animals, health status, blood collection, and nutritionCalves stayed the first two days of life with their mothers, then they were fed 1.5 l mature cow milk at 8:00 a.m. and 6:00 p.m.", [["blood", "ANATOMY", 65, 70], ["milk", "ANATOMY", 193, 197], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["C", "GENE_OR_GENE_PRODUCT", 25, 26], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["mothers", "ORGANISM", 148, 155], ["cow", "ORGANISM", 189, 192], ["milk", "ORGANISM_SUBSTANCE", 193, 197], ["Calves", "SPECIES", 96, 102], ["cow", "SPECIES", 189, 192], ["cow", "SPECIES", 189, 192], ["Plasma", "TEST", 0, 6], ["blood collection", "TEST", 65, 81], ["nutritionCalves", "TREATMENT", 87, 102]]], ["From the 10th day of life calves were given 3 l standard milk replacer twice a day.", [["calves", "ORGANISM", 26, 32], ["calves", "SPECIES", 26, 32], ["3 l standard milk replacer", "TREATMENT", 44, 70]]], ["During diarrhea, calves received only an electrolyte substitution therapy consisting of 100 g Floracid Comp./1.5 l water (containing 35.9 mg glucose monohydrate; A. Albrecht, Aulendorf/Germany).", [["diarrhea", "DISEASE", 7, 15], ["glucose monohydrate", "CHEMICAL", 141, 160], ["glucose monohydrate", "CHEMICAL", 141, 160], ["calves", "ORGANISM", 17, 23], ["glucose", "SIMPLE_CHEMICAL", 141, 148], ["calves", "SPECIES", 17, 23], ["diarrhea", "PROBLEM", 7, 15], ["an electrolyte substitution therapy", "TREATMENT", 38, 73]]], ["Calves consumed always all of the offered food.", [["Calves", "ORGANISM", 0, 6], ["Calves", "SPECIES", 0, 6]]], ["Starting at the first week of age, calves were offered hay and maize silage and some concentrates; water was always freely accessible.Radio-and enzyme-immunoassaysBlood plasma concentrations of GH were analyzed by RIA using bGH antiserum (monkey; AFPB55), highly purified bGH (AFP-11182B) for iodination and USDA-bGH-B-1 as standard.", [["Blood plasma", "ANATOMY", 163, 175], ["AFP-11182B", "CHEMICAL", 277, 287], ["USDA-bGH-B", "CHEMICAL", 308, 318], ["calves", "ORGANISM", 35, 41], ["Blood", "ORGANISM_SUBSTANCE", 163, 168], ["plasma", "ORGANISM_SUBSTANCE", 169, 175], ["GH", "GENE_OR_GENE_PRODUCT", 194, 196], ["bGH antiserum", "GENE_OR_GENE_PRODUCT", 224, 237], ["monkey", "ORGANISM", 239, 245], ["AFPB55", "GENE_OR_GENE_PRODUCT", 247, 253], ["bGH", "GENE_OR_GENE_PRODUCT", 272, 275], ["AFP-11182B", "GENE_OR_GENE_PRODUCT", 277, 287], ["bGH-B-1", "GENE_OR_GENE_PRODUCT", 313, 320], ["AFP", "PROTEIN", 277, 280], ["calves", "SPECIES", 35, 41], ["maize", "SPECIES", 63, 68], ["calves", "SPECIES", 35, 41], ["maize", "SPECIES", 63, 68], ["Radio", "TEST", 134, 139], ["Blood plasma concentrations", "TEST", 163, 190], ["GH", "TEST", 194, 196], ["RIA", "TEST", 214, 217], ["bGH antiserum", "TEST", 224, 237], ["AFPB55", "TEST", 247, 253], ["AFP", "TEST", 277, 280], ["iodination", "TEST", 293, 303], ["USDA", "TEST", 308, 312], ["bGH", "TEST", 313, 316]]], ["Cortisol was quantified after sample extraction with tertiary-butylmethyl ether [7] .", [["sample", "ANATOMY", 30, 36], ["Cortisol", "CHEMICAL", 0, 8], ["tertiary-butylmethyl ether", "CHEMICAL", 53, 79], ["Cortisol", "CHEMICAL", 0, 8], ["tertiary-butylmethyl ether", "CHEMICAL", 53, 79], ["Cortisol", "SIMPLE_CHEMICAL", 0, 8], ["tertiary-butylmethyl ether", "SIMPLE_CHEMICAL", 53, 79], ["Cortisol", "TEST", 0, 8], ["sample extraction", "TEST", 30, 47], ["tertiary-butylmethyl ether", "TREATMENT", 53, 79]]], ["The cortisol antibody used (code \"HCo-21-HS; S16; 9.1.84\") was raised in rabbits against cortisol-21-hemisuccinat-BSA.", [["cortisol", "CHEMICAL", 4, 12], ["cortisol-21-hemisuccinat-BSA", "CHEMICAL", 89, 117], ["cortisol", "CHEMICAL", 4, 12], ["cortisol", "CHEMICAL", 89, 97], ["cortisol antibody", "GENE_OR_GENE_PRODUCT", 4, 21], ["rabbits", "ORGANISM", 73, 80], ["cortisol-21-hemisuccinat-BSA", "SIMPLE_CHEMICAL", 89, 117], ["cortisol antibody", "PROTEIN", 4, 21], ["rabbits", "SPECIES", 73, 80], ["rabbits", "SPECIES", 73, 80], ["The cortisol antibody", "TEST", 0, 21], ["HCo", "TEST", 34, 37], ["cortisol", "TEST", 89, 97]]], ["Cross-reactivities are as follows: cortisol: 100%, pregnenolone \u03fd 1%, corticosterone 15%, DOC 19%, progesterone 7.5%.", [["cortisol", "CHEMICAL", 35, 43], ["pregnenolone", "CHEMICAL", 51, 63], ["corticosterone", "CHEMICAL", 70, 84], ["DOC", "CHEMICAL", 90, 93], ["progesterone", "CHEMICAL", 99, 111], ["cortisol", "CHEMICAL", 35, 43], ["pregnenolone", "CHEMICAL", 51, 63], ["corticosterone", "CHEMICAL", 70, 84], ["DOC", "CHEMICAL", 90, 93], ["progesterone", "CHEMICAL", 99, 111], ["cortisol", "SIMPLE_CHEMICAL", 35, 43], ["pregnenolone", "SIMPLE_CHEMICAL", 51, 63], ["corticosterone", "SIMPLE_CHEMICAL", 70, 84], ["DOC", "SIMPLE_CHEMICAL", 90, 93], ["progesterone", "SIMPLE_CHEMICAL", 99, 111], ["Cross-reactivities", "TEST", 0, 18], ["cortisol", "TEST", 35, 43], ["pregnenolone", "TEST", 51, 63], ["corticosterone", "TEST", 70, 84], ["DOC", "TEST", 90, 93], ["progesterone", "TREATMENT", 99, 111]]], ["The cortisol antibody dilution was 1 : 165,000.", [["cortisol", "CHEMICAL", 4, 12], ["cortisol", "CHEMICAL", 4, 12], ["cortisol antibody", "GENE_OR_GENE_PRODUCT", 4, 21], ["The cortisol antibody dilution", "TEST", 0, 30]]], ["LH was measured by an EIA according to Mutayoba et al. [8] with some modifications.", [["LH", "GENE_OR_GENE_PRODUCT", 0, 2], ["an EIA", "TEST", 19, 25]]], ["The monoclonal antibody to LH generated against bovine LH (bLH, Lot 10/518b 7 ) was a characterized by Matteri et al. [9] .", [["LH", "GENE_OR_GENE_PRODUCT", 27, 29], ["bovine", "ORGANISM", 48, 54], ["LH", "GENE_OR_GENE_PRODUCT", 55, 57], ["monoclonal antibody", "PROTEIN", 4, 23], ["LH", "PROTEIN", 27, 29], ["bovine", "SPECIES", 48, 54], ["The monoclonal antibody", "TEST", 0, 23], ["bovine LH", "TEST", 48, 57], ["bLH", "TEST", 59, 62]]], ["As a tracer, 40 g USDA-bLH-B5 (AFP5500) was biotinylated as previously described [8] .", [["USDA-bLH-B5", "CHEMICAL", 18, 29], ["a tracer", "TEST", 3, 11], ["bLH", "TEST", 23, 26]]], ["Microtiter plates (96 well Easy Wash, Corning, NY, USA) were coated with antibodies raised against mouse IgG in sheep.", [["mouse", "ORGANISM", 99, 104], ["IgG", "GENE_OR_GENE_PRODUCT", 105, 108], ["sheep", "ORGANISM", 112, 117], ["antibodies", "PROTEIN", 73, 83], ["mouse IgG", "PROTEIN", 99, 108], ["mouse", "SPECIES", 99, 104], ["sheep", "SPECIES", 112, 117], ["mouse", "SPECIES", 99, 104], ["sheep", "SPECIES", 112, 117], ["Microtiter plates", "TEST", 0, 17], ["antibodies", "TEST", 73, 83], ["mouse IgG in sheep", "PROBLEM", 99, 117]]], ["Antibodies were precipitated [10] and used in a concentration of 1 g/100 l carbonate buffer (0.05 M NaHCO 3 , pH 9.6) per well.", [["carbonate", "CHEMICAL", 75, 84], ["NaHCO 3", "CHEMICAL", 100, 107], ["Antibodies", "TEST", 0, 10], ["l carbonate buffer", "TREATMENT", 73, 91], ["NaHCO", "TREATMENT", 100, 105], ["pH", "TEST", 110, 112]]], ["After 24 hr of incubation at 4\u00b0C the plates were blocked with 300 l 2.5% casein in 0.05 M NaOH (adjusted to pH 7.2 with HCl) at room temperature for 2 hr.", [["casein", "CHEMICAL", 73, 79], ["NaOH", "CHEMICAL", 90, 94], ["HCl", "CHEMICAL", 120, 123], ["NaOH", "CHEMICAL", 90, 94], ["HCl", "CHEMICAL", 120, 123], ["casein", "SIMPLE_CHEMICAL", 73, 79], ["NaOH", "SIMPLE_CHEMICAL", 90, 94], ["HCl", "SIMPLE_CHEMICAL", 120, 123], ["incubation", "TREATMENT", 15, 25], ["C the plates", "TREATMENT", 31, 43], ["pH", "TEST", 108, 110], ["HCl", "TREATMENT", 120, 123]]], ["The plates were washed four times with 300 l 0.05% Tween 20 in 10% PBS.", [["Tween 20", "CHEMICAL", 51, 59], ["The plates", "TREATMENT", 0, 10], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The air-dried plates were stored at \u03ea20\u00b0C for up to 12 wk without appreciable loss of binding capacity.", [["C", "GENE_OR_GENE_PRODUCT", 40, 41], ["The air-dried plates", "TEST", 0, 20], ["appreciable loss of binding capacity", "PROBLEM", 66, 102], ["plates", "OBSERVATION_MODIFIER", 14, 20], ["binding capacity", "OBSERVATION", 86, 102]]], ["Standard (USDA-bLH-B-5) or plasma samples (50 l) were pipetted into the wells and 100 l monoclonal LH antibody (1 ng/ml) in assay buffer (0.1% hydrolyzed gelatin, 0.12 M NaCl, 0.02 M Na 2 HPO 4 , 0.01 M EDTA, 0.05% Tween 20, 0.005% chlorhexidine digluconate (20%), 0.002% phenol red and 5% bull plasma containing less than 0.1 ng LH/ml).", [["plasma samples", "ANATOMY", 27, 41], ["plasma", "ANATOMY", 295, 301], ["USDA-bLH-B-5", "CHEMICAL", 10, 22], ["gelatin", "CHEMICAL", 154, 161], ["NaCl", "CHEMICAL", 170, 174], ["Na", "CHEMICAL", 183, 185], ["chlorhexidine digluconate", "CHEMICAL", 232, 257], ["phenol", "CHEMICAL", 272, 278], ["NaCl", "CHEMICAL", 170, 174], ["Na 2 HPO", "CHEMICAL", 183, 191], ["EDTA", "CHEMICAL", 203, 207], ["Tween 20", "CHEMICAL", 215, 223], ["chlorhexidine digluconate", "CHEMICAL", 232, 257], ["phenol red", "CHEMICAL", 272, 282], ["bLH-B-5", "CELL", 15, 22], ["plasma samples", "ORGANISM_SUBSTANCE", 27, 41], ["LH", "GENE_OR_GENE_PRODUCT", 99, 101], ["gelatin", "SIMPLE_CHEMICAL", 154, 161], ["EDTA", "SIMPLE_CHEMICAL", 203, 207], ["chlorhexidine digluconate", "SIMPLE_CHEMICAL", 232, 257], ["bull", "ORGANISM", 290, 294], ["plasma", "ORGANISM_SUBSTANCE", 295, 301], ["monoclonal LH antibody", "PROTEIN", 88, 110], ["USDA", "TEST", 10, 14], ["bLH", "TEST", 15, 18], ["plasma samples", "TEST", 27, 41], ["l monoclonal LH antibody", "TEST", 86, 110], ["hydrolyzed gelatin", "TREATMENT", 143, 161], ["NaCl", "TEST", 170, 174], ["Na", "TEST", 183, 185], ["EDTA", "TEST", 203, 207], ["chlorhexidine digluconate", "TREATMENT", 232, 257], ["0.002% phenol red", "TREATMENT", 265, 282], ["5% bull plasma", "TREATMENT", 287, 301]]], ["After incubation at room temperature for 20 h plates were washed twice and 100 l of tracer (5 ng/ml assay buffer) was added.", [["20 h plates", "TREATMENT", 41, 52], ["tracer", "TREATMENT", 84, 90]]], ["After two washing steps, 100 l of a streptavidin-peroxidase conjugate (Sigma, Deisenhofen, Germany) solution (200 ng/ml assay buffer) were added per well.", [["streptavidin-peroxidase conjugate", "SIMPLE_CHEMICAL", 36, 69], ["Sigma", "SIMPLE_CHEMICAL", 71, 76], ["Deisenhofen", "SIMPLE_CHEMICAL", 78, 89], ["a streptavidin-peroxidase conjugate", "TREATMENT", 34, 69], ["Sigma, Deisenhofen, Germany) solution", "TREATMENT", 71, 108]]], ["The further assay steps are comparable to Mutayoba et al. [8] .", [["The further assay steps", "TEST", 0, 23]]], ["The minimum detectable level was 0.1 ng bLH/ml plasma.", [["plasma", "ANATOMY", 47, 53], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["The minimum detectable level", "TEST", 0, 28]]], ["Cross-reactions with ovine FSH, bovine prolactin, bovine growth hormone were less than 0.1% and 0.5% with bovine TSH.", [["ovine", "ORGANISM", 21, 26], ["FSH", "GENE_OR_GENE_PRODUCT", 27, 30], ["bovine", "ORGANISM", 32, 38], ["prolactin", "GENE_OR_GENE_PRODUCT", 39, 48], ["bovine", "ORGANISM", 50, 56], ["growth hormone", "GENE_OR_GENE_PRODUCT", 57, 71], ["bovine", "ORGANISM", 106, 112], ["TSH", "GENE_OR_GENE_PRODUCT", 113, 116], ["bovine", "SPECIES", 32, 38], ["bovine", "SPECIES", 50, 56], ["bovine", "SPECIES", 106, 112], ["ovine", "SPECIES", 21, 26], ["bovine", "SPECIES", 32, 38], ["bovine", "SPECIES", 106, 112], ["Cross-reactions", "TEST", 0, 15], ["ovine FSH, bovine prolactin", "TEST", 21, 48], ["bovine growth hormone", "TEST", 50, 71], ["bovine TSH", "TEST", 106, 116]]], ["Serial dilutions of bull plasma were parallel to the standard curve and the recovery of added hormone to plasma samples in the EIA was 102 \u03ee 7%.", [["bull plasma", "ANATOMY", 20, 31], ["plasma samples", "ANATOMY", 105, 119], ["bull", "ORGANISM", 20, 24], ["plasma", "ORGANISM_SUBSTANCE", 25, 31], ["plasma samples", "ORGANISM_SUBSTANCE", 105, 119], ["bull plasma", "TEST", 20, 31], ["the standard curve", "TEST", 49, 67], ["plasma samples", "TEST", 105, 119], ["the EIA", "TEST", 123, 130]]], ["Concentrations of insulin were determined by a commercially available RIA-kit (CIS Diagnostik GmbH, Dreieich, Germany).", [["insulin", "GENE_OR_GENE_PRODUCT", 18, 25], ["insulin", "PROTEIN", 18, 25], ["insulin", "TREATMENT", 18, 25], ["RIA", "TEST", 70, 73]]], ["Coefficients of variation within and between assays were as follows: GH 10% and 12%, cortisol 6% and 10%, LH 9% and 11%, and insulin 10% and 13%.StatisticsPlasma GH, cortisol, LH, and insulin concentrations were analyzed using procedure mixed of SAS [11] .", [["cortisol", "CHEMICAL", 85, 93], ["cortisol", "CHEMICAL", 166, 174], ["cortisol", "CHEMICAL", 85, 93], ["cortisol", "CHEMICAL", 166, 174], ["GH", "GENE_OR_GENE_PRODUCT", 69, 71], ["insulin", "GENE_OR_GENE_PRODUCT", 125, 132], ["Plasma", "ORGANISM_SUBSTANCE", 155, 161], ["GH", "GENE_OR_GENE_PRODUCT", 162, 164], ["cortisol", "SIMPLE_CHEMICAL", 166, 174], ["LH", "GENE_OR_GENE_PRODUCT", 176, 178], ["insulin", "GENE_OR_GENE_PRODUCT", 184, 191], ["assays", "TEST", 45, 51], ["GH", "TEST", 69, 71], ["cortisol", "TEST", 85, 93], ["LH", "TEST", 106, 108], ["insulin", "TREATMENT", 125, 132], ["StatisticsPlasma GH", "TEST", 145, 164], ["cortisol", "TEST", 166, 174], ["LH", "TEST", 176, 178], ["insulin concentrations", "TREATMENT", 184, 206], ["procedure mixed of SAS", "TREATMENT", 227, 249]]], ["Differences in mean hormone concentrations were analyzed by SAS using a mixed model.", [["mean hormone concentrations", "TEST", 15, 42]]], ["All factors were tested by F-test as implemented in the SAS procedure.", [["the SAS procedure", "TREATMENT", 52, 69]]], ["When the F-test indicated significance, linear contrasts of least square means were performed.", [["the F-test", "TEST", 5, 15]]], ["GH and LH pulses were determined by the PULSAR program by using standard deviation criteria [12] .", [["GH", "GENE_OR_GENE_PRODUCT", 0, 2], ["LH", "GENE_OR_GENE_PRODUCT", 7, 9], ["LH pulses", "TEST", 7, 16], ["standard deviation criteria", "TEST", 64, 91]]], ["Basal concentrations, pulse amplitude and pulse frequency were thereby determined and the GH secretion parameters were subsequently analyzed by procedure mixed of SAS.", [["GH", "GENE_OR_GENE_PRODUCT", 90, 92], ["Basal concentrations", "TEST", 0, 20], ["pulse amplitude", "TEST", 22, 37], ["pulse frequency", "TEST", 42, 57], ["the GH secretion parameters", "TEST", 86, 113], ["concentrations", "OBSERVATION_MODIFIER", 6, 20]]], ["Significance of differences in calves from Group 1 versus 2 or 3 were tested by linear contrasts.", [["calves", "ORGANISM", 31, 37], ["calves", "SPECIES", 31, 37], ["differences", "OBSERVATION_MODIFIER", 16, 27]]], ["Data are presented as least square means and their standard errors (LSM \u03ee SE).GH-effects of age, sex, or breedBasal GH concentrations were highest at Day 3 and decreased thereafter (P \u03fd 0.001; Table 1 ).", [["GH", "GENE_OR_GENE_PRODUCT", 78, 80], ["GH", "GENE_OR_GENE_PRODUCT", 116, 118], ["breedBasal GH concentrations", "PROBLEM", 105, 133]]], ["There was no effect due to sex or breed on mean plasma concentrations of GH (P \u03fe 0.7).GH-effects of diarrheaMean concentrations of GH in ill calves in Groups 2 and 3 were higher than in control calves at Day 3 ( Fig. 1 ; P \u03fd 0.01; P \u03fd 0.001).", [["plasma", "ANATOMY", 48, 54], ["plasma", "ORGANISM_SUBSTANCE", 48, 54], ["GH", "GENE_OR_GENE_PRODUCT", 73, 75], ["GH", "GENE_OR_GENE_PRODUCT", 86, 88], ["GH", "GENE_OR_GENE_PRODUCT", 131, 133], ["calves", "ORGANISM", 194, 200], ["calves", "SPECIES", 141, 147], ["calves", "SPECIES", 194, 200], ["mean plasma concentrations", "TEST", 43, 69], ["GH (P \u03fe", "TEST", 73, 80], ["diarrheaMean concentrations of GH in ill calves in Groups", "PROBLEM", 100, 157], ["P", "TEST", 221, 222], ["P", "TEST", 231, 232], ["no", "UNCERTAINTY", 10, 12], ["ill calves", "OBSERVATION", 137, 147]]], ["By Day 9 calves in Groups 2 and 3 had lower Table 1 Basal GH concentrations, frequency, and amplitudes of GH pulses (LSM \u03ee SE) in healthy calves (Group 1; n \u03ed 9) and in calves with diarrhea at Day 9 (Group 2; n \u03ed 7) or Days 3 and 9 (Group 3; n \u03ed 4) a but not significantly different mean GH concentrations than control calves (P \u03ed 0.3; P \u03ed 0.14).", [["diarrhea", "DISEASE", 181, 189], ["calves", "ORGANISM", 9, 15], ["GH", "GENE_OR_GENE_PRODUCT", 58, 60], ["GH", "GENE_OR_GENE_PRODUCT", 106, 108], ["calves", "ORGANISM", 169, 175], ["GH", "SIMPLE_CHEMICAL", 288, 290], ["calves", "SPECIES", 9, 15], ["calves", "SPECIES", 138, 144], ["calves", "SPECIES", 169, 175], ["calves", "SPECIES", 319, 325], ["calves", "SPECIES", 169, 175], ["GH pulses", "TEST", 106, 115], ["diarrhea", "PROBLEM", 181, 189], ["P", "TEST", 327, 328], ["P", "TEST", 336, 337], ["Basal", "ANATOMY_MODIFIER", 52, 57], ["GH concentrations", "OBSERVATION", 58, 75], ["healthy calves", "ANATOMY", 130, 144], ["calves", "ANATOMY", 169, 175], ["diarrhea", "OBSERVATION", 181, 189]]], ["At Day 21, these calves had similar mean concentrations of GH compared to calves in the control group (P \u03fe 0.4; P \u03fe 0.8).", [["calves", "ORGANISM", 17, 23], ["GH", "GENE_OR_GENE_PRODUCT", 59, 61], ["calves", "ORGANISM", 74, 80], ["calves", "SPECIES", 17, 23], ["calves", "SPECIES", 74, 80], ["P", "TEST", 103, 104], ["P", "TEST", 112, 113]]], ["Basal GH concentrations were higher (P \u03fd 0.001) in calves in Group 3 than in controls at Day 3 (Table 1 ).", [["GH", "GENE_OR_GENE_PRODUCT", 6, 8], ["calves", "ORGANISM", 51, 57], ["calves", "SPECIES", 51, 57], ["Basal GH concentrations", "TEST", 0, 23], ["concentrations", "OBSERVATION_MODIFIER", 9, 23], ["higher", "OBSERVATION_MODIFIER", 29, 35]]], ["At Day 9 basal GH concentrations in calves that had been ill until Day 9 had decreased slightly more compared to the control group (P \u03ed 0.2) than in those that had diarrhea at Day 3 only (Group 2; P \u03ed 0.4).", [["diarrhea", "DISEASE", 164, 172], ["GH", "GENE_OR_GENE_PRODUCT", 15, 17], ["calves", "ORGANISM", 36, 42], ["calves", "SPECIES", 36, 42], ["basal GH concentrations in calves", "TREATMENT", 9, 42], ["diarrhea", "PROBLEM", 164, 172], ["diarrhea", "OBSERVATION", 164, 172]]], ["No effects on the frequency and the amplitude of GH release were observed (Table 1) .Cortisol-effects of age, sex, or breedMean plasma concentrations of cortisol were highest at Day 3 and decreased (P \u03fd 0.001) until Day 21 (Fig. 2) .", [["plasma", "ANATOMY", 128, 134], ["cortisol", "CHEMICAL", 153, 161], ["Cortisol", "CHEMICAL", 85, 93], ["cortisol", "CHEMICAL", 153, 161], ["GH", "GENE_OR_GENE_PRODUCT", 49, 51], ["Cortisol", "SIMPLE_CHEMICAL", 85, 93], ["plasma", "ORGANISM_SUBSTANCE", 128, 134], ["cortisol", "GENE_OR_GENE_PRODUCT", 153, 161], ["GH release", "TREATMENT", 49, 59], ["Cortisol", "TEST", 85, 93], ["breedMean plasma concentrations", "TEST", 118, 149], ["cortisol", "TEST", 153, 161]]], ["When cortisol concentrations were averaged over the entire experiment, female calves tended to have higher concentrations than males (8.0 \u03ee 0.7 versus 6.2 \u03ee 0.6 ng/ml; P \u03ed 0.07) and Red Holstein calves had higher plasma concentrations than Holstein Friesian calves (8.6 \u03ee 0.7 versus 5.7 \u03ee 0.6 ng/ml; P \u03fd 0.01).Cortisol-effects of diarrheaAt Day 3, calves in Groups 2 and 3 had lower (P \u03fd 0.001 and P \u03fd 0.05) concentrations than the healthy control calves.", [["plasma", "ANATOMY", 213, 219], ["cortisol", "CHEMICAL", 5, 13], ["cortisol", "CHEMICAL", 5, 13], ["Cortisol", "CHEMICAL", 310, 318], ["cortisol", "SIMPLE_CHEMICAL", 5, 13], ["calves", "ORGANISM", 78, 84], ["calves", "ORGANISM", 195, 201], ["plasma", "ORGANISM_SUBSTANCE", 213, 219], ["Holstein Friesian calves", "ORGANISM", 240, 264], ["Cortisol", "SIMPLE_CHEMICAL", 310, 318], ["calves", "ORGANISM", 348, 354], ["calves", "ORGANISM", 448, 454], ["calves", "SPECIES", 78, 84], ["calves", "SPECIES", 195, 201], ["calves", "SPECIES", 258, 264], ["calves", "SPECIES", 348, 354], ["calves", "SPECIES", 448, 454], ["Red Holstein calves", "SPECIES", 182, 201], ["Holstein Friesian calves", "SPECIES", 240, 264], ["cortisol concentrations", "PROBLEM", 5, 28], ["higher concentrations", "PROBLEM", 100, 121], ["P", "TEST", 168, 169], ["\u03ed", "TEST", 170, 171], ["Red Holstein calves", "TEST", 182, 201], ["higher plasma concentrations", "PROBLEM", 206, 234], ["Holstein Friesian calves", "TEST", 240, 264], ["P", "TEST", 300, 301], ["Cortisol", "TEST", 310, 318], ["diarrheaAt", "TEST", 330, 340], ["P", "TEST", 398, 399]]], ["At Days 9 and 21, concentrations of cortisol in calves in Groups 2 and 3 were similar to controls (P \u03fe 0.1).LH-effects of age, sex, or breedNo secretory pulses were observed in healthy calves at Day 3.", [["cortisol", "CHEMICAL", 36, 44], ["cortisol", "CHEMICAL", 36, 44], ["cortisol", "GENE_OR_GENE_PRODUCT", 36, 44], ["calves", "ORGANISM", 48, 54], ["LH", "GENE_OR_GENE_PRODUCT", 108, 110], ["calves", "ORGANISM", 185, 191], ["calves", "SPECIES", 48, 54], ["calves", "SPECIES", 185, 191], ["cortisol", "TEST", 36, 44], ["secretory pulses", "PROBLEM", 143, 159], ["secretory pulses", "OBSERVATION", 143, 159]]], ["At Days 9 and 21, three and 10 pulses (0.1-0.5 ng LH/ml basal, 1.5-4.0 ng LH during pulses) were observed in healthy calves.", [["calves", "ORGANISM", 117, 123], ["calves", "SPECIES", 117, 123], ["pulses", "TEST", 31, 37], ["LH", "TEST", 50, 52], ["basal", "TEST", 56, 61], ["pulses", "TEST", 84, 90], ["healthy calves", "ANATOMY", 109, 123]]], ["There was no effect of sex or breed on LH concentrations (P \u03fe 0.8; P \u03fe 0.2).LH-effects of diarrheaMean LH concentrations in the calves in all three groups were similar (P \u03fe 0.4; Fig. 3 ).", [["LH", "SIMPLE_CHEMICAL", 39, 41], ["LH", "GENE_OR_GENE_PRODUCT", 76, 78], ["LH", "GENE_OR_GENE_PRODUCT", 103, 105], ["calves", "ORGANISM", 128, 134], ["calves", "SPECIES", 128, 134], ["LH concentrations", "TEST", 39, 56], ["P", "TEST", 58, 59], ["\u03fe", "TEST", 60, 61], ["P", "TEST", 67, 68], ["LH", "TEST", 76, 78], ["diarrheaMean LH concentrations", "PROBLEM", 90, 120], ["no", "UNCERTAINTY", 10, 12], ["calves", "ANATOMY", 128, 134]]], ["No secretory pulses were observed in ill calves at Day 3.", [["calves", "ORGANISM", 41, 47], ["calves", "SPECIES", 41, 47], ["secretory pulses", "PROBLEM", 3, 19], ["secretory pulses", "OBSERVATION", 3, 19]]], ["Only one LH pulse was observed in one ill male calf at Day 9.Insulin-effects of age, sex, breed, or feedingInsulin concentrations decreased after Day 3 until Day 9 (P \u03fd 0.01; Fig. 4 ) and had increased again by Day 21.", [["Insulin", "CHEMICAL", 107, 114], ["LH", "GENE_OR_GENE_PRODUCT", 9, 11], ["calf", "ORGANISM_SUBDIVISION", 47, 51], ["Insulin", "GENE_OR_GENE_PRODUCT", 61, 68], ["Insulin", "GENE_OR_GENE_PRODUCT", 107, 114], ["calf", "SPECIES", 47, 51], ["one LH pulse", "TEST", 5, 17], ["Insulin", "TREATMENT", 61, 68], ["feedingInsulin concentrations", "TREATMENT", 100, 129]]], ["There was no effect of sex or breed on insulin concentrations (P \u03fe 0.7).", [["insulin", "GENE_OR_GENE_PRODUCT", 39, 46], ["insulin concentrations", "TREATMENT", 39, 61], ["no", "UNCERTAINTY", 10, 12], ["effect", "OBSERVATION_MODIFIER", 13, 19]]], ["Insulin concentrations increased after feeding in the morning and decreased thereafter (P \u03fd 0.001).Insulin-effects of diarrheaAt Day 9, insulin concentrations in calves that were ill during the experiment tended to be higher (Group 3: P \u03ed 0.04; Group 2: P \u03ed 0.18) than those in the healthy ones in Group 1.", [["Insulin", "CHEMICAL", 0, 7], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["Insulin", "GENE_OR_GENE_PRODUCT", 99, 106], ["insulin", "GENE_OR_GENE_PRODUCT", 136, 143], ["calves", "ORGANISM", 162, 168], ["calves", "SPECIES", 162, 168], ["Insulin concentrations", "TREATMENT", 0, 22], ["Insulin", "TREATMENT", 99, 106], ["diarrheaAt Day", "TREATMENT", 118, 132], ["insulin concentrations in calves", "TREATMENT", 136, 168]]], ["At Day 21 insulin concentrations in the calves in Groups 1, 2, and 3 were similar (P \u03fe 0.4).DiscussionWithin the first three weeks of life, blood plasma concentrations of GH were initially high and then decreased in healthy calves.", [["blood plasma", "ANATOMY", 140, 152], ["insulin", "GENE_OR_GENE_PRODUCT", 10, 17], ["calves", "ORGANISM", 40, 46], ["blood", "ORGANISM_SUBSTANCE", 140, 145], ["plasma", "ORGANISM_SUBSTANCE", 146, 152], ["GH", "GENE_OR_GENE_PRODUCT", 171, 173], ["calves", "ORGANISM", 224, 230], ["insulin", "PROTEIN", 10, 17], ["calves", "SPECIES", 40, 46], ["calves", "SPECIES", 224, 230], ["insulin concentrations in the calves in Groups", "TREATMENT", 10, 56], ["blood plasma concentrations of GH", "TEST", 140, 173], ["high", "OBSERVATION_MODIFIER", 189, 193], ["decreased", "OBSERVATION_MODIFIER", 203, 212], ["healthy calves", "OBSERVATION", 216, 230]]], ["This is comparable to the findings of Ronge and Blum [13] who described that in new-born calves GH concentrations tended to decrease during the first five weeks of life.", [["calves", "ORGANISM", 89, 95], ["GH", "GENE_OR_GENE_PRODUCT", 96, 98], ["calves", "SPECIES", 89, 95], ["new-born calves GH concentrations", "TREATMENT", 80, 113]]], ["The high concentrations of GH may have a comparable action a) on the increase in the depth of crypts and b) on the rate of proliferation of the villi of the gut [14] .", [["crypts", "ANATOMY", 94, 100], ["villi", "ANATOMY", 144, 149], ["gut", "ANATOMY", 157, 160], ["GH", "GENE_OR_GENE_PRODUCT", 27, 29], ["crypts", "MULTI-TISSUE_STRUCTURE", 94, 100], ["villi", "MULTI-TISSUE_STRUCTURE", 144, 149], ["proliferation", "OBSERVATION", 123, 136], ["villi", "ANATOMY_MODIFIER", 144, 149], ["gut", "ANATOMY", 157, 160]]], ["In this study GH concentrations were elevated before symptoms of diarrhea could be observed.", [["diarrhea", "DISEASE", 65, 73], ["GH", "GENE_OR_GENE_PRODUCT", 14, 16], ["this study GH concentrations", "TEST", 3, 31], ["symptoms", "PROBLEM", 53, 61], ["diarrhea", "PROBLEM", 65, 73]]], ["We consider it most likely that subclinical stages of infection have started to affect GH concentrations before clinical symptoms become apparent.", [["infection", "DISEASE", 54, 63], ["GH", "GENE_OR_GENE_PRODUCT", 87, 89], ["subclinical stages of infection", "PROBLEM", 32, 63], ["GH concentrations", "PROBLEM", 87, 104], ["clinical symptoms", "PROBLEM", 112, 129], ["most likely", "UNCERTAINTY", 15, 26], ["infection", "OBSERVATION", 54, 63]]], ["Diarrhea was the clinical sign or symptom of the presence of the underlying infection.", [["Diarrhea", "DISEASE", 0, 8], ["infection", "DISEASE", 76, 85], ["Diarrhea", "PROBLEM", 0, 8], ["symptom", "PROBLEM", 34, 41], ["the underlying infection", "PROBLEM", 61, 85], ["underlying", "OBSERVATION_MODIFIER", 65, 75], ["infection", "OBSERVATION", 76, 85]]], ["The host response to the infection organism establishes the water balance perturbations that result in diarrhea.", [["infection", "DISEASE", 25, 34], ["diarrhea", "DISEASE", 103, 111], ["the infection organism", "PROBLEM", 21, 43], ["the water balance perturbations", "PROBLEM", 56, 87], ["diarrhea", "PROBLEM", 103, 111], ["host response", "OBSERVATION", 4, 17], ["infection", "OBSERVATION", 25, 34], ["diarrhea", "OBSERVATION", 103, 111]]], ["It has to be taken into account that some aspects of dehydration associated with the loss of water can compromise the interpretation of how plasma concentrations of hormones change during this process, largely because the majority of the water entering the bowl comes from the plasma compartment and the concentrations can therefore be different.", [["plasma", "ANATOMY", 140, 146], ["plasma compartment", "ANATOMY", 277, 295], ["dehydration", "DISEASE", 53, 64], ["plasma", "ORGANISM_SUBSTANCE", 140, 146], ["water", "SIMPLE_CHEMICAL", 238, 243], ["plasma", "ORGANISM_SUBSTANCE", 277, 283], ["compartment", "IMMATERIAL_ANATOMICAL_ENTITY", 284, 295], ["dehydration", "PROBLEM", 53, 64], ["the loss of water", "PROBLEM", 81, 98], ["how plasma concentrations of hormones change", "PROBLEM", 136, 180], ["dehydration", "OBSERVATION", 53, 64], ["bowl", "OBSERVATION", 257, 261]]], ["Calves in Group 2 had markedly higher plasma concentrations of GH at Day 3.", [["plasma", "ANATOMY", 38, 44], ["Calves", "ORGANISM", 0, 6], ["plasma", "ORGANISM_SUBSTANCE", 38, 44], ["GH", "GENE_OR_GENE_PRODUCT", 63, 65], ["Calves", "SPECIES", 0, 6]]], ["These calves had diarrhea six days later.", [["diarrhea", "DISEASE", 17, 25], ["calves", "ORGANISM", 6, 12], ["calves", "SPECIES", 6, 12], ["diarrhea", "PROBLEM", 17, 25], ["calves", "ANATOMY", 6, 12], ["diarrhea", "OBSERVATION", 17, 25]]], ["Calves in Group 3 that already had diarrhea showed an even more pronounced increase in plasma concentrations of GH at Day 3.", [["plasma", "ANATOMY", 87, 93], ["diarrhea", "DISEASE", 35, 43], ["Calves", "ORGANISM", 0, 6], ["plasma", "ORGANISM_SUBSTANCE", 87, 93], ["GH", "GENE_OR_GENE_PRODUCT", 112, 114], ["Calves", "SPECIES", 0, 6], ["diarrhea", "PROBLEM", 35, 43], ["plasma concentrations of GH", "TREATMENT", 87, 114], ["more pronounced", "OBSERVATION_MODIFIER", 59, 74], ["increase", "OBSERVATION_MODIFIER", 75, 83]]], ["Comparable to the results of the present study is the finding that endotoxin administration increased GH concentrations in sheep [15] , in finishing gilts [16] , and in humans [17] .", [["endotoxin", "CHEMICAL", 67, 76], ["endotoxin", "SIMPLE_CHEMICAL", 67, 76], ["GH", "GENE_OR_GENE_PRODUCT", 102, 104], ["sheep", "ORGANISM", 123, 128], ["humans", "ORGANISM", 169, 175], ["sheep", "SPECIES", 123, 128], ["humans", "SPECIES", 169, 175], ["sheep", "SPECIES", 123, 128], ["humans", "SPECIES", 169, 175], ["the present study", "TEST", 29, 46], ["endotoxin administration", "TREATMENT", 67, 91]]], ["Short-term GH treatments can ameliorate some of the symptoms of the acute phase response to endotoxemia [18] .", [["endotoxemia", "DISEASE", 92, 103], ["Short-term GH treatments", "TREATMENT", 0, 24], ["the symptoms", "PROBLEM", 48, 60], ["the acute phase response", "PROBLEM", 64, 88], ["endotoxemia", "PROBLEM", 92, 103], ["acute", "OBSERVATION_MODIFIER", 68, 73]]], ["The increase in GH concentrations before any clinical signs of diarrhea were observed may be interpreted as an induction of the body's defense system.", [["body", "ANATOMY", 128, 132], ["diarrhea", "DISEASE", 63, 71], ["GH", "GENE_OR_GENE_PRODUCT", 16, 18], ["body", "ORGANISM_SUBDIVISION", 128, 132], ["The increase in GH concentrations", "PROBLEM", 0, 33], ["diarrhea", "PROBLEM", 63, 71], ["the body's defense system", "TREATMENT", 124, 149], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["diarrhea", "OBSERVATION", 63, 71]]], ["Higher concentrations of GH result in a lower permeability of the gut [19] ; consequently the transportation of endotoxin from the lumen of the gut into the blood circulation may be reduced and inflammation reactions may be decreased [19] .", [["gut", "ANATOMY", 66, 69], ["lumen", "ANATOMY", 131, 136], ["gut", "ANATOMY", 144, 147], ["blood", "ANATOMY", 157, 162], ["endotoxin", "CHEMICAL", 112, 121], ["inflammation", "DISEASE", 194, 206], ["GH", "GENE_OR_GENE_PRODUCT", 25, 27], ["endotoxin", "GENE_OR_GENE_PRODUCT", 112, 121], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 131, 136], ["gut", "ORGANISM_SUBDIVISION", 144, 147], ["blood", "ORGANISM_SUBSTANCE", 157, 162], ["endotoxin", "PROTEIN", 112, 121], ["Higher concentrations of GH result", "PROBLEM", 0, 34], ["endotoxin", "TREATMENT", 112, 121], ["inflammation reactions", "PROBLEM", 194, 216], ["lower permeability", "OBSERVATION_MODIFIER", 40, 58], ["gut", "ANATOMY", 66, 69], ["lumen", "ANATOMY_MODIFIER", 131, 136], ["gut", "ANATOMY", 144, 147], ["blood circulation", "ANATOMY", 157, 174], ["may be", "UNCERTAINTY", 175, 181], ["reduced", "OBSERVATION_MODIFIER", 182, 189], ["inflammation", "OBSERVATION", 194, 206]]], ["In contrast to the typical actions of GH that are mediated by IGF, GH can also act directly on gut tissue via specific receptors even when serum IGF-1 is suppressed, as reported for infected animals [20] .", [["gut tissue", "ANATOMY", 95, 105], ["serum", "ANATOMY", 139, 144], ["GH", "GENE_OR_GENE_PRODUCT", 38, 40], ["IGF", "GENE_OR_GENE_PRODUCT", 62, 65], ["GH", "GENE_OR_GENE_PRODUCT", 67, 69], ["gut tissue", "TISSUE", 95, 105], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["IGF-1", "GENE_OR_GENE_PRODUCT", 145, 150], ["IGF", "PROTEIN", 62, 65], ["serum IGF-1", "PROTEIN", 139, 150], ["specific receptors", "TEST", 110, 128], ["serum IGF", "TEST", 139, 148]]], ["The increase in GH concentration suggests that GH may play-in addition to its well-known role as a regulator of growth and immune function-an important role in intestinal healing in early postnatal calves.DiscussionDuring acute diarrhea the plasma concentrations of GH tended to be lower in calves that had been ill for a longer time.", [["intestinal", "ANATOMY", 160, 170], ["plasma", "ANATOMY", 241, 247], ["GH", "CHEMICAL", 47, 49], ["diarrhea", "DISEASE", 228, 236], ["GH", "GENE_OR_GENE_PRODUCT", 16, 18], ["GH", "GENE_OR_GENE_PRODUCT", 47, 49], ["intestinal", "ORGAN", 160, 170], ["calves", "ORGANISM", 198, 204], ["plasma", "ORGANISM_SUBSTANCE", 241, 247], ["GH", "GENE_OR_GENE_PRODUCT", 266, 268], ["calves", "ORGANISM", 291, 297], ["calves", "SPECIES", 198, 204], ["calves", "SPECIES", 291, 297], ["The increase in GH concentration", "TREATMENT", 0, 32], ["immune function", "PROBLEM", 123, 138], ["intestinal healing", "PROBLEM", 160, 178], ["acute diarrhea", "PROBLEM", 222, 236], ["the plasma concentrations of GH", "PROBLEM", 237, 268], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["intestinal", "ANATOMY", 160, 170], ["healing", "OBSERVATION", 171, 178], ["acute", "OBSERVATION_MODIFIER", 222, 227], ["diarrhea", "OBSERVATION", 228, 236]]], ["One major consequence of disease conditions is a reduced growth rate that may range from temporary growth restraint to permanent growth inhibition [21] .", [["disease conditions", "PROBLEM", 25, 43], ["a reduced growth rate", "PROBLEM", 47, 68], ["temporary growth restraint", "TREATMENT", 89, 115], ["permanent growth inhibition", "PROBLEM", 119, 146], ["disease", "OBSERVATION", 25, 32], ["reduced", "OBSERVATION_MODIFIER", 49, 56], ["growth", "OBSERVATION_MODIFIER", 57, 63]]], ["The mechanism for this reduced growth rate in cattle is thought to be due to reduced plasma concentrations of GH and IGF-1, and hence reduced anabolic stimuli [22, 23] .", [["plasma", "ANATOMY", 85, 91], ["cattle", "ORGANISM", 46, 52], ["plasma", "ORGANISM_SUBSTANCE", 85, 91], ["GH", "GENE_OR_GENE_PRODUCT", 110, 112], ["IGF-1", "GENE_OR_GENE_PRODUCT", 117, 122], ["IGF", "PROTEIN", 117, 120], ["cattle", "SPECIES", 46, 52], ["cattle", "SPECIES", 46, 52], ["this reduced growth rate", "PROBLEM", 18, 42], ["reduced plasma concentrations", "PROBLEM", 77, 106], ["IGF", "TEST", 117, 120], ["reduced anabolic stimuli", "PROBLEM", 134, 158]]], ["At Day 21 of age GH concentrations were similar in the reconvalescent and the healthy calves thus, indicating that GH concentration is not stimulated beyond this time.DiscussionPlasma concentrations of cortisol in early postnatal calves seem to be of particular importance for the susceptibility to diarrhea.", [["cortisol", "CHEMICAL", 202, 210], ["diarrhea", "DISEASE", 299, 307], ["cortisol", "CHEMICAL", 202, 210], ["GH", "GENE_OR_GENE_PRODUCT", 17, 19], ["calves", "ORGANISM", 86, 92], ["GH", "GENE_OR_GENE_PRODUCT", 115, 117], ["cortisol", "GENE_OR_GENE_PRODUCT", 202, 210], ["calves", "ORGANISM", 230, 236], ["calves", "SPECIES", 86, 92], ["calves", "SPECIES", 230, 236], ["GH concentration", "PROBLEM", 115, 131], ["cortisol", "TREATMENT", 202, 210], ["diarrhea", "PROBLEM", 299, 307]]], ["Cortisol may vary extensively [24, 25] , but there is indication that concentrations are high after birth and decrease during the first week of life in ruminants.", [["Cortisol", "CHEMICAL", 0, 8], ["Cortisol", "CHEMICAL", 0, 8], ["Cortisol", "GENE_OR_GENE_PRODUCT", 0, 8], ["Cortisol", "TEST", 0, 8], ["high", "OBSERVATION_MODIFIER", 89, 93], ["decrease", "OBSERVATION_MODIFIER", 110, 118]]], ["The number of leukocytes, glucose concentrations and the weight gains increase in accordance with the concentrations of cortisol [26] .", [["leukocytes", "ANATOMY", 14, 24], ["glucose", "CHEMICAL", 26, 33], ["cortisol", "CHEMICAL", 120, 128], ["glucose", "CHEMICAL", 26, 33], ["cortisol", "CHEMICAL", 120, 128], ["leukocytes", "CELL", 14, 24], ["glucose", "SIMPLE_CHEMICAL", 26, 33], ["cortisol", "SIMPLE_CHEMICAL", 120, 128], ["leukocytes", "CELL_TYPE", 14, 24], ["glucose concentrations", "TREATMENT", 26, 48], ["cortisol", "TEST", 120, 128], ["leukocytes", "OBSERVATION", 14, 24], ["concentrations", "OBSERVATION_MODIFIER", 34, 48]]], ["The results of the current work indicate that even before calves suffered from clinically apparent diarrhea, cortisol concentrations were decreased.", [["diarrhea", "DISEASE", 99, 107], ["cortisol", "CHEMICAL", 109, 117], ["cortisol", "CHEMICAL", 109, 117], ["calves", "ORGANISM", 58, 64], ["cortisol", "SIMPLE_CHEMICAL", 109, 117], ["calves", "SPECIES", 58, 64], ["calves", "SPECIES", 58, 64], ["clinically apparent diarrhea", "PROBLEM", 79, 107], ["cortisol concentrations", "TEST", 109, 132], ["diarrhea", "OBSERVATION", 99, 107]]], ["Although the possibility exists that the calves of Group 2 and 3 had a low cortisol level at birth, which in turn may have induced a lower absorption of IgG [27] and a lower resistance to diarrhea, we have no data to support this.", [["cortisol", "CHEMICAL", 75, 83], ["diarrhea", "DISEASE", 188, 196], ["cortisol", "CHEMICAL", 75, 83], ["calves", "ORGANISM", 41, 47], ["cortisol", "GENE_OR_GENE_PRODUCT", 75, 83], ["IgG", "PROTEIN", 153, 156], ["calves", "SPECIES", 41, 47], ["a low cortisol level", "PROBLEM", 69, 89], ["a lower absorption of IgG", "PROBLEM", 131, 156], ["a lower resistance to diarrhea", "PROBLEM", 166, 196], ["lower resistance", "OBSERVATION_MODIFIER", 168, 184]]], ["However, our results, taken together with those of other research workers [3] , lead to the speculation that glucocorticoid concentrations increase to a peak around the time of onset of labor and then decline [28] .", [["glucocorticoid", "SIMPLE_CHEMICAL", 109, 123], ["glucocorticoid concentrations", "PROBLEM", 109, 138], ["labor", "PROBLEM", 186, 191]]], ["Thus, any delay in the birth process could result in lower glucocorticoid concentrations at the time of delivery, and perhaps a subsequent decrease in the ability of the calf to absorb colostral immunoglobulins.", [["calf", "ANATOMY", 170, 174], ["glucocorticoid", "SIMPLE_CHEMICAL", 59, 73], ["calf", "ORGANISM", 170, 174], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 195, 210], ["colostral immunoglobulins", "PROTEIN", 185, 210], ["calf", "SPECIES", 170, 174], ["any delay in the birth process", "PROBLEM", 6, 36], ["lower glucocorticoid concentrations", "PROBLEM", 53, 88], ["delivery", "TREATMENT", 104, 112], ["a subsequent decrease", "PROBLEM", 126, 147], ["absorb colostral immunoglobulins", "TREATMENT", 178, 210], ["decrease", "OBSERVATION_MODIFIER", 139, 147], ["calf", "ANATOMY", 170, 174]]], ["Therefore, it may be speculated that those calves that had low concentrations of cortisol had a higher susceptibility to diarrhea because their passage rate of IgG out of the colostrum into the blood circulation was diminished.", [["colostrum", "ANATOMY", 175, 184], ["blood", "ANATOMY", 194, 199], ["cortisol", "CHEMICAL", 81, 89], ["diarrhea", "DISEASE", 121, 129], ["cortisol", "CHEMICAL", 81, 89], ["calves", "ORGANISM", 43, 49], ["cortisol", "GENE_OR_GENE_PRODUCT", 81, 89], ["IgG", "GENE_OR_GENE_PRODUCT", 160, 163], ["colostrum", "ORGANISM", 175, 184], ["blood", "ORGANISM_SUBSTANCE", 194, 199], ["IgG", "PROTEIN", 160, 163], ["calves", "SPECIES", 43, 49], ["low concentrations of cortisol", "PROBLEM", 59, 89], ["a higher susceptibility to diarrhea", "PROBLEM", 94, 129], ["IgG", "TEST", 160, 163], ["diminished", "PROBLEM", 216, 226], ["blood", "ANATOMY", 194, 199], ["diminished", "OBSERVATION_MODIFIER", 216, 226]]], ["However, it is well known that cortisol may modulate susceptibility by mechanisms involving systems other than just IgG passage rate.DiscussionIncreased cortisol concentrations were reported for calves during Escherichia coli infections [29] and endotoxin treatment [18] , whereas cortisol concentrations were not changed in diarrheic calves during Ostertagia ostertagi infections [30] .", [["cortisol", "CHEMICAL", 31, 39], ["cortisol", "CHEMICAL", 153, 161], ["Escherichia coli infections", "DISEASE", 209, 236], ["endotoxin", "CHEMICAL", 246, 255], ["cortisol", "CHEMICAL", 281, 289], ["Ostertagia ostertagi infections", "DISEASE", 349, 380], ["cortisol", "CHEMICAL", 31, 39], ["cortisol", "CHEMICAL", 153, 161], ["cortisol", "CHEMICAL", 281, 289], ["cortisol", "SIMPLE_CHEMICAL", 31, 39], ["IgG", "GENE_OR_GENE_PRODUCT", 116, 119], ["cortisol", "GENE_OR_GENE_PRODUCT", 153, 161], ["calves", "ORGANISM", 195, 201], ["Escherichia coli", "ORGANISM", 209, 225], ["endotoxin", "SIMPLE_CHEMICAL", 246, 255], ["cortisol", "SIMPLE_CHEMICAL", 281, 289], ["calves", "ORGANISM_SUBDIVISION", 335, 341], ["Ostertagia ostertagi", "ORGANISM", 349, 369], ["IgG", "PROTEIN", 116, 119], ["calves", "SPECIES", 195, 201], ["Escherichia coli", "SPECIES", 209, 225], ["calves", "SPECIES", 335, 341], ["Ostertagia ostertagi", "SPECIES", 349, 369], ["Escherichia coli", "SPECIES", 209, 225], ["Ostertagia ostertagi", "SPECIES", 349, 369], ["IgG passage rate", "TEST", 116, 132], ["Increased cortisol concentrations", "PROBLEM", 143, 176], ["Escherichia coli infections", "PROBLEM", 209, 236], ["endotoxin treatment", "TREATMENT", 246, 265], ["cortisol concentrations", "TEST", 281, 304], ["diarrheic calves", "PROBLEM", 325, 341], ["Ostertagia ostertagi infections", "PROBLEM", 349, 380]]], ["Also, in the present study no significant increases in cortisol concentrations were observed during diarrhea.", [["cortisol", "CHEMICAL", 55, 63], ["diarrhea", "DISEASE", 100, 108], ["cortisol", "CHEMICAL", 55, 63], ["cortisol", "SIMPLE_CHEMICAL", 55, 63], ["the present study", "TEST", 9, 26], ["significant increases in cortisol concentrations", "PROBLEM", 30, 78], ["diarrhea", "PROBLEM", 100, 108], ["no", "UNCERTAINTY", 27, 29], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["increases", "OBSERVATION_MODIFIER", 42, 51], ["cortisol concentrations", "OBSERVATION", 55, 78]]], ["These results may be typical for mild forms of diarrhea.DiscussionThe low basal concentrations of LH were unchanged by diarrhea, but the onset of pulsatile LH release was delayed.", [["diarrhea", "DISEASE", 47, 55], ["diarrhea", "DISEASE", 119, 127], ["LH", "GENE_OR_GENE_PRODUCT", 98, 100], ["LH", "GENE_OR_GENE_PRODUCT", 156, 158], ["diarrhea", "PROBLEM", 47, 55], ["The low basal concentrations of LH", "PROBLEM", 66, 100], ["diarrhea", "PROBLEM", 119, 127], ["pulsatile LH release", "PROBLEM", 146, 166], ["mild", "OBSERVATION_MODIFIER", 33, 37], ["diarrhea", "OBSERVATION", 47, 55], ["unchanged", "OBSERVATION_MODIFIER", 106, 115]]], ["The concentrations of LH in calves of the same age or slightly older ones correspond with results of previous reports [31, 32] .", [["LH", "GENE_OR_GENE_PRODUCT", 22, 24], ["calves", "ORGANISM", 28, 34], ["calves", "SPECIES", 28, 34], ["concentrations", "OBSERVATION_MODIFIER", 4, 18]]], ["The pituitary is sensitive to exogenous GnRH stimulation in the infantile bull calf at 4 to 6 wk of life [33] .", [["pituitary", "ANATOMY", 4, 13], ["bull calf", "ANATOMY", 74, 83], ["infantile", "DISEASE", 64, 73], ["pituitary", "ORGAN", 4, 13], ["GnRH", "GENE_OR_GENE_PRODUCT", 40, 44], ["bull calf", "ORGANISM_SUBDIVISION", 74, 83], ["calf", "SPECIES", 79, 83], ["exogenous GnRH stimulation", "TREATMENT", 30, 56], ["pituitary", "ANATOMY", 4, 13], ["GnRH stimulation", "OBSERVATION", 40, 56]]], ["Stressors inducing a rise of cortisol concentration may cause a decrease in LH concentration via down-regulating the sensitivity of the adenopituitary toward GnRH in adult cattle, but in new-born cattle the pituitary is more likely to be influenced by opioids [34] .", [["pituitary", "ANATOMY", 207, 216], ["cortisol", "CHEMICAL", 29, 37], ["cortisol", "CHEMICAL", 29, 37], ["cortisol", "SIMPLE_CHEMICAL", 29, 37], ["LH", "GENE_OR_GENE_PRODUCT", 76, 78], ["GnRH", "GENE_OR_GENE_PRODUCT", 158, 162], ["cattle", "ORGANISM", 172, 178], ["cattle", "ORGANISM", 196, 202], ["pituitary", "ORGAN", 207, 216], ["cattle", "SPECIES", 172, 178], ["cattle", "SPECIES", 196, 202], ["cattle", "SPECIES", 172, 178], ["cattle", "SPECIES", 196, 202], ["cortisol concentration", "TREATMENT", 29, 51], ["a decrease in LH concentration", "PROBLEM", 62, 92], ["decrease", "OBSERVATION_MODIFIER", 64, 72], ["pituitary", "ANATOMY", 207, 216], ["more likely", "UNCERTAINTY", 220, 231]]], ["Therefore, it may be concluded that the low basal concentration of LH is not modified by early postnatal diarrhea.", [["diarrhea", "DISEASE", 105, 113], ["LH", "GENE_OR_GENE_PRODUCT", 67, 69], ["the low basal concentration of LH", "PROBLEM", 36, 69], ["early postnatal diarrhea", "PROBLEM", 89, 113], ["diarrhea", "OBSERVATION", 105, 113]]], ["However, the delayed onset in LH pulses may result in delayed gonadal development, because in bull calves the early increase in pulsatile LH release is critical for initiation of reproductive performance [35] .DiscussionInsulin concentrations have recently been shown to be reduced in milk-fed calves with acute, but mild diarrhea due to cryptosporidia or coronavirus infections [36] .", [["gonadal", "ANATOMY", 62, 69], ["DiscussionInsulin", "CHEMICAL", 210, 227], ["diarrhea", "DISEASE", 322, 330], ["cryptosporidia", "DISEASE", 338, 352], ["coronavirus infections", "DISEASE", 356, 378], ["LH", "GENE_OR_GENE_PRODUCT", 30, 32], ["gonadal", "ORGAN", 62, 69], ["bull calves", "ORGANISM", 94, 105], ["LH", "GENE_OR_GENE_PRODUCT", 138, 140], ["DiscussionInsulin", "GENE_OR_GENE_PRODUCT", 210, 227], ["milk", "ORGANISM_SUBSTANCE", 285, 289], ["calves", "ORGANISM", 294, 300], ["calves", "SPECIES", 99, 105], ["calves", "SPECIES", 294, 300], ["the delayed onset in LH pulses", "PROBLEM", 9, 39], ["delayed gonadal development", "PROBLEM", 54, 81], ["bull calves", "PROBLEM", 94, 105], ["pulsatile LH release", "TREATMENT", 128, 148], ["mild diarrhea", "PROBLEM", 317, 330], ["cryptosporidia", "PROBLEM", 338, 352], ["coronavirus infections", "PROBLEM", 356, 378], ["early", "OBSERVATION_MODIFIER", 110, 115], ["increase", "OBSERVATION_MODIFIER", 116, 124], ["reduced", "OBSERVATION_MODIFIER", 274, 281], ["acute", "OBSERVATION_MODIFIER", 306, 311], ["mild", "OBSERVATION_MODIFIER", 317, 321], ["diarrhea", "OBSERVATION", 322, 330]]], ["However, after E. coli endotoxin treatment increased insulin concentrations were reported [29] that correspond with the results of the present study in which mainly E. coli and only one case with corona-and rotavirus infection was observed.", [["endotoxin", "CHEMICAL", 23, 32], ["rotavirus infection", "DISEASE", 207, 226], ["E. coli", "ORGANISM", 15, 22], ["endotoxin", "ORGANISM", 23, 32], ["insulin", "GENE_OR_GENE_PRODUCT", 53, 60], ["E. coli", "ORGANISM", 165, 172], ["rotavirus", "ORGANISM", 207, 216], ["insulin", "PROTEIN", 53, 60], ["E. coli", "SPECIES", 15, 22], ["E. coli", "SPECIES", 165, 172], ["E. coli", "SPECIES", 15, 22], ["E. coli", "SPECIES", 165, 172], ["rotavirus", "SPECIES", 207, 216], ["E. coli endotoxin treatment increased insulin concentrations", "TREATMENT", 15, 75], ["the present study", "TEST", 131, 148], ["E. coli", "PROBLEM", 165, 172], ["corona", "PROBLEM", 196, 202], ["rotavirus infection", "PROBLEM", 207, 226], ["coli", "OBSERVATION", 168, 172], ["rotavirus", "OBSERVATION_MODIFIER", 207, 216], ["infection", "OBSERVATION", 217, 226]]], ["This might be the reason that only slight effects of diarrhea on the concentration of insulin were observed in the present study.", [["diarrhea", "DISEASE", 53, 61], ["insulin", "GENE_OR_GENE_PRODUCT", 86, 93], ["insulin", "PROTEIN", 86, 93], ["diarrhea", "PROBLEM", 53, 61], ["the concentration of insulin", "TREATMENT", 65, 93], ["the present study", "TEST", 111, 128], ["slight", "OBSERVATION_MODIFIER", 35, 41], ["diarrhea", "OBSERVATION", 53, 61]]], ["However, there was always a distinct stimulating effect on blood plasma concentrations of insulin after feeding the calves in the morning one hour before the start of the blood sampling intervals.DiscussionIn summary, low cortisol concentrations were related to a higher susceptibility toward diarrhea in neonatal calves.", [["blood plasma", "ANATOMY", 59, 71], ["blood", "ANATOMY", 171, 176], ["cortisol", "CHEMICAL", 222, 230], ["diarrhea", "DISEASE", 293, 301], ["cortisol", "CHEMICAL", 222, 230], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["insulin", "GENE_OR_GENE_PRODUCT", 90, 97], ["calves", "ORGANISM", 116, 122], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["cortisol", "SIMPLE_CHEMICAL", 222, 230], ["calves", "ORGANISM", 314, 320], ["insulin", "PROTEIN", 90, 97], ["calves", "SPECIES", 116, 122], ["calves", "SPECIES", 314, 320], ["blood plasma concentrations of insulin", "TREATMENT", 59, 97], ["the blood sampling intervals", "TREATMENT", 167, 195], ["low cortisol concentrations", "PROBLEM", 218, 245], ["a higher susceptibility toward diarrhea in neonatal calves", "PROBLEM", 262, 320], ["distinct", "OBSERVATION_MODIFIER", 28, 36], ["stimulating effect", "OBSERVATION", 37, 55], ["diarrhea", "OBSERVATION", 293, 301], ["neonatal calves", "ANATOMY", 305, 320]]], ["Increased GH concentrations that are evident even before the clinical appearance of infections may be contribute to lower permeability of the gut for infectious agents.", [["gut", "ANATOMY", 142, 145], ["infections", "DISEASE", 84, 94], ["GH", "GENE_OR_GENE_PRODUCT", 10, 12], ["gut", "ORGANISM_SUBDIVISION", 142, 145], ["Increased GH concentrations", "PROBLEM", 0, 27], ["infections", "PROBLEM", 84, 94], ["infectious agents", "TREATMENT", 150, 167], ["GH concentrations", "OBSERVATION", 10, 27], ["infections", "OBSERVATION", 84, 94], ["lower permeability", "OBSERVATION_MODIFIER", 116, 134], ["gut", "ANATOMY", 142, 145], ["infectious", "OBSERVATION", 150, 160]]], ["GH may therefore play an important role in activating the body's defenses against diarrheic infections and, additionally in intestinal healing.", [["body", "ANATOMY", 58, 62], ["intestinal", "ANATOMY", 124, 134], ["diarrheic infections", "DISEASE", 82, 102], ["GH", "GENE_OR_GENE_PRODUCT", 0, 2], ["body", "ORGANISM_SUBDIVISION", 58, 62], ["intestinal", "ORGAN", 124, 134], ["diarrheic infections", "PROBLEM", 82, 102], ["intestinal healing", "PROBLEM", 124, 142], ["intestinal", "ANATOMY", 124, 134], ["healing", "OBSERVATION", 135, 142]]], ["In diarrheic calves the onset of pulsatile LH release was delayed.", [["diarrheic", "DISEASE", 3, 12], ["calves", "ORGANISM", 13, 19], ["LH", "GENE_OR_GENE_PRODUCT", 43, 45], ["calves", "SPECIES", 13, 19], ["diarrheic", "PROBLEM", 3, 12], ["pulsatile LH release", "PROBLEM", 33, 53], ["diarrheic", "OBSERVATION", 3, 12]]], ["In conclusion, even mild diarrhea alters the concentration of reproductive and metabolic hormones in early postnatal calves.", [["diarrhea", "DISEASE", 25, 33], ["calves", "ORGANISM", 117, 123], ["calves", "SPECIES", 117, 123], ["mild diarrhea", "PROBLEM", 20, 33], ["reproductive and metabolic hormones in early postnatal calves", "PROBLEM", 62, 123], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["diarrhea", "OBSERVATION", 25, 33], ["metabolic hormones", "OBSERVATION", 79, 97], ["postnatal calves", "ANATOMY", 107, 123]]], ["Whether the observed disturbances might have consequences for reproductive performance and growth remains to be investigated. cortisol antibody, E La\u2424 for her technical assistance, and the staff of the research station Karkendamm for the care and the management of the animals.", [["cortisol", "CHEMICAL", 126, 134], ["cortisol", "CHEMICAL", 126, 134], ["cortisol antibody", "GENE_OR_GENE_PRODUCT", 126, 143], ["the observed disturbances", "PROBLEM", 8, 33], ["reproductive performance", "PROBLEM", 62, 86], ["cortisol antibody", "TEST", 126, 143], ["the care", "TREATMENT", 234, 242]]]], "543317336df71e388affc79fdf0019732ba323fe": [["To the Editor-The COVID-19 pandemic of 2020, caused by a severe coronavirus strain named SARS-CoV-2, and has created shortages of personal protective equipment (PPE).", [["coronavirus", "DISEASE", 64, 75], ["SARS", "DISEASE", 89, 93], ["coronavirus", "SPECIES", 64, 75], ["SARS-CoV", "SPECIES", 89, 97], ["a severe coronavirus strain", "PROBLEM", 55, 82], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["coronavirus", "OBSERVATION", 64, 75]]], ["1 The Centers for Disease Control and Prevention (CDC) released a PPE burn rate calculator for hospitals to project future PPE supplies.", [["Disease Control", "TREATMENT", 18, 33], ["a PPE burn rate calculator", "TREATMENT", 64, 90], ["PPE supplies", "TREATMENT", 123, 135]]], ["2 This tool requires that hospital systems have an understanding of daily PPE usage patterns.", [["daily PPE usage patterns", "TREATMENT", 68, 92]]], ["This calculator also does not differentiate usage at various healthcare provider (HCP) and patient capacities.", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98]]], ["Vital factors that affect PPE supplies, namely decontamination, are not considered in the CDC PPE burn rate calculator.", [["Vital factors", "TEST", 0, 13], ["PPE supplies", "TREATMENT", 26, 38]]], ["We designed a sampling approach to steward our current PPE supply, and we developed an institutional burn rate calculator to project usage patterns at various patient and/or provider volumes.", [["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166], ["a sampling approach", "TREATMENT", 12, 31], ["an institutional burn rate calculator", "TREATMENT", 84, 121]]]], "770e5fe89399378bcc9f35a003c5a0cf3e8b1d9c": [["IntroductionThe relationship between sponges and medicines goes back to Alexandrian physicians and was thoroughly describes by the Roman historian Plinius.", [["medicines", "TREATMENT", 49, 58]]], ["Physicians used sponges that were saturated with iodine to stimulate coagulation of the blood, or with bioactive plant extracts to anesthetize patients.", [["blood", "ANATOMY", 88, 93], ["extracts", "ANATOMY", 119, 127], ["iodine", "CHEMICAL", 49, 55], ["iodine", "CHEMICAL", 49, 55], ["iodine", "SIMPLE_CHEMICAL", 49, 55], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["extracts", "ORGANISM_SUBSTANCE", 119, 127], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["sponges", "TREATMENT", 16, 23], ["iodine", "TREATMENT", 49, 55], ["bioactive plant extracts", "TREATMENT", 103, 127]]], ["Sponges were soaked with pure wine and put on the left part of the chest in case of heartaches and soaked in urine to treat bites of poisonous animals.", [["Sponges", "ANATOMY", 0, 7], ["left part", "ANATOMY", 50, 59], ["chest", "ANATOMY", 67, 72], ["heartaches", "ANATOMY", 84, 94], ["urine", "ANATOMY", 109, 114], ["chest", "ORGANISM_SUBDIVISION", 67, 72], ["urine", "ORGANISM_SUBSTANCE", 109, 114], ["Sponges", "TREATMENT", 0, 7], ["pure wine", "TREATMENT", 25, 34], ["heartaches", "PROBLEM", 84, 94], ["soaked in urine", "PROBLEM", 99, 114], ["poisonous animals", "PROBLEM", 133, 150], ["left", "ANATOMY_MODIFIER", 50, 54], ["chest", "ANATOMY", 67, 72]]], ["Plinius recommended the use of sponges against sunstrokes, and they were used against all kinds of wounds, bone fractures, dropsy, stomach aches, infectious diseases, and testicular tumors (Hofrichter and Sidri, 2001), or even as implants after breast operations (Arndt, 1938) .", [["wounds", "ANATOMY", 99, 105], ["bone", "ANATOMY", 107, 111], ["stomach", "ANATOMY", 131, 138], ["testicular tumors", "ANATOMY", 171, 188], ["breast", "ANATOMY", 245, 251], ["sunstrokes", "DISEASE", 47, 57], ["wounds", "DISEASE", 99, 105], ["bone fractures", "DISEASE", 107, 121], ["stomach aches", "DISEASE", 131, 144], ["infectious diseases", "DISEASE", 146, 165], ["testicular tumors", "DISEASE", 171, 188], ["wounds", "PATHOLOGICAL_FORMATION", 99, 105], ["bone", "TISSUE", 107, 111], ["stomach", "ORGANISM_SUBDIVISION", 131, 138], ["testicular tumors", "CANCER", 171, 188], ["sponges", "TREATMENT", 31, 38], ["sunstrokes", "TREATMENT", 47, 57], ["wounds", "PROBLEM", 99, 105], ["bone fractures", "PROBLEM", 107, 121], ["dropsy", "PROBLEM", 123, 129], ["stomach aches", "PROBLEM", 131, 144], ["infectious diseases", "PROBLEM", 146, 165], ["testicular tumors", "PROBLEM", 171, 188], ["breast operations", "TREATMENT", 245, 262], ["wounds", "OBSERVATION", 99, 105], ["bone", "ANATOMY", 107, 111], ["fractures", "OBSERVATION", 112, 121], ["stomach", "ANATOMY", 131, 138], ["infectious", "OBSERVATION_MODIFIER", 146, 156], ["testicular", "ANATOMY", 171, 181], ["tumors", "OBSERVATION", 182, 188], ["breast", "ANATOMY", 245, 251], ["operations", "OBSERVATION", 252, 262]]], ["At least since the 18th century, Russian, Ukrainian, and Polish physicians have used a freshwater sponge they call Badiaga (Figure 1 ) for the treatment of patients (Nozeman, 1788).", [["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["a freshwater sponge", "TREATMENT", 85, 104]]], ["The dry powder of this sponge is rubbed on the chest or back of patients with lung diseases or on the sore places in cases of foot and leg aches (such as rheumatism (Schroder, 1942) .", [["chest", "ANATOMY", 47, 52], ["lung", "ANATOMY", 78, 82], ["foot", "ANATOMY", 126, 130], ["leg", "ANATOMY", 135, 138], ["lung diseases", "DISEASE", 78, 91], ["foot and leg aches", "DISEASE", 126, 144], ["rheumatism", "DISEASE", 154, 164], ["chest", "ORGANISM_SUBDIVISION", 47, 52], ["patients", "ORGANISM", 64, 72], ["lung", "ORGAN", 78, 82], ["foot", "ORGANISM_SUBDIVISION", 126, 130], ["leg aches", "ORGANISM_SUBDIVISION", 135, 144], ["patients", "SPECIES", 64, 72], ["The dry powder", "TREATMENT", 0, 14], ["this sponge", "TREATMENT", 18, 29], ["lung diseases", "PROBLEM", 78, 91], ["foot and leg aches", "PROBLEM", 126, 144], ["rheumatism", "PROBLEM", 154, 164], ["dry", "OBSERVATION_MODIFIER", 4, 7], ["powder", "OBSERVATION", 8, 14], ["sponge", "OBSERVATION", 23, 29], ["rubbed", "OBSERVATION", 33, 39], ["chest", "ANATOMY", 47, 52], ["lung", "ANATOMY", 78, 82], ["diseases", "OBSERVATION", 83, 91], ["foot", "ANATOMY", 126, 130], ["leg", "ANATOMY", 135, 138], ["aches", "OBSERVATION", 139, 144], ["rheumatism", "OBSERVATION", 154, 164]]], ["Oficjalski (1937) discovered that Badiaga is not really one sponge, but mixtures of several freshwater sponges that differ depending on the region.", [["several freshwater sponges", "TREATMENT", 84, 110], ["sponge", "OBSERVATION", 60, 66]]], ["In Poland it consisted of powder of Euspongilla lacustris, Ephydatia fluviatilis, and Meyenia muelleri, while the Russian Badiaga was a mixture of Euspongilla lacustris, Ephydatia fluviatilis, Spongilla fragilis, and Carterius stepanowi.", [["Euspongilla lacustris", "ORGANISM", 36, 57], ["Ephydatia fluviatilis", "ORGANISM", 59, 80], ["Meyenia muelleri", "ORGANISM", 86, 102], ["Euspongilla lacustris", "ORGANISM", 147, 168], ["Ephydatia fluviatilis", "ORGANISM", 170, 191], ["Spongilla fragilis", "ORGANISM", 193, 211], ["Carterius stepanowi", "ORGANISM", 217, 236], ["Euspongilla lacustris", "SPECIES", 36, 57], ["Ephydatia fluviatilis", "SPECIES", 59, 80], ["Meyenia muelleri", "SPECIES", 86, 102], ["Euspongilla lacustris", "SPECIES", 147, 168], ["Ephydatia fluviatilis", "SPECIES", 170, 191], ["Spongilla fragilis", "SPECIES", 193, 211], ["Carterius stepanowi", "SPECIES", 217, 236], ["Euspongilla lacustris", "SPECIES", 36, 57], ["Ephydatia fluviatilis", "SPECIES", 59, 80], ["Meyenia muelleri", "SPECIES", 86, 102], ["Euspongilla lacustris", "SPECIES", 147, 168], ["Ephydatia fluviatilis", "SPECIES", 170, 191], ["Spongilla fragilis", "SPECIES", 193, 211], ["Carterius stepanowi", "SPECIES", 217, 236], ["Euspongilla lacustris", "PROBLEM", 36, 57], ["Ephydatia fluviatilis", "PROBLEM", 59, 80], ["Euspongilla lacustris", "PROBLEM", 147, 168], ["Ephydatia fluviatilis", "PROBLEM", 170, 191], ["Spongilla fragilis", "PROBLEM", 193, 211], ["Ephydatia fluviatilis", "OBSERVATION", 59, 80], ["Spongilla fragilis", "ANATOMY", 193, 211]]], ["He suggested that the high iodine concentration in all sponge species gives rise to the wholesome effect of Badiaga.", [["iodine", "CHEMICAL", 27, 33], ["iodine", "CHEMICAL", 27, 33], ["iodine", "SIMPLE_CHEMICAL", 27, 33], ["the high iodine concentration", "TREATMENT", 18, 47], ["all sponge species", "PROBLEM", 51, 69]]], ["At present Stodal, syrup containing roasted Spongia officinalis, is used for homeopathic treatment of dry and asthmatic cough in the Western world (Stodal, 2003) .IntroductionPharmaceutical interest in sponges was aroused in the early 1950s by the discovery of a nucleosides spongothymidine and spongouridine in the marine sponge Cryptotethia crypta Feeney, 1950, 1951) .", [["dry and asthmatic cough", "DISEASE", 102, 125], ["spongothymidine", "CHEMICAL", 275, 290], ["spongouridine", "CHEMICAL", 295, 308], ["nucleosides", "CHEMICAL", 263, 274], ["spongothymidine", "CHEMICAL", 275, 290], ["spongouridine", "CHEMICAL", 295, 308], ["syrup", "ORGANISM_SUBSTANCE", 19, 24], ["Spongia officinalis", "ORGANISM", 44, 63], ["spongothymidine", "SIMPLE_CHEMICAL", 275, 290], ["spongouridine", "SIMPLE_CHEMICAL", 295, 308], ["roasted", "SPECIES", 36, 43], ["Spongia officinalis", "SPECIES", 44, 63], ["Cryptotethia crypta", "SPECIES", 330, 349], ["Spongia officinalis", "SPECIES", 44, 63], ["roasted Spongia officinalis", "TREATMENT", 36, 63], ["homeopathic treatment", "TREATMENT", 77, 98], ["dry and asthmatic cough", "PROBLEM", 102, 125], ["IntroductionPharmaceutical interest in sponges", "TREATMENT", 163, 209], ["a nucleosides spongothymidine", "TREATMENT", 261, 290], ["spongouridine", "TREATMENT", 295, 308], ["Spongia officinalis", "OBSERVATION", 44, 63], ["asthmatic cough", "OBSERVATION", 110, 125]]], ["These nucleosides were the basis for the synthesis of Ara-C, the first marine-derived anticancer agent, and the antiviral drug Ara-A (Proksch et al., 2002) .", [["anticancer", "ANATOMY", 86, 96], ["nucleosides", "CHEMICAL", 6, 17], ["Ara-C", "CHEMICAL", 54, 59], ["Ara-A", "CHEMICAL", 127, 132], ["nucleosides", "CHEMICAL", 6, 17], ["Ara-C", "CHEMICAL", 54, 59], ["Ara-A", "CHEMICAL", 127, 132], ["Ara-C", "SIMPLE_CHEMICAL", 54, 59], ["anticancer", "CANCER", 86, 96], ["Ara-A", "SIMPLE_CHEMICAL", 127, 132], ["These nucleosides", "TREATMENT", 0, 17], ["Ara", "TEST", 54, 57], ["anticancer agent", "TREATMENT", 86, 102]]], ["Ara-C is currently used in the routine treatment of patients with leukemia and lymphoma.", [["leukemia", "ANATOMY", 66, 74], ["lymphoma", "ANATOMY", 79, 87], ["Ara-C", "CHEMICAL", 0, 5], ["leukemia and lymphoma", "DISEASE", 66, 87], ["Ara-C", "CHEMICAL", 0, 5], ["Ara-C", "SIMPLE_CHEMICAL", 0, 5], ["patients", "ORGANISM", 52, 60], ["leukemia", "CANCER", 66, 74], ["lymphoma", "CANCER", 79, 87], ["patients", "SPECIES", 52, 60], ["the routine treatment", "TREATMENT", 27, 48], ["leukemia", "PROBLEM", 66, 74], ["lymphoma", "PROBLEM", 79, 87], ["leukemia", "OBSERVATION", 66, 74], ["lymphoma", "OBSERVATION", 79, 87]]], ["One of its fluorinated derivatives has also been approved for use in patients with pan-Correspondence to: Detmer Sipkema; E-mail: detmer.sipkema@ wur.nl creatic, breast, bladder, and lung cancer (Schwartsmann, 2000) .", [["breast", "ANATOMY", 162, 168], ["bladder", "ANATOMY", 170, 177], ["lung cancer", "ANATOMY", 183, 194], ["breast, bladder, and lung cancer", "DISEASE", 162, 194], ["fluorinated derivatives", "SIMPLE_CHEMICAL", 11, 34], ["patients", "ORGANISM", 69, 77], ["breast", "CANCER", 162, 168], ["bladder", "ORGAN", 170, 177], ["lung cancer", "CANCER", 183, 194], ["patients", "SPECIES", 69, 77], ["its fluorinated derivatives", "TREATMENT", 7, 34], ["lung cancer", "PROBLEM", 183, 194], ["breast", "ANATOMY", 162, 168], ["bladder", "ANATOMY", 170, 177], ["lung", "ANATOMY", 183, 187], ["cancer", "OBSERVATION", 188, 194]]], ["At the same time it was revealed that certain lipid components such as fatty acids, sterols and other unsaponifiable compounds occur in lower invertebrates in a diversity far greater than that encountered among animals of higher organization (Bergmann and Swift, 1951) .", [["fatty acids", "CHEMICAL", 71, 82], ["sterols", "CHEMICAL", 84, 91], ["fatty acids", "CHEMICAL", 71, 82], ["sterols", "CHEMICAL", 84, 91], ["fatty acids", "SIMPLE_CHEMICAL", 71, 82], ["sterols", "SIMPLE_CHEMICAL", 84, 91], ["certain lipid components", "PROBLEM", 38, 62], ["fatty acids", "TEST", 71, 82], ["other unsaponifiable compounds", "PROBLEM", 96, 126], ["fatty acids", "OBSERVATION", 71, 82], ["higher organization", "OBSERVATION_MODIFIER", 222, 241]]], ["These early promises have now been substantiated by an overwhelming number of bioactive compounds that have been discovered in marine organisms.", [["bioactive compounds", "PROBLEM", 78, 97], ["overwhelming", "OBSERVATION_MODIFIER", 55, 67], ["number", "OBSERVATION_MODIFIER", 68, 74], ["bioactive compounds", "OBSERVATION", 78, 97], ["marine organisms", "OBSERVATION", 127, 143]]], ["More than 15,000 marine products have been described thus for (MarinLit, 1999; Faulkner, 2000 Faulkner, , 2001 Faulkner, , 2002 .IntroductionSponges, in particular, are responsible for more than 5300 different products, and every year hundreds of new compounds are being discovered (Faulkner 2000 (Faulkner , 2001 (Faulkner , 2002 .IntroductionMost bioactive compounds from sponges can be classified as antiinflammatory, antitumor, immunosuppressive or neurosuppressive, antiviral, antimalarial, antibiotic, or antifouling.", [["antitumor", "ANATOMY", 421, 430], ["antitumor", "CANCER", 421, 430], ["IntroductionSponges", "TREATMENT", 129, 148], ["sponges", "TREATMENT", 374, 381], ["antitumor", "TREATMENT", 421, 430], ["immunosuppressive", "TREATMENT", 432, 449], ["neurosuppressive", "TREATMENT", 453, 469], ["antiviral", "TREATMENT", 471, 480], ["antimalarial", "TREATMENT", 482, 494], ["antibiotic", "TREATMENT", 496, 506], ["antifouling", "TREATMENT", 511, 522], ["Sponges", "OBSERVATION", 141, 148], ["new", "OBSERVATION_MODIFIER", 247, 250]]], ["The chemical diversity of sponge products is remarkable.", [["sponge products", "TREATMENT", 26, 41], ["chemical", "OBSERVATION_MODIFIER", 4, 12], ["diversity", "OBSERVATION_MODIFIER", 13, 22], ["sponge products", "OBSERVATION", 26, 41], ["remarkable", "OBSERVATION_MODIFIER", 45, 55]]], ["In addition to the unusual nucleosides, bioactive terpenes, sterols, cyclic peptides, alkaloids, fatty acids, peroxides, and amino acid derivatives (which are frequently halogenated) have been described from sponges ( Figure 2 ).IntroductionFor this review we have surveyed the discoveries of products derived from marine sponges up to now, and attempted to show the variety of potential medical applications of metabolites from sponges and the mechanisms by which they interfere with the pathogenesis of human diseases.", [["sterols", "CHEMICAL", 60, 67], ["cyclic peptides, alkaloids, fatty acids", "CHEMICAL", 69, 108], ["peroxides", "CHEMICAL", 110, 119], ["amino acid", "CHEMICAL", 125, 135], ["nucleosides", "CHEMICAL", 27, 38], ["terpenes", "CHEMICAL", 50, 58], ["sterols", "CHEMICAL", 60, 67], ["fatty acids", "CHEMICAL", 97, 108], ["peroxides", "CHEMICAL", 110, 119], ["amino acid", "CHEMICAL", 125, 135], ["bioactive terpenes", "SIMPLE_CHEMICAL", 40, 58], ["sterols", "SIMPLE_CHEMICAL", 60, 67], ["cyclic peptides", "SIMPLE_CHEMICAL", 69, 84], ["alkaloids", "SIMPLE_CHEMICAL", 86, 95], ["fatty acids", "SIMPLE_CHEMICAL", 97, 108], ["peroxides", "SIMPLE_CHEMICAL", 110, 119], ["amino acid derivatives", "SIMPLE_CHEMICAL", 125, 147], ["human", "ORGANISM", 505, 510], ["human", "SPECIES", 505, 510], ["human", "SPECIES", 505, 510], ["the unusual nucleosides", "TREATMENT", 15, 38], ["bioactive terpenes", "TREATMENT", 40, 58], ["cyclic peptides", "TREATMENT", 69, 84], ["alkaloids", "TREATMENT", 86, 95], ["fatty acids", "TREATMENT", 97, 108], ["peroxides", "TREATMENT", 110, 119], ["amino acid derivatives", "TREATMENT", 125, 147], ["sponges", "TREATMENT", 429, 436], ["human diseases", "PROBLEM", 505, 519], ["bioactive terpenes", "OBSERVATION", 40, 58]]], ["For example, many secondary metabolites inhibit growth of cancer cell lines, but this does not imply that they will be suitable as a medicine against cancer, because they may exhibit important side effects.", [["cancer cell lines", "ANATOMY", 58, 75], ["cancer", "ANATOMY", 150, 156], ["cancer", "DISEASE", 58, 64], ["cancer", "DISEASE", 150, 156], ["cancer cell lines", "CELL", 58, 75], ["cancer", "CANCER", 150, 156], ["cancer cell lines", "CELL_LINE", 58, 75], ["cancer cell lines", "PROBLEM", 58, 75], ["cancer", "PROBLEM", 150, 156], ["growth", "OBSERVATION_MODIFIER", 48, 54], ["cancer cell lines", "OBSERVATION", 58, 75], ["cancer", "OBSERVATION", 150, 156]]], ["The following sections summarize compounds by disease type and describe their mode of action, and discuss the reasons why sponges would produce these metabolites.Sponge ProductsAntiinflammatory Compounds.", [["Sponge Products", "TREATMENT", 162, 177], ["Antiinflammatory Compounds", "TREATMENT", 177, 203], ["Antiinflammatory Compounds", "OBSERVATION", 177, 203]]], ["Acute inflammations in the human body can result from microbial infection, physical damage, or chemical agents.", [["body", "ANATOMY", 33, 37], ["inflammations", "DISEASE", 6, 19], ["infection", "DISEASE", 64, 73], ["human", "ORGANISM", 27, 32], ["body", "ORGANISM_SUBDIVISION", 33, 37], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["Acute inflammations in the human body", "PROBLEM", 0, 37], ["microbial infection", "PROBLEM", 54, 73], ["physical damage", "PROBLEM", 75, 90], ["chemical agents", "TREATMENT", 95, 110], ["inflammations", "OBSERVATION", 6, 19], ["human body", "ANATOMY", 27, 37], ["microbial", "OBSERVATION_MODIFIER", 54, 63], ["infection", "OBSERVATION", 64, 73]]], ["The body reacts by changing the blood flow, increasing the permeability of blood vessels, and allowing the escape of cells from the blood into the tissues (Tan et al., 1999) .", [["body", "ANATOMY", 4, 8], ["blood", "ANATOMY", 32, 37], ["blood vessels", "ANATOMY", 75, 88], ["cells", "ANATOMY", 117, 122], ["blood", "ANATOMY", 132, 137], ["tissues", "ANATOMY", 147, 154], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 75, 88], ["cells", "CELL", 117, 122], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["tissues", "TISSUE", 147, 154], ["the blood flow", "TEST", 28, 42], ["body", "ANATOMY_MODIFIER", 4, 8], ["blood flow", "OBSERVATION", 32, 42], ["increasing", "OBSERVATION_MODIFIER", 44, 54], ["permeability", "OBSERVATION_MODIFIER", 59, 71], ["blood vessels", "ANATOMY", 75, 88], ["blood", "ANATOMY", 132, 137], ["tissues", "ANATOMY", 147, 154]]], ["Chronic inflammation of the skin or joints may severely damage the body if it leads to psoriasis or rheumatic arthritis (Pope et at., 1999) .", [["skin", "ANATOMY", 28, 32], ["joints", "ANATOMY", 36, 42], ["body", "ANATOMY", 67, 71], ["inflammation of the skin or joints", "DISEASE", 8, 42], ["psoriasis", "DISEASE", 87, 96], ["rheumatic arthritis", "DISEASE", 100, 119], ["skin", "ORGAN", 28, 32], ["joints", "MULTI-TISSUE_STRUCTURE", 36, 42], ["body", "ORGANISM_SUBDIVISION", 67, 71], ["Chronic inflammation of the skin or joints", "PROBLEM", 0, 42], ["severely damage the body", "PROBLEM", 47, 71], ["psoriasis", "PROBLEM", 87, 96], ["rheumatic arthritis", "PROBLEM", 100, 119], ["inflammation", "OBSERVATION", 8, 20], ["skin", "ANATOMY", 28, 32], ["joints", "ANATOMY", 36, 42], ["body", "ANATOMY", 67, 71], ["psoriasis", "OBSERVATION", 87, 96], ["rheumatic", "OBSERVATION_MODIFIER", 100, 109], ["arthritis", "OBSERVATION", 110, 119]]], ["Sponges have proved to be an interesting source of antiinflammatory compounds (Table 1) .Sponge ProductsManoalide, one of the first sesterterpenoids to be isolated from a marine sponge (Luffariella variabilis), was found to be an antibiotic (De Silva and Scheuer, 1980) and an analgesic (Mayer and Jacobs, 1988 ).", [["Manoalide", "CHEMICAL", 104, 113], ["Luffariella variabilis", "CHEMICAL", 186, 208], ["Manoalide", "CHEMICAL", 104, 113], ["sesterterpenoids", "CHEMICAL", 132, 148], ["Manoalide", "SIMPLE_CHEMICAL", 104, 113], ["sesterterpenoids", "SIMPLE_CHEMICAL", 132, 148], ["Luffariella variabilis", "ORGANISM", 186, 208], ["Luffariella variabilis", "SPECIES", 186, 208], ["Luffariella variabilis", "SPECIES", 186, 208], ["Sponges", "TREATMENT", 0, 7], ["antiinflammatory compounds", "TREATMENT", 51, 77], ["Sponge ProductsManoalide", "TREATMENT", 89, 113], ["a marine sponge", "TREATMENT", 169, 184], ["an analgesic", "TREATMENT", 274, 286]]], ["In addition, its antiinflammatory properties have been studied extensively (Bennet et al., 1987) .", [["antiinflammatory", "OBSERVATION_MODIFIER", 17, 33]]], ["The antiinflammatory action is based on the irreversible inhibition of the release of arachidonic acid from membrane phospholipids by preventing the enzyme phospholipase A 2 from binding to the membranes (Glaser et al., 1989) .", [["membrane", "ANATOMY", 108, 116], ["membranes", "ANATOMY", 194, 203], ["arachidonic acid", "CHEMICAL", 86, 102], ["arachidonic acid", "CHEMICAL", 86, 102], ["arachidonic acid", "SIMPLE_CHEMICAL", 86, 102], ["membrane phospholipids", "SIMPLE_CHEMICAL", 108, 130], ["phospholipase A 2", "GENE_OR_GENE_PRODUCT", 156, 173], ["membranes", "CELLULAR_COMPONENT", 194, 203], ["enzyme phospholipase A 2", "PROTEIN", 149, 173], ["The antiinflammatory action", "TREATMENT", 0, 27], ["arachidonic acid", "TREATMENT", 86, 102], ["membrane phospholipids", "TREATMENT", 108, 130], ["the enzyme phospholipase", "TEST", 145, 169], ["antiinflammatory", "OBSERVATION_MODIFIER", 4, 20]]], ["A rise in the intracellular arachidonic acid concentration would lead to upregulation of the synthesis of inflammation mediators as prostaglandins and leukotrienes (Figure 3) .", [["intracellular", "ANATOMY", 14, 27], ["arachidonic acid", "CHEMICAL", 28, 44], ["inflammation", "DISEASE", 106, 118], ["prostaglandins", "CHEMICAL", 132, 146], ["leukotrienes", "CHEMICAL", 151, 163], ["arachidonic acid", "CHEMICAL", 28, 44], ["prostaglandins", "CHEMICAL", 132, 146], ["leukotrienes", "CHEMICAL", 151, 163], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["arachidonic acid", "SIMPLE_CHEMICAL", 28, 44], ["prostaglandins", "SIMPLE_CHEMICAL", 132, 146], ["leukotrienes", "SIMPLE_CHEMICAL", 151, 163], ["inflammation mediators", "PROTEIN", 106, 128], ["A rise", "PROBLEM", 0, 6], ["the intracellular arachidonic acid concentration", "PROBLEM", 10, 58], ["the synthesis of inflammation mediators", "TREATMENT", 89, 128], ["prostaglandins and leukotrienes", "TREATMENT", 132, 163], ["rise", "OBSERVATION_MODIFIER", 2, 6], ["arachidonic acid", "OBSERVATION", 28, 44]]], ["Phospholipase A 2 inhibition has been recorded for many sesterterpenes from sponges of the order Dictyoceratida, but also for bis-indole alkaloids such as topsentin (Jacobs et al., 1994) .", [["sesterterpenes", "CHEMICAL", 56, 70], ["bis-indole alkaloids", "CHEMICAL", 126, 146], ["topsentin", "CHEMICAL", 155, 164], ["sesterterpenes", "CHEMICAL", 56, 70], ["bis-indole alkaloids", "CHEMICAL", 126, 146], ["topsentin", "CHEMICAL", 155, 164], ["Phospholipase A 2", "GENE_OR_GENE_PRODUCT", 0, 17], ["sesterterpenes", "SIMPLE_CHEMICAL", 56, 70], ["Dictyoceratida", "GENE_OR_GENE_PRODUCT", 97, 111], ["bis-indole alkaloids", "SIMPLE_CHEMICAL", 126, 146], ["topsentin", "SIMPLE_CHEMICAL", 155, 164], ["Phospholipase A 2 inhibition", "TREATMENT", 0, 28], ["bis-indole alkaloids", "TREATMENT", 126, 146], ["topsentin", "TREATMENT", 155, 164]]], ["The mechanism by which they affect the inflammation process is different from commonly used nonsteroidal antiinflammatory drugs.", [["nonsteroidal", "ANATOMY", 92, 104], ["inflammation", "DISEASE", 39, 51], ["nonsteroidal antiinflammatory drugs", "SIMPLE_CHEMICAL", 92, 127], ["the inflammation process", "PROBLEM", 35, 59], ["nonsteroidal antiinflammatory drugs", "TREATMENT", 92, 127], ["inflammation", "OBSERVATION", 39, 51]]], ["Only a few sponge-derived terpenoids have been found to inhibit lipoxygenase, another enzyme that is involved in the inflammatory response (Carroll et al., 2001) .Sponge ProductsThe antiinflammatory sponge products are selective inhibitors of specific enzymes of a range of diseases, like psoriasis or rheumatic arthritis.", [["psoriasis", "DISEASE", 289, 298], ["rheumatic arthritis", "DISEASE", 302, 321], ["terpenoids", "CHEMICAL", 26, 36], ["lipoxygenase", "SIMPLE_CHEMICAL", 64, 76], ["lipoxygenase", "PROTEIN", 64, 76], ["a few sponge-derived terpenoids", "PROBLEM", 5, 36], ["lipoxygenase", "TEST", 64, 76], ["another enzyme", "TEST", 78, 92], ["the inflammatory response", "PROBLEM", 113, 138], ["Sponge Products", "TREATMENT", 163, 178], ["The antiinflammatory sponge products", "TREATMENT", 178, 214], ["selective inhibitors", "TREATMENT", 219, 239], ["specific enzymes", "TEST", 243, 259], ["diseases", "PROBLEM", 274, 282], ["psoriasis", "PROBLEM", 289, 298], ["rheumatic arthritis", "PROBLEM", 302, 321], ["inflammatory", "OBSERVATION_MODIFIER", 117, 129], ["antiinflammatory sponge", "OBSERVATION", 182, 205], ["psoriasis", "OBSERVATION", 289, 298], ["rheumatic", "OBSERVATION_MODIFIER", 302, 311], ["arthritis", "OBSERVATION", 312, 321]]], ["The currently used nonsteroidal antiinflammatory drugs often fail to control the disease and present important side effects such as risk of gastrointestinal bleeding and renal complications (De Rosa, 2002) .", [["nonsteroidal", "ANATOMY", 19, 31], ["gastrointestinal", "ANATOMY", 140, 156], ["renal", "ANATOMY", 170, 175], ["gastrointestinal bleeding", "DISEASE", 140, 165], ["renal complications", "DISEASE", 170, 189], ["gastrointestinal", "ORGANISM_SUBDIVISION", 140, 156], ["renal", "ORGAN", 170, 175], ["nonsteroidal antiinflammatory drugs", "TREATMENT", 19, 54], ["the disease", "PROBLEM", 77, 88], ["gastrointestinal bleeding", "PROBLEM", 140, 165], ["renal complications", "PROBLEM", 170, 189], ["gastrointestinal", "ANATOMY", 140, 156], ["bleeding", "OBSERVATION", 157, 165], ["renal", "ANATOMY", 170, 175], ["complications", "OBSERVATION", 176, 189]]], ["These are caused by unselective inhibition of cyclooxygenases, some of which are also involved in the promotion of the production of the natural mucus that protects the gastrointestinal tract (Bjarnason et al., 1993) .", [["mucus", "ANATOMY", 145, 150], ["gastrointestinal tract", "ANATOMY", 169, 191], ["cyclooxygenases", "GENE_OR_GENE_PRODUCT", 46, 61], ["mucus", "ORGANISM_SUBSTANCE", 145, 150], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 169, 191], ["cyclooxygenases", "PROTEIN", 46, 61], ["cyclooxygenases", "TREATMENT", 46, 61], ["unselective", "OBSERVATION_MODIFIER", 20, 31], ["inhibition", "OBSERVATION", 32, 42], ["cyclooxygenases", "OBSERVATION", 46, 61], ["natural", "OBSERVATION_MODIFIER", 137, 144], ["mucus", "OBSERVATION", 145, 150], ["gastrointestinal tract", "ANATOMY", 169, 191]]], ["A number of isolated sponge compounds are inhibitors of protein kinase C (PKC).", [["protein kinase C", "GENE_OR_GENE_PRODUCT", 56, 72], ["PKC", "GENE_OR_GENE_PRODUCT", 74, 77], ["protein kinase C", "PROTEIN", 56, 72], ["PKC", "PROTEIN", 74, 77], ["isolated sponge compounds", "TREATMENT", 12, 37], ["protein kinase C", "TEST", 56, 72], ["sponge compounds", "OBSERVATION", 21, 37]]], ["PKC inhibitors have attracted interest worldwide, as there is evidence that too high levels of PKC enzyme are involved both in the pathogenesis of arthritis and psoriasis (owing to regulation of phospholipase A 2 activity), and in tumor development (Bradshaw et al., 1993; Yoshiji et al., 1999) .", [["tumor", "ANATOMY", 231, 236], ["arthritis", "DISEASE", 147, 156], ["psoriasis", "DISEASE", 161, 170], ["tumor", "DISEASE", 231, 236], ["PKC", "GENE_OR_GENE_PRODUCT", 0, 3], ["PKC enzyme", "GENE_OR_GENE_PRODUCT", 95, 105], ["phospholipase A 2", "GENE_OR_GENE_PRODUCT", 195, 212], ["tumor", "CANCER", 231, 236], ["PKC", "PROTEIN", 0, 3], ["PKC enzyme", "PROTEIN", 95, 105], ["phospholipase A 2", "PROTEIN", 195, 212], ["PKC inhibitors", "TREATMENT", 0, 14], ["too high levels of PKC enzyme", "PROBLEM", 76, 105], ["arthritis", "PROBLEM", 147, 156], ["psoriasis", "PROBLEM", 161, 170], ["phospholipase", "TREATMENT", 195, 208], ["arthritis", "OBSERVATION", 147, 156], ["psoriasis", "OBSERVATION", 161, 170], ["tumor", "OBSERVATION", 231, 236]]], ["PKC is believed to be the receptor protein of tumor-promoting phorbol esters, and PKC inhibitors prevent binding of carcinosarcoma cells to the endothelium (B. Liu et al., 1991) .", [["tumor", "ANATOMY", 46, 51], ["carcinosarcoma cells", "ANATOMY", 116, 136], ["endothelium", "ANATOMY", 144, 155], ["tumor", "DISEASE", 46, 51], ["phorbol esters", "CHEMICAL", 62, 76], ["carcinosarcoma", "DISEASE", 116, 130], ["phorbol esters", "CHEMICAL", 62, 76], ["PKC", "GENE_OR_GENE_PRODUCT", 0, 3], ["tumor", "CANCER", 46, 51], ["phorbol esters", "SIMPLE_CHEMICAL", 62, 76], ["PKC", "GENE_OR_GENE_PRODUCT", 82, 85], ["carcinosarcoma cells", "CELL", 116, 136], ["endothelium", "TISSUE", 144, 155], ["PKC", "PROTEIN", 0, 3], ["PKC", "PROTEIN", 82, 85], ["carcinosarcoma cells", "CELL_TYPE", 116, 136], ["PKC", "TEST", 0, 3], ["the receptor protein of tumor", "PROBLEM", 22, 51], ["phorbol esters", "TREATMENT", 62, 76], ["PKC inhibitors", "TREATMENT", 82, 96], ["carcinosarcoma cells", "PROBLEM", 116, 136], ["believed to be", "UNCERTAINTY", 7, 21], ["tumor", "OBSERVATION", 46, 51], ["phorbol esters", "OBSERVATION", 62, 76], ["carcinosarcoma cells", "OBSERVATION", 116, 136], ["endothelium", "ANATOMY", 144, 155]]], ["Glycosylation of the receptors, and especially the presence of fucose residues, plays an important role in the binding of carcinosarcoma cells and leukocytes to the receptors in the endothelium (Springer and Lasky, 1991) .Sponge ProductsFucosyltransferase inhibitors, such as the octaand nonaprenylhydroquinone sulfates that were isolated from a Sarcotragus sp.", [["carcinosarcoma cells", "ANATOMY", 122, 142], ["leukocytes", "ANATOMY", 147, 157], ["endothelium", "ANATOMY", 182, 193], ["carcinosarcoma", "DISEASE", 122, 136], ["nonaprenylhydroquinone", "CHEMICAL", 288, 310], ["fucose", "CHEMICAL", 63, 69], ["octaand nonaprenylhydroquinone sulfates", "CHEMICAL", 280, 319], ["carcinosarcoma cells", "CELL", 122, 142], ["leukocytes", "CELL", 147, 157], ["endothelium", "TISSUE", 182, 193], ["Fucosyltransferase", "GENE_OR_GENE_PRODUCT", 237, 255], ["octaand nonaprenylhydroquinone sulfates", "SIMPLE_CHEMICAL", 280, 319], ["Sarcotragus sp", "ORGANISM", 346, 360], ["carcinosarcoma cells", "CELL_TYPE", 122, 142], ["leukocytes", "CELL_TYPE", 147, 157], ["Glycosylation of the receptors", "TREATMENT", 0, 30], ["fucose residues", "PROBLEM", 63, 78], ["carcinosarcoma cells", "PROBLEM", 122, 142], ["leukocytes", "PROBLEM", 147, 157], ["Sponge ProductsFucosyltransferase inhibitors", "TREATMENT", 222, 266], ["the octaand nonaprenylhydroquinone sulfates", "TREATMENT", 276, 319], ["a Sarcotragus sp", "TREATMENT", 344, 360], ["fucose residues", "OBSERVATION", 63, 78], ["carcinosarcoma cells", "OBSERVATION", 122, 142], ["endothelium", "ANATOMY", 182, 193], ["Fucosyltransferase inhibitors", "OBSERVATION", 237, 266]]], ["(Wakimoto et al., 1999) , may therefore be promising candidates for controlling inflammatory processes such as arthritis or for combating tumor growth.Sponge ProductsIn addition to PKC inhibitors and fucosyl transferase inhibitors, numerous anticancer molecules with a different mode of action have been discovered in marine sponges (Table 2) .", [["tumor", "ANATOMY", 138, 143], ["anticancer", "ANATOMY", 241, 251], ["arthritis", "DISEASE", 111, 120], ["tumor", "DISEASE", 138, 143], ["fucosyl", "CHEMICAL", 200, 207], ["tumor", "CANCER", 138, 143], ["PKC", "GENE_OR_GENE_PRODUCT", 181, 184], ["fucosyl transferase", "GENE_OR_GENE_PRODUCT", 200, 219], ["anticancer", "CANCER", 241, 251], ["PKC", "PROTEIN", 181, 184], ["controlling inflammatory processes", "PROBLEM", 68, 102], ["arthritis", "PROBLEM", 111, 120], ["combating tumor growth", "PROBLEM", 128, 150], ["Sponge Products", "TREATMENT", 151, 166], ["PKC inhibitors", "TREATMENT", 181, 195], ["fucosyl transferase inhibitors", "TREATMENT", 200, 230], ["numerous anticancer molecules", "TREATMENT", 232, 261], ["arthritis", "OBSERVATION", 111, 120], ["anticancer molecules", "OBSERVATION", 241, 261]]], ["These compounds can be divided in 3 classes:Sponge Products(1) nonspecific inhibitors of cell growth; (2) specific inhibitors of cancer cells; and (3) inhibitors of cancer cells of a certain type of cancer (as the aforementioned PKC inhibitors).Sponge ProductsMany nonspecific cell growth inhibitors have been discovered in sponges.", [["cell", "ANATOMY", 89, 93], ["cancer cells", "ANATOMY", 129, 141], ["cancer cells", "ANATOMY", 165, 177], ["cancer", "ANATOMY", 199, 205], ["cell", "ANATOMY", 277, 281], ["cancer", "DISEASE", 129, 135], ["cancer", "DISEASE", 165, 171], ["cancer", "DISEASE", 199, 205], ["cell", "CELL", 89, 93], ["cancer cells", "CELL", 129, 141], ["cancer cells", "CELL", 165, 177], ["cancer", "CANCER", 199, 205], ["PKC", "GENE_OR_GENE_PRODUCT", 229, 232], ["cell", "CELL", 277, 281], ["cancer cells", "CELL_TYPE", 129, 141], ["cancer cells", "CELL_TYPE", 165, 177], ["PKC", "PROTEIN", 229, 232], ["Sponge Products", "TREATMENT", 44, 59], ["nonspecific inhibitors of cell growth", "PROBLEM", 63, 100], ["cancer cells", "PROBLEM", 129, 141], ["cancer cells", "PROBLEM", 165, 177], ["cancer", "PROBLEM", 199, 205], ["the aforementioned PKC inhibitors", "TREATMENT", 210, 243], ["Sponge Products", "TREATMENT", 245, 260], ["Many nonspecific cell growth inhibitors", "PROBLEM", 260, 299], ["cancer cells", "OBSERVATION", 129, 141], ["cancer", "OBSERVATION", 199, 205], ["nonspecific", "OBSERVATION_MODIFIER", 265, 276], ["cell", "OBSERVATION", 277, 281], ["growth inhibitors", "OBSERVATION", 282, 299]]], ["They are valuable for treating cancer under certain conditions, but they also affect the division of healthy cells.", [["cancer", "ANATOMY", 31, 37], ["cells", "ANATOMY", 109, 114], ["cancer", "DISEASE", 31, 37], ["cancer", "CANCER", 31, 37], ["cells", "CELL", 109, 114], ["healthy cells", "CELL_TYPE", 101, 114], ["treating cancer", "PROBLEM", 22, 37], ["cancer", "OBSERVATION", 31, 37], ["healthy cells", "OBSERVATION", 101, 114]]], ["The cytoskeleton is an interesting target for cancer therapy, as the microtubules and microfilaments are involved in cellular organization during cell division.", [["cytoskeleton", "ANATOMY", 4, 16], ["cancer", "ANATOMY", 46, 52], ["microtubules", "ANATOMY", 69, 81], ["microfilaments", "ANATOMY", 86, 100], ["cellular", "ANATOMY", 117, 125], ["cell", "ANATOMY", 146, 150], ["cancer", "DISEASE", 46, 52], ["cytoskeleton", "CELLULAR_COMPONENT", 4, 16], ["cancer", "CANCER", 46, 52], ["microtubules", "CELLULAR_COMPONENT", 69, 81], ["microfilaments", "CELLULAR_COMPONENT", 86, 100], ["cellular", "CELL", 117, 125], ["cell", "CELL", 146, 150], ["cancer therapy", "TREATMENT", 46, 60], ["cancer", "OBSERVATION", 46, 52], ["cellular organization", "OBSERVATION", 117, 138], ["cell division", "OBSERVATION", 146, 159]]], ["A number of adociasulfates (triterpenoid hydroquinones) from a Haticlona sp. were the first inhibitors of the kinesin motor protein to be discovered.", [["adociasulfates", "CHEMICAL", 12, 26], ["triterpenoid hydroquinones", "CHEMICAL", 28, 54], ["adociasulfates", "CHEMICAL", 12, 26], ["triterpenoid hydroquinones", "CHEMICAL", 28, 54], ["adociasulfates", "SIMPLE_CHEMICAL", 12, 26], ["triterpenoid hydroquinones", "SIMPLE_CHEMICAL", 28, 54], ["Haticlona sp", "ORGANISM", 63, 75], ["kinesin", "GENE_OR_GENE_PRODUCT", 110, 117], ["kinesin motor protein", "PROTEIN", 110, 131], ["adociasulfates (triterpenoid hydroquinones", "TREATMENT", 12, 54], ["the kinesin motor protein", "TEST", 106, 131]]], ["These toxins are believed to inhibit the protein by binding to the microtubule binding site, ''locking up'' the protein\u00d5s motor function, and thereby blocking cell division (Blackburn et al., 1999) .", [["microtubule", "ANATOMY", 67, 78], ["cell", "ANATOMY", 159, 163], ["microtubule", "CELLULAR_COMPONENT", 67, 78], ["cell", "CELL", 159, 163], ["microtubule binding site", "DNA", 67, 91], ["the protein", "PROBLEM", 37, 48], ["the microtubule binding site", "PROBLEM", 63, 91]]], ["In addition to these triterpenoid hydroquinones, a number of potent microtubule-interfering compounds have been discovered in marine sponges, such as halichondrin B (Bai et al., 1991) , spongistatin (Bai et al., 1993) , discodermolide (Ter Haar et al., 1996) , laulimalide (Moobeny et al., 1999), peloruside A (Hood et al., 2002) , and dictyostatin (Isbrucker et al., 2003) .", [["microtubule", "ANATOMY", 68, 79], ["hydroquinones", "CHEMICAL", 34, 47], ["halichondrin B", "CHEMICAL", 150, 164], ["spongistatin", "CHEMICAL", 186, 198], ["discodermolide", "CHEMICAL", 220, 234], ["laulimalide", "CHEMICAL", 261, 272], ["dictyostatin", "CHEMICAL", 336, 348], ["triterpenoid hydroquinones", "CHEMICAL", 21, 47], ["halichondrin B", "CHEMICAL", 150, 164], ["dictyostatin", "CHEMICAL", 336, 348], ["triterpenoid hydroquinones", "SIMPLE_CHEMICAL", 21, 47], ["halichondrin B", "SIMPLE_CHEMICAL", 150, 164], ["spongistatin", "SIMPLE_CHEMICAL", 186, 198], ["discodermolide", "SIMPLE_CHEMICAL", 220, 234], ["laulimalide", "SIMPLE_CHEMICAL", 261, 272], ["dictyostatin", "SIMPLE_CHEMICAL", 336, 348], ["microtubule", "PROTEIN", 68, 79], ["these triterpenoid hydroquinones", "TREATMENT", 15, 47], ["potent microtubule-interfering compounds", "TREATMENT", 61, 101], ["triterpenoid hydroquinones", "OBSERVATION", 21, 47], ["potent microtubule", "OBSERVATION_MODIFIER", 61, 79], ["marine sponges", "OBSERVATION", 126, 140]]], ["Other metabolites, such as latrunculin A from Latrunculia magnifica (Coue et al., 1987) and swinholide A from Theonella swinhoei (Bubb et al., 1998), disrupt the polymerization of actin.", [["latrunculin A", "CHEMICAL", 27, 40], ["latrunculin A", "CHEMICAL", 27, 40], ["swinholide A", "CHEMICAL", 92, 104], ["latrunculin A", "SIMPLE_CHEMICAL", 27, 40], ["Latrunculia magnifica", "ORGANISM", 46, 67], ["swinholide A", "SIMPLE_CHEMICAL", 92, 104], ["Theonella swinhoei", "ORGANISM", 110, 128], ["actin", "GENE_OR_GENE_PRODUCT", 180, 185], ["actin", "PROTEIN", 180, 185], ["Latrunculia magnifica", "SPECIES", 46, 67], ["Theonella swinhoei", "SPECIES", 110, 128], ["Latrunculia magnifica", "SPECIES", 46, 67], ["Theonella swinhoei", "SPECIES", 110, 128]]], ["Actin which is the key element of the microfilaments, and it can block many cellular processes including cell division.", [["microfilaments", "ANATOMY", 38, 52], ["cellular", "ANATOMY", 76, 84], ["cell", "ANATOMY", 105, 109], ["Actin", "GENE_OR_GENE_PRODUCT", 0, 5], ["microfilaments", "CELLULAR_COMPONENT", 38, 52], ["cellular", "CELL", 76, 84], ["cell", "CELL", 105, 109], ["Actin", "PROTEIN", 0, 5], ["cellular processes", "OBSERVATION", 76, 94], ["cell division", "OBSERVATION", 105, 118]]], ["Spongiacidin B (Inaba et al., 1998) and fascaplysin (Soni et al., 2000) are examples of sponge-derived metabolites that inhibit cell division by inhibition of cyclin-dependent kinase 4, which leads to arrest of cells in the G1 phase.", [["cell", "ANATOMY", 128, 132], ["cells", "ANATOMY", 211, 216], ["Spongiacidin B", "CHEMICAL", 0, 14], ["fascaplysin", "CHEMICAL", 40, 51], ["Spongiacidin B", "CHEMICAL", 0, 14], ["fascaplysin", "CHEMICAL", 40, 51], ["Spongiacidin B", "GENE_OR_GENE_PRODUCT", 0, 14], ["fascaplysin", "SIMPLE_CHEMICAL", 40, 51], ["cell", "CELL", 128, 132], ["cyclin-dependent kinase 4", "GENE_OR_GENE_PRODUCT", 159, 184], ["cells", "CELL", 211, 216], ["cyclin-dependent kinase 4", "PROTEIN", 159, 184], ["sponge-derived metabolites", "PROBLEM", 88, 114], ["cyclin-dependent kinase", "TREATMENT", 159, 182], ["arrest of cells", "PROBLEM", 201, 216]]], ["Other metabolites, such as mycalamide (Burres and Clement, 1989) and aragusterol (Fukuoka et al., 2000) , disturb cell division by inhibition of protein synthesis.", [["cell", "ANATOMY", 114, 118], ["mycalamide", "CHEMICAL", 27, 37], ["aragusterol", "CHEMICAL", 69, 80], ["mycalamide", "CHEMICAL", 27, 37], ["Burres", "CHEMICAL", 39, 45], ["aragusterol", "CHEMICAL", 69, 80], ["mycalamide", "SIMPLE_CHEMICAL", 27, 37], ["Burres", "SIMPLE_CHEMICAL", 39, 45], ["aragusterol", "SIMPLE_CHEMICAL", 69, 80], ["cell", "CELL", 114, 118], ["protein synthesis", "TREATMENT", 145, 162], ["protein synthesis", "OBSERVATION", 145, 162]]], ["Neoamphimedine (De Guzman et al., 1999) and elenic acid (Juagdan et al., 1995) inhibit the development of tumors by blocking topoisomerase II, the nuclear enzyme which makes transient DNA breaks that are required for replication (L.F. Liu and Chen, 1994) .Sponge ProductsNitric oxide synthetase inhibitors, such as the imidazole alkaloid Na amine D that was isolated from the calcareous sponge Leucetta cf. chagosensis (Dunbar et al., 2000) , are not involved in growth inhibition of cancer cells, but may prevent events in the early phases of tumorigenesis.", [["tumors", "ANATOMY", 106, 112], ["nuclear", "ANATOMY", 147, 154], ["cancer cells", "ANATOMY", 484, 496], ["Neoamphimedine", "CHEMICAL", 0, 14], ["elenic acid", "CHEMICAL", 44, 55], ["tumors", "DISEASE", 106, 112], ["Nitric oxide", "CHEMICAL", 271, 283], ["imidazole", "CHEMICAL", 319, 328], ["Na", "CHEMICAL", 338, 340], ["cancer", "DISEASE", 484, 490], ["Neoamphimedine", "CHEMICAL", 0, 14], ["elenic acid", "CHEMICAL", 44, 55], ["Nitric oxide", "CHEMICAL", 271, 283], ["imidazole", "CHEMICAL", 319, 328], ["Na amine D", "CHEMICAL", 338, 348], ["Neoamphimedine", "SIMPLE_CHEMICAL", 0, 14], ["elenic acid", "SIMPLE_CHEMICAL", 44, 55], ["tumors", "CANCER", 106, 112], ["topoisomerase II", "GENE_OR_GENE_PRODUCT", 125, 141], ["nuclear", "CELLULAR_COMPONENT", 147, 154], ["DNA", "CELLULAR_COMPONENT", 184, 187], ["Nitric oxide synthetase", "SIMPLE_CHEMICAL", 271, 294], ["imidazole alkaloid", "SIMPLE_CHEMICAL", 319, 337], ["Na amine D", "SIMPLE_CHEMICAL", 338, 348], ["chagosensis", "ORGANISM", 407, 418], ["cancer cells", "CELL", 484, 496], ["topoisomerase II", "PROTEIN", 125, 141], ["nuclear enzyme", "PROTEIN", 147, 161], ["cancer cells", "CELL_TYPE", 484, 496], ["chagosensis", "SPECIES", 407, 418], ["Neoamphimedine", "TREATMENT", 0, 14], ["elenic acid", "TREATMENT", 44, 55], ["tumors", "PROBLEM", 106, 112], ["blocking topoisomerase II", "PROBLEM", 116, 141], ["the nuclear enzyme", "TEST", 143, 161], ["transient DNA breaks", "PROBLEM", 174, 194], ["Sponge Products", "TREATMENT", 256, 271], ["Nitric oxide synthetase inhibitors", "TREATMENT", 271, 305], ["the imidazole alkaloid Na amine D", "TREATMENT", 315, 348], ["the calcareous sponge Leucetta cf", "TREATMENT", 372, 405], ["cancer cells", "PROBLEM", 484, 496], ["tumorigenesis", "PROBLEM", 544, 557], ["tumors", "OBSERVATION", 106, 112], ["cancer cells", "OBSERVATION", 484, 496], ["tumorigenesis", "OBSERVATION", 544, 557]]], ["Nitric oxide could participate in the tumorigenesis by mediating DNA Fig. 3 .", [["Nitric oxide", "CHEMICAL", 0, 12], ["Nitric oxide", "CHEMICAL", 0, 12], ["Nitric oxide", "SIMPLE_CHEMICAL", 0, 12], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["Nitric oxide", "TREATMENT", 0, 12], ["the tumorigenesis", "PROBLEM", 34, 51]]], ["Inflammatory cascade inside the cell.", [["cell", "ANATOMY", 32, 36], ["cell", "CELL", 32, 36], ["Inflammatory cascade inside the cell", "PROBLEM", 0, 36], ["cell", "ANATOMY", 32, 36]]], ["Phospholipase A 2 (PLA 2 ) catalyzes the release of membrane-bound arachidonic acid (AA) to free arachidonic acid.", [["membrane", "ANATOMY", 52, 60], ["arachidonic acid", "CHEMICAL", 67, 83], ["AA", "CHEMICAL", 85, 87], ["arachidonic acid", "CHEMICAL", 97, 113], ["arachidonic acid", "CHEMICAL", 67, 83], ["arachidonic acid", "CHEMICAL", 97, 113], ["Phospholipase A 2", "GENE_OR_GENE_PRODUCT", 0, 17], ["PLA 2", "GENE_OR_GENE_PRODUCT", 19, 24], ["membrane", "CELLULAR_COMPONENT", 52, 60], ["arachidonic acid", "SIMPLE_CHEMICAL", 67, 83], ["AA", "SIMPLE_CHEMICAL", 85, 87], ["free arachidonic acid", "SIMPLE_CHEMICAL", 92, 113], ["Phospholipase A 2", "PROTEIN", 0, 17], ["PLA 2", "PROTEIN", 19, 24], ["Phospholipase A 2 (PLA", "TREATMENT", 0, 22], ["membrane-bound arachidonic acid (AA)", "TREATMENT", 52, 88], ["free arachidonic acid", "TREATMENT", 92, 113], ["arachidonic acid", "OBSERVATION", 97, 113]]], ["Arachidonic acid is converted to leukotrienes and prostaglandins by lipoxygenase (LOX) and cyclooxygenase-2 (COX-2), respectively.", [["Arachidonic acid", "CHEMICAL", 0, 16], ["leukotrienes", "CHEMICAL", 33, 45], ["prostaglandins", "CHEMICAL", 50, 64], ["Arachidonic acid", "CHEMICAL", 0, 16], ["prostaglandins", "CHEMICAL", 50, 64], ["Arachidonic acid", "SIMPLE_CHEMICAL", 0, 16], ["leukotrienes", "SIMPLE_CHEMICAL", 33, 45], ["prostaglandins", "SIMPLE_CHEMICAL", 50, 64], ["lipoxygenase", "SIMPLE_CHEMICAL", 68, 80], ["LOX", "GENE_OR_GENE_PRODUCT", 82, 85], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 91, 107], ["COX-2", "GENE_OR_GENE_PRODUCT", 109, 114], ["lipoxygenase", "PROTEIN", 68, 80], ["LOX", "PROTEIN", 82, 85], ["cyclooxygenase-2", "PROTEIN", 91, 107], ["COX", "PROTEIN", 109, 112], ["Arachidonic acid", "TEST", 0, 16], ["leukotrienes", "TREATMENT", 33, 45], ["prostaglandins", "TREATMENT", 50, 64], ["lipoxygenase (LOX", "TREATMENT", 68, 85], ["cyclooxygenase", "TEST", 91, 105], ["COX", "TEST", 109, 112]]], ["Spongederived antiinflammatory molecules are mainly inhibitors of PLA 2 or LOX, while nonsteroidal antiinflammatory drugs inhibit COX-2, but also the constitutive COX-1. damage and support tumor progression through the induction of angiogenesis (Lala and Orucevic, 1998) .", [["tumor", "ANATOMY", 189, 194], ["damage", "DISEASE", 170, 176], ["tumor", "DISEASE", 189, 194], ["PLA 2", "CHEMICAL", 66, 71], ["PLA 2", "GENE_OR_GENE_PRODUCT", 66, 71], ["LOX", "GENE_OR_GENE_PRODUCT", 75, 78], ["nonsteroidal antiinflammatory drugs", "SIMPLE_CHEMICAL", 86, 121], ["COX-2", "GENE_OR_GENE_PRODUCT", 130, 135], ["COX-1", "GENE_OR_GENE_PRODUCT", 163, 168], ["tumor", "CANCER", 189, 194], ["PLA 2", "PROTEIN", 66, 71], ["LOX", "PROTEIN", 75, 78], ["COX-2", "PROTEIN", 130, 135], ["COX-1", "PROTEIN", 163, 168], ["Spongederived antiinflammatory molecules", "TREATMENT", 0, 40], ["nonsteroidal antiinflammatory drugs", "TREATMENT", 86, 121], ["COX", "TEST", 130, 133], ["damage", "PROBLEM", 170, 176], ["tumor progression", "PROBLEM", 189, 206], ["antiinflammatory molecules", "OBSERVATION", 14, 40], ["tumor", "OBSERVATION", 189, 194]]], ["However, inhibition of nitric oxide synthetase may also affect other physiologic processes in which nitric oxide is involved, such as intracellular or transcellular messaging, and it is involved in regulation of the immunogenic respons by T lymphocytes.", [["intracellular", "ANATOMY", 134, 147], ["T lymphocytes", "ANATOMY", 239, 252], ["nitric oxide", "CHEMICAL", 23, 35], ["nitric oxide", "CHEMICAL", 100, 112], ["nitric oxide", "CHEMICAL", 23, 35], ["nitric oxide", "CHEMICAL", 100, 112], ["nitric oxide synthetase", "GENE_OR_GENE_PRODUCT", 23, 46], ["nitric oxide", "SIMPLE_CHEMICAL", 100, 112], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 134, 147], ["transcellular", "IMMATERIAL_ANATOMICAL_ENTITY", 151, 164], ["T lymphocytes", "CELL", 239, 252], ["nitric oxide synthetase", "PROTEIN", 23, 46], ["T lymphocytes", "CELL_TYPE", 239, 252], ["nitric oxide synthetase", "TREATMENT", 23, 46], ["nitric oxide", "TREATMENT", 100, 112], ["transcellular messaging", "TREATMENT", 151, 174]]], ["Agelasphin (KRN7000) from Agelas mauritianus (E. Kobayashi et al., 1995) has been found to stimulate the immune system by activation of dendritic and natural killer T (NKT) cells.", [["immune system", "ANATOMY", 105, 118], ["dendritic", "ANATOMY", 136, 145], ["natural killer T (NKT) cells", "ANATOMY", 150, 178], ["Agelasphin", "CHEMICAL", 0, 10], ["KRN7000", "CHEMICAL", 12, 19], ["Agelasphin", "SIMPLE_CHEMICAL", 0, 10], ["KRN7000", "SIMPLE_CHEMICAL", 12, 19], ["Agelas mauritianus", "ORGANISM", 26, 44], ["dendritic", "CELL", 136, 145], ["natural killer T (NKT) cells", "CELL", 150, 178], ["dendritic and natural killer T (NKT) cells", "CELL_TYPE", 136, 178], ["Agelas mauritianus", "SPECIES", 26, 44], ["Agelas mauritianus", "SPECIES", 26, 44], ["Agelasphin", "TREATMENT", 0, 10], ["natural killer", "OBSERVATION", 150, 164]]], ["The NKT cell level is lower in the blood of patients with cancer or autoimmune disease, such as type 1 diabetes (Shimosaka, 2002) , and in mice it was shown that tumors could be rejected by stimulation of the immune system by agelasphin (Yamaguchi et al., 1996) .", [["NKT cell", "ANATOMY", 4, 12], ["blood", "ANATOMY", 35, 40], ["cancer", "ANATOMY", 58, 64], ["tumors", "ANATOMY", 162, 168], ["immune system", "ANATOMY", 209, 222], ["cancer", "DISEASE", 58, 64], ["autoimmune disease", "DISEASE", 68, 86], ["type 1 diabetes", "DISEASE", 96, 111], ["tumors", "DISEASE", 162, 168], ["agelasphin", "CHEMICAL", 226, 236], ["agelasphin", "CHEMICAL", 226, 236], ["NKT cell", "CELL", 4, 12], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["patients", "ORGANISM", 44, 52], ["cancer", "CANCER", 58, 64], ["mice", "ORGANISM", 139, 143], ["tumors", "CANCER", 162, 168], ["immune system", "ANATOMICAL_SYSTEM", 209, 222], ["agelasphin", "SIMPLE_CHEMICAL", 226, 236], ["patients", "SPECIES", 44, 52], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 139, 143], ["The NKT cell level", "TEST", 0, 18], ["cancer", "PROBLEM", 58, 64], ["autoimmune disease", "PROBLEM", 68, 86], ["type 1 diabetes", "PROBLEM", 96, 111], ["tumors", "PROBLEM", 162, 168], ["NKT cell", "OBSERVATION", 4, 12], ["lower", "OBSERVATION_MODIFIER", 22, 27], ["cancer", "OBSERVATION", 58, 64], ["autoimmune disease", "OBSERVATION", 68, 86], ["tumors", "OBSERVATION", 162, 168]]], ["The activity of other compounds is more specific toward tumor cells.", [["tumor cells", "ANATOMY", 56, 67], ["tumor", "DISEASE", 56, 61], ["tumor cells", "CELL", 56, 67], ["tumor cells", "CELL_TYPE", 56, 67], ["activity", "OBSERVATION_MODIFIER", 4, 12]]], ["Multidrug resistance in human carcinoma cells caused by overexpression of two kinds of membrane glycoproteins is reversed by agosterol A from the marine sponge Spongia sp.", [["carcinoma cells", "ANATOMY", 30, 45], ["membrane", "ANATOMY", 87, 95], ["carcinoma", "DISEASE", 30, 39], ["agosterol A", "CHEMICAL", 125, 136], ["agosterol A", "CHEMICAL", 125, 136], ["human", "ORGANISM", 24, 29], ["carcinoma cells", "CELL", 30, 45], ["membrane", "CELLULAR_COMPONENT", 87, 95], ["agosterol A", "SIMPLE_CHEMICAL", 125, 136], ["Spongia sp", "ORGANISM", 160, 170], ["human carcinoma cells", "CELL_TYPE", 24, 45], ["membrane glycoproteins", "PROTEIN", 87, 109], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["Multidrug resistance in human carcinoma cells", "PROBLEM", 0, 45], ["membrane glycoproteins", "TREATMENT", 87, 109], ["resistance", "OBSERVATION_MODIFIER", 10, 20], ["human carcinoma cells", "OBSERVATION", 24, 45], ["overexpression", "OBSERVATION_MODIFIER", 56, 70], ["two kinds", "OBSERVATION_MODIFIER", 74, 83], ["membrane glycoproteins", "OBSERVATION", 87, 109], ["marine sponge", "OBSERVATION", 146, 159]]], ["It has been suggested that an altered cytosolic pH plays a role in drug resistance.", [["cytosolic", "ANATOMY", 38, 47], ["cytosolic", "CELLULAR_COMPONENT", 38, 47], ["an altered cytosolic pH", "PROBLEM", 27, 50], ["altered", "OBSERVATION_MODIFIER", 30, 37], ["cytosolic pH", "OBSERVATION", 38, 50], ["drug resistance", "OBSERVATION", 67, 82]]], ["Vascular (H + ) AT-Pase (v-ATPase) is an enzyme involved in many cellular processes that are often upregulated in cancer cells, such as acidic vesicular organelle formation, which is a response to radiation injury or manipulation of the pH to decrease entry of chemotherapeutics into the cells (Martinez-Zaguilan et al., 1999).", [["Vascular", "ANATOMY", 0, 8], ["cellular", "ANATOMY", 65, 73], ["cancer cells", "ANATOMY", 114, 126], ["vesicular organelle", "ANATOMY", 143, 162], ["cells", "ANATOMY", 288, 293], ["cancer", "DISEASE", 114, 120], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["H + ) AT-Pase", "GENE_OR_GENE_PRODUCT", 10, 23], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 25, 33], ["cellular", "CELL", 65, 73], ["cancer cells", "CELL", 114, 126], ["vesicular organelle", "CELLULAR_COMPONENT", 143, 162], ["cells", "CELL", 288, 293], ["Vascular (H + ) AT-Pase (v-ATPase", "PROTEIN", 0, 33], ["cancer cells", "CELL_TYPE", 114, 126], ["an enzyme", "TEST", 38, 47], ["many cellular processes", "PROBLEM", 60, 83], ["cancer cells", "PROBLEM", 114, 126], ["acidic vesicular organelle formation", "PROBLEM", 136, 172], ["radiation injury", "PROBLEM", 197, 213], ["the pH", "PROBLEM", 233, 239], ["cellular processes", "OBSERVATION", 65, 83], ["cancer cells", "OBSERVATION", 114, 126], ["acidic", "OBSERVATION_MODIFIER", 136, 142], ["vesicular organelle formation", "OBSERVATION", 143, 172]]], ["Salicylihamide A was isolated from a Haliclona sp. as a selective inhibitor of v-ATPase and has been shown to be 60-fold more cytotoxic to certain cancer cells than to their normal noncancerous counterparts (Erickson et al., 1997).", [["cancer cells", "ANATOMY", 147, 159], ["noncancerous counterparts", "ANATOMY", 181, 206], ["Salicylihamide A", "CHEMICAL", 0, 16], ["cancer", "DISEASE", 147, 153], ["Salicylihamide A", "CHEMICAL", 0, 16], ["Salicylihamide A", "SIMPLE_CHEMICAL", 0, 16], ["Haliclona sp", "ORGANISM", 37, 49], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 79, 87], ["cancer cells", "CELL", 147, 159], ["v-ATPase", "PROTEIN", 79, 87], ["cancer cells", "CELL_TYPE", 147, 159], ["Salicylihamide A", "TREATMENT", 0, 16], ["a selective inhibitor of v-ATPase", "TREATMENT", 54, 87], ["cancer cells", "PROBLEM", 147, 159]]], ["The first natural 6-hydroximino-4-en-3-one steroids were isolated from Cinachyrella spp.", [["6-hydroximino-4-en-3-one steroids", "CHEMICAL", 18, 51], ["6-hydroximino-4-en-3-one steroids", "CHEMICAL", 18, 51], ["6-hydroximino-4-en-3-one steroids", "SIMPLE_CHEMICAL", 18, 51], ["Cinachyrella spp", "ORGANISM", 71, 87], ["Cinachyrella spp", "SPECIES", 71, 87], ["hydroximino", "TEST", 20, 31], ["one steroids", "TREATMENT", 39, 51]]], ["(Rodriguez et al., 1997) and are examples of molecules that can be deployed against a specific type of cancer.", [["cancer", "ANATOMY", 103, 109], ["cancer", "DISEASE", 103, 109], ["cancer", "CANCER", 103, 109], ["cancer", "PROBLEM", 103, 109], ["cancer", "OBSERVATION", 103, 109]]], ["They displayed high affinity to aromatase (Holland et al., 1992), which is the rate-limiting enzyme that catalyzes the conversion of androgens to estrogens ( Figure 4 ).", [["estrogens", "CHEMICAL", 146, 155], ["androgens", "CHEMICAL", 133, 142], ["estrogens", "CHEMICAL", 146, 155], ["aromatase", "GENE_OR_GENE_PRODUCT", 32, 41], ["androgens", "SIMPLE_CHEMICAL", 133, 142], ["estrogens", "SIMPLE_CHEMICAL", 146, 155], ["the rate", "TEST", 75, 83], ["androgens to estrogens", "TREATMENT", 133, 155], ["high affinity", "OBSERVATION", 15, 28]]], ["Blockade of this step allows treatment of hormone-sensitive breast cancer that is dependent on estrogen (Lonning et al., 2003) .", [["breast cancer", "ANATOMY", 60, 73], ["breast cancer", "DISEASE", 60, 73], ["estrogen", "CHEMICAL", 95, 103], ["estrogen", "CHEMICAL", 95, 103], ["breast cancer", "CANCER", 60, 73], ["estrogen", "SIMPLE_CHEMICAL", 95, 103], ["Blockade", "TREATMENT", 0, 8], ["treatment", "TREATMENT", 29, 38], ["hormone-sensitive breast cancer", "PROBLEM", 42, 73], ["breast", "ANATOMY", 60, 66], ["cancer", "OBSERVATION", 67, 73], ["dependent", "OBSERVATION_MODIFIER", 82, 91]]], ["A peculiar fact about the 6-hydroximi no-4-en-3-one steroids is that they were chemically synthesized before they were even discovered in nature.Sponge ProductsIn addition, many more compounds that displayed growth inhibition activity of tumor cell lines have been isolated (Table 2) Immunosuppressive Compounds.", [["tumor cell lines", "ANATOMY", 238, 254], ["6-hydroximi", "CHEMICAL", 26, 37], ["-4-en-3-one steroids", "CHEMICAL", 40, 60], ["tumor", "DISEASE", 238, 243], ["6-hydroximi", "CHEMICAL", 26, 37], ["steroids", "CHEMICAL", 52, 60], ["6-hydroximi", "SIMPLE_CHEMICAL", 26, 37], ["-4-en-3-one steroids", "SIMPLE_CHEMICAL", 40, 60], ["tumor cell lines", "CELL", 238, 254], ["tumor cell lines", "CELL_LINE", 238, 254], ["one steroids", "TREATMENT", 48, 60], ["Sponge Products", "TREATMENT", 145, 160], ["growth inhibition activity of tumor cell lines", "PROBLEM", 208, 254], ["Immunosuppressive Compounds", "TREATMENT", 284, 311], ["tumor cell lines", "OBSERVATION", 238, 254]]], ["In addition to their potential for treatment of cancer, nitric oxide synthetase inhibitors downregulate T-cells are, suppressing the immune system, and they diminish the fierceness of migraine attacks (Griffith and Gross, 1996).", [["cancer", "ANATOMY", 48, 54], ["T-cells", "ANATOMY", 104, 111], ["immune system", "ANATOMY", 133, 146], ["cancer", "DISEASE", 48, 54], ["nitric oxide", "CHEMICAL", 56, 68], ["migraine", "DISEASE", 184, 192], ["nitric oxide", "CHEMICAL", 56, 68], ["cancer", "CANCER", 48, 54], ["nitric oxide synthetase", "GENE_OR_GENE_PRODUCT", 56, 79], ["T-cells", "CELL", 104, 111], ["nitric oxide synthetase", "PROTEIN", 56, 79], ["T-cells", "CELL_TYPE", 104, 111], ["treatment", "TREATMENT", 35, 44], ["cancer", "PROBLEM", 48, 54], ["nitric oxide synthetase inhibitors", "TREATMENT", 56, 90], ["migraine attacks", "PROBLEM", 184, 200], ["cancer", "OBSERVATION", 48, 54]]], ["Immune system suppression is desired in cases of hypersensitivity to certain antigens (e.g., allergies) or organ transplantations.", [["Immune system", "ANATOMY", 0, 13], ["organ", "ANATOMY", 107, 112], ["Immune system suppression", "DISEASE", 0, 25], ["hypersensitivity", "DISEASE", 49, 65], ["allergies", "DISEASE", 93, 102], ["organ", "ORGAN", 107, 112], ["antigens", "PROTEIN", 77, 85], ["Immune system suppression", "TREATMENT", 0, 25], ["hypersensitivity", "PROBLEM", 49, 65], ["allergies", "PROBLEM", 93, 102], ["organ transplantations", "TREATMENT", 107, 129], ["organ", "ANATOMY", 107, 112], ["transplantations", "OBSERVATION", 113, 129]]], ["Patients who receive a donor organ need life-long medication to prevent rejection by the immune system, and for that reason it is extremely important that these medicines are very specific suppressors.", [["organ", "ANATOMY", 29, 34], ["immune system", "ANATOMY", 89, 102], ["Patients", "ORGANISM", 0, 8], ["organ", "ORGAN", 29, 34], ["Patients", "SPECIES", 0, 8], ["a donor organ", "TREATMENT", 21, 34], ["life-long medication", "TREATMENT", 40, 60], ["rejection", "PROBLEM", 72, 81], ["these medicines", "TREATMENT", 155, 170], ["rejection", "OBSERVATION", 72, 81]]], ["Therefore there is a continuous demand for new immunosuppressives.", [["a continuous demand", "TREATMENT", 19, 38], ["new immunosuppressives", "TREATMENT", 43, 65]]], ["A number of new molecules with immunosuppressive activity, which interfere at different points of the immune response have been discovered in marine sponges (Table 3; Figure 5 ).Sponge ProductsThree polyoxygenated sterols from a Dysidea sp. from Northern Australia are selective immunosuppressive compounds that inhibit the binding of interleukin 8 (IL-8), a cytokine that attracts neutrophils into an area of tissue injury, to the IL-8 receptor (Leone et al., 2000) .", [["neutrophils", "ANATOMY", 382, 393], ["tissue", "ANATOMY", 410, 416], ["sterols", "CHEMICAL", 214, 221], ["sterols", "CHEMICAL", 214, 221], ["sterols", "SIMPLE_CHEMICAL", 214, 221], ["interleukin 8", "GENE_OR_GENE_PRODUCT", 335, 348], ["IL-8", "GENE_OR_GENE_PRODUCT", 350, 354], ["neutrophils", "CELL", 382, 393], ["tissue", "TISSUE", 410, 416], ["IL-8 receptor", "GENE_OR_GENE_PRODUCT", 432, 445], ["interleukin 8 (IL-8", "PROTEIN", 335, 354], ["cytokine", "PROTEIN", 359, 367], ["neutrophils", "CELL_TYPE", 382, 393], ["IL-8 receptor", "PROTEIN", 432, 445], ["immunosuppressive activity", "TREATMENT", 31, 57], ["Sponge Products", "TREATMENT", 178, 193], ["a Dysidea sp", "PROBLEM", 227, 239], ["selective immunosuppressive compounds", "TREATMENT", 269, 306], ["interleukin", "TEST", 335, 346], ["tissue injury", "PROBLEM", 410, 423], ["new", "OBSERVATION_MODIFIER", 12, 15], ["molecules", "OBSERVATION", 16, 25], ["immunosuppressive activity", "OBSERVATION", 31, 57], ["immune response", "OBSERVATION", 102, 117], ["polyoxygenated sterols", "OBSERVATION", 199, 221], ["selective", "OBSERVATION_MODIFIER", 269, 278], ["immunosuppressive", "OBSERVATION", 279, 296], ["area", "OBSERVATION_MODIFIER", 402, 406], ["tissue", "ANATOMY", 410, 416], ["injury", "OBSERVATION", 417, 423]]], ["The simplexides from the Caribbean sponge Plakortis simplex are a group of immunosuppressive glycolipids that inhibit proliferation of activated T cells by a noncytotoxic mechanism (Costantino et al., 1999).", [["T cells", "ANATOMY", 145, 152], ["simplexides", "SIMPLE_CHEMICAL", 4, 15], ["Plakortis simplex", "ORGANISM", 42, 59], ["T cells", "CELL", 145, 152], ["activated T cells", "CELL_TYPE", 135, 152], ["Plakortis simplex", "SPECIES", 42, 59], ["Plakortis simplex", "SPECIES", 42, 59], ["The simplexides", "TREATMENT", 0, 15], ["the Caribbean sponge Plakortis simplex", "TREATMENT", 21, 59], ["immunosuppressive glycolipids", "TREATMENT", 75, 104], ["activated T cells", "PROBLEM", 135, 152]]], ["Pateamine A, from a Mycale sp., inhibits the production of IL-2 (Romo et al., 1998) and thereby the activation of resting T cells and B cells to a lesser extent.", [["T cells", "ANATOMY", 122, 129], ["B cells", "ANATOMY", 134, 141], ["Pateamine A", "CHEMICAL", 0, 11], ["Pateamine A", "CHEMICAL", 0, 11], ["Pateamine A", "SIMPLE_CHEMICAL", 0, 11], ["Mycale sp.", "ORGANISM", 20, 30], ["IL-2", "GENE_OR_GENE_PRODUCT", 59, 63], ["T cells", "CELL", 122, 129], ["B cells", "CELL", 134, 141], ["IL", "PROTEIN", 59, 61], ["resting T cells", "CELL_TYPE", 114, 129], ["B cells", "CELL_TYPE", 134, 141], ["resting T cells", "PROBLEM", 114, 129], ["lesser extent", "OBSERVATION_MODIFIER", 147, 160]]], ["Contignasterol from Petrosia contignata (Burgoyne and Andersen, 1992) inhibits allergen-induced histamine release from rat mast cells (Takei et al., 1994) and from guinea-pig lung tissue in vitro (Bramley et al., 1995) , and the activation of eosinophils into airways in guinea-pigs and could be used to treat asthma (Langlands et al., 1995) .Sponge ProductsCardiovascular Agents.", [["mast cells", "ANATOMY", 123, 133], ["lung tissue", "ANATOMY", 175, 186], ["eosinophils", "ANATOMY", 243, 254], ["airways", "ANATOMY", 260, 267], ["Cardiovascular", "ANATOMY", 358, 372], ["Contignasterol", "CHEMICAL", 0, 14], ["Petrosia contignata", "CHEMICAL", 20, 39], ["histamine", "CHEMICAL", 96, 105], ["asthma", "DISEASE", 310, 316], ["Contignasterol", "CHEMICAL", 0, 14], ["histamine", "CHEMICAL", 96, 105], ["Contignasterol", "SIMPLE_CHEMICAL", 0, 14], ["Petrosia contignata", "ORGANISM", 20, 39], ["Burgoyne", "SIMPLE_CHEMICAL", 41, 49], ["histamine", "SIMPLE_CHEMICAL", 96, 105], ["rat", "ORGANISM", 119, 122], ["mast cells", "CELL", 123, 133], ["pig", "ORGANISM", 171, 174], ["lung tissue", "TISSUE", 175, 186], ["eosinophils", "CELL", 243, 254], ["airways", "MULTI-TISSUE_STRUCTURE", 260, 267], ["guinea-pigs", "ORGANISM", 271, 282], ["rat mast cells", "CELL_TYPE", 119, 133], ["eosinophils", "CELL_TYPE", 243, 254], ["Petrosia contignata", "SPECIES", 20, 39], ["rat", "SPECIES", 119, 122], ["guinea-pig", "SPECIES", 164, 174], ["guinea-pigs", "SPECIES", 271, 282], ["Petrosia contignata", "SPECIES", 20, 39], ["pig", "SPECIES", 171, 174], ["allergen-induced histamine release", "TREATMENT", 79, 113], ["pig lung tissue", "PROBLEM", 171, 186], ["asthma", "PROBLEM", 310, 316], ["mast cells", "OBSERVATION", 123, 133], ["pig lung", "ANATOMY", 171, 179], ["tissue", "OBSERVATION", 180, 186], ["airways", "ANATOMY", 260, 267]]], ["In addition to regulators of the white blood cells, a number of spongederived molecules have been found to interfere with other blood-related diseases such as thrombosis, atherosclerosis, or diabetes ( Table 4 ).", [["white blood cells", "ANATOMY", 33, 50], ["blood", "ANATOMY", 128, 133], ["thrombosis", "DISEASE", 159, 169], ["atherosclerosis", "DISEASE", 171, 186], ["diabetes", "DISEASE", 191, 199], ["white blood cells", "CELL", 33, 50], ["blood", "ORGANISM_SUBSTANCE", 128, 133], ["white blood cells", "CELL_TYPE", 33, 50], ["spongederived molecules", "PROTEIN", 64, 87], ["the white blood cells", "TEST", 29, 50], ["spongederived molecules", "PROBLEM", 64, 87], ["other blood-related diseases", "PROBLEM", 122, 150], ["thrombosis", "PROBLEM", 159, 169], ["atherosclerosis", "PROBLEM", 171, 186], ["diabetes", "PROBLEM", 191, 199], ["thrombosis", "OBSERVATION", 159, 169], ["atherosclerosis", "OBSERVATION", 171, 186], ["diabetes", "OBSERVATION", 191, 199]]], ["The process of blood coagulation is triggered by a complex proteolytic cascade that leads to the formation of fibrin.", [["blood", "ANATOMY", 15, 20], ["blood coagulation", "DISEASE", 15, 32], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["fibrin", "GENE_OR_GENE_PRODUCT", 110, 116], ["fibrin", "PROTEIN", 110, 116], ["blood coagulation", "TEST", 15, 32], ["a complex proteolytic cascade", "PROBLEM", 49, 78], ["fibrin", "PROBLEM", 110, 116], ["blood coagulation", "OBSERVATION", 15, 32], ["complex", "OBSERVATION_MODIFIER", 51, 58], ["proteolytic cascade", "OBSERVATION", 59, 78], ["fibrin", "OBSERVATION", 110, 116]]], ["Thrombin is a serine protease that cleaves a peptide fragment from fibrinogen, which then leads to the generation of fibrin, a major component of blood clots (Shuman et al., 1993) .", [["blood clots", "ANATOMY", 146, 157], ["serine", "CHEMICAL", 14, 20], ["Thrombin", "GENE_OR_GENE_PRODUCT", 0, 8], ["serine", "AMINO_ACID", 14, 20], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 67, 77], ["fibrin", "GENE_OR_GENE_PRODUCT", 117, 123], ["blood", "ORGANISM_SUBSTANCE", 146, 151], ["clots", "ORGANISM_SUBSTANCE", 152, 157], ["Thrombin", "PROTEIN", 0, 8], ["serine protease", "PROTEIN", 14, 29], ["fibrinogen", "PROTEIN", 67, 77], ["fibrin", "PROTEIN", 117, 123], ["Thrombin", "TREATMENT", 0, 8], ["a serine protease", "TREATMENT", 12, 29], ["a peptide fragment", "PROBLEM", 43, 61], ["fibrinogen", "TEST", 67, 77], ["fibrin", "PROBLEM", 117, 123], ["blood clots", "PROBLEM", 146, 157], ["fibrin", "OBSERVATION", 117, 123], ["major", "OBSERVATION_MODIFIER", 127, 132], ["component", "OBSERVATION_MODIFIER", 133, 142], ["blood clots", "OBSERVATION", 146, 157]]], ["Cyclotheonarnide A, Callyspongynic acid, isolated from Callyspongia truncata, is an a-glucosidase inhibitor (Nakao et al., 2002) . a-Glucosidase inhibitors interfere with the hydrolysis of glycogen, keeping the glucose concentration in the blood at a lower level, and can be used to treat patients with diabetes (Lebovitz, 1992) .NeurosuppressiveCompounds.", [["blood", "ANATOMY", 240, 245], ["Cyclotheonarnide A", "CHEMICAL", 0, 18], ["Callyspongynic acid", "CHEMICAL", 20, 39], ["glycogen", "CHEMICAL", 189, 197], ["glucose", "CHEMICAL", 211, 218], ["diabetes", "DISEASE", 303, 311], ["Cyclotheonarnide A", "CHEMICAL", 0, 18], ["Callyspongynic acid", "CHEMICAL", 20, 39], ["glucose", "CHEMICAL", 211, 218], ["Cyclotheonarnide A", "SIMPLE_CHEMICAL", 0, 18], ["Callyspongynic acid", "SIMPLE_CHEMICAL", 20, 39], ["Callyspongia truncata", "ORGANISM", 55, 76], ["a-glucosidase", "GENE_OR_GENE_PRODUCT", 84, 97], ["a-Glucosidase", "SIMPLE_CHEMICAL", 131, 144], ["glycogen", "SIMPLE_CHEMICAL", 189, 197], ["glucose", "SIMPLE_CHEMICAL", 211, 218], ["blood", "ORGANISM_SUBSTANCE", 240, 245], ["patients", "ORGANISM", 289, 297], ["Callyspongia truncata", "SPECIES", 55, 76], ["patients", "SPECIES", 289, 297], ["Callyspongia truncata", "SPECIES", 55, 76], ["Cyclotheonarnide", "TREATMENT", 0, 16], ["Callyspongynic acid", "PROBLEM", 20, 39], ["an a-glucosidase inhibitor", "TREATMENT", 81, 107], ["a-Glucosidase inhibitors", "TREATMENT", 131, 155], ["the hydrolysis of glycogen", "TREATMENT", 171, 197], ["the glucose concentration", "TEST", 207, 232], ["the blood", "TEST", 236, 245], ["diabetes", "PROBLEM", 303, 311]]], ["Keramidine, isolated from an Agelas sp.", [["Keramidine", "CHEMICAL", 0, 10], ["Keramidine", "CHEMICAL", 0, 10], ["Keramidine", "SIMPLE_CHEMICAL", 0, 10], ["Agelas sp", "ORGANISM", 29, 38], ["Keramidine", "TREATMENT", 0, 10]]], ["(Nakamura et al., 1984) , is an example of a number of neurosuppressive compounds that have been isolated from marine sponges (Table 5) .", [["neurosuppressive compounds", "PROBLEM", 55, 81]]], ["It is a serotonergic receptor antagonist and blocks serotonin-mediated neural communication.", [["neural", "ANATOMY", 71, 77], ["serotonin", "CHEMICAL", 52, 61], ["serotonin", "CHEMICAL", 52, 61], ["serotonin", "SIMPLE_CHEMICAL", 52, 61], ["neural", "CELL", 71, 77], ["a serotonergic receptor antagonist", "TREATMENT", 6, 40], ["blocks serotonin", "TREATMENT", 45, 61], ["neural communication", "OBSERVATION", 71, 91]]], ["Several different serotonin receptors have been identified.", [["serotonin", "CHEMICAL", 18, 27], ["serotonin", "CHEMICAL", 18, 27], ["serotonin receptors", "GENE_OR_GENE_PRODUCT", 18, 37], ["serotonin receptors", "PROTEIN", 18, 37], ["Several different serotonin receptors", "PROBLEM", 0, 37], ["serotonin receptors", "OBSERVATION", 18, 37]]], ["They are related to (1) platelet aggregation, and may therefore be useful against thrombosis (Ruomei et al., 1996) (Lundberg, 1995; Edgar et al., 2002) .", [["platelet", "ANATOMY", 24, 32], ["platelet aggregation", "DISEASE", 24, 44], ["thrombosis", "DISEASE", 82, 92], ["platelet", "CELL", 24, 32], ["1) platelet aggregation", "PROBLEM", 21, 44], ["thrombosis", "PROBLEM", 82, 92]]], ["In addition to the above-mentioned centrally acting muscle relaxants, which mediate neuromuscular communication, peripherally acting muscle relaxant may be used for local muscle relaxation.", [["muscle", "ANATOMY", 52, 58], ["neuromuscular", "ANATOMY", 84, 97], ["peripherally", "ANATOMY", 113, 125], ["muscle", "ANATOMY", 133, 139], ["muscle", "ANATOMY", 171, 177], ["muscle", "ORGAN", 52, 58], ["muscle", "ORGAN", 133, 139], ["muscle", "ORGAN", 171, 177], ["centrally acting muscle relaxants", "TREATMENT", 35, 68], ["peripherally acting muscle relaxant", "TREATMENT", 113, 148], ["local muscle relaxation", "TREATMENT", 165, 188], ["muscle relaxants", "ANATOMY", 52, 68]]], ["They are applied for relief of strokes, or during intubations and surgery (Frakes, 2001).", [["strokes", "DISEASE", 31, 38], ["strokes", "PROBLEM", 31, 38], ["intubations", "TREATMENT", 50, 61], ["surgery", "TREATMENT", 66, 73], ["strokes", "OBSERVATION", 31, 38]]], ["1-Methylguanosine from Tedania digitata (Quinn et al., 1980 ) and xestospongin C, which was isolated from a Xestospongia sp.", [["1-Methylguanosine", "CHEMICAL", 0, 17], ["1-Methylguanosine", "CHEMICAL", 0, 17], ["xestospongin C", "CHEMICAL", 66, 80], ["1-Methylguanosine", "SIMPLE_CHEMICAL", 0, 17], ["Tedania digitata", "ORGANISM", 23, 39], ["xestospongin C", "SIMPLE_CHEMICAL", 66, 80], ["Xestospongia sp", "ORGANISM", 108, 123], ["Tedania digitata", "SPECIES", 23, 39], ["Tedania digitata", "SPECIES", 23, 39], ["Methylguanosine", "TREATMENT", 2, 17], ["xestospongin C", "PROBLEM", 66, 80]]], ["(Gafni et al., 1997) , are examples of muscle relaxants that discovered in sponges (Table 5 ).", [["muscle", "ANATOMY", 39, 45], ["muscle", "ORGAN", 39, 45], ["muscle relaxants", "TREATMENT", 39, 55], ["muscle", "ANATOMY", 39, 45]]], ["Xestospongin C is a potent inhibitor of the inositol 1,4,5-triphosphate (IP 3 ) receptors and the endoplasmic-reticulum Ca 2+ pumps (De Smet et al., 1999) and inhibits IP 3 -induced increase in the oscillatory contraction of muscles (Miyamoto et al., 2000) . \u00df-Adrenoreceptor agonists, such as S1319 isolated from a Dysidea sp.", [["endoplasmic-reticulum", "ANATOMY", 98, 119], ["muscles", "ANATOMY", 225, 232], ["Xestospongin C", "CHEMICAL", 0, 14], ["inositol 1,4,5-triphosphate", "CHEMICAL", 44, 71], ["Ca", "CHEMICAL", 120, 122], ["S1319", "CHEMICAL", 294, 299], ["Xestospongin C", "CHEMICAL", 0, 14], ["inositol 1,4,5-triphosphate", "CHEMICAL", 44, 71], ["Ca 2+", "CHEMICAL", 120, 125], ["S1319", "CHEMICAL", 294, 299], ["Xestospongin C", "SIMPLE_CHEMICAL", 0, 14], ["inositol 1,4,5-triphosphate", "SIMPLE_CHEMICAL", 44, 71], ["IP 3 ) receptors", "GENE_OR_GENE_PRODUCT", 73, 89], ["IP 3", "GENE_OR_GENE_PRODUCT", 168, 172], ["muscles", "ORGAN", 225, 232], ["\u00df-Adrenoreceptor", "GENE_OR_GENE_PRODUCT", 259, 275], ["S1319", "SIMPLE_CHEMICAL", 294, 299], ["Dysidea sp", "ORGANISM", 316, 326], ["inositol 1,4,5-triphosphate (IP 3 ) receptors", "PROTEIN", 44, 89], ["a potent inhibitor", "TREATMENT", 18, 36], ["the inositol", "TREATMENT", 40, 52], ["triphosphate (IP 3 ) receptors", "TREATMENT", 59, 89], ["Adrenoreceptor agonists", "TREATMENT", 261, 284], ["a Dysidea sp", "PROBLEM", 314, 326], ["increase", "OBSERVATION_MODIFIER", 182, 190], ["oscillatory contraction", "OBSERVATION", 198, 221], ["muscles", "ANATOMY", 225, 232]]], ["(Suzuki et al., 1999) , have utero-relaxant properties, which can be therapeutically used for the preterm delivery of infants (Dennedy et al., 2002) , and are widely used as antiasthmatic drugs (Suzuki et al., 1999) .", [["infants", "ORGANISM", 118, 125], ["infants", "SPECIES", 118, 125], ["utero-relaxant properties", "TREATMENT", 29, 54], ["the preterm delivery", "TREATMENT", 94, 114], ["antiasthmatic drugs", "TREATMENT", 174, 193]]], ["However, owing to their low selectivity \u00dfadrenoreceptor agonists may have severe side effects such as arterial hypertension, corony heart disease, and tachycardia (Borchard, 1998) .", [["arterial", "ANATOMY", 102, 110], ["heart", "ANATOMY", 132, 137], ["arterial hypertension", "DISEASE", 102, 123], ["corony heart disease", "DISEASE", 125, 145], ["tachycardia", "DISEASE", 151, 162], ["arterial", "MULTI-TISSUE_STRUCTURE", 102, 110], ["heart", "ORGAN", 132, 137], ["severe side effects", "PROBLEM", 74, 93], ["arterial hypertension", "PROBLEM", 102, 123], ["corony heart disease", "PROBLEM", 125, 145], ["tachycardia", "PROBLEM", 151, 162], ["arterial", "ANATOMY", 102, 110], ["hypertension", "OBSERVATION", 111, 123], ["heart", "ANATOMY", 132, 137], ["disease", "OBSERVATION", 138, 145]]], ["Therefore, there is continued interest in finding more selective \u00df-adrenoreceptor agonists such as S1319.NeurosuppressiveAntiviral Compounds.", [["S1319", "CHEMICAL", 99, 104], ["S1319", "CHEMICAL", 99, 104], ["S1319", "SIMPLE_CHEMICAL", 99, 104]]], ["Sponges are also a rich source of compounds with antiviral properties (Table 6).", [["Sponges", "TREATMENT", 0, 7], ["antiviral properties", "TREATMENT", 49, 69]]], ["The high number of HIV-inhibiting compounds discovered does not reflect greater potential of sponges to fight AIDS compared with other viral diseases, but rather the interest of many researchers.", [["AIDS", "DISEASE", 110, 114], ["viral diseases", "DISEASE", 135, 149], ["HIV", "ORGANISM", 19, 22], ["HIV", "SPECIES", 19, 22], ["HIV-inhibiting compounds", "PROBLEM", 19, 43], ["sponges", "PROBLEM", 93, 100], ["fight AIDS", "PROBLEM", 104, 114], ["other viral diseases", "PROBLEM", 129, 149], ["high", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["HIV", "OBSERVATION", 19, 22], ["sponges", "OBSERVATION", 93, 100]]], ["The strong focus on screening for anti-HIV activity has led to discovery of numerous compounds, but the mechanism of inhibition is still poorly characterized.", [["anti-HIV", "CANCER", 34, 42], ["screening", "TEST", 20, 29], ["anti-HIV activity", "PROBLEM", 34, 51], ["numerous compounds", "PROBLEM", 76, 94], ["strong", "OBSERVATION_MODIFIER", 4, 10], ["focus", "OBSERVATION", 11, 16], ["numerous", "OBSERVATION_MODIFIER", 76, 84], ["compounds", "OBSERVATION", 85, 94], ["poorly characterized", "OBSERVATION_MODIFIER", 137, 157]]], ["Papuamides C and D (Ford et al., 1999), haplosamates A and B (Qureshi and Faulkner, 1999) , and avarol (Muller et al., 1987) , which has also been patented as antipsoriasis , are examples of HIV-inhibiting compounds from different sponges.", [["avarol", "CHEMICAL", 96, 102], ["Papuamides C and D", "CHEMICAL", 0, 18], ["haplosamates A and B", "CHEMICAL", 40, 60], ["Papuamides C", "SIMPLE_CHEMICAL", 0, 12], ["D", "SIMPLE_CHEMICAL", 17, 18], ["haplosamates A", "SIMPLE_CHEMICAL", 40, 54], ["B", "CELL", 59, 60], ["HIV", "ORGANISM", 191, 194], ["HIV", "SPECIES", 191, 194], ["HIV", "PROBLEM", 191, 194], ["different sponges", "TREATMENT", 221, 238]]], ["Avarol is one of the few compounds for which the mechanism by which it inhibits progression of HIV infection is more or less known.", [["Avarol", "CHEMICAL", 0, 6], ["HIV infection", "DISEASE", 95, 108], ["Avarol", "CHEMICAL", 0, 6], ["Avarol", "SIMPLE_CHEMICAL", 0, 6], ["HIV", "ORGANISM", 95, 98], ["HIV", "SPECIES", 95, 98], ["Avarol", "TREATMENT", 0, 6], ["HIV infection", "PROBLEM", 95, 108], ["progression", "OBSERVATION_MODIFIER", 80, 91], ["HIV", "OBSERVATION_MODIFIER", 95, 98], ["infection", "OBSERVATION", 99, 108]]], ["In vitro and animal data indicate that avarol combines useful properties of an increased humoral immune response, as IgG and IgM production is significantly increased, and interference with the posttranscriptional processes of viral infection (Muller et al., 1987) .", [["avarol", "CHEMICAL", 39, 45], ["viral infection", "DISEASE", 227, 242], ["avarol", "CHEMICAL", 39, 45], ["avarol", "SIMPLE_CHEMICAL", 39, 45], ["IgG", "GENE_OR_GENE_PRODUCT", 117, 120], ["IgM", "GENE_OR_GENE_PRODUCT", 125, 128], ["IgG", "PROTEIN", 117, 120], ["IgM", "PROTEIN", 125, 128], ["avarol", "TREATMENT", 39, 45], ["an increased humoral immune response", "PROBLEM", 76, 112], ["IgG", "TEST", 117, 120], ["IgM production", "PROBLEM", 125, 139], ["viral infection", "PROBLEM", 227, 242], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["humoral immune response", "OBSERVATION", 89, 112], ["significantly", "OBSERVATION_MODIFIER", 143, 156], ["increased", "OBSERVATION_MODIFIER", 157, 166], ["viral infection", "OBSERVATION", 227, 242]]], ["Avarol inhibits HIV by almost completely blocking the synthesis of the natural UAG suppressor glutamine transfer tRNA.", [["Avarol", "CHEMICAL", 0, 6], ["glutamine", "CHEMICAL", 94, 103], ["Avarol", "CHEMICAL", 0, 6], ["glutamine", "CHEMICAL", 94, 103], ["Avarol", "SIMPLE_CHEMICAL", 0, 6], ["HIV", "ORGANISM", 16, 19], ["glutamine transfer tRNA", "GENE_OR_GENE_PRODUCT", 94, 117], ["natural UAG suppressor glutamine transfer tRNA", "PROTEIN", 71, 117], ["HIV", "SPECIES", 16, 19], ["Avarol", "TREATMENT", 0, 6], ["HIV", "PROBLEM", 16, 19], ["the natural UAG suppressor glutamine transfer tRNA", "TREATMENT", 67, 117]]], ["Synthesis of this tRNA is upregulated after viral infection, and it is important for the synthesis of a viral protease, which is necessary for viral proliferation .", [["viral infection", "DISEASE", 44, 59], ["viral protease", "PROTEIN", 104, 118], ["this tRNA", "TREATMENT", 13, 22], ["viral infection", "PROBLEM", 44, 59], ["a viral protease", "TREATMENT", 102, 118], ["viral proliferation", "PROBLEM", 143, 162], ["upregulated", "OBSERVATION_MODIFIER", 26, 37], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["infection", "OBSERVATION", 50, 59]]], ["Low concentrations of only 0.9 and 0.3 lM avarol resulted in 80% and 50% inhibition of virus release from infected cells, respectively , while (Figure 6 ), were very potent inhibitors of HIV reverse transcriptase.", [["cells", "ANATOMY", 115, 120], ["avarol", "CHEMICAL", 42, 48], ["avarol", "CHEMICAL", 42, 48], ["cells", "CELL", 115, 120], ["HIV reverse transcriptase", "GENE_OR_GENE_PRODUCT", 187, 212], ["infected cells", "CELL_TYPE", 106, 120], ["HIV reverse transcriptase", "PROTEIN", 187, 212], ["HIV", "SPECIES", 187, 190], ["Low concentrations", "PROBLEM", 0, 18], ["virus release", "PROBLEM", 87, 100], ["infected cells", "PROBLEM", 106, 120], ["HIV reverse transcriptase", "TREATMENT", 187, 212], ["infected cells", "OBSERVATION", 106, 120]]], ["This enzyme has a key role in the early stages of HIV infection and is a specific target for antiviral drugs, as it is responsible for converting the viral genomic RNA into proviral double-stranded DNA, which is subsequently integrated into the host chromosomal DNA (Loya and Hizi, 1990 ).", [["chromosomal", "ANATOMY", 250, 261], ["HIV infection", "DISEASE", 50, 63], ["HIV", "ORGANISM", 50, 53], ["DNA", "CELLULAR_COMPONENT", 198, 201], ["chromosomal DNA", "CELLULAR_COMPONENT", 250, 265], ["viral genomic RNA", "RNA", 150, 167], ["proviral double-stranded DNA", "DNA", 173, 201], ["host chromosomal DNA", "DNA", 245, 265], ["HIV", "SPECIES", 50, 53], ["This enzyme", "TEST", 0, 11], ["HIV infection", "PROBLEM", 50, 63], ["antiviral drugs", "TREATMENT", 93, 108], ["the viral genomic RNA", "PROBLEM", 146, 167], ["proviral double-stranded DNA", "TREATMENT", 173, 201], ["early stages", "OBSERVATION_MODIFIER", 34, 46], ["HIV", "OBSERVATION_MODIFIER", 50, 53], ["infection", "OBSERVATION", 54, 63], ["viral genomic RNA", "OBSERVATION", 150, 167], ["stranded DNA", "OBSERVATION_MODIFIER", 189, 201]]], ["In addition to their applications to treat diabetes, a-glucosidase inhibitors, such as callyspongymc acid, are potentially broad-based antiviral agents.NeurosuppressiveThey disturb protein glycosylation and cause some viral envelope proteins to be misfolded, which leads to arrest of these proteins within the endoplasmic reticulum, where protein folding takes place.", [["endoplasmic reticulum", "ANATOMY", 310, 331], ["diabetes", "DISEASE", 43, 51], ["callyspongymc acid", "CHEMICAL", 87, 105], ["callyspongymc acid", "CHEMICAL", 87, 105], ["a-glucosidase", "SIMPLE_CHEMICAL", 53, 66], ["callyspongymc acid", "SIMPLE_CHEMICAL", 87, 105], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 310, 331], ["viral envelope proteins", "PROTEIN", 218, 241], ["diabetes", "PROBLEM", 43, 51], ["a-glucosidase inhibitors", "TREATMENT", 53, 77], ["callyspongymc acid", "TREATMENT", 87, 105], ["broad-based antiviral agents", "TREATMENT", 123, 151], ["protein glycosylation", "TREATMENT", 181, 202], ["some viral envelope proteins", "PROBLEM", 213, 241], ["arrest of these proteins", "PROBLEM", 274, 298], ["protein folding", "PROBLEM", 339, 354], ["proteins", "OBSERVATION", 290, 298], ["endoplasmic reticulum", "OBSERVATION", 310, 331], ["protein folding", "OBSERVATION", 339, 354]]], ["It has been demonstrated that alteration of the glycosylation pattern of HIV, hepatitis B virus, and bovine viral diarrhea virus by a-glucosidase inhibitors attenuates viral infectivity (Ratner et al., 1991; Mehta et al., 1998).NeurosuppressiveA very different class of virus inhibitors that has been found in many different sponges are 2\u00a2-5\u00a2 oligoadenylates (2-5A), which are involved in the interferon-mediated response against a wide range of viruses in mammals.", [["HIV, hepatitis B", "DISEASE", 73, 89], ["viral diarrhea", "DISEASE", 108, 122], ["HIV", "ORGANISM", 73, 76], ["hepatitis B virus", "ORGANISM", 78, 95], ["bovine viral diarrhea virus", "ORGANISM", 101, 128], ["a-glucosidase", "GENE_OR_GENE_PRODUCT", 132, 145], ["2\u00a2-5\u00a2 oligoadenylates", "SIMPLE_CHEMICAL", 337, 358], ["2-5A", "SIMPLE_CHEMICAL", 360, 364], ["interferon", "GENE_OR_GENE_PRODUCT", 393, 403], ["interferon", "PROTEIN", 393, 403], ["HIV", "SPECIES", 73, 76], ["hepatitis B virus", "SPECIES", 78, 95], ["bovine", "SPECIES", 101, 107], ["viral diarrhea virus", "SPECIES", 108, 128], ["HIV", "SPECIES", 73, 76], ["hepatitis B virus", "SPECIES", 78, 95], ["bovine viral diarrhea virus", "SPECIES", 101, 128], ["the glycosylation pattern", "PROBLEM", 44, 69], ["HIV", "PROBLEM", 73, 76], ["hepatitis B virus", "PROBLEM", 78, 95], ["bovine viral diarrhea virus", "PROBLEM", 101, 128], ["a-glucosidase inhibitors", "TREATMENT", 132, 156], ["viral infectivity", "PROBLEM", 168, 185], ["virus inhibitors", "TREATMENT", 270, 286], ["virus inhibitors", "OBSERVATION", 270, 286], ["many", "OBSERVATION_MODIFIER", 310, 314], ["different", "OBSERVATION_MODIFIER", 315, 324], ["sponges", "OBSERVATION", 325, 332], ["wide", "OBSERVATION_MODIFIER", 432, 436], ["viruses", "OBSERVATION", 446, 453]]], ["The antiviral action is based on the activation of a latent endoribonuclease that prevents viral replication by degradation of its mRNA as well as cellular RNA (Kelve et al., 2003) .", [["cellular", "ANATOMY", 147, 155], ["cellular", "CELL", 147, 155], ["latent endoribonuclease", "PROTEIN", 53, 76], ["mRNA", "RNA", 131, 135], ["cellular RNA", "RNA", 147, 159], ["The antiviral action", "TREATMENT", 0, 20], ["a latent endoribonuclease", "TREATMENT", 51, 76], ["viral replication", "TREATMENT", 91, 108], ["antiviral", "OBSERVATION", 4, 13], ["viral replication", "OBSERVATION", 91, 108]]], ["For many other antivirals, the mechanism of inhibition is still unclear, but they are active against range of viruses.", [["many other antivirals", "TREATMENT", 4, 25], ["viruses", "OBSERVATION", 110, 117]]], ["Hamigeran B from Hamigera tarangaensis, for example, showed 100 % in vitro inhibition against both the herpes and polio viruses (Wellington et al., 2000) , and the weinbersterols A and B from Petrosia weinbergi exhibited in vitro activity against feline leukemia virus, mouse influenza virus, and mouse corona virus (Sun et al., 1991; Koehn et al., 1991) .NeurosuppressiveIn general, antiviral molecules from sponges do not give protection against viruses, but they may result in drugs to treat already infected persons.", [["Hamigeran B", "CHEMICAL", 0, 11], ["herpes and polio viruses", "DISEASE", 103, 127], ["weinbersterols A and B", "CHEMICAL", 164, 186], ["feline leukemia virus", "DISEASE", 247, 268], ["influenza virus", "DISEASE", 276, 291], ["Hamigeran B", "CHEMICAL", 0, 11], ["weinbersterols A and B", "CHEMICAL", 164, 186], ["Hamigeran B", "GENE_OR_GENE_PRODUCT", 0, 11], ["Hamigera tarangaensis", "ORGANISM", 17, 38], ["herpes", "ORGANISM", 103, 109], ["polio viruses", "ORGANISM", 114, 127], ["weinbersterols A", "SIMPLE_CHEMICAL", 164, 180], ["B", "GENE_OR_GENE_PRODUCT", 185, 186], ["Petrosia weinbergi", "ORGANISM", 192, 210], ["feline leukemia virus", "ORGANISM", 247, 268], ["mouse influenza virus", "ORGANISM", 270, 291], ["mouse", "ORGANISM", 297, 302], ["corona virus", "ORGANISM", 303, 315], ["persons", "ORGANISM", 512, 519], ["antiviral molecules", "PROTEIN", 384, 403], ["Hamigera tarangaensis", "SPECIES", 17, 38], ["Petrosia weinbergi", "SPECIES", 192, 210], ["feline leukemia virus", "SPECIES", 247, 268], ["mouse", "SPECIES", 270, 275], ["influenza virus", "SPECIES", 276, 291], ["mouse", "SPECIES", 297, 302], ["corona virus", "SPECIES", 303, 315], ["persons", "SPECIES", 512, 519], ["Hamigera tarangaensis", "SPECIES", 17, 38], ["Petrosia weinbergi", "SPECIES", 192, 210], ["feline leukemia virus", "SPECIES", 247, 268], ["mouse influenza virus", "SPECIES", 270, 291], ["mouse corona virus", "SPECIES", 297, 315], ["vitro inhibition", "TREATMENT", 69, 85], ["the herpes", "PROBLEM", 99, 109], ["polio viruses", "PROBLEM", 114, 127], ["the weinbersterols A and B from Petrosia weinbergi", "PROBLEM", 160, 210], ["feline leukemia virus", "PROBLEM", 247, 268], ["mouse influenza virus", "PROBLEM", 270, 291], ["mouse corona virus", "PROBLEM", 297, 315], ["antiviral molecules", "TREATMENT", 384, 403], ["sponges", "TREATMENT", 409, 416], ["viruses", "PROBLEM", 448, 455], ["drugs", "TREATMENT", 480, 485], ["herpes", "OBSERVATION", 103, 109], ["polio viruses", "OBSERVATION", 114, 127], ["leukemia virus", "OBSERVATION", 254, 268], ["influenza virus", "OBSERVATION", 276, 291]]], ["In addition, broad-based antiviral agents such as 2-5A and a-glucosidase inhibitors may be useful in cases of sudden outbreaks of (unfamiliar) viruses like SARS and Ebola.NeurosuppressiveAntimalarial Compounds.", [["2-5A", "CHEMICAL", 50, 54], ["sudden outbreaks of (unfamiliar) viruses", "DISEASE", 110, 150], ["SARS", "DISEASE", 156, 160], ["Ebola", "DISEASE", 165, 170], ["2-5A", "SIMPLE_CHEMICAL", 50, 54], ["a-glucosidase", "SIMPLE_CHEMICAL", 59, 72], ["Ebola", "ORGANISM", 165, 170], ["broad-based antiviral agents", "TREATMENT", 13, 41], ["A and a-glucosidase inhibitors", "TREATMENT", 53, 83], ["sudden outbreaks of (unfamiliar) viruses", "PROBLEM", 110, 150], ["SARS", "PROBLEM", 156, 160], ["Ebola", "PROBLEM", 165, 170]]], ["Several sponge-derived antimalarial compounds have been discovered during the last decade (Table 7) .", [["Several sponge-derived antimalarial compounds", "TREATMENT", 0, 45], ["antimalarial compounds", "OBSERVATION", 23, 45]]], ["New antimalarial drugs are needed to cope with the increasing number of multidrug-resistant Plasmodium strains that cause malaria.", [["malaria", "DISEASE", 122, 129], ["Plasmodium", "ORGANISM", 92, 102], ["New antimalarial drugs", "TREATMENT", 0, 22], ["multidrug-resistant Plasmodium strains", "TREATMENT", 72, 110], ["malaria", "PROBLEM", 122, 129], ["antimalarial drugs", "OBSERVATION", 4, 22], ["malaria", "OBSERVATION", 122, 129]]], ["Plasmodium falciparum has become resistant against chloroquinone, pyrimethamine, and sulfadoxine (Bwijo et al., 2003) .", [["Plasmodium falciparum", "DISEASE", 0, 21], ["chloroquinone", "CHEMICAL", 51, 64], ["pyrimethamine", "CHEMICAL", 66, 79], ["sulfadoxine", "CHEMICAL", 85, 96], ["chloroquinone", "CHEMICAL", 51, 64], ["pyrimethamine", "CHEMICAL", 66, 79], ["sulfadoxine", "CHEMICAL", 85, 96], ["Plasmodium falciparum", "ORGANISM", 0, 21], ["chloroquinone", "SIMPLE_CHEMICAL", 51, 64], ["pyrimethamine", "SIMPLE_CHEMICAL", 66, 79], ["sulfadoxine", "SIMPLE_CHEMICAL", 85, 96], ["Plasmodium falciparum", "SPECIES", 0, 21], ["Plasmodium falciparum", "SPECIES", 0, 21], ["Plasmodium falciparum", "PROBLEM", 0, 21], ["chloroquinone", "TREATMENT", 51, 64], ["pyrimethamine", "TREATMENT", 66, 79], ["sulfadoxine", "TREATMENT", 85, 96], ["falciparum", "OBSERVATION", 11, 21]]], ["Kalihinol A from a Acanthella sp.", [["Kalihinol A", "CHEMICAL", 0, 11], ["Kalihinol A", "CHEMICAL", 0, 11], ["Kalihinol A", "SIMPLE_CHEMICAL", 0, 11], ["Acanthella sp", "ORGANISM", 19, 32]]], ["(Miyaoka et al., 1998 ) and a number of terpenoid isocyanates, isothiocyanates, and isonitriles from Cymbastela hooperi (Konig et al., 1996) display selective in vitro antimalarial activity against P. falciparum.", [["terpenoid isocyanates", "CHEMICAL", 40, 61], ["isothiocyanates", "CHEMICAL", 63, 78], ["isonitriles", "CHEMICAL", 84, 95], ["P. falciparum", "DISEASE", 198, 211], ["terpenoid isocyanates", "CHEMICAL", 40, 61], ["isothiocyanates", "CHEMICAL", 63, 78], ["isonitriles", "CHEMICAL", 84, 95], ["terpenoid isocyanates", "SIMPLE_CHEMICAL", 40, 61], ["isothiocyanates", "SIMPLE_CHEMICAL", 63, 78], ["isonitriles", "SIMPLE_CHEMICAL", 84, 95], ["Cymbastela hooperi", "ORGANISM", 101, 119], ["P. falciparum", "ORGANISM", 198, 211], ["Cymbastela hooperi", "SPECIES", 101, 119], ["P. falciparum", "SPECIES", 198, 211], ["Cymbastela hooperi", "SPECIES", 101, 119], ["P. falciparum", "SPECIES", 198, 211], ["terpenoid isocyanates", "TREATMENT", 40, 61], ["isothiocyanates", "TREATMENT", 63, 78], ["isonitriles", "TREATMENT", 84, 95], ["selective in vitro antimalarial activity", "TREATMENT", 149, 189], ["P. falciparum", "PROBLEM", 198, 211], ["terpenoid isocyanates", "OBSERVATION", 40, 61]]], ["Also a number of free carboxylic acids from Diacarnus levii were used as precursors to yield new cyclic norditerpene peroxides after esterification.", [["carboxylic acids", "CHEMICAL", 22, 38], ["Diacarnus levii", "CHEMICAL", 44, 59], ["norditerpene", "CHEMICAL", 104, 116], ["carboxylic acids", "CHEMICAL", 22, 38], ["cyclic norditerpene peroxides", "CHEMICAL", 97, 126], ["free carboxylic acids", "SIMPLE_CHEMICAL", 17, 38], ["Diacarnus levii", "ORGANISM", 44, 59], ["cyclic norditerpene peroxides", "SIMPLE_CHEMICAL", 97, 126], ["Diacarnus levii", "SPECIES", 44, 59], ["Diacarnus levii", "SPECIES", 44, 59], ["free carboxylic acids", "TREATMENT", 17, 38], ["Diacarnus levii", "TREATMENT", 44, 59], ["new cyclic norditerpene peroxides", "TREATMENT", 93, 126], ["carboxylic acids", "OBSERVATION", 22, 38]]], ["These epidioxy-substituted norditerpenes and norsesterterpenes displayed selective activity against both chloroquine-sensitive and chloroquine-resistant P. falciparum strains (D\u00d5 Ambrosio et al., 1998).", [["epidioxy-substituted norditerpenes", "CHEMICAL", 6, 40], ["norsesterterpenes", "CHEMICAL", 45, 62], ["chloroquine", "CHEMICAL", 105, 116], ["chloroquine", "CHEMICAL", 131, 142], ["P. falciparum", "DISEASE", 153, 166], ["epidioxy-substituted norditerpenes", "CHEMICAL", 6, 40], ["norsesterterpenes", "CHEMICAL", 45, 62], ["chloroquine", "CHEMICAL", 105, 116], ["chloroquine", "CHEMICAL", 131, 142], ["epidioxy-substituted norditerpenes", "SIMPLE_CHEMICAL", 6, 40], ["norsesterterpenes", "SIMPLE_CHEMICAL", 45, 62], ["chloroquine", "SIMPLE_CHEMICAL", 105, 116], ["chloroquine", "SIMPLE_CHEMICAL", 131, 142], ["P. falciparum", "ORGANISM", 153, 166], ["P. falciparum", "SPECIES", 153, 166], ["P. falciparum", "SPECIES", 153, 166], ["These epidioxy-substituted norditerpenes", "TREATMENT", 0, 40], ["norsesterterpenes", "TREATMENT", 45, 62], ["both chloroquine", "TREATMENT", 100, 116], ["chloroquine", "TREATMENT", 131, 142], ["resistant P. falciparum strains", "PROBLEM", 143, 174]]], ["The manzamines, the most promising antimalarial compound, have been discovered in a number of sponges (Sakai et al., 1986; Ang et al., 2000; Youssaf et al., 2002) .", [["manzamines", "CHEMICAL", 4, 14], ["manzamines", "CHEMICAL", 4, 14], ["manzamines", "SIMPLE_CHEMICAL", 4, 14], ["The manzamines", "TREATMENT", 0, 14], ["antimalarial compound", "OBSERVATION", 35, 56]]], ["It has been suggested that the antimalarial effect of manzamine A is due to an enhanced immune response (Ang et al., 2001) .NeurosuppressiveAntibiotics and Fungicides.", [["manzamine A", "CHEMICAL", 54, 65], ["NeurosuppressiveAntibiotics", "CHEMICAL", 124, 151], ["Fungicides", "CHEMICAL", 156, 166], ["manzamine A", "CHEMICAL", 54, 65], ["Fungicides", "CHEMICAL", 156, 166], ["manzamine A", "SIMPLE_CHEMICAL", 54, 65], ["Fungicides", "SIMPLE_CHEMICAL", 156, 166], ["an enhanced immune response", "PROBLEM", 76, 103], ["NeurosuppressiveAntibiotics", "TREATMENT", 124, 151], ["Fungicides", "TREATMENT", 156, 166]]], ["With respect to antibiotics and fungicides, similar multiresistance problems have concerned physicians for a long time.", [["antibiotics", "TREATMENT", 16, 27], ["fungicides", "TREATMENT", 32, 42], ["similar multiresistance problems", "PROBLEM", 44, 76]]], ["Many new molecules with antibiotic properties are discovered every year, but in marine sponges their ubiquity is remarkable (Table 8 ).", [["antibiotic properties", "TREATMENT", 24, 45], ["new", "OBSERVATION_MODIFIER", 5, 8], ["molecules", "OBSERVATION", 9, 18], ["antibiotic properties", "OBSERVATION_MODIFIER", 24, 45]]], ["An early screening by Burkholder and Ruetzler (1969) revealed that 18 of 31 sponges tested showed antimicrobial effects, of which some were very strong against a range of gram-positive and gram-negative bacteria.", [["An early screening", "TEST", 0, 18], ["31 sponges", "TEST", 73, 83], ["antimicrobial effects", "PROBLEM", 98, 119], ["gram", "TEST", 171, 175], ["gram-negative bacteria", "PROBLEM", 189, 211], ["antimicrobial effects", "OBSERVATION", 98, 119], ["negative bacteria", "OBSERVATION", 194, 211]]], ["The added value of some new sponge-derived antibiotics was shown by the inhibitory effect of arenosclerins A-C from Arenosclera brasiliensis on 12 antibioticresistant bacteria isolated from a hospital (Torres et al., 2002) .", [["arenosclerins A-C", "CHEMICAL", 93, 110], ["arenosclerins A-C", "CHEMICAL", 93, 110], ["arenosclerins A-C", "SIMPLE_CHEMICAL", 93, 110], ["Arenosclera brasiliensis", "ORGANISM", 116, 140], ["Arenosclera brasiliensis", "SPECIES", 116, 140], ["Arenosclera brasiliensis", "SPECIES", 116, 140], ["some new sponge-derived antibiotics", "TREATMENT", 19, 54], ["arenosclerins A-C", "PROBLEM", 93, 110], ["Arenosclera brasiliensis", "PROBLEM", 116, 140], ["12 antibioticresistant bacteria", "PROBLEM", 144, 175]]], ["Fungicides that are currently used are less diverse than antimicrobials, and the use of many of them is restricted because of toxic effects to humans, animals, and plants (Nakagawa and Moore, 1995; Rahden-Staron, 2002) .", [["Fungicides", "CHEMICAL", 0, 10], ["humans", "ORGANISM", 143, 149], ["humans", "SPECIES", 143, 149], ["humans", "SPECIES", 143, 149], ["Fungicides", "TREATMENT", 0, 10], ["antimicrobials", "TREATMENT", 57, 71], ["toxic effects", "PROBLEM", 126, 139], ["less", "OBSERVATION_MODIFIER", 39, 43], ["diverse", "OBSERVATION_MODIFIER", 44, 51]]], ["It remains to be demonstrated whether antifungals like topsentiasterols D and E from Topsentia sp.", [["topsentiasterols D", "CHEMICAL", 55, 73], ["topsentiasterols D and E", "CHEMICAL", 55, 79], ["topsentiasterols D", "SIMPLE_CHEMICAL", 55, 73], ["E", "SIMPLE_CHEMICAL", 78, 79], ["Topsentia sp", "ORGANISM", 85, 97], ["antifungals", "TREATMENT", 38, 49], ["topsentiasterols D and E from Topsentia sp", "PROBLEM", 55, 97], ["antifungals", "OBSERVATION", 38, 49]]], ["(Fusetani et al., 1994) , acanthosterol sulfates I and J from an Acanthodendrilla sp.", [["acanthosterol sulfates", "CHEMICAL", 26, 48], ["acanthosterol sulfates I and J", "CHEMICAL", 26, 56], ["acanthosterol sulfates I", "SIMPLE_CHEMICAL", 26, 50], ["Acanthodendrilla sp", "ORGANISM", 65, 84], ["acanthosterol sulfates I", "TREATMENT", 26, 50], ["an Acanthodendrilla sp", "TREATMENT", 62, 84]]], ["(Tsukamoto et al., 1998) or the macrolide leucascandrolide A from the calcareous sponge Leucascandra caveolata (D\u00d5Ambrosio et al., 1996) will have different characteristics than the fungicides that are currently used, but the fact that they are produced by eukaryotic organism (if not produced by a symbiont) may imply that they are less toxic to other nonfungal eukaryotes.NeurosuppressiveAntifouling Compounds.", [["macrolide", "CHEMICAL", 32, 41], ["leucascandrolide A", "CHEMICAL", 42, 60], ["macrolide leucascandrolide A", "CHEMICAL", 32, 60], ["macrolide leucascandrolide A", "SIMPLE_CHEMICAL", 32, 60], ["Leucascandra caveolata", "ORGANISM", 88, 110], ["Leucascandra caveolata", "SPECIES", 88, 110], ["Leucascandra caveolata", "SPECIES", 88, 110], ["the macrolide leucascandrolide", "TREATMENT", 28, 58], ["the calcareous sponge Leucascandra caveolata", "TREATMENT", 66, 110], ["the fungicides", "TREATMENT", 178, 192]]], ["A last class of bioactive compounds from marine sponges are antifouling molecules (Table 9 ).", [["bioactive compounds", "TREATMENT", 16, 35], ["marine sponges", "TREATMENT", 41, 55], ["bioactive compounds", "OBSERVATION", 16, 35]]], ["They are not associated with the development of new drugs, but could be environmentally friendly substitutes for chemical antifoulants.", [["chemical antifoulants", "TREATMENT", 113, 134], ["not associated with", "UNCERTAINTY", 9, 28]]], ["Biofouling organisms such as blue mussels, barnacles, and macroalgae cause serious problems to ship\u00d5s hulls, cooling systems of power plants, and aquaculture materials (Holmes, 1970; Houghton, 1978) .", [["barnacles", "ANATOMY", 43, 52], ["blue mussels", "ORGANISM", 29, 41], ["blue mussels", "SPECIES", 29, 41], ["Biofouling organisms", "PROBLEM", 0, 20], ["blue mussels", "PROBLEM", 29, 41], ["serious problems to ship\u00d5s hulls", "PROBLEM", 75, 107], ["blue mussels", "OBSERVATION", 29, 41]]], ["Long-term use of chemical antifoulants has led to increased concentrations of tributyltin and its current replacements in coastal sediments (Konstantinou and Albanis, 2004) and to mortality and change of sex of nontarget organisms (Katranitsas et al., 2003) .", [["antifoulants", "CHEMICAL", 26, 38], ["tributyltin", "CHEMICAL", 78, 89], ["tributyltin", "CHEMICAL", 78, 89], ["tributyltin", "SIMPLE_CHEMICAL", 78, 89], ["chemical antifoulants", "TREATMENT", 17, 38], ["tributyltin", "TREATMENT", 78, 89], ["its current replacements", "TREATMENT", 94, 118], ["coastal sediments", "PROBLEM", 122, 139], ["Albanis", "TREATMENT", 158, 165]]], ["Natural marine antifouling molecules have recently been reviewed (Fusetani, 2004) and may provide less toxic and more specific antifouling activity.", [["Natural marine antifouling molecules", "TREATMENT", 0, 36]]], ["Sponge-derived antifouling molecules have been found to inhibit the settlement of barnacle larvae (Okino et al., 1995; (Sera et al., 1999) .NeurosuppressiveEcologic Role of Sponge Metabolites.", [["barnacle larvae", "ORGANISM", 82, 97], ["Sponge", "TREATMENT", 0, 6], ["Sponge Metabolites", "OBSERVATION", 173, 191]]], ["Such an extensive collection of sponge-derived bioactive compounds raises the question of why sponges produce so many metabolites that can be useful to treat our human diseases.", [["human", "ORGANISM", 162, 167], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 162, 167], ["an extensive collection of sponge-derived bioactive compounds", "PROBLEM", 5, 66], ["why sponges", "PROBLEM", 90, 101], ["our human diseases", "PROBLEM", 158, 176], ["extensive", "OBSERVATION_MODIFIER", 8, 17], ["collection", "OBSERVATION", 18, 28], ["sponge", "OBSERVATION", 32, 38], ["bioactive compounds", "OBSERVATION", 47, 66]]], ["The huge number of different secondary metabolites discovered in marine sponges and the complexity of the compounds and their biosynthetic pathways (and corresponding kilobases of DNA for the programming of their synthesis) can be regarded as an indication of their importance for survival.", [["DNA", "CELLULAR_COMPONENT", 180, 183], ["different secondary metabolites", "PROBLEM", 19, 50], ["marine sponges", "TREATMENT", 65, 79], ["huge", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["different", "OBSERVATION_MODIFIER", 19, 28], ["secondary metabolites", "OBSERVATION", 29, 50], ["marine sponges", "OBSERVATION", 65, 79]]], ["An obvious example of the benefits of their secondary metabolites for the sponge itself, is the presence of antifouling products.", [["antifouling products", "TREATMENT", 108, 128], ["antifouling products", "OBSERVATION", 108, 128]]], ["To safeguard their water-pumping capacity, sponges cannot tolerate biofilm formation or settlement of barnacles or bryozoans on their surface (Proksch, 1994) , The level of cytotoxicity of some sponge products is high enough to even create a bare zone around the sponge (Thompson, 1985) that is maintained by the emission of a mucus containing the toxins (Sullivan et al., 1981) .", [["biofilm", "ANATOMY", 67, 74], ["barnacles", "ANATOMY", 102, 111], ["surface", "ANATOMY", 134, 141], ["mucus", "ANATOMY", 327, 332], ["mucus", "ORGANISM_SUBSTANCE", 327, 332], ["sponges", "TREATMENT", 43, 50], ["biofilm formation", "TREATMENT", 67, 84], ["some sponge products", "PROBLEM", 189, 209], ["cytotoxicity", "OBSERVATION_MODIFIER", 173, 185], ["some", "OBSERVATION_MODIFIER", 189, 193], ["sponge products", "OBSERVATION", 194, 209], ["high", "OBSERVATION_MODIFIER", 213, 217], ["bare", "OBSERVATION_MODIFIER", 242, 246], ["zone", "OBSERVATION_MODIFIER", 247, 251], ["sponge", "OBSERVATION", 263, 269]]], ["This allows the conquest of densely populated rocks or corals and competition with faster growing organisms, but it is striking that the sponge can selectively use its poisons without self-destruction.NeurosuppressiveSecondary metabolites can protect the organism against predation, which is especially important for physically unprotected sessile organisms like sponges (Becerro et al., 1997) .", [["faster growing organisms", "PROBLEM", 83, 107], ["the sponge", "PROBLEM", 133, 143], ["self-destruction", "PROBLEM", 184, 200], ["NeurosuppressiveSecondary metabolites", "PROBLEM", 201, 238], ["rocks", "OBSERVATION", 46, 51]]], ["Relatively few animals, such as the hawksbill turtle and some highly evolved teleost fishes (Meylan, 1990) , are largely dependent on sponges for their diet.", [["hawksbill turtle", "ANATOMY", 36, 52], ["hawksbill turtle", "ORGANISM", 36, 52], ["hawksbill turtle", "SPECIES", 36, 52], ["the hawksbill turtle", "PROBLEM", 32, 52], ["few", "OBSERVATION_MODIFIER", 11, 14], ["animals", "OBSERVATION", 15, 22], ["dependent", "OBSERVATION_MODIFIER", 121, 130]]], ["Also some nudibranches feed on sponges and even manage to use the sponge\u00d5s metabolites for their own chemical defence (Pawlik et al., 1988) .", [["sponges", "TREATMENT", 31, 38], ["the sponge\u00d5s metabolites", "TREATMENT", 62, 86]]], ["However, these spongivores represent only a tiny fraction of the animals inhabiting the seas.", [["spongivores", "ANATOMY", 15, 26], ["spongivores", "CANCER", 15, 26], ["tiny", "OBSERVATION_MODIFIER", 44, 48], ["fraction", "OBSERVATION", 49, 57], ["seas", "ANATOMY", 88, 92]]], ["Secondary metabolites can also protect their producers against bacteria, fungi, or parasites (Davies, 1992).", [["Secondary metabolites", "PROBLEM", 0, 21], ["bacteria", "PROBLEM", 63, 71], ["fungi", "PROBLEM", 73, 78], ["parasites", "PROBLEM", 83, 92]]], ["In sponges the role of the chemical constituents is clouded by the complexity of the sponge-symbiont relationship (Dumdei et al., 1998).", [["clouded", "OBSERVATION", 52, 59]]], ["Many different bacterial species permanently inhabit sponges and contribute considerably to the total sponge biomass (Wilkinson, 1978) .", [["Many different bacterial species", "PROBLEM", 0, 32], ["the total sponge biomass", "TREATMENT", 92, 116], ["different", "OBSERVATION_MODIFIER", 5, 14], ["bacterial species", "OBSERVATION", 15, 32], ["permanently", "OBSERVATION_MODIFIER", 33, 44], ["inhabit sponges", "OBSERVATION", 45, 60], ["sponge biomass", "OBSERVATION", 102, 116]]], ["It has been suggested that the growth of ''useful'' microorganisms may be under control of the sponge host and serve as source of food or supply other metabolic products (Muller et al., 1981) .", [["''useful'' microorganisms", "PROBLEM", 41, 66], ["the sponge host", "TREATMENT", 91, 106]]], ["However, it has also been found that associated bacteria might be the actual producers of a number of compounds that Table 8 . have been isolated from sponges.", [["associated bacteria", "PROBLEM", 37, 56], ["bacteria", "OBSERVATION", 48, 56], ["sponges", "OBSERVATION", 151, 158]]], ["Oscillatoria spongelia, a cyanobacterial symbiont that can constitute up to 40% of Dysidea herbacea, is the producer of antimicrobial polybrominated biphenyl ethers and might keep the sponge free of other bacteria (Unson, et al., 1994) .", [["polybrominated biphenyl ethers", "CHEMICAL", 134, 164], ["polybrominated biphenyl ethers", "CHEMICAL", 134, 164], ["Oscillatoria spongelia", "ORGANISM", 0, 22], ["Dysidea herbacea", "ORGANISM", 83, 99], ["antimicrobial polybrominated biphenyl ethers", "SIMPLE_CHEMICAL", 120, 164], ["Oscillatoria spongelia", "SPECIES", 0, 22], ["Dysidea herbacea", "SPECIES", 83, 99], ["Oscillatoria spongelia", "SPECIES", 0, 22], ["Dysidea herbacea", "SPECIES", 83, 99], ["Oscillatoria spongelia", "PROBLEM", 0, 22], ["a cyanobacterial symbiont", "PROBLEM", 24, 49], ["Dysidea herbacea", "PROBLEM", 83, 99], ["antimicrobial polybrominated biphenyl ethers", "TREATMENT", 120, 164], ["other bacteria", "PROBLEM", 199, 213], ["cyanobacterial symbiont", "OBSERVATION", 26, 49]]], ["It is clear, however, that sponges are responsible for the production of a rich arsenal of ''chemical weapons.''", [["sponges", "TREATMENT", 27, 34], ["clear", "OBSERVATION", 6, 11], ["sponges", "OBSERVATION", 27, 34]]], ["Their early appearance in evolution has given them a lot of time for the development of an advanced chemical defense system.", [["an advanced chemical defense system", "PROBLEM", 88, 123], ["early", "OBSERVATION_MODIFIER", 6, 11], ["advanced", "OBSERVATION_MODIFIER", 91, 99], ["chemical defense system", "OBSERVATION", 100, 123]]], ["It is interesting to note that the synthesis of secondary metabolites is regulated depending on conditions that the sponge experiences.", [["secondary metabolites", "PROBLEM", 48, 69]]], ["Specimens of Crambe crambe in wellilluminated regions grow faster than their counterparts exposed to darker conditions, but the specimens in the dark are better defended as they accumulate higher concentrations of cytotoxic metabolites (Turon et al., 1998) .", [["Specimens", "ANATOMY", 0, 9], ["specimens", "ANATOMY", 128, 137], ["Crambe crambe", "ORGANISM", 13, 26], ["Crambe crambe", "SPECIES", 13, 26], ["Specimens", "TEST", 0, 9], ["Crambe crambe in wellilluminated regions", "PROBLEM", 13, 53], ["darker conditions", "PROBLEM", 101, 118], ["the specimens", "TEST", 124, 137], ["Crambe crambe", "OBSERVATION", 13, 26], ["faster", "OBSERVATION_MODIFIER", 59, 65], ["higher concentrations", "OBSERVATION_MODIFIER", 189, 210], ["cytotoxic metabolites", "OBSERVATION", 214, 235]]], ["Another example is the production of halichondrin B by Lissodendoryx sp., which varies seasonally, with depth, and with the condition of the sponge.", [["halichondrin B", "CHEMICAL", 37, 51], ["halichondrin B", "CHEMICAL", 37, 51], ["halichondrin B", "GENE_OR_GENE_PRODUCT", 37, 51], ["Lissodendoryx sp.", "ORGANISM", 55, 72], ["halichondrin B", "PROTEIN", 37, 51], ["Lissodendoryx sp.", "SPECIES", 55, 72], ["Lissodendoryx sp.", "SPECIES", 55, 72], ["halichondrin B", "TREATMENT", 37, 51], ["the sponge", "TREATMENT", 137, 147], ["sponge", "OBSERVATION", 141, 147]]], ["Halichondrin B yields could be enhanced by an order of magnitude during serial cloning, suggesting a defensive response to damage (Battershill et al., 2002) .", [["Halichondrin B", "CHEMICAL", 0, 14], ["Halichondrin B", "CHEMICAL", 0, 14], ["Halichondrin B", "GENE_OR_GENE_PRODUCT", 0, 14], ["Halichondrin B", "PROTEIN", 0, 14], ["Halichondrin", "TREATMENT", 0, 12], ["serial cloning", "TEST", 72, 86]]], ["The ability to stimulate the production of secondary metabolites by sponges is an important consideration when one wants to harvest compounds from sponges for the production of potential new medicines.ConclusionMarine sponges produce an enormous array of antitumor, antiviral, antiinflammatory, immunosup-pressive, antibiotic, and other bioactive molecules that can affect the pathogenesis of many human diseases.", [["antitumor", "ANATOMY", 255, 264], ["antitumor", "CANCER", 255, 264], ["human", "ORGANISM", 398, 403], ["human", "SPECIES", 398, 403], ["human", "SPECIES", 398, 403], ["secondary metabolites", "PROBLEM", 43, 64], ["sponges", "TREATMENT", 147, 154], ["potential new medicines", "TREATMENT", 177, 200], ["Marine sponges", "TREATMENT", 211, 225], ["antitumor", "TREATMENT", 255, 264], ["antiviral", "TREATMENT", 266, 275], ["antiinflammatory", "TREATMENT", 277, 293], ["immunosup", "TREATMENT", 295, 304], ["pressive", "TREATMENT", 305, 313], ["antibiotic", "TREATMENT", 315, 325], ["other bioactive molecules", "TREATMENT", 331, 356], ["many human diseases", "PROBLEM", 393, 412], ["many human diseases", "OBSERVATION", 393, 412]]], ["The relationship between the chemical structures of the secondary metabolites from sponges and the diseases they affect is usually not obvious.", [["sponges", "TREATMENT", 83, 90], ["the diseases", "PROBLEM", 95, 107], ["secondary metabolites", "OBSERVATION", 56, 77], ["sponges", "OBSERVATION", 83, 90], ["diseases", "OBSERVATION", 99, 107]]], ["Different components affect the targeted disease by different mechanisms (e.g., microtubule stabilization or interaction with DNA to combat tumors).", [["microtubule", "ANATOMY", 80, 91], ["tumors", "ANATOMY", 140, 146], ["tumors", "DISEASE", 140, 146], ["microtubule", "CELLULAR_COMPONENT", 80, 91], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["tumors", "CANCER", 140, 146], ["microtubule", "PROTEIN", 80, 91], ["the targeted disease", "PROBLEM", 28, 48], ["microtubule stabilization", "TREATMENT", 80, 105], ["tumors", "PROBLEM", 140, 146], ["targeted", "OBSERVATION_MODIFIER", 32, 40], ["disease", "OBSERVATION", 41, 48]]], ["Moreover, inhibitors of transcription may be effective against both cancer and viral diseases.", [["cancer", "ANATOMY", 68, 74], ["cancer and viral diseases", "DISEASE", 68, 93], ["cancer", "CANCER", 68, 74], ["inhibitors of transcription", "TREATMENT", 10, 37], ["both cancer", "PROBLEM", 63, 74], ["viral diseases", "PROBLEM", 79, 93], ["cancer", "OBSERVATION", 68, 74], ["viral diseases", "OBSERVATION", 79, 93]]], ["To make things more complex, there are many relations between, for instance, inflammation, cancer, and viral infections via the immune system, which plays a key role in certain responses of the body to these diseases.", [["cancer", "ANATOMY", 91, 97], ["immune system", "ANATOMY", 128, 141], ["body", "ANATOMY", 194, 198], ["inflammation", "DISEASE", 77, 89], ["cancer", "DISEASE", 91, 97], ["viral infections", "DISEASE", 103, 119], ["cancer", "CANCER", 91, 97], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["inflammation", "PROBLEM", 77, 89], ["cancer", "PROBLEM", 91, 97], ["viral infections via the immune system", "PROBLEM", 103, 141], ["these diseases", "PROBLEM", 202, 216], ["inflammation", "OBSERVATION", 77, 89], ["cancer", "OBSERVATION", 91, 97], ["viral infections", "OBSERVATION", 103, 119], ["diseases", "OBSERVATION", 208, 216]]], ["Chronic inflammation of the lungs by cigarette smoke often leads to lung cancer (Ohwada et al., 1995) and cervical and liver cancer can follow chronic inflammation caused by papilloma viruses (Smith-McCune et al., 1996) and hepatitis B and C viruses, respectively (Zhu et al., 1997) .", [["lungs", "ANATOMY", 28, 33], ["lung cancer", "ANATOMY", 68, 79], ["cervical", "ANATOMY", 106, 114], ["liver cancer", "ANATOMY", 119, 131], ["inflammation", "DISEASE", 8, 20], ["lung cancer", "DISEASE", 68, 79], ["cervical and liver cancer", "DISEASE", 106, 131], ["inflammation", "DISEASE", 151, 163], ["papilloma viruses", "DISEASE", 174, 191], ["hepatitis B and C viruses", "DISEASE", 224, 249], ["lungs", "ORGAN", 28, 33], ["cigarette", "ORGANISM", 37, 46], ["lung cancer", "CANCER", 68, 79], ["cervical", "ORGAN", 106, 114], ["liver cancer", "CANCER", 119, 131], ["papilloma viruses", "ORGANISM", 174, 191], ["hepatitis B and C viruses", "ORGANISM", 224, 249], ["Chronic inflammation of the lungs", "PROBLEM", 0, 33], ["lung cancer", "PROBLEM", 68, 79], ["cervical and liver cancer", "PROBLEM", 106, 131], ["chronic inflammation", "PROBLEM", 143, 163], ["papilloma viruses", "PROBLEM", 174, 191], ["hepatitis B and C viruses", "PROBLEM", 224, 249], ["inflammation", "OBSERVATION", 8, 20], ["lungs", "ANATOMY", 28, 33], ["cigarette smoke", "OBSERVATION", 37, 52], ["lung", "ANATOMY", 68, 72], ["cancer", "OBSERVATION", 73, 79], ["cervical", "ANATOMY", 106, 114], ["liver", "ANATOMY", 119, 124], ["cancer", "OBSERVATION", 125, 131], ["chronic", "OBSERVATION_MODIFIER", 143, 150], ["inflammation", "OBSERVATION", 151, 163], ["papilloma", "OBSERVATION", 174, 183], ["hepatitis", "ANATOMY", 224, 233]]], ["In addition, limited activity testing (e.g., only on cell growth inhibition and not on antiviral properties) yields an incomplete overview of the actual properties of the metabolites.", [["cell", "ANATOMY", 53, 57], ["cell", "CELL", 53, 57], ["limited activity testing", "TEST", 13, 37], ["cell growth inhibition", "TREATMENT", 53, 75], ["antiviral properties", "TREATMENT", 87, 107]]], ["Finally, for many bioactive molecules from sponges, the exact mode of action and their origin (sponge or symbiont) are still unclear.", [["many bioactive molecules", "PROBLEM", 13, 37], ["sponges", "TREATMENT", 43, 50]]], ["Most bioactive metabolites from sponges are inhibitors of certain enzymes, which often mediate or produce mediators of intracellular or intercellular messengers involved in the pathogenesis of a disease.", [["intracellular", "ANATOMY", 119, 132], ["intercellular", "ANATOMY", 136, 149], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 119, 132], ["enzymes", "PROTEIN", 66, 73], ["Most bioactive metabolites", "PROBLEM", 0, 26], ["sponges", "TREATMENT", 32, 39], ["inhibitors", "TREATMENT", 44, 54], ["certain enzymes", "TEST", 58, 73], ["a disease", "PROBLEM", 193, 202], ["intercellular messengers", "OBSERVATION", 136, 160], ["disease", "OBSERVATION", 195, 202]]], ["As this is usually a cascade of reactions inside the cell or tissue, many enzymes in the cascade are targets for potential therapy.", [["cell", "ANATOMY", 53, 57], ["tissue", "ANATOMY", 61, 67], ["cell", "CELL", 53, 57], ["tissue", "TISSUE", 61, 67], ["many enzymes", "TEST", 69, 81], ["potential therapy", "TREATMENT", 113, 130], ["cell", "OBSERVATION", 53, 57]]], ["The different enzymes in the cascade can be structurally completely different proteins; therefore, it is not surprising that a wide range of metabolites can be used for the treatment of one disease.", [["The different enzymes", "TEST", 0, 21], ["structurally completely different proteins", "PROBLEM", 44, 86], ["one disease", "PROBLEM", 186, 197], ["disease", "OBSERVATION", 190, 197]]], ["This applies in particular to a complex disease, such as cancer, which is affected by so many different factors.", [["cancer", "ANATOMY", 57, 63], ["cancer", "DISEASE", 57, 63], ["cancer", "CANCER", 57, 63], ["a complex disease", "PROBLEM", 30, 47], ["cancer", "PROBLEM", 57, 63], ["complex", "OBSERVATION_MODIFIER", 32, 39], ["disease", "OBSERVATION", 40, 47], ["cancer", "OBSERVATION", 57, 63]]], ["Furthermore, antiviral molecules also appear to encamps a wide array of chemical structures, such as peptides, lipids, alkaloids, sterols, oligonucleotides, and a phenolic macrolide.", [["lipids, alkaloids, sterols", "CHEMICAL", 111, 137], ["macrolide", "CHEMICAL", 172, 181], ["sterols", "CHEMICAL", 130, 137], ["phenolic macrolide", "CHEMICAL", 163, 181], ["lipids", "SIMPLE_CHEMICAL", 111, 117], ["alkaloids", "SIMPLE_CHEMICAL", 119, 128], ["sterols", "SIMPLE_CHEMICAL", 130, 137], ["phenolic macrolide", "SIMPLE_CHEMICAL", 163, 181], ["antiviral molecules", "PROTEIN", 13, 32], ["antiviral molecules", "PROBLEM", 13, 32], ["lipids", "TREATMENT", 111, 117], ["alkaloids", "TREATMENT", 119, 128], ["sterols", "TREATMENT", 130, 137], ["oligonucleotides", "TREATMENT", 139, 155], ["a phenolic macrolide", "TREATMENT", 161, 181], ["antiviral molecules", "OBSERVATION", 13, 32], ["wide", "OBSERVATION_MODIFIER", 58, 62], ["chemical structures", "ANATOMY", 72, 91], ["phenolic macrolide", "OBSERVATION", 163, 181]]], ["A similar diverse pattern is observed for antibacterial and immunosuppressive metabolites.", [["A similar diverse pattern", "PROBLEM", 0, 25], ["antibacterial", "TREATMENT", 42, 55], ["immunosuppressive metabolites", "TREATMENT", 60, 89], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["diverse pattern", "OBSERVATION", 10, 25], ["immunosuppressive metabolites", "OBSERVATION", 60, 89]]], ["Most compounds that display antiinflammatory activity are sesterterpenoids.", [["sesterterpenoids", "CHEMICAL", 58, 74], ["sesterterpenoids", "SIMPLE_CHEMICAL", 58, 74], ["antiinflammatory activity", "OBSERVATION", 28, 53]]], ["Nevertheless, in these cases the activity of the sponge metabolites is concentrated on certain steps; for instance, most antiinflammatory compounds act against phospholipase A 2 .ConclusionThe potency of sponge-derived medicines lies in the fact that each of these thousands of metabolites and their derivatives has its own specific dose-related inhibitory effect, efficacy, and potential (diminished) side effects that determine its suitability for medicinal use.", [["phospholipase A 2", "GENE_OR_GENE_PRODUCT", 160, 177], ["phospholipase A 2", "PROTEIN", 160, 177], ["sponge-derived medicines", "TREATMENT", 204, 228], ["their derivatives", "TREATMENT", 294, 311], ["potential (diminished) side effects", "PROBLEM", 379, 414]]], ["In addition, the skeleton or active core of these molecules may be used as a vehicle to develop derivatives with their own specific efficacy and side effects.", [["derivatives", "TREATMENT", 96, 107], ["side effects", "PROBLEM", 145, 157], ["skeleton", "ANATOMY", 17, 25], ["active", "OBSERVATION_MODIFIER", 29, 35]]], ["Therefore, the most important challenge in transforming bioactive molecules into medicines is now to screen the treasurehouse of sponge metabolites and select those that display a specific mode of action with the desired characteristics against a disease.", [["transforming bioactive molecules into medicines", "TREATMENT", 43, 90], ["sponge metabolites", "TREATMENT", 129, 147], ["a disease", "PROBLEM", 245, 254], ["disease", "OBSERVATION", 247, 254]]], ["An important question for the future remains how to actually prepare the potential novel drugs on a large scale.", [["novel drugs", "TREATMENT", 83, 94], ["a large scale", "TREATMENT", 98, 111]]]], "PMC7109695": [["Methods", [["Methods", "TREATMENT", 0, 7]]]]}